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Abstract
To date, prostate cancer is the most common male cancer diagnosed in the United 
Kingdom. Our rudimentary knowledge of the aetiology and molecular pathways implicated 
in prostate tumourigenesis is probably responsible for its poor prognosis. To address this, a 
conditional transgenic approach was employed to investigate the role of the tumour 
suppressor Lkbl and the proto-oncogenes p-catenin and K-ras within the murine prostate.
LKB1 is a tumour suppressor commonly mutated in Peutz-Jegher’s syndrome (PJS), 
which predominantly predisposes to gastrointestinal hamartomas and various extra- 
intestinal tumours. Using a conditional transgenic approach, recombination of a LoxP- 
flanked Lkbl transgene was mediated by the inducible Ah (p450 CYP1A1) promoter. Loss 
of Lkbl in un-induced AhCre+L k b l^  mice predisposed to prostate intra-epithelial neoplasia 
(PIN) within 2-4 months. Molecular analysis revealed that neoplastic foci had lost cellular 
polarity and showed enhanced PI3K/AKT and Wnt signalling pathway activity, ultimately 
leading to tumour growth. Loss of Lkbl did not result in activation of the AMPK/mTOR 
pathway, suggesting that a feedback mechanism suppresses mTOR in Lkbl deficient 
conditions. Study of disease progression in this model is limited owing to decreased 
longevity, which is thought to be caused by the development of bulbourethral gland cysts. 
Additional GU tract phenotypes were also observed in un-induced AhCre+L k b l^  urethral 
glands and seminal vesicles and all L k b ^  male mice were infertile.
To address the problem of reduced longevity in the AhCre+L k b l^  cohort, 
PBCre+L k b l^  transgenic mice were derived. Here, Oe-recombinase expression is 
mediated by the composite rat Probasin promoter. All cohorts showed life-spans 
comparable to wild-type mice at 500 days. PBCre* Lkbl ^  prostates were normal, while 
Cre'Lkbl^1 mice developed low grade-PIN, demonstrating the hypomorphic nature of the 
Lkbl floxed allele. PBCre * L k b l^  mice demonstrated atypical hyperplasia of the prostate, 
arguing a critical role for Lkbl levels in cancer initiation. Long-term Lkbl deficiency also 
predisposed to kidney abnormalities, preputial gland squamous metaplasia and PJS-linked 
phenotypes, including stomach hamartomas and Sertoli-cell-only syndrome at 500 days.
To investigate the deregulation of Wnt signalling in the murine prostate, conditional 
transgenic mice carrying a dominant stable form of p-catenin in the prostate were generated 
(PBCre' Catnb /lox(ex3)). At 3 months, males manifested PIN-like keratinised squamous 
metaplasia that advanced to adenocarcinoma by 6 months. No evidence for synergy was
8
determined between Lkbl loss and activated P-catenin, although investigations were limited 
to PBCre Lkbl^:C atnb /lox(ex3) mice owing to a time constraint and partial embryonic 
lethality of L k b l^  mice.
Synergism between Wnt and Ras signalling has been well documented in many 
human cancers, including intestine, liver and kidney. To address the cooperativity of these 
pathways in the prostate, the PBCre transgenic line was employed to express an activated 
K-rasVI2 mutation and a dominant stabilised form of p-catenin (PBCre K- 
ras+/VI2;Catnb*/lox(ex3)). PBCre+K-ras+/vl2 mice were predisposed to low grade-PIN at 16 
months and demonstrated elevated MAPK signalling. Double mutants demonstrated rapid 
tumourigenesis to invasive carcinoma at 6 months, which displayed elevated Wnt and 
MAPK signalling. Further molecular analysis determined that activated K-ras and P-catenin 
synergise to facilitate prostate tumourigenesis by elevating the number of androgen receptor 
positive cells and upregulating Wnt targets, such as COX-2 and c-Myc. This evidence 
suggests androgen-independent tumour growth and presents a direct mechanism whereby 
tumour progression is accelerated via the canonical Wnt pathway.
In summary, this thesis reports the first correlation between Lkbl loss and prostate 
neoplasia, and demonstrates synergy between Wnt and Ras signalling in murine prostate 
tumourigenesis. Together, these data provide a valuable resource for genetic based studies 
and establish the multi-step nature of tumourigenesis.
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bp - base pairs.
BrdU - Bromodeoxyuridine.
BRG1 - Brahma related gene-1.
BUG - Bulbourethral gland.
BZS - Bannayan zonana syndrome.
Catnb -p-catenin (CTNNB1).
CD - Cowden’s disease.
CD44 - CD44 antigen (homing function and Indian b blood group system). 
CK2 - Casein kinase-2.
Cre - Cyclisation recombination.
CZ - Central zone.
DEPC - Diethyl pyrocarbonate.
DHT - 5-alpha-dihydrotestosterone.
DLP - Dorsolateral prostate.
DP - Dorsal prostate.
DPX - Distrene plasticizer and xylene.
Dsh - Dishevelled.
E - Embryonic day.
EM - Electron microscopy.
ERK - Extracellular signal-regulated kinase.
FAP - Familial adenomatous polyposis.
FGF - Fibroblast growth factor.
FI - Floxed.
Foxal - Forkhead box A1.
FSH - Follicle stimulating hormone.
GSK3P - Glycogen synthase kinase-3 p.
GU - Genitourinary.
H&E - Haematoxylin and eosin.
HG-PIN - High-grade prostate intra-epithelial neoplasia.
Hh - Hedgehog.
HK2 - Human kallikrein-2.
HNPCC - Hereditary non-polyposis colorectal cancer.
HPC-1 - Hereditary prostate cancer-1.
IGF-1 - Insulin growth factor-1.
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i.p. - intra-peritoneal.
JNK - Janus kinase.
JPS - Juvenile polyposis syndrome. 
kDa - kilodalton.
Ki-67 - antigen identified by monoclonal antibody Ki-67 (MKI-67).
LCMD - Laser capture microdissection.
LG-PIN - Low-grade prostate intra-epithelial neoplasia.
LH - Luteinising hormone.
LIP1 - LKB1 interacting protein-1.
LKB1 - Serine threonine kinase-11 (STK11).
LOH - Loss of heterozygosity.
LoxP - Locus x of crossover PI site.
LP - Lamina propria.
MAPK - Mitogen-activated protein kinase.
MARK - Microtubule affinity regulated kinases.
MeCP2 - Methyl CpG binding protein 2.
MEK1/2 - Mitogen-activated protein kinase kinase 1/2. 
mRNA - Messenger RNA.
mTOR - FK506 binding protein 12-rapamycin associated protein 1 (FRAP1).
Nkx3.1 - NK-3 transcription factor, locus 1.
NLS - Nuclear localisation sequence.
O/N - Overnight.
p53 - Transformation related protein 53, Trp53. 
p63 - Transformation related protein 63, Trp63.
PAP - Prostate acid phosphatase.
PARI A - MAP/microtubule affinity-regulating kinase 3 (MARK3), Cdc25C-associated 
kinase 1 (cTAKl).
PB - Probasin promoter.
PBS - Phosphate buffered saline.
PCR - Polymerase chain reaction.
PDK1 - Pyruvate dehydrogenase kinase, isozyme 1.
PI3K - Phosphoinositol-3 kinase.
PIN - Prostate intra-epithelial neoplasia.
PJS - Peutz-Jeghers syndrome.
pS6 - p70 S6 ribosomal protein (RpS6).
PSA - Prostate specific antigen.
PSCA - Prostate stem cell antigen.
PTEN - Phosphatase and tensin homolog deleted on chromosome 10, MMAC1.
PZ - Peripheral zone.
Rb - Retinoblastoma.
RHEB - Ras homolog enriched in brain.
RT-PCR - Reverse transcription polymerase chain reaction.
S6K - Ribosomal protein S6 kinase, 70kDa, polypeptide 1 (RPS6K).
SCID - Severe combined immunodeficiency.
SCOS - Sertoli-cell-only syndrome.
SD - Standard deviation.
SDS - Sodium dodecyl sulphate.
Sox 17 - Sry-related HMG box gene 17.
STRAD - Ste20-related adaptor.
SqM - Seminal vesicle squamous metaplasia.
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SV - Seminal vesicle.
T - Testosterone.
TBS - Tris buffered saline.
TCF/LEF - T-cell factor/ lymphocyte enhancer factor.
TCF4 - Transcription factor-4.
TGFp - Transforming growth factor-p.
TZ - Transitional zone.
TSC1 - Tuberous sclerosis 1 (hamartin).
TSC2 - Tuberous sclerosis 2 (tuberin).
UG - Urethral glands.
UGH - Urethral gland hyperplasia.
UGS - Urogenital sinus.
VEGF - Vascular endothelial growth factor.
VP - Ventral prostate.
Wnt - Wingless type MMTV integration site family member. 
Xeekl - Xenopus egg and embryonic kinase-1.
ZO-1 - Zona occludens-1.
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Chapter 1: Introduction
1.1 The prostate
The prostate is a small gland of the male reproductive system consisting of a 
network of ducts that are growth stimulated by androgens, such as testosterone. This section 
shall focus on the function, morphology, growth and development of the prostate. 
Moreover, a description of the similarities and differences between human and mouse 
prostate highlights the benefits of this model organism in the study of prostate cancer.
1.1.1 Prostate function
The male accessory glands consist of the prostate, seminal vesicles, bulbourethral 
glands, urethral glands, preputial glands and ampullary glands. The prostate is fundamental 
to the male reproductive tract and primarily functions to secrete a protease-rich milky fluid 
(pH 6.5) that contributes to approximately 30% of the ejaculate (Fair and Cordonnier, 
1978). To increase sperm motility and viability, prostatic fluid contains hormones, lipids, 
growth factors, nutrients, citric acid for ATP production and enzymes for seminal 
liquefaction (Fair and Cordonnier, 1978; Zaichick et a l , 1997). In humans, prostate acid 
phosphatases (PAPs), prostate specific antigen (PSA, also termed kallikrein-related 
peptidase 3, KLK3) are also present. PAPs convert phosphatidic acid to diacylglycerol and 
functions in glycerolipid synthesis and phospholipase D signal transduction. PSA is 
believed to participate in the liquefaction of seminal coagulum by cleaving seminogelins, 
which allow sperm to swim more freely (Fair and Cordonnier, 1978; Zaichick et a l , 1997). 
The serum level of these enzymes is frequently used to determine tumour stage at diagnosis 
and to monitor prostate cancer progression (Deras et a l , 2008). More recently, the PCA3 
(prostate cancer antigen 3, DD3) gene has emerged as a clinical prostate cancer marker, 
where a high level of PC A3 mRNA in urine correlates to prostate cancer (Deras et a l , 
2008). One study has shown that 95% of primary prostate cancer specimens over-express 
the PC A 3 gene (deKok et a l , 2002).
All mammals have a prostate and the principle functions remain analogous between 
species, despite the varying number of accessory glands. For example, aquatic cetaceans 
lack seminal vesicles, ampullary glands and bulbourethral glands (Price, 1963). 
Furthermore, the female prostate termed the gland of Skene is histologically similar to the 
male prostate (Price, 1963).
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1.1.2 Development of the prostate
Development of the human prostate has been previously well documented 
(Holyrood, 1997). In brief, at week 7 the male human embryo undergoes degeneration of the 
paramesonephric ducts to form the prostatic utricle. The urethers separate from the 
mesonephric ducts to become the proximal urethra and the mesonephric ducts differentiate 
to generate the ejaculatory ducts. During week 10, the urogenital sinus (UGS) mesenchyme 
induces epithelial buds in the early prostatic urethra and lumens of primitive acini develop. 
During weeks 13-15, testosterone levels elevate and remain high until week 25 to induce 
epithelial differentiation. The secretory cells become functional and the basal and 
neuroendocrine cell populations arise. At week 25, testosterone production is reduced and 
the gland remains in a quiescent state until puberty, in a similar manner to mice (Wang et 
al., 2001). During puberty, testosterone levels increase to induce epithelial proliferation of 
membrane infoldings, to generate a mature prostate. At 45-50 years of age, androgen levels 
deplete and the prostate involutes. With increasing age, atrophication of the gland may 
occur, increasing the risk of prostate disorders (Holyrood, 1997).
Mouse prostate development has been described in detail previously (Kasper and 
Matusik, 2000; Staack et al., 2003). Briefly, during E l0-11 the UGS begins to emerge and 
the testes commence androgen production at E l2.5-13, which peaks during E l7-18 and then 
drops until puberty. At E l4.5, the Wolffian ducts differentiate into the epididymis, seminal 
vesicles and ductus deferens and the Mullarian duct degenerates. By E l8.5, the rudimentary 
prostate can be distinguished as a pair of ventral buds and anterior lobe outgrowths. At birth, 
the prostatic lobes have differentiated and over the next 1.5 months mucosal membranous 
infoldings form and further growth occurs, until sexual maturation is complete (Kasper and 
Matusik, 2000; Staack et al., 2003).
In mammals, the development of organs composed of epithelial parenchyma relies 
upon mesenchymal-epithelial cross-talk, where paracrine signals from the mesenchyme 
direct epithelial differentiation and morphology (Cunha et al., 2004; Hayward and Cunha, 
2000). Early prostate ductal budding and morphogenesis is accompanied by the transient 
elevation of multiple signalling molecules; Shh, Bmp4, Fgf7/10, Foxal, Notchl 
(Mirosevich et al., 2005) and Homeobox (HOX) genes (Shappell et al., 2004).
1.1.3 Prostate morphology
The prostate is essentially a collection of tubular-alveolar glands that secrete 
components of the seminal fluid into the prostatic urethra (Shappell et al., 2004). Figure 1.1
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depicts a cross-section of normal human prostate epithelium composed of three established 
different cell types; basal, luminal (also termed secretory cells) and neuroendocrine (Lam, 
2006). A fourth controversial population of prostate stem cells also exists and is speculated 
to give rise to a fifth population, termed the transit-amplifying cells (discussed in section 
1.1.4). Currently, the relationship between the prostate cell lineages is not well understood.
In humans, basal cells form a continuous layer adjacent to the basement membrane 
and express a number of specific biomarkers; p63 (a p53 homologue), cytokeratins 5 and 
14, Bcl-2, CD44, telomerase and GST -71 (Huss et al., 2001; Lam, 2006; Tang et a l , 2007). 
The basal cell lineage comprises -10%  of the prostate epithelial cells, is generally 
undifferentiated and display a low proliferative index (0-1%) and apoptotic index (0-1.3%) 
(Faith et al., 2005; Thorson et al., 2003). Although basal cells are considered to be 
androgen-independent, they have been shown to express a low level of androgen receptor 
(AR) mRNA, suggesting they have the potential to respond to androgens (Lam, 2006). 
Luminal (secretory) cells face the lumen and function to secrete seminal protein from the 
apical surface. The luminal cells are androgen-dependent and express AR, CD57, PSA, 
PAP, 15-lopoxygenase-2 (15-LOX-2) and cytokeratins 8/18 (Lam, 2006; Tang et al., 2007).
Stem  cell Keratin 5/14 and p63 
Basal cells
Luminal cells 
Keratin 8/18 <3>
Secretions
Lumen
Stroma
Neuroendocrine cell 
Svnaptophvsin
B asal Lamina
Figure 1.1: Schematic cross-section of a human prostatic duct. Basal cells are positioned 
adjacent to the basement membrane and are sandwiched in by the luminal (secretory) cells. The rare 
neuroendocrine cells representing 1% of the cellular population are morphologically distinguishable 
from the basal cells (red). Stem cells are speculated to form -1%  of the basal cell layer (green) and 
may give rise to the transit-amplifying cells. Specific biomarkers for each cell type have been 
underlined and this figure is adapted from Abate-Shen and Shen 2002.
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The androgen-independent neuroendocrine cells comprise only 1% of the prostate 
epithelial cells (<0.3% in mice) and express synaptophysin and chromogranin A (Shappell 
et al., 2004). Neuroendocrine cells secrete a variety of growth factors and paracrine signals 
that are considered to support the growth and maintenance of the luminal cells (Garabedian 
et al., 1998; Roy-Burman et al., 2004). Finally, the stroma consists o f connective tissue 
containing smooth muscle fibres that surround the ducts and is rich in blood vessels and 
nerve endings (Price, 1963).
1.1.3.1 Human prostate
Human prostate is located at the base of the bladder and rectum and surrounds the 
urethra, forming an anatomically compact structure enclosed by a fibromuscular sheath 
(figure 1.2a) (Shappell et al., 2004). The gland is divided into three compartments, the 
peripheral (PZ), central (CZ) and transitional (TZ) zones (figure 1,2b). The PZ accounts for 
70% of the glandular tissue and comprises the posterolateral aspects of the prostate, as it 
surrounds both the CZ and TZ (Roy-Burman et al., 2004; Shappell et al., 2004). The CZ 
surrounds the ejaculatory ducts and the TZ is located interiorly between the urethra and the 
surrounding PZ and CZ.
Human prostate acini histologically resemble that of mice, supporting the generation 
of murine models to study prostate cancer (fig. 1.2c-e). The PZ consists of a moderate 
amount of infoldings and the nuclei are basally located. CZ glands are larger in diameter 
than the PZ glands and have more papillary infoldings and roman arches (Shappell et al., 
2004). The TZ contains the mucosal glands and is exclusively the site of benign prostatic 
hyperplasia (BPH). The TZ tall columnar cells typically contain basally located nuclei 
within small acini that do not develop frequent infoldings (Shappell et al., 2004).
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Figure 1.2: Anatomy and histology of normal human prostate, (a) Human prostate (box) is 
located beneath the bladder and is contained within a fibromuscular sheath that surrounds the 
prostatic urethra (U). (b) The three human prostate lobes; central, peripheral and transitional form an 
anatomically compact structure. H&E staining of normal human central zone (arrows indicate roman 
arches) (c), peripheral zone hyperplasia (d) and a typical transitional zone BPH showing large nuclei 
with prominent nucleoli (e). Figures were adapted from (a) medicalcenter.osu.edu, (b) Abate-Shen 
and Shen (2002) and (c-e) Shappell et al (2004).
1.1.3.2 Mouse prostate
Although mouse and human prostate differs in several respects, there are similarities 
between the two species. Figure 1.3a illustrates the male murine genitourinary (GU) tract, 
indicating that the murine prostate is located in a similar position to the human prostate, 
surrounding the neck of the bladder. Mouse prostate consists of four distinct lobes termed 
the anterior (AP), dorsal (DP), lateral (LP) and ventral (VP) prostate (figure 1.3a-b) 
(Pinheiro et al., 2003; Shappell et al., 2004; Xue et al., 1997c). The luminal epithelium of 
each lobe is specialised to produce specific protein products (Kasper and Matusik, 2000) 
and have distinct histology (figure 1.3c-f).
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Figure 13: Anatomy and histology of normal mouse prostate, (a) Ventral view of the male 
murine genitourinary (GU) tract where A=Ampullary, AP=Anterior prostate, B=Bladder, 
BG=BuIbourethral Gland, BM= Bulbourethral Muscle, DD=Ductus Deferens, DP=Dorsal Prostate, 
EC=Epididymis Caput, ED=Epididymis Cauda, LP=Lateral Prostate, P=Penis, PG=Preputial Gland, 
PU=Penile Urethra, SV=Seminal Vesicle, T=Testis, U=Urethra, VP=Ventral Prostate, (b) Lateral 
view of the murine prostate. The anterior prostate branches to lie underneath the seminal vesicles, 
while the dorsal, lateral and ventral lobes surround the neck of the bladder. Histological analysis of 
formalin-fixed, paraffin-embedded H&E sections from the anterior (c), dorsal (d), lateral (e) and 
ventral (f) prostate lobes of an adult mouse shows similarities with human prostate. Pictures were 
taken at 20x magnification and scale bars represent 100 pm. Figures were adapted from (a) Pinheiro 
et al (2003) and (b) Shappell et al (2004).
The AP is a paired gland embedded in the peritoneal sheath along the concave 
surface of the seminal vesicles. The AP functions to secrete a seminal fluid coagulation 
enzyme, hence its alternate name, the coagulating gland (Dmochowski and Homing, 1946). 
Within each AP acinous, the mucous membrane is thrown into many mucosal folds, creating 
finger-like projections into the lumen. Here, the epithelial columnar cells contain small, 
round, central nuclei (Xue et al., 1997a). The AP and DP are both androgen sensitive and 
secrete similar products, although DP ducts all enter the dorsal wall of the urethra, whereas 
the two AP ducts enter the anterior urethra (Dmochowski and Homing, 1946). Compared to 
the AP, the DP lobes are narrower, surrounded by a thick muscle layer and the nuclei are 
larger in a more granular cytoplasm (Xue et al., 1997b). The LP is positioned adjacent to the
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base of the bladder along side the urethra and is termed the dorsolateral prostate (DLP) 
together with the DP (Dmochowski and Homing, 1946). Less muscle surrounds the LP 
compared to the DP and the tall columnar cells, that contain basally located nuclei, only 
form only a moderate amount of mucosal folds (Xue et al., 1997a). The VP consists of four 
ducts which enter the ventral wall of the urethra near the bladder (Dmochowski and 
Homing, 1946). VP is devoid of infoldings and nuclei are located near the base of the low 
columnar epithelial cells (Roy-Burman et al., 2004; Shappell et al., 2004; Sugimura et al., 
1986).
1.1.3.3 Similarities and differences in human and mouse prostate
Despite showing androgen-dependent growth and similar development from the 
Wolffian duct and UGS (section 1.1.2), the gross and microscopic anatomy of the mouse 
and human prostate glands display significant similarities and differences (Roy-Burman et 
al., 2004; Shappell et al., 2004). These discrepancies need to be acknowledged when 
comparing murine models with the human disease.
The mouse prostate gland has four paired lobes, which unlike humans have not 
merged into a compact single lobular structure, which consists of three zones (Shappell et 
al., 2004). Besides this anatomic difference, acini from both species contain basal, 
neuroendocrine and luminal epithelial cells, albeit with some discrepancy in the ratio and 
location (Shappell et al., 2004). In humans, basal cells lie adjacent to the basement 
membrane, forming a layer underneath the luminal cells (Roy-Burman et al., 2004). In 
mice, the basal cell population is discontinuous and contains a significantly lower ratio of 
basal to luminal cells (Roy-Burman et al., 2004; Wang et al., 2001). In addition, human 
basal cells are positive for p27 and BCL-2, whereas murine basal cells only occasionally 
express p27 and BCL-2 (Wang et al., 2006b). Rare neuroendocrine cells are scattered across 
both human and murine acini, however, the population of this lineage is significantly 
smaller in the mouse prostate (i.e. 1% in humans and <0.3% in mice) (Roy-Burman et al., 
2004). Tall columnar luminal cells that secrete prostatic proteins and fluids from their apical 
surfaces into the lumen are common to both species (Roy-Burman et al., 2004).
The stromal content of the human and mouse prostate is significantly different and 
must be taken into account when comparing the local invasiveness of prostate cancer (Roy- 
Burman et al., 2004). Human prostate ducts are encapsulated by a thick fibromuscular 
sheath, while the individual lobes o f the murine prostate are surrounded by a thin stromal 
component (Roy-Burman et al., 2004). Both human and mouse stroma expresses AR,
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indicating it is hormone regulated (Cunha et al., 2003). It should also be noted that in the 
developing rodent prostate smooth muscle differentiates adjacent to the epithelium, while in 
the developing human prostate the smooth muscle initially differentiates some distance 
away from the epithelium and gradually fills in the space between the differentiated muscle 
and the epithelial basement membrane (Hayward et al., 1998). The different location of the 
neurovasculature within the stroma also prevents a direct comparison of disease progression 
between species (Roy-Burman et al., 2004). Despite these differences, many studies have 
supported a functional relationship between the murine DLP and the human PZ, where 70% 
of carcinomas arise (Roy-Burman et al., 2004). The mouse AP is considered analogous to 
the human CZ, which rarely transforms in humans (Huss et al., 2001). The VP has no 
known human equivalent and the TZ, predominantly associated with benign prostatic 
hyperplasia (BPH), is not considered to have a murine homologue (Roy-Burman et al., 
2004). It is important to note that these connections are based on descriptive information 
and are yet to be defined by molecular characterisation (Lamb and Zhang, 2005).
1.1.4 Prostate stem cells
Somatic stem cells function to maintain the normal turnover o f cells within an organ. 
These cells are generally characterised by their ability to self-renew, proliferate indefinitely 
and ultimately provide all the different cell types required by the tissue they reside in (Lam, 
2006; Tysnes and Bjerkvig, 2007). To ensure self-renewal, stem cells are considered to 
undergo both symmetric and asymmetric divisions, producing either two identical daughter 
cells with stem cell properties or one stem cell and a progenitor cell respectively (Lam,
2006). The progenitor cell is thought to have a limited self-renewal potential and following 
several divisions (transit-amplification) may become terminally differentiated. The transit- 
amplifying cells are considered the major contributors to normal tissue renewal, while the 
stem cells are regarded as quiescent and do not proliferate (Lam, 2006). Stem cells are 
thought to reside in a “niche”, where interactions of the stem cell with its microenvironment 
regulate stem cell function (Lam, 2006). The presence and identification of prostate stem 
cells may be vital for generating novel therapeutic interventions and is currently a highly 
controversial topic.
The rodent prostate can undergo multiple rounds o f castration-induced regression 
and testosterone-induced regeneration, suggesting the presence of stem cells (Isaacs and 
Isaacs, 2004; Lawson and Witte, 2007). Androgen-deprived adult prostate regresses, with 
nearly all epithelial cells reported to undergo apoptosis (predominantly luminal cells), while
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the androgen-independent basal cells are thought to remain (Sawicki and Rothman, 2002). 
Further evidence for prostate stem cells arises from grafting experiments. Prostate epithelial 
cells (e.g. L A P C -4/9  derived from lymph node and bone metastases respectively) have been 
shown to form prostate glands when transplanted under the renal capsule with UGS 
mesenchymal cells ('rang et al., 2007). Current literature presents two potential scenarios 
for the observed regenerative capacity of the adult prostate; (a) independent self-renewal of 
basal and luminal cells or (b) multipotent stem cells that comprise 1-15% of the basal cell 
population (Collins et a/•, 2005; English et al., 1989; Tokar et al., 2005). Current consensus 
favours a stem cell-driven hierarchical renewal mechanism, similar to that demonstrated for 
other epithelial tissue*^ such as the skin and colon (Sawicki and Rothman, 2002). Consistent 
with multi-potent stem cell coordination, a transit-amplifying compartment has also been 
postulated in the prostate, harbouring a subset o f cells morphologically classified as 
intermediates between basal and luminal cells (Signoretti et al., 2000; Wang et al., 2001). 
Nonetheless, the exact location of prostate stem cells remains under debate.
1.1.4.1 prostate stem cell location
In humans and mice, each prostate gland comprises a proximal region that connects 
to the urethra, an intermediate region and a distal tip. The majority of the literature indicates 
that stem cells are proximally located (Tsujimura et al., 2002; Watabe et al., 2002; Zhou et 
al., 2007). Compared to the intermediate and distal regions, the proximal cells have been 
shown to display elevated telomerase activity and a higher proliferative index in vitro 
(Tsujimura et al., 200^; Watabe et al., 2002). Experiments taking advantage of the fact that 
stem cells probably retain the long-term S-Phase marker BrdU (bromodeoxyuridine), have 
shown that while the rapidly dividing cells of the transit-amplifying layer quickly dilute the 
BrdU label, label-retaining cells are concentrated in the proximal region (Tsujimura et al., 
2002). This region is characterized by a thick band of morphologically distinct smooth 
muscle cells that secrete high levels of TGF-p, making it a compelling location for the 
prostate stem cell niche, since this factor is known to promote stem cell quiescence (Lawson 
and Witte, 2007). In addition, studies in mice deficient in p53 and Rb have also reported that 
the proximal region o f  mouse prostatic ducts enrich for stem cells (Zhou et al., 2007). 
However, it is possible that stem cells are not restricted to the proximal zone, as some 
studies have shown that not all the regenerative capacity is located in the proximal region 
(Kinbara et al., 1996; Lawson and Witte, 2007; Watabe et al., 2002). Indeed, the distal tip 
also shows a relatively high rate of proliferation when transplanted under the kidney capsule
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with UGS mesenchymal cells (Kinbara et al., 1996). The fact that the distal tip is positive 
for PSCA has led to the hypothesis that the distal tip comprises the bulk of the transit- 
amplifying cells (Watabe et al., 2002).
The notion that the basal lineage contains the prostate stem cells is widely accepted, 
although not definitively demonstrated. Consistent with this, basal cells have been shown to 
express survival factors, such as BCL-2 (Verhagen et al., 1992). Furthermore, p63 null 
mice (basal cell deficient) that die shortly after birth, develop defects in prostatic bud 
development in addition to rudimentary limb development and loss o f skin (Signoretti et al., 
2000). Signoretti et al (2000) also showed that chimeric animals created from p63 ' 
blastocysts complemented with p 6 3 i/+ P-galactosidase-positive ES cells, produced P- 
galactosidase-positive luminal cells in prostate epithelium. This suggests that the basal cells 
are probably required to restrict multipotent UGS endodermal cells to a prostate lineage and 
implicates p63+ cells in prostate maintenance and luminal cell survival (Signoretti et al., 
2000). Morphometric analysis of basal and luminal cells, before and after androgen ablation, 
has shown that basal cells are highly proliferative during regeneration (Bonkhoff and 
Remberger, 1996). Together, this evidence suggests that the basal cells can differentiate into 
luminal cells however, this trans-differentiation process is yet to be confirmed (Collins et 
al., 2001; Foster et al., 2002; Uzgare et al., 2004). In support of this hypothesis, both rat 
and human basal cell lines have been shown to differentiate into luminal cells in response to 
different growth medium (Danielpour, 1999; Robinson et al., 1998). Furthermore, Tran et al 
(2002) also reported that PSCA (prostate stem cell antigen) identifies late intermediate 
(transit-amplifying) prostate epithelial cells in vitro. PSCA-negative cells were shown to 
give rise to more differentiated PSCA-positive cells that express both basal and luminal 
cytokeratins but do not express p63, resembling the characteristics o f a putative transit- 
amplifying cell (Tran et al., 2002).
In contrast, a luminal self-renewing population of putative stem cells has also been 
speculated (Kurita et al., 2004; Lawson and Witte, 2007). Kurita et al (2004) argue that 
luminal cells can develop independently of basal cells. Experiments grafting normal or p63 
null UGS into male adult nude mice revealed that p63 deficient grafts developed androgen- 
dependent prostate ducts, where basal cells are absent (Kurita et al., 2004). This data was 
speculated to imply that p63+ cells are required for the differentiation of the basal cells and 
maintenance o f proper luminal cell differentiation, but are not required to regenerate 
prostate acini following androgen ablation. However, there are other explanations for these 
observations, one example being that loss of p63 expression causes differentiation defects
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that make basal cells unidentifiable in regenerated tissue (Lawson and Witte, 2007). 
Alternatively, distinct luminal and basal progenitor cells may exist (Lawson and Witte,
2007).
1.1.4.2 Prostate stem cell markers
Although the exact number and location of prostate stem cells is yet to be 
determined, the general consensus is that prostate stem cells reside within the basal cell 
population. Currently, several potential human prostate stem cell markers have been 
identified, such as p63, CD44, Keratin 5, Keratin 6, BCL-2, CD 133 (AC 133), integrin a 2 pi 
and integrin ct6 (Collins et al., 2005; Collins et al., 2001; Hurt et al., 2008; Liu et al., 1997; 
Schmelz et al., 2005). Mouse prostate markers include, prominin (CD 133), stem cell 
antigen-1 (Sca-1) and CD49f (Lawson et al., 2007; Tsujimura et al., 2007; Xin et al., 2005). 
The discovery of prostate stem cell markers is summarised in Table 1.1.
Richardson et al (2004) combined the use of oi2 pihl and CD133+ markers to enrich 
the prostate stem cell population from normal human prostate. Recently, Lawson et al 
(2007) demonstrated that the CD45/CD317Terl 19/Sca-1+/CD49f mouse prostate cell 
subpopulation is enriched for cells capable of both colony and sphere formation in vitro. 
These cells can self-renew to form spheres for multiple generations and can differentiate to 
produce prostatic tubule structures containing both basal and luminal cells in vivo, similarly 
to the a2pihl/CD133+ subpopulation in humans (Richardson et a l,  2004). In mice, prominin 
(CD133) expressing cells from the basal layer within the proximal region o f the dorsal 
prostate also enrich for prostate stem cells and can generate large branched structures in 3D 
culture, while prominin negative cells did not form these structures (Tsujimura et al., 2007).
Notably, CD 133 is also a stem cell marker of kidney, lung, brain, mammary gland 
and primitive haematopoietic stem cells (Singh et al., 2003; Tsujimura et al., 2007; Yin et 
al., 1997). Furthermore, CD49f is a known marker of mammary gland, neural and 
haematopoietic stem cells (Lawson et al., 2007; Stingl et al., 2006). Together, these data 
suggest that common stem cell markers may exist in an array of different tissues and also in 
humans and mice.
Sca-1 enriches for murine prostate cells capable of regenerating tubular structures 
containing basal and luminal cell lineages, demonstrated by transplanting Scal+ cells under 
the kidney capsule of immunodeficient mice with UGS mesenchyme (Xin et al., 2005). 
Androgen ablation studies have also shown enrichment of androgen-independent and Sca-1 + 
cells, which can initiate tumourigenesis in conjunction with activated AKT in vivo (Xin et
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al., 2005). Consistent with this, mice harbouring a Pten deficiency in the prostate 
(PBCre+Pter/W) also enhances the proportion of pre-malignant cells expressing p63, Sca-1 
and Bcl-2 in vivo (Wang et al., 2006b). Furthermore, elevated Sca-1 expression has been 
associated with mammary tumour stem cell activity (Li et a l,  2003).
Table 1.1: Prostate stem cell markers
Human Description Reference
CD44 CD44+ basal cells purified and co-cultured with stromal 
cells and DHT, PSA secretions are elevated suggesting 
differentiation of CD44+ cells into luminal cells.
(Liu et al., 1997)
a 2p r  integrin a2Pi-integrin cells represent ~1% of the basal cell 
population
(Collins et al., 2001)
CK6 4.9% of basal cells express CK6, which possess a high 
proliferative potential.
(Schmelz et al., 2005)
a 2Pih' CD133, 
CD44+
CD133+/a,2Pi cells represent 0.75% of basal cell 
population, possess a high proliferative index and can 
reconstitute prostate acini in vivo. 
a 2Pih,/CD 133 7CD44+ cells isolated from human 
prostate tumours enrich for prostate cancer stem cells.
(Richardson et al., 
2004)
(Collins et al., 2005)
CD44+ CD 24’ CD44+/CD24- LNCaP cells form tumours when 
injected into NOD/SCID mice. These cells express 
genes required for stem cell maintenance e.g. BMI-1, 
Oct3/4 and B-catenin.
(Hurt et al., 2008)
Mouse Description Reference
p63 p63' '  mice develop small prostatic buds demonstrating 
p63 is essential for basal cell differentiation and normal 
luminal cell differentiation.
(Signoretti et al., 
2000)
K5 and Bcl2 K5+/BCL2+ mouse prostate epithelial cells 
demonstrated self-maintenance in vitro.
(Sawicki and 
Rothman, 2002)
Sca-1 An in vivo prostate reconstitution assay determined that 
Sca-1 + cells isolated from the murine proximal region 
show high regenerative abilities. Scal + cells can also 
initiate tumourigenesis upon Akt activation.
(Burger et al., 2005) 
(Xin et al., 2005)
Prom inin 
(CD 133)
Prominin positive cells from the mouse proximal region 
basal layer enriched for prostate stem cells that generate 
prostatic ducts in culture.
(Tsujimura et al., 
2007)
CD49f+ 
(integrin a6)
CD45-/CD31 -/Ter 119-/Sca-1 +/CD49f+ proximal duct 
prostate cells self renew in vitro and in vivo and can 
differentiate into luminal and basal cells within prostate 
tubule structures.
(Lawson et al., 2007)
The expression status of androgen receptor (AR) in stem cells is also controversial. 
Although basal cells do not express detectable levels of AR, it is thought that stem cells may 
gain the ability to express AR in androgen deficient tissue (Lawson et al., 2007). This has 
been observed in vivo where elevated AR expression correlates to the development of
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hormone refractory tumours (Chen et al., 2004; Maitland and Collins, 2005). Hormone 
ablation therapy essentially destroys all AR-expressing cells, while the prostate stem cells 
and cancer stem cells that do not express AR remain. It is speculated that the surviving cells 
may begin to over-express AR, allowing prostate growth to occur in response to low 
androgen levels (Chen et al., 2004; Maitland and Collins, 2005).
1.1.4.3 The origin of prostate cancer
To account for prostate cancer heterogeneity, recent evidence suggests that prostate 
tumourigenesis may arise as a result of malignant transformation of normal prostatic 
epithelial stem cells or transit amplifying cells (Li et al., 2007a). Consistent with this, cancer 
stem cells are thought to retain some phenotypic properties of the original normal stem cell. 
Prostate cancer stem cells have been isolated from primary and metastatic human prostate 
tumours, with a ot2Pih7CD133+/CD44+ phenotype (Collins et al., 2005). In culture, these 
cells were capable o f self-renewal and generated phenotypically mixed populations that 
expressed differentiated cell products, such as AR, suggesting that these cells are tumour 
initiating (Collins et al., 2005). This is suggestive of a prostate cancer stem cell population 
that has the capacity to proliferate, self-renew, differentiate and invade. Furthermore, 
CD133+ cells enrich for brain tumour stem cells and have been shown to differentiate into 
tumours that resemble the original human tumour, in vitro and in vivo (Singh et al., 2003; 
Singh et a l , 2004). Singh et al (2004) demonstrated that CD133+ cells can form tumours 
when grafted into NOD-SCID (non-obese diabetic, severe combined immunodeficient) 
mouse brains, while CD 133" cells cannot, further implicating that CD133+ cells are tumour 
initiating.
Currently, it remains unclear whether prostate cancer is derived from the normal 
prostate stem cell or the transit-amplifying population (Lam, 2006; Signoretti and Loda, 
2006 ; Tang et al., 2007). In the first scenario, a slight change in stem cell number leads to a 
dramatic expansion of the transit-amplifying population, which is considered to serve as a 
precursor for luminal epithelial cells. In this case, the tumour-initiating cells are the mutated 
stem cells (Wang et al., 2006b). The second scenario suggests that oncogenic transformation 
of the stem cells does not occur and the transit-amplifying cells, with limited proliferative 
capacity, can be transformed by acquiring self-renewal potential (Wang et al., 2006b).
Understanding normal stem cells and cancer stem cells is of paramount importance 
and could provide insights into the origin of prostate cancer and novel therapeutic strategies 
that specifically target the elimination of the cancer stem cells (Maitland and Collins, 2005).
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Potential therapeutic targets include pathways implicated in the regulation of stem cell self­
renewal. These include hedgehog, Notch, Wnt, PTEN/AKT, p53 and TGFp cascades 
(Korkaya and Wicha, 2007; Tysnes and Bjerkvig, 2007). Telomerase is also emerging as a 
therapeutic drug target, given the synergistic relationship between telomerase, senescence 
and the cancer stem cell (Keith et al., 2007). Telomerase activity is a hallmark of cancer and 
its inhibition in cancer has highlighted how important the induction of cellular senescence 
can be as a tumour suppressor mechanism (Keith et al., 2007). To conclude, further 
characterisation of surface markers and signalling pathways specific to cancer stem cells 
remains crucial to targeting them for elimination.
1.1.5 Introduction to prostate cancer
Prostate cancer is a heterogeneous and multifocal disease arising from multiple 
genetic and epigenetic changes (Hill, 2005). It is currently the most common malignancy in 
men and accounts for 24% of the newly diagnosed male cancers (CRUK, 2004). The life­
time risk of developing prostate cancer is 1 in 14 in the UK (CRUK, 2004). The most 
significant single risk factor for prostate cancer is age, yet ethnicity (particularly African 
Americans), family history and a high fat diet all increase the risk of prostate 
tumourigenesis. The majority of cases are diagnosed between 70 and 74 years of age (figure 
1.4a), although these figures are expected to increase in concert with increasing life-time 
expectancy (CRUK, 2004).
Survival rates over the last 4 decades have improved drastically owing to early 
detection and novel treatment strategies (figure 1.4b), (CRUK, 2004). Interestingly, one 
study has shown that men taking Aspirin regularly have a 15-18% reduced risk of 
developing prostate cancer (CRUK, 2004; Jacobs et al., 2005).
Prostate problems or symptoms tend to fall into three common categories; (a) non­
life threatening prostatitis, or chronic inflammation of the gland, (b) benign prostatic 
hyperplasia (BPH), a non-neoplastic growth common to the transitional zone that constricts 
the urethra and (c) prostate cancer, often located in the peripheral zone (Bostwick et al., 
1996). Human prostate cancer that has breached the basement membrane commonly results 
in metastasis to the lymph nodes in the pelvis, bone and pancreas (Shappell et al., 2004).
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Figure 1.4: Prostate cancer incidence and risk associated with age. Statistical data indicates the 
average age at diagnosis of prostate cancer is 72 (a). The 5 year relative survival rate o f prostate 
cancer patients was 70% during 2000-2001 in the UK (b). Figures are adapted from CRUK (2004).
There are three major treatment options currently available; surgical treatment, 
radiation therapy and androgen ablation (hormone therapy), (Duchesne, 2001; Quade, 
2005). Benign prostatic hyperplasia (BPH) is commonly treated by a surgical procedure 
known as TURP (Transurethral resection of the prostate). This technique removes portions 
of the hyperplastic prostate to relieve pressure on the urethra (Quade, 2005). A radical 
prostectomy is common in patients under 70 years old who have been diagnosed with low- 
grade prostate cancer (grades I-II). Radiation treatment includes brachytherapy and external 
beam radiation, although these processes have a low success rate (Duchesne, 2001; Quade, 
2005). Brachytherapy is also known as sealed source radiotherapy and is used to treat 
localised form of prostate cancer, where the radioactive source is placed inside or next to the 
area requiring treatment (Quade, 2005). More recent strategies include cryosurgery, where 
prostate cancer cells are destroyed by intermittent freezing of the prostate tissue with 
cryoprobes (Quade, 2005). In addition, a flavanoid anti-oxidant called Silibinin has also 
been shown to prevent hormone refractory prostate cancer by inhibiting AR-mediated 
proliferation and inducing Gi arrest (Amanatullah et al., 2000).
Following surgical failure, the first line of effective treatment for malignant prostate 
cancer is androgen ablation, which has been shown to dramatically increase survival. Anti­
androgens administered include steroidal anti-androgens (e.g. Cyproterone) that inhibit AR 
and testosterone production and non-steroidal anti-androgens (e.g. Flutamide and Casodex) 
that are competitive inhibitors of AR (Amanatullah et al., 2000). Zoladex, a synthetic 
analogue of luteinising hormone releasing hormone (LHRH) is also commonly used to treat 
prostate cancer. Zoladex antagonises LHRH receptors on pituitary cells, causing their
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depletion and preventing luteinising hormone (LH) production, which ultimately inhibits 
androgen synthesis and prostate growth (Wells et al., 2002). Although this strategy 
increases survival, it inevitably leads to the development of lethal androgen-independent or 
hormone refractory disease, which is resistant to anti-androgen therapy (Pflug et al., 2003). 
Currently, pulsed regimes of androgen ablation have been successful in reducing the rate of 
androgen refractory disease development (Pflug et al., 2003).
1.1.6 Prostate cancer pathology
Prostate cancer is a linear multi-step process whereby normal prostatic epithelium 
progresses to invasive prostate cancer via several intermediate steps (Mitsumori and Elwell, 
1994; Shappell et al., 2004; Trotman et a l, 2003); atypical hyperplasia (AH) -> 
dysplasia/low grade prostate intra-epithelial neoplasia (LG-PIN) -> high grade intra- 
epithelial neoplasia (HG-PIN) -> locally invasive prostate cancer (adenocarcinoma) -> 
diffuse prostate cancer (invasive carcinoma) and metastasis (figure 1.5). This process is 
considered to require the acquisition of multiple genetic mutations and the later stages of 
progression frequently develop hormone refractory disease.
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Figure 1.5: Linear pathway of human prostate cancer progression. Stages of progression reveal 
hyperplasia as a precursor to PIN, which progresses to adenocarcinoma and invasive carcinoma that 
may become androgen-independent. This process is thought to require the acquisition of multiple 
genetic mutations. Ultimately invasive lesions result in incurable metastatic disease where secondary 
tumour formation occurs at distant locations. This figure is adapted from Shappell et al (2004).
Human prostate biopsies are scored using the Gleason grading system, where a high 
score correlates with increasing severity (DeMarzo et al., 2003). The proliferation of non­
neoplastic cells, termed hyperplasia, is the least severe phenotype and is considered to be a 
precursor to PIN (Shappell et al., 2004). PIN is classified as the neoplastic proliferation of 
atypical epithelial cells which may predispose to invasive carcinoma. PIN is characterised
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by four architectural patterns; tufting, micropapillary, cribriform and flat (Bostwick et al., 
1996). Invasive carcinoma consists of malignant cells penetrating the basement membrane 
into the stroma, resulting in invasive carcinoma, a malignant epithelial neoplasm (Shappell 
et al., 2004). If glandular differentiation is maintained, the invasive carcinoma is classified 
as an adenocarcinoma (Shappell et al., 2004). Squamous cell carcinoma is an invasive 
malignant epithelial neoplasm that exhibits squamous differentiation, such as keratinisation 
and/or intercellular bridges (Shappell et al., 2004). An adenosquamous carcinoma consists 
of a mixture of foci with squamous and glandular differentiation. Mucinous adenocarcinoma 
is a variant of the classic acinotubular adenocarcinoma of the prostate that displays 
differentiated cells that secrete mucin (Curtis et al., 2005; Odom et al., 1986).
Specific biomarkers of epithelial-mesenchymal interactions, deemed necessary for 
prostate differentiation and stromal responses to tumourigenesis, have provided a valuable 
resource for the detection and diagnosis of prostate cancer (Cunha et al., 1987). In humans, 
elevated PSA (prostate specific antigen) levels in serum and high tissue expression of 
AMACR (a-methylacyl-CoA racemase) label HG-PIN and in some cases, BPH (DeMarzo 
et al., 2003). PSA is a serine protease and AMACR is responsible for converting the 2R- 
isomer of pristanic acid (as the coenzyme A ester) to its 2S form, facilitating p-oxidation of 
the fatty acid (Bostwick et al., 1996). Other potential serum biomarkers o f prostate cancer 
include the RM2 antigen (Saito et al., 2005) and an 80 kDa fragment of E-cadherin (Kuefer 
et al., 2005). To date, there is no known serum prostate cancer marker for murine models, 
although one possible candidate is probasin (Huss et al., 2001).
1.1.7 Mechanisms underlying prostate tumourigenesis
Several genetic mutations and the deregulation of endogenous hormones and 
environmental influences that induce differentiation and proliferation of the prostate 
epithelium have been shown to play a role in prostate tumourigenesis (Cunha et al., 2004). 
These processes shall be discussed in this section.
Familial/hereditary prostate cancer (HPC) has been shown to be associated with 
germline mutations in a number of genes, particularly HPC1 that encodes the tumour 
suppressor ribonuclease L (RNASEL) and PCAP (HPC2) that map to the lq24-25 locus, 
where many mutations linked to prostate cancer have been found (DeMarzo et al., 2003; Xu 
et al., 1998). The X-linked HPCX  gene is also highly mutated in hereditary prostate cancers 
(16%) (Xu et al., 1998). Additional modes of genomic instability in prostate cancer include 
microsatellite instability (defective DNA mismatch repair) and structural changes to
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chromosomes (DeMarzo et al., 2003). For instance, the length of the polymorphic CAG 
repeat in exon 1 of the AR gene correlates inversely with AR transcriptional activity 
(Zitzmann et al., 2003). Mutations in the AR gene may also alter ligand specificity to non­
androgens or anti-androgens (Zitzmann et al., 2003). Functional mutations in AR co­
activators or co-repressors that regulate AR activity can also facilitate tumour progression 
and provide rationale for androgen-independent prostate cancer (DeMarzo et al., 2003).
Common signalling cascades that are deregulated in prostate cancer include the 
PI3K/AKT, Wnt, Ras, Hedgehog (Hh) and the Notch signal transduction pathways 
(Belandia et al., 2005; Le-Page et al., 2006; Sheng et al., 2004; Weber and Gioeli, 2004; 
Yardy and Brewster, 2005). Notably, all of these pathways can regulate AR signalling and 
play vital roles within the cell, including cell proliferation, polarity and differentiation 
(Belandia et a l ,  2005; Le-Page et al., 2006; Sheng et al., 2004; Weber and Gioeli, 2004; 
Yardy and Brewster, 2005). As such, deregulation of these pathways can further promote 
prostate tumourigenesis and progression.
PTEN (MMAC1) is a tyrosine phosphatase homologous to tensin that acts as a 
tumour suppressor by antagonising PI3K and inhibiting AKT activation (Di Cristofano et 
al., 2001; Di Cristofano et al., 1998). PTEN interactions with AR inhibit AR nuclear 
translocation (Lin et al., 2004a). This evidence suggests that PTEN loss of function in 
prostate cancer may activate the PI3K/AKT pathway to drive proliferation and survival, as 
well as permitting androgen signalling (Lin et al., 2004a). Consistent with this, inactivating 
mutations in PTEN are a common event in human prostate cancer (Yoshimoto et al., 2007) 
and elevated expression levels of AKT are associated with a poor prognosis (Le-Page et al., 
2006; Malik et al., 2002). In mice, Pten loss predisposes to invasive carcinoma and 
metastasis, concomitant with elevated Akt expression, resembling the kinetics of human 
disease progression (Wang et al., 2003).
PTEN contains multiple phosphorylation sites that play a crucial role in regulating 
its stability and activity (Okahara et al., 2004). Post-translational regulation of PTEN by 
phosphorylation o f a cluster of serine and threonine residues in its C-terminus has been 
shown to regulate the stability and half-life of PTEN (Al-Khouri et al., 2005) however, this 
process is not fully understood. In general, unphosphorylated PTEN is considered more 
active than the phosphorylated form, however its conformation is more open to allow 
substrate interactions and is thought to reduce PTEN stability (Shukla et al., 2005). Casein 
kinase II (CK2) has been shown to phosphorylate PTEN, reducing its biological activity in 
vitro (Al-Khouri et a l,  2005). Given the fact that PTEN loss is associated with prostate
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tumourigenesis and that CK2 is over-expressed in human prostate cancer, it is speculated 
that PTEN post-translational regulation by CK2 plays a fundamental role in promoting 
prostate cancer formation by decreasing PTEN activity (Wang et al., 2006a).
Wnt signalling plays a crucial role in prostate epithelium proliferation, survival, 
androgen signalling and differentiation (discussed in section 1.4). Activation of the Wnt 
pathway results in P-catenin nuclear translocation where it binds additional transcription 
factors to mediate transcription of Wnt target genes (Yardy and Brewster, 2005). p-catenin 
has also been shown to act as an AR co-activator (Yardy and Brewster, 2005). Aberrant Wnt 
signalling is a common occurrence in human prostate cancer and can occur following 
mutations in the oncogenes P-catenin and APC  (Voeller et al., 1998; Yardy and Brewster, 
2005). In mice, Ape loss and P-catenin hyperactivation predispose to keratinised squamous 
metaplasia o f the prostate and adenocarcinoma (Bierie et al., 2003; Bruxvoort et al., 2007; 
Gounari et al., 2002). Targets of the Wnt pathway are also upregulated in prostate cancer, 
driving disease progression. For example, c-Myc expression has been shown to correlate to 
tumour progression in humans and mice (Thompson et al., 1989; Yang et al., 2005).
Ras signalling results in the activation of numerous Ras effector signalling 
pathways, such as the mitogen-activated protein kinase (MAPK) cascade, to coordinate 
essential cellular events that include proliferation, differentiation and cell polarity 
(Schubbert et al., 2007), (detailed in section 1.5). The MAPK pathway has also been shown 
to activate AR-mediated transcription via Src, indicating that Ras signalling can regulate 
prostate growth (Weber and Gioeli, 2004). Hyperactivating mutations of the proto-oncogene 
Ras are uncommon in human prostate cancer, yet enhanced Ras signalling during human 
prostate tumourigenesis is a frequent event (Papatsoris et al., 2007; Weber and Gioeli, 
2004). Elevated Ras signalling in prostate tumours is postulated to equate to increased levels 
of growth factors that can stimulate Ras activation by binding to tyrosine kinase receptors 
(RTKs) (Weber and Gioeli, 2004). Consistent with this, oncogenic Ras transformations in 
transgenic mice have shown that elevated Ras signalling causes hyperplasia and LG-PIN 
(Barrios et al., 1996; Scherl et al., 2004).
Hedgehog (Hh) signalling pathways are required for prostate development and have 
been shown to play a role in stem/progenitor cell proliferation (Shaw and Bushman, 2007). 
There are three mammalian Hh genes; Sonic, Desert and Indian. The Hh genes are ligands 
for the trans-membrane receptor Patched (PTCH), which upon activation alleviates 
suppression of smoothened (SMO) and leads to the stimulation of Gli transcription factors
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that in turn initiate transcription of Hh target genes (Shaw and Bushman, 2007). Transgenic 
loss of Gli2 function demonstrated a developmental role for the Hh pathway in the mouse 
prostate. Ductal budding abnormalities were associated with decreased Hh target gene 
expression, decreased expression of the stem cell marker Nestin and hyperplasia of p63+ 
basal cells (Shaw and Bushman, 2007). Interestingly, Hh signalling components have been 
observed to co-localise to the p63T basal cells in hyperplastic foci, speculated to reflect 
transformation of prostate stem cells into cancer stem cells (Chen et a l , 2007).
Several recent reports have highlighted a role for the Hh pathway in prostate cancer 
(Karhadkar et a l ,  2004; Shaw and Bushman, 2007; Sheng et a l,  2004). Advanced tumours 
have demonstrated high levels of Hh target genes, namely PTCH1 and hedgehog-interacting 
protein (HIP), consistent with a low expression of Su(Fu) (Sheng et a l ,  2004). Su(Fu) is a 
negative regulator of the Hh pathway and Su(Fu) mutations have been reported in human 
prostate cancer (Sheng et al., 2004). Whether this data represents mutational activation or an 
increased responsiveness of the tumour cell or ectopic stroma to Hh ligand is not known 
(Shaw and Bushman, 2007). Molecular analysis of the LADY transgenic mouse model (see 
section 1.2.3) did not report any generalised increase in Hh signalling during tumour 
development, although elevated Indian Hh expression correlated to decreased expression of 
terminal differentiation markers and increased progenitor cell markers (Gipp et al., 2007). 
Furthermore, in vitro studies have shown conflicting reports as to whether inhibition of Hh 
signalling in human prostate cancer cell lines prevents cell growth (Sanchez et a l,  2004; 
Zhang et a l , 2007). Zhang et al (2007) recently reported that three different human prostate 
cancer cell lines does not respond to the Hh signalling pathway inhibitor Cyclopamine and 
that expression of Ptch and Glil is lower than normal human prostate tissue. Meanwhile, 
Sanchez et al (2004) previously reported that Cyclopamine can inhibit cell proliferation of 
PC3 and LNCaP cell lines in culture. In support, human prostate cancer xenografts showed 
tumour regression following Cyclopamine treatment (Karhadkar et al., 2004). To conclude, 
further investigation is necessary to fully comprehend the role Hh signalling in prostate 
cancer, together with the generation of models that accurately represent the disease.
Notch signalling also plays a vital role in the prostate, particularly during 
development and growth, as well as coordinating stem/progenitor cell maintenance (Wang 
et a l,  2006c; Wang et a l ,  2004b). This suggests that deregulation of the Notch pathway in 
prostate epithelium may play a role in tumourigenesis. Consistent with this notion, an ex 
vivo organ culture system revealed that treating rat ventral prostate lobes with a y-secretase 
inhibitor (that prevents Notch protein maturation), results in reduced branching o f the
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prostate ducts, elevated proliferation and increased numbers of cells co-expressing basal 
(K14) and luminal (K8 ) cell markers (Wang et al., 2006c). This data suggests that Notch 
signalling plays a role in prostate development and differentiation. A Notch 1 conditional 
transgenic mouse model also revealed that loss of Notch signalling results in hyperplastic 
foci (Wang et al., 2006c). This evidence correlates to human studies that have reported 
Notch signalling is elevated in human prostate cancer and Heyl, a mediator o f notch 
signalling and an AR co-repressor, is frequently mislocalised in prostate tumours (Belandia 
et al., 2005). Jagged 1 (a notch receptor ligand) is also found to be elevated in a large 
number of human prostate patients and Notch signalling is thought to augment AKT 
signalling, further promoting growth and survival of prostate epithelial cells (Santagata et 
al., 2004).
Interestingly, Nguyen et al (2006) showed that p63 expression is suppressed by 
Notch 1 activation in human and mouse keratinocytes. In turn, elevated p63 expression was 
shown to prevent Notch signalling from restricting cell growth and inducing differentiation 
(Nguyen et al., 2006). Together, this evidence suggests that p63 regulation of Notch 
signalling could in fact play a role in basal cell differentiation and self-renewal within 
prostate epithelium.
1.1.8 Male hormone regulation and AR signalling
The steroidal androgens, principally testosterone (T) and its metabolite 5-Alpha- 
Dihydrotestosterone (DHT), mediate a wide range of physiological processes. Androgens 
play a key role in the development and maintenance of the male GU tract, sexual 
maturation, spermatogenesis and regulation of male gonadotrophin (Heinlein and Chang,
2002). Gonadotrophin-releasing hormone (GnRH) is secreted by neurons in the 
hypothalamus to stimulate androgen production (Chang and Heinlein, 2004). GnRH is 
transported by capillaries to the anterior pituitary gland where it triggers the production of 
pituitary gonadotrophins termed luteinising hormone (LH) and follicle stimulating hormone 
(FSH) (Scher et al., 2004). LH and FSH are transported through the blood to the testes or 
ovaries where they stimulate the production of steroid hormones from cholesterol. Female 
(oestrogen and progesterone) or male (testosterone) steroid hormones to maintain ova or 
sperm production respectively, as well as maintaining the sex organs (Lattouf et al., 2006). 
In response to LH, Leydig (or interstitial) cells in the testis synthesise testosterone which 
diffuses into the seminiferous tubules to maintain spermatogenesis (together with FSH) and 
into the blood to maintain hormone homeostasis. This hormone cascade is controlled by a
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series of feedback mechanisms (figure 1.6 a). For example, elevated levels of testosterone in 
the blood results in decreased GnRH, which in turn reduces LH secretion (Scher et al., 
2004). The adrenal glands that are positioned above the kidneys also produce androgens, in 
a process regulated by ACTH (adrenocorticotrophic hormone) produced in the anterior 
pituitary (Lattouf et al., 2006).
Androgen receptor (AR) is a member of the nuclear receptor family that functions as 
a ligand-inducible transcription factor (Chang and Heinlein, 2004). Androgens 
predominantly bind to AR in the cytoplasm, which upon activation dimerize and translocate 
to the nucleus (figure 1.6 b). In the nucleus, the AR homodimer binds to the ARE (Androgen 
Response Element) and recruits co-regulators, such as steroid coactivator-1 (SRC-1) and 
Creb-binding protein (CBP) to trigger transcription of target genes (Lee and Chang, 2003). 
In its unbound ligand conformation, AR is bound to heat-shock proteins and co-repressors, 
such as prohibitin and Heyl to repress transcription (Belandia et al., 2005).
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Figure 1.6: Male hormone regulation and AR signalling, (a) Hormone regulation in males is 
controlled by gonadotrophin-releasing hormone (GnRH) from the hypothalamus, which stimulates 
the production of both follicle stimulating hormone (FSH) and luteinising hormone (LH) in the 
anterior pituitary. LH stimulates testosterone production in the Leydig cells to maintain the Sertoli 
cells and spermatogenesis, together with FSH. FSH and LH also act to maintain the male accessory 
organs, (b) AR is stimulated by its ligand 5a-dihydrotestosterone (DHT), metabolised from 
testosterone by 5a-reducatse in the cytoplasm. Here, DHT binds to the AR and causes its 
dimerisation and nuclear translocalisation. In the nucleus, AR binds to the Androgen Response 
Element (ARE) and initiates transcription of target genes. Alternatively, androgen-independent 
pathways exist, including the JAK/STAT3 pathway, the PI3K/AKT pathway and the MAPK 
cascade. Figure (a) is adapted from http://en.wikibooks.org/wiki/Human Physiology/Print Version 
and (b) is adapted from Lattouf et al (2006).
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AR is also reported to form heterodimers with other nuclear receptors, including the 
estrogen receptor (ER), glucocorticoid receptor (GR) and testicular orphan receptor-4 
(TR4), reducing AR transcriptional activity (Isaacs and Isaacs, 2004). Androgen- 
independent AR activation can also occur in response to growth factors (figure 1.6 b). For 
example, hormone-refractory prostate cancer cells have been shown to mediate AR 
signalling by alternative mechanisms, such as the MAPK, AKT and Jak/Stat3 pathways and 
more recently, through Wnt signaling (Lattouf et al., 2006; Terry et al., 2006; Yardy and 
Brewster, 2005).
Androgens are also thought to modulate intracellular events independently of AR by 
interacting with the SHBG (sex hormone binding globulin) receptor to regulate intracellular 
calcium levels. In addition, AR interactions with the SH3 domain o f SRC stimulates kinase 
signalling pathways, including the MAPK cascade, which induces transcription of AR 
(Heinlein and Chang, 2002). Given that androgens can regulate ion channel activation and 
that androgens have been observed at the plasma membrane, it is hypothesized that a novel 
membrane-bound AR exists (Benten et al., 1999; Benten et al., 1997). However, the 
alleged membrane AR is yet to be purified and it is argued that this data might reflect 
androgen:SHBG receptor or androgen:SRC interactions (Heinlein and Chang, 2002).
1.1.9 AR signalling in prostate cancer
Prostate growth is hormone-regulated in a paracrine process that mediates various 
responses in different cell types (figure 1.7a). In the stromal cells, androgens induce the 
production of andromedins (growth and survival factors) and AR activation. In prostate 
epithelial cells, andromedins bind to their respective receptors to initiate growth and 
survival through signalling networks that regulate AR (Isaacs and Isaacs, 2004). Activated 
AR translocates to the nucleus of luminal cells to stimulate the transcription of prostate- 
specific differentiation markers, such as PSA, NKX3.1 and human kallikrein-2, HK2 (Isaacs 
and Isaacs, 2004). Although AR stimulates transcription of these markers, it does not 
stimulate growth and survival, instead, it is considered to prevent andromedin-induced 
proliferation of the luminal cells (Isaacs and Isaacs, 2004).
Anti-androgen therapy inevitably results in hormone refractory disease where AR is 
over-expressed in prostate epithelial cells, resulting in them becoming supersensitive to 
androgens, rather than being independent of them (Litvinov et al., 2003). It has been 
speculated that supersensitivity is a consequence of accumulating molecular changes that 
trigger a gain of function in the AR signalling pathways (Litvinov et al., 2003). During this
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process, the paracrine mechanism of AR action is thought to be replaced by an autocrine 
mechanism, whereby cancer cells are less dependent on stromal cell factors and have gained 
the ability to activate novel AR signalling pathways for their proliferation and survival, 
without requiring the physiological androgen ligand binding (Isaacs and Isaacs, 2004; 
Litvinov et al., 2003), (figure 1.7b). Paradoxically, prostate epithelial cells may also become 
sensitive to anti-androgens, rather than becoming androgen-independent (Isaacs and Isaacs, 
2004).
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Figure 1.7: AR signalling in the normal and malignant prostate epithelium, (a) Growth and 
maintenance of normal prostate epithelium depends on growth factors and survival factors produced 
by stromal cells (smooth muscle and fibroblasts) in response to androgens, (b) Model depicting 
hormones sensitive prostate cancer as an autocrine process, (c) Mechanisms for AR deregulation in 
hormone-refractory prostate cancer. This figure is adapted from Isaacs and Isaacs (2004).
Currently, there are three mechanisms believed to explain the development of 
hormone refractory disease (Isaacs and Isaacs, 2004), (figure 1.7c). First, AR signalling may 
be bypassed by alternative signalling pathways that drive proliferation and growth. Second, 
ligand-independent activation of the AR could be a direct consequence of deregulated 
signalling cascades (such as activated MAPK or Wnt pathways) or indeed indirect 
activation owing to altered AR co-activator and co-repressor ratios. Third, AR mutations 
might allow AR activation in response to alternative ligands, such as estrogen or AR 
antagonists (Isaacs and Isaacs, 2004). About 30% of human prostate cancer patients harbour 
an AR mutation, suggesting that the majority of hormone refractory prostate cancers are 
likely to be caused by AR independent mechanisms or through aberrant AR signalling
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(Isaacs and Isaacs, 2004). Evidence for deregulated AR signalling stems from the fact that 
microarray-based profiling of isogenic prostate cancer xenograft models showed hormone 
refractory prostate cancer correlates with increased AR mRNA expression 2-5 fold, (Chen et 
al., 2004). This data suggests that AR upregulation is both necessary and sufficient for 
hormone-refractory progression (Chen et al., 2004). Current studies are now focusing on the 
generation of therapies that inhibit AR function or expression using heat-shock protein 
inhibitors and RNA interference mechanisms respectively (Chen et al., 2004).
1.2 Mouse model systems of prostate cancer
Many innovative rodent cancer models have provided mechanistic insights into the 
multistep process of prostate tumourigenesis and have identified and validated potential 
novel targets for chemotherapeutic intervention. The next generation of models aim to 
predispose to prostate cancer that can progress through the defined kinetics of human 
prostate cancer (figure 1.5), ultimately developing hormone-independent tumours that can 
metastasise, as well as displaying the biochemical properties and genetic events common to 
the human disease (Huss et al., 2001). Importantly, owing to the fact that spontaneous 
prostate cancer in mice is extremely rare, interspecies differences between experimental 
models and clinical cases must be acknowledged (Huss et a l 2001).
1.2.1 Xenograft prostate cancer models
Human prostate cancer cell lines have played a fundamental role in studying prostate 
cancer. Some common lines include LNCaP hormone sensitive cells that were derived from 
a lymph node metastasis and harbour an AR mutation in the steroid binding domain, T877A 
(Veldscholte et a l,  1992). Androgen-independent cell lines include PC-3 and DU 145 that 
originated from the bone and brain metastases respectively. Although these in vitro cell 
lines have identified key genetic events and validated the use of novel therapeutics in 
treating prostate cancer, they are difficult to establish, lack certain features of the disease, 
including PSA, and are frequently derived from rare sites o f metastases from patients who 
have received hormone ablation therapy. In vivo xenograft studies have proved beneficial in 
resolving the latter problem, allowing the onset and progression of prostate cancer to be 
investigated as a 3-dimensional structure, complete with angiogenesis, stromal interactions, 
metastasis and paracrine and hormonal factors (Lamb and Zhang, 2005). Xenografts involve
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cell lines being transplanted into immunodeficient mice, typically male SCID mice in 
prostate studies. The host is compromised immunologically to prevent rejection of the 
transfected tissue at the cost of increasing the risk of opportunistic infections.
Recent advances have investigated the role of interleukin- 6  (IL-6 ), an important 
growth regulator in prostate cancer (Steiner et al., 2003). Male nude mice inoculated with 
either LNCaP cells or LNCaP-IL6 + transfected cells have shown that IL- 6  expression 
reduces Rb expression and elevates the MAPK pathway to accelerate tumour growth 
(Steiner et a l , 2003). Rodent prostate cancer cell lines have also been utilised and 
genetically manipulated to examine the role of tumour suppressors and oncogenes in the 
prostate. For example, the dunning rat prostate adenocarcinoma cell line AT2.1 transfected 
with v-H-ras showed increased metastatic frequency, suggesting that aberrant Ras signalling 
may play a role in prostate cancer progression (Treiger and Isaacs, 1988). Furthermore, 
xenografts have been employed to demonstrate subpopulations of cells enrich for prostate 
stem cells. Lawson et al (2007) have shown that a subpopulation of cells expressing CD45' 
/CD31/Ter 119‘/Sca-l+/CD49f* enriches for prostate stem cells that can self renew in vivo 
when injected subcutaneously into SCID mice.
Xenograft models have also proved beneficial in validating potential 
chemotherapeutic targets. For example, Ke et al (2006) employed an inducible lentiviral 
RNAi vector to silence the known cancer therapeutic target mTOR in PC3 cells. Once 
transplanted into male hosts, induction with Doxycycline resulted in tumour regression in 
vivo (Ke et al., 2006). This novel approach permits staged tumour progression and target 
validation without the limitations associated with conventional siRNA techniques, which 
often fail to establish tumours in hosts (Ke et al., 2006). To conclude, xenograft models 
stimulate genetic and clinical manifestations o f the human disease in vivo, facilitating 
research into the physiological mechanisms involved.
1.2.2 Mouse prostate reconstitution (MPR) models
MPR models involve grafting the murine foetal urogenital sinus (UGS) under the 
renal capsule of adult isogenic male hosts, resulting in differentiation into a mature prostate. 
Genetic manipulation is achievable in the UGS using the retroviral transduction method 
(Navone et al., 1998). For example, MPR models have successfully manifested dysplasia 
and hyperplasia when the UGS is transfected with activated vHa-Ras or Myc oncogenes 
respectively prior to transplantation into the renal capsule of a male host (Thompson et al., 
1989). Experiments analysing the synergy between vHa-Ras and c-Myc mutation in the
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MPR model revealed accelerated progression to a more advanced phenotype, highlighting 
the multi-step nature of prostate cancer (Thompson et al., 1989).
1.2.3 Transgenic mouse prostate cancer models
Knockout and knockin transgenic mice have provided powerful insights into the 
molecular mechanisms of prostate carcinogenesis. Two genes in particular, Nkx3.1 and Pten 
have been well characterised using knockout mouse models, revealing their importance in 
suppressing prostate tumourigenesis.
The Nkx3.1 homeobox gene is a prostate cancer tumour suppressor that undergoes 
epigenetic inactivation, which is essential for prostate function (Kim et al., 2002a). Nkx3.1 
undergoes allelic deletion in about 80% of human prostate cancers and has been implicated 
at the onset and during progression of the disease (Abate-Shen et a l , 2003). Nkx3.1 null 
mice exhibit hyperplasia and dysplasia (within 2  months), mimicking early stages of human 
prostate cancer (Kim et al., 2002a). PIN-like lesions from Nkx3.1 mutants have also been 
shown to undergo progressively severe histopathological alterations after serial 
transplantation in nude mice, suggesting that loss of Nkx3.1 plays a role in prostate cancer 
progression (Kim et al., 2002a).
In humans, the tumour suppressor PTEN has been reported to be frequently deleted 
in prostate adenocarcinomas (Schmitz et al., 2007; Trotman et al., 2003; Wang et al., 2003). 
PTEN is required to regulate the normal proliferation and differentiation of the intestinal 
mucosa, prostate and skin (Wang et al., 2003). Pten null mice are embryonic lethal and 
P t e n mice are viable (Podsypanina et al., 1999). Pten haploinsufficiency results in 
pathologies with features similar to those of Cowden’s disease (CD), such as intestinal 
hamartomas, thyroid and breast tumours, and Bannayan-Zonana Syndrome (BZS), which 
predisposes to intestinal polyps, enlarged heads and a developmental delay (Di Cristofano et 
al., 1998). PtenT/' mice develop PIN and neoplasms of the endometrium, liver, thyroid, 
thymus and the gastrointestinal tract (Di Cristofano et al., 1998; Podsypanina et al., 1999). 
This phenotype can be accelerated by additional homozygous deletion of Cdknlb or Nkx3.1, 
with carcinomas occurring within 3 months on this background, thus highlighting the multi- 
step nature of tumourigenesis (Di Cristofano et a l,  2001; Kim et al., 2002b). For example, 
Nkx3.V ~.Pten ' compound mutant transgenic mice have demonstrated that loss of function 
of Nkx3.1 cooperates with loss of function of the Pten tumour suppressor gene in cancer 
progression in vivo (Kim et al., 2002b). This cooperativity results in increased HG- 
PIN/early carcinoma incidence within 3 months and the synergistic activation of Akt, a key
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modulator of cell growth and survival (Kim et al., 2002b). This compound transgenic model 
has also proved beneficial in the validation of novel chemotherapeutic agents. Interestingly, 
vitamin D treatment reduced PIN incidence and severity in the Nkx3.1 :Pten mutants 
(Banach-Petrosky et al., 2006). This suggests that the chemopreventative actions of vitamin 
D (1,25 D3 ), presumed to be mediated by its interaction with vitamin D receptor, are likely 
be useful in the treatment of human prostate cancer (Banach-Petrosky et al., 2006).
Although knock-out/in models have been extremely beneficial in recapitulating 
disease progression and validating chemotherapeutic strategies, these models have two 
major limitations; (a) development of multiple phenotypes in non-prostate tissues and (b) 
disease progression can be limited by embryonic lethality in knock-out/in studies of 
essential genes, such as Pten. To address this, the next generation of transgenic mouse 
models aim to specifically target transgenes to prostate epithelium.
To elicit a phenotype in the prostate, a strong, prostate-specific promoter is 
necessary, such as the rat probasin (Prostatic basic protein, PB), prostate specific antigen 
(PSA), prostate steroid binding protein C3(J) and Keratin-5 (K5) promoters and the mouse 
Cryptdin-2 (CR2) promoter (Kasper, 2005). Many target genes have been investigated using 
this approach, including growth factors, cell cycle regulators, pro- and anti-apoptotic 
proteins, steroid hormone and growth factor receptors, oncogenes, tumour suppressors, and 
homeobox genes (Kasper, 2005). To this end, many experimental approaches have been 
utilised to derive genetically modified mice that permit up/down-regulated, knock-out/in 
and conditional (Cre-LoxP technology) expression of the transgene in prostate epithelium.
The most widely exploited prostate-specific promoter to generate transgenic prostate 
cancer models is the rat probasin (PB) promoter. PB is a member of the lipocalcin 
superfamily and is found in the secretions and nuclei of prostate epithelial cells. PB 
expression is regulated by hormones (e.g. androgens) and zinc (Johnson et a l ,  2000; Kasper 
and Matusik, 2000). The function of PB is unknown, although it is speculated to play a role 
in shuttling an unidentified hydrophobic ligand in seminal fluid (Johnson et a l,  2000).
The PB promoter contains two androgen receptor binding sites (ARBS-1/2) within 
the PB promoter’s androgen responsive region (ARR, +244/-96 bp). The presence of the 
ARR in the PB promoter is required for elevated expression of transgene reporter constructs 
(Kasper, 2005). Novel PB promoters were generated bearing the ARR, including the 
minimal PB promoter (-426/+28 bp), the long PB promoter (LPB) (12 kb of the PB 
promoter region) and the composite PB promoter (ARR2PB), where two ARRs are linked to 
the endogenous PB promoter (Kasper, 2005).
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The first PB promoter prostate cancer models were the TRAMP (Transgenic 
Adenocarcinoma of Mouse Prostate) and LADY (LPB-Tag) transgenic mice. In TRAMP 
mice, the minimal PB promoter is used to drive the expression of the SV40 viral large T 
antigen within prostate epithelium, while the LPB promoter drives the expression of both 
the large T and small t tumour antigens in the LADY prostate (Abate-Shen and Shen, 2002). 
The SV40 viral large T antigens act as oncogenes through interactions with Rb and p53 
tumour suppressors and the small t antigen interacts with protein phosphatase 2A to 
facilitate tumourigenesis (Greenberg et al., 1995). The TRAMP model develops androgen- 
dependent PIN by 12 weeks and metastasis by 30 weeks, primarily to the lung, lymph 
nodes, bone, kidneys and adrenal gland (Greenberg et al., 1995; Pflug et al., 2003). The 
LADY model is less aggressive than the TRAMP model and develops multi-focal LG-PIN 
between 1 2 - 2 0  weeks that progresses to early invasive carcinoma but generally fails to 
metastasise (Abate-Shen and Shen, 2002).
In combination with knockout/knockin mice, the LADY and the TRAMP models 
have provided mechanistic insights into prostate tumourigenesis. For example, 
TRAMP:Pten+/' mice have shown invasive adenocarcinoma and frequent metastasis to the 
lung, liver, lymph nodes and kidney, demonstrating the role of Pten loss in promoting late 
stage progression (Kwabi-Addo et al., 2001). TRAMP:Fgf2~~ mutant mice show decreased 
tumour progression/metastasis and improved survival, implicating Fg/2 -mediated 
angiogenesis and intranuclear activities in prostate cancer progression (Polnaszek et a l,
2003). Recently, Gipp et al (2007) reported no generalised increase in Hh signalling during 
tumour development in the LADY transgenic mouse model, although Indian Hh expression 
was shown to increase with enhanced expression of progenitor cell markers.
The LADY and the TRAMP models have also validated several potential 
chemotherapeutic agents. For example, reduced primary tumour incidence and metastasis 
has been demonstrated in response to the COX-2 selective inhibitor Celecoxib (Pandha et 
a l, 2005), green tea polyphenols that inhibit IGF 1-induced signalling (Adhami et a l,  2004), 
dietary restriction (Suttie et a l,  2005), the y-secretase inhibitor E-7869 (R-Flurbiprofen) 
(Wechter et a l , 2000) and anti-estrogen (Raghow et a l , 2002).
Although these models are highly successful at recapitulating the full spectrum of 
human prostate disease progression, it is important to note that the viral antigens and the 
phenotype observed are not naturally associated with human prostate cancer. Furthermore, 
the SV40 models exhibit neoplastic neuroendocrine cells which are uncommon in clinical
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cases (Roy-Burman et al., 2004). To this end, the PB promoter has also been utilised to 
over-express a number o f genes. These include AR, FGF8b, FGF7, FGFR1/2 and SKP2 (to 
target P27K,pl for proteolysis), all of which predisposed HG-PIN (Kasper, 2005) and PB-H- 
ras transgenic mice that manifest LG-PIN and metaplastic changes towards an intestinal 
goblet cell phenotype (Scherl et al., 2004).
The PB promoter has also been exploited to over-express Akt, highlighting its 
crucial role during prostate tumourigenesis and progression (Majumder et al., 2003). AKT 
promotes cell survival and growth by targeting GSK-3p, BCL-2, eNOS, S6K1, angiogenein- 
3, the mTOR pathway and forkhead box (FOX) transcription factors (Majumder et al.,
2003). The MPAKT (Murine Prostate restricted Akt Kinase activity in Transgenic mice) 
model showed that over-expressing Aktl in the prostate causes PIN (Majumder et al., 2003). 
Consistent with this, loss of PTEN, which suppresses Akt activity, predisposes to an 
approximate phenocopy of the MPAKT model (Kwabi-Addo et al., 2001).
In addition to the PB promoter, the C3(l), K5 and CR2 promoters have proven to be 
successful in targeting gene expression to the prostates of transgenic mice. The C3(l) 
promoter has been employed to drive expression o f Bel2, c-Myc and the SV40 tumour 
antigens in the VP, giving rise to hyperplasia, LG-PIN and adenocarcinoma respectively 
(Kasper, 2005; Zhang et al., 2000). The K5 promoter specifically targets basal cells and has 
been employed to over-express the insulin growth factor-1 ([Igfl). K5-Igfl mice developed 
epithelial hyperplasia at 8  weeks, which progressed to adenocarcinomas (DiGiovanni et al.,
2000). The CR2 promoter is expressed endogenously post-puberty (week 7-8 onwards) and 
was originally employed in intestinal studies. CR2 targets the neuroendocrine lineage and 
has been employed to drive expression of the SV40 large T antigen (CR2-T-Ag). Mice 
demonstrated PIN within 1 week o f C7?2-mediated T antigen expression and progressed to 
androgen-independent carcinoma and metastasis by 6  months o f age (Garabedian et al.,
1998). The X-linked transcription factor, early growth response gene-1 (Erg-1) regulates 
cell growth, differentiation, apoptosis and wound healing and is frequently upregulated in 
human prostate cancer (Eid et al., 1998). CR2-T-Ag:Erg~/~ mice showed that loss of Ergl 
delays tumour progression to invasive carcinomas from PIN, suggesting that Ergl plays a 
role in driving progression to late stage disease (Abdulkadir et al., 2001; Eid et al., 1998).
More recently, the EZC-prostate model has emerged, permitting both ex vivo and in 
vivo imaging of the prostate by utilising the human kallikrein2 based promoter, HK2-E3/P, 
to incorporate firefly Luciferase and enhanced green fluorescent protein expression in
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prostate epithelium (Xie et al., 2004). This allows therapeutics to be monitored throughout 
an entire treatment regime by visualising these fluorescent molecules (Xie et al., 2004). In a 
similar project, the human PSA promoter has also been employed (Lyons, 2005). Additional 
non-invasive techniques include magnetic resonance imaging (MRI) and positron emission 
tomography (PET), which ultimately permit the tracking of transgene expression and 
visualisation of tumour progression (Lyons, 2005).
1.2.4 Cre-LoxP technology
The Cre-LoxP recombination system is a powerful molecular approach for the 
conditional and tissue specific inactivation or expression of target genes (Hoess and 
Abremski, 1984). Cre-LoxP technology provides a means to circumvent some o f the 
limitations of conventional gene knockouts, such as embryonic lethality, permitting direct 
evaluation o f gene function in vivo (Maddison and Clarke, 2005). The bactriophage PI Cre 
gene (Cyclisation recombination, a type-1 topoisomerase) encodes a site-specific DNA 
recombinase that excises intervening DNA flanked between two 34 bp unidirectional 
bacterial LoxP sites (‘floxed’, fl) (Lakso et al., 1992). The reciprocal recombination event 
produces a circular excised fragment of DNA containing one LoxP sequence which is 
quickly degraded, while the second LoxP site remains within the linear DNA (Clarke, 2002; 
Wu et al., 2001). This approach can be employed to target gene ablation and gene 
expression. A floxed gene, where LoxP sites flank the gene of interest will result in excision 
of the gene (figure 1.8a). Gene ablation may also be accomplished by flanking the activating 
domain of the gene o f interest with LoxP sites. Gene expression can occur by floxing the 
deactivating domain of the target gene or by inserting a floxed STOP cassette upstream of 
the target gene (figure 1.8b). Upon Cre recombinase expression, the STOP cassette is 
excised and transcription o f the target gene is permitted.
The Rosa26 reporter system has been used extensively to confirm the profile of 
endogenous recombination events (Soriano, 1999). This construct contains a LoxP-flanked 
NEO-STOP cassette situated upstream of the LacZ reporter gene, similar to that depicted in 
figure 1.8b. Cre recombinase expression results in excision o f the STOP cassette and 
transcription of P-galactosidase, which forms a blue product upon LacZ staining (Soriano,
1999). As the Rosa26 reporter transgene is present in all cells o f the organism (e.g. mouse), 
this facilitates the visualisation of recombination driven by different promoters.
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Figure 1.8: The Cre-LoxP system, (a) Conditional knockout: Transgenic mice harbouring a floxed 
gene of interest (i.e. flanked by LoxP sites, red arrow heads) are inter-crossed with mice bearing Cre 
recombinase under the control of a tissue specific promoter. Upon Cre recombinase expression, 
recombination at the LoxP sites takes place and the target gene is excised from the genome, (b) 
Conditional knockin: Transgenic mice carrying a floxed STOP cassette upstream of the silenced 
gene of interest are crossed to mice bearing the tissue-specific Cre recombinase. Expression of Cre 
recombinase results in cleavage at LoxP sequences, excision of the STOP cassette and transcription 
of the target gene. This figure is adapted from Maddison and Clarke (2005).
To regulate the Cre-Lox? system it is necessary to create a transgenic organism 
(initially via pronuclear injection) with a tissue specific promoter to drive Cre recombinase 
expression, either constitutively or by induction. This method allows researchers to isolate 
the effects of genes in tissues of interest and is only limited by the availability of a 
transcriptionally strong promoter and its specificity. It is important to avoid spontaneous 
background recombination, which may cause multiple phenotypes. Inducible promoters are 
a useful tool for transgenic models, allowing temporal and spatial regulation of the 
transgene (Maddison and Clarke, 2005). For example, xenobiotics, such as p- 
naphthoflavone, target the dioxin response element within the C yplal p450 (Ah) promoter 
to drive Cre-recombinase expression, resulting in the over-expression, activation, deficiency 
or inactivation of floxed transgenes in the liver, kidneys and gastrointestinal tract (Ireland et 
a l , 2004).
1.2.5 Conditional transgenic mouse prostate cancer models
Cre-LoxP technology has become a powerful strategy for generating conditional 
transgenic mouse prostate cancer models (Abate-Shen and Shen, 2002; Kasper, 2005). The 
PSA promoter has been employed to drive Cre recombinase expression, allowing genetic 
manipulation to take place within the prostate. For example, PSACre-Nkx3. / ^  mice 
deficient for Nkx3.1 develop hyperplasia and dysplasia, similar to the Nkx3.1 knockout
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model (Abdulkadir et al., 2002). The PBCre transgene (also termed PBCre4) has also been 
successful in delivering high levels of the Cre transgene in the prostate, with 100% (LP), 
33% (DP), 14% (AP) and 4% (VP) efficiency at week 8  (Wu et al., 2001). Positive staining 
was also detected in newborn mice (Wu et al., 2001). Here, transcription of Cre 
Recombinase is mediated by the composite PB promoter (Wu et al., 2001). This strategy has 
been employed to monitor the role of many genes within the prostate epithelium, including 
Ape (Bruxvoort et al., 2007), RetinoidXreceptor alpha (RXRa) (Huang et al., 2002), Rb 
(Maddison et al., 2000) and Pten (Ma et al., 2005; Trotman et al., 2003; Wang et al., 2003). 
PBCre4 Pter^/fl mice recapitulate the full spectrum of human prostate cancer progression 
from hyperplasia, LG-PIN, HG-PIN, androgen independent carcinoma and metastasis 
(Wang et al., 2003). This phenotype has also been shown using the PSA-Cre transgenic line 
to mediate Pten biallelic excision (Ma et al., 2005).
To conclude, rodent transgenic prostate cancer models have proved to be beneficial 
in determining the genetic events that predispose to prostate tumourigenesis (summarised in 
figure 1.9). The primary objective of the next generation of prostate cancer models is to 
derive animal models that display all the pathophysiological characteristics of the human 
disease, including androgen-independence and metastasis.
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Figure 1.9 Summary of the multi-step nature of prostate cancer and current transgenic mouse 
models. This diagram depicts the large number of prostate cancer mouse models available and how 
synergy between tumour suppressors and/or oncogenes is a common event for the development of 
advanced stages of tumour progression. This figure was adapted from Kasper (2005).
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1.3 LKB1: a master tumour suppressor
Germline mutations of the tumour suppressor LKB1 play a central role in the 
development of Peutz-Jeghers syndrome (PJS) (Alessi et al., 2006) and somatic inactivating 
mutations of LKB1 have also been linked to lung adenocarcinomas (Ji et al., 2007), 
pancreatic and biliary cancers (Su et al., 1999), as well as malignant melanomas (Guldberg 
et al., 1999). Together, this evidence suggests LKB1 exerts its tumour suppressive role in a 
variety of tissues. The normal cellular functions of LKB1 and implications o f LKB1 loss in 
tumourigenesis are discussed below.
1.3.1 Peutz-Jeghers syndrome
PJS was first described in 1922 by Dr. Johannes Peutz and further characterised by 
Dr. Harold Jeghers and colleagues in 1940 (Alessi et al., 2006). PJS is a rare, autosomal 
dominant human disorder (estimated 1 per 250,000 - 300,000 people) characterised by 
melanin deposits on the buccal mucosa, lips and digits and an increased lifetime risk ( 1 0 - 
fold) of developing malignant neoplasia (Yoo et al., 2002). Patients are particularly 
predisposed to hamartomatous polyps and carcinomas throughout the gastrointestinal tract 
(with a 93% risk) (Giardiello et al., 1987). PJS hamartomas are benign overgrowths of 
tissue that show an elongated epithelium with cystic dilation of glands overlying a network 
of smooth muscle bundles (Sancho et al., 2004). A number of extra-intestinal malignancies 
are also associated with PJS including cancers of the thyroid, stomach, lung, breast, ovary, 
uterus, cervix, testis, oesophagus and pancreas (Boardman et al., 1998). PJS patients are 
typically diagnosed with a cancer at an average age of 43 years and the average age at death 
is 57 years (Yoo et al., 2002).
The key molecular event responsible for predisposing to cancer in 70-80% of PJS 
patients is a variety of multiple independent germline mutations in LKB1 (Boardman et a l, 
1998). The majority of these mutations are within the kinase domain o f LKB1, resulting in 
inactivation of the tumour suppressor. Epigenetic inactivation of LKB1 by hypermethylation 
of normally unmethylated CpG islands within the LKB1 promoter is also associated with 
PJS and is speculated to inhibit LKB1 transcription (Esteller et al., 2000). It is important to 
note that a significant number of PJS families have no LKB1 mutations, indicating the 
existence of a second causative locus for PJS. However, no mutations in proteins known to 
interact with LKB1, such as LKB1 interacting protein-1 (LIP1), M 025, STRAD or BRG1 
have been identified (Alhopuro et al., 2005; Yoo et al., 2002).
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Whether haploinsufficiency of Lkbl is sufficient for tumour formation is currently 
under debate. It is possible that transgenic mice lack human tumour suppression 
mechanisms and allow haploinsufficiency to cause gastrointestinal polyps (Karuman et al.,
2001). Consistent with this, heterozygous, L kb l+/' knockout mice develop PJS symptoms, 
predominantly gastrointestinal hamartomatous polyposis, directly resembling the human 
disorder (Miyoshi et al., 2002; Nakau, 2002). Currently, haploinsufficiency o f LKB1 is 
linked to the onset o f cancer yet loss of heterozygosity (LOH) is deemed necessary in 
human disease progression (Gruber et al., 1998; Yoo et al., 2002). LKB1 mutations 
commonly arise in the epithelium and not the stroma in PJS polyps. This directly connects 
germline mutations with cell proliferation after the loss o f a second allele and supports a 
hamartomas-adenoma-carcinoma sequence in neoplastic transformation (Bosman, 1999). 
However, a recent study on human PJS polyps demonstrated that the wild-type LKB1 allele 
is present in both epithelial and stromal cells of the hamartomatous polyp (Heman et al.,
2004). The evidence indicates that biallelic inactivation o f LKB1 is not required for 
hamartomatous polyp formation and may provide some further growth advantage (Katajisto 
et al., 2007). It is hoped that conditional knockouts o f Lkbl will help resolve this debate 
(Sakamoto et al., 2005).
1.3.2 LKB1 structure and tumour suppressive function
LKB1 (or STK11) is an evolutionarily conserved 60 kDa (433 amino acids) 
serine/threonine kinase that functions as a tumour suppressor consisting o f 1 0  exons that 
map to chromosome 19pl3.3 in humans (Yoo et al., 2002). LKB1 is also an orthologue of 
C.elegans Par4 and Drosophila melanogaster dLKBl mammalian polarity genes. The 
mouse {Lkbl) and Xenopus laevis {Xeekl) homologues are 8 8 % and 83.7% homologous to 
human LKB1 (Karuman et al., 2001). Gene function is speculated to vary between species; 
Xeekl is found solely in the cytoplasm of Xenopus laevis primarily oocytes, while hLKBl 
and mLkbl are both found in the cytoplasm and nucleus (Conde et al., 2007; Marignani et 
al., 2001). LKB1 consists of a large kinase domain, two NLSs and a C4 3 3AAX box (for 
prenylation) in the C-terminus which is not homologous to any known protein (figure 1.10a) 
(Karuman et a l,  2001). Previous work has shown that LKB1 is highly regulated by many 
post-translational modifications and is capable o f autophosphorylation at residues Thrl85, 
Thrl89, Thr366 and Ser404, to regulate its own catalytic activity (Alessi et al., 2006), 
(figure 1.10a). p90 ribosomal protein kinase (RSK) and PKA are also thought to regulate 
cell growth by phosphorylating LKB1 at Ser431 (Alessi et al., 2006). Consistent with this,
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mutation at Ser431 determined that this residue regulates LK Bl’s ability to suppress growth 
in G361 cells (Alessi et al., 2006). Phosphorylation at Thr366 in response to ionising 
radiation is thought to be carried out by the DNA-damage activated ataxia-telangiectasia- 
mutated (ATM) kinase (Alessi et al., 2006). In addition, the fact that Ser31 lies in a 
consensus sequence for AMP-activated protein kinase (AMPK) mediated phosphorylation 
suggests that AMPK or an AMPK-related kinase may regulate LKB1 activity at this residue 
(Alessi et al., 2006).
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Figure 1.10: LKB1 structure and function, a) Schematic o f mouse Lkbl illustrating the post- 
translational modification sites; two N-terminal NLSs, a large conserved kinase domain containing 
the Thrl85/189 autophosphorylation site (red) and the C-terminus where prenylation may occur at 
Cys433 (green). Residues Thr366, Ser404, Ser431 and Cys433 correspond to human LKB1 residues 
Thr363, Thr402, Ser428 and Cys430 respectively. Below, the two transcript variants o f murine Lkbl 
are shown (Ensemble ENSF00000005137). Figure 1.10a is adapted from Alessi et al (2006). The 
functions LKB1 fulfils within the cell are summarised in (b).
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LKB1 is an essential gene required for normal foetal development and its expression 
is significantly reduced in the epithelial cells of most human and mouse adult organs 
(Collins et al., 2000; Conde et al., 2007). High levels of LKB1 expression are found in the 
testis, pancreas, liver, skeletal muscle, small intestine and stomach (Conde et al., 2007). A 
low level of LKB1 expression has also been detected in the cytoplasm o f prostate luminal 
epithelial cells in humans (Conde et al., 2007). Furthermore, Lkbl mRNA transcript 
expression in the mouse correlates to the human pattern of expression (Collins et al., 2000) 
and has been shown to overlap that of Pten in mice (Luukko et al., 1999). LKB1 encodes a 
full-length mRNA of about 3.0 kb that is present in all adult human tissues (Jenne et al., 
1998; Resta et al., 2002). However, it has also been documented that a 3.3 kb mRNA exists 
as well as a unique 2.4 kb variant specific to the testis (Jenne et al., 1998; Resta et al.,
2002). Consistent with this, Sakamoto et al (2005) also reported two Lkbl isoforms in the 
murine testis; full length Lkbl protein (50 kDa) and a smaller species (48 kDa), believed to 
be a C-terminal splice variant of Lkbl (figure 1.10a).
1.3.2.1 LKB1 mediates the cell cycle and apoptosis
LKB1 has been implicated as a regulator o f multiple biological processes and 
signalling pathways which underlie its tumour suppressive function (summarised in figure 
1.10b). Lkbl null mice die at stage El 1, with neural tube defects emerging at E8 , along with 
mesenchymal cell death and vascular abnormalities (Ylikorkala et al., 2001). This suggests 
that LKB1 plays a crucial role during development and may regulate angiogenesis. LKB1 is 
also considered to regulate the cell cycle through interactions with a number of proteins to 
mediate G (l) arrest, such as an ATPase related to SW1/SNF chromatin-remodelling 
complexes termed brahma related gene-1 (BRG1), LIP1 and the cyclin dependent kinase 
inhibitor p21W AF1 (Yoo et al., 2002).
LKB1 is present in both the cytoplasm and nucleus and translocates to mitochondria 
during apoptosis (Karuman et al., 2001). LKB1 can regulate p53-mediated apoptosis by 
directly phosphorylating and activating p53 to drive the transcription o f genes critical for 
growth inhibition, cell senescence and apoptosis (Trotman and Pandolfi, 2003; Yoo et al.,
2002). LKB1 induces cell cycle G (l) arrest by phosphorylating p53 at residues Seri 5 (also 
an AMPK target) and Ser392 (Trotman and Pandolfi, 2003; Yoo et al., 2002). In its 
phosphorylated state, p53 is recruited directly to the p21/WAFl promoter to initiate 
p21/WAFl transcription (Zeng and Berger, 2006). Consistent with this, in vitro studies have 
shown that LKB1 over-expression in cancer cell lines, including the G361 melanoma cells,
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results in LKB1-dependent growth inhibition, owing to p53 activity and elevated levels of 
p21WAFI (Tianen et al., 2002). In addition, Lkbl expression in mice has been shown to be 
high at the tip of intestinal villi, where older, apoptosing epithelial cells are shed into the 
lumen, while Lkbl expression in younger, proliferating cells is much lower (Karuman et a l , 
2001). LKB1 substrates NUAK1 and NUAK2 have also been indirectly linked to apoptosis 
and a kinase involved in DNA damage checkpoint and p53-dependent apoptosis, termed 
ATM (ataxia telangiectasia mutated), has been shown to phosphorylate LKB1 at Thr366 
(Katajisto et al., 2007). Together, this evidence suggests that LKB1 is a key player in 
triggering apoptosis, a fundamental characteristic of a tumour suppressor.
1.3.2.2 LKB1 regulates the AMPK/mTOR pathway
LKB1 plays a crucial role in regulating energy homeostasis by mediating AMPK 
(AMP activating protein kinase), a sensor of cellular energy. LKB1 is a member of the Snfl 
family of kinases (Yoo et al., 2002) and has sequence homology to upstream kinases to Snfl 
(an AMPK homolog in yeast), namely Elm l, Pakl and Tos3 (Marignani et al., 2005), 
implicating LKB1 as an effective AMPK kinase (AMPKK) (Lizcano et al., 2004). During 
low ATP conditions, LKB1 is thought to phosphorylate AMPK at Thrl72, a conserved 
residue that lies within the activation T-loop. AMPK phosphorylation and activation results 
in suppression of the mTOR pathway, ultimately suppressing cell growth and proliferation 
to minimise energy consumption (Baas et ah, 2004b; Corradetti et al., 2004; Spicer and 
Ashworth, 2004). AMPK is a highly conserved heterotrimeric kinase in eukaryotes (Lizcano 
et al., 2004). The T-loop is conserved in >10 other protein kinases in the human genome, 
the majority of which are also activated by LKB1 (Figure 1.11a), (Hardie, 2005). The 
variety o f LKB1 substrates enables this tumour suppressor to coordinate several cellular 
processes, such as energy metabolism, polarity and differentiation (Lizcano et al., 2004; 
Rider, 2006).
AMP binding to AMPK is postulated to induce a conformational change in the 
kinase, thus presenting AMPK as a better substrate for upstream activating kinases such as 
LKBl. However, it has also been demonstrated that LKB1-mediated phosphorylation and 
activation of AMPK can be independent of the ATP:AMP ratio (Woods et al., 2003) and 
instead, the a l  and a2  AMPK subunits are speculated to respond to energy stress levels 
(Shaw et al., 2004). To enhance AMPK activation (up to 100-fold), LKB1 is anchored in the 
cytoplasm in a heterotrimeric complex with STRAD (STE20-related adaptor) and M025 
(Boudeau et al., 2003), (figure 1.11b). To date, regulation of the formation and destruction
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of the LKB1/STRAD/M025 complex is not fully understood. The pseudokinase STRAD 
may activate LKB1 and induce its cytoplasmic translocation. In turn, STRAD is postulated 
to be phosphorylated by LKB1 at two distinct sites (Baas et al., 2004a). Although the role of 
M025 is uncertain, it is generally considered to act as a scaffolding protein, stabilising 
LKB 1: STRAD interactions. Consistent with this, LKB1 kinase activity is diminished when 
M025 is absent from the complex (Boudeau et a l,  2003; Hawley et al., 2003). 
Interestingly, the AMPK phosphatases PPly and PP2Aj have been purified with the 
LKB1:STRAD:M025 complex, possibly providing a convenient route for rapid 
deactivation of LKB 1-stimulated AMPK (Hawley et al., 2003). LKB1 post-translational 
modifications may also be significant in regulating AMPK activity given that AMPK and 
LKB1 expression levels do not act in concert and LKB1 stabilisation has been shown to 
require interaction with heat shock protein-90 (Hsp90) (Yoo et al., 2002). Further analysis 
of LKB1 post-translational modifications has not yet identified alternative mechanisms that 
can regulate the LKB1:STRAD:M025 ternary complex. For instance, in vitro mutational 
analysis of LKB 1 phosphorylation by PKA or p90RSK at Ser431 and prenylation at Cys433 
did not disrupt complex formation (Boudeau et al., 2003). 
a
Figure 1.11: AMPK-related kinases and LKBl-mediated AMPK regulation, (a) Dendogram to 
illustrate the AMPK-related kinases; brain-specific kinases-1/2 (BRSK1/2), microtubule-affinity 
regulating kinases-1-4 (MARK 1-4), maternal embryonic leucine zipper (MELK), AMP-regulated 
kinase 5 (ARK5/NUAK1), SNF1/AMPK related kinase (SNARK/NUAK2), Qin-induced kinase 
(QIK), QSK and salt-induced kinase (SIK). (b) Model of AMPK activation. During low energy 
conditions, AMP binds and allosterically activates AMPK, resulting in Thrl72 phosphorylation. 
Maximum AMPK activity is achieved when AMPK binds the LKB 1:STRAD:M025 complex. 
Figures are adapted from (a) Hardie (2005) and (b) Kyriakis at al (2003).
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mTOR (FRAP1) is a highly conserved Ser/Thr kinase that regulates protein 
synthesis and cell growth through multisite phosphorylation o f  S6K and 4E-BP1 (Sakamoto 
et al., 2005). S6K activates its substrate p-Rps6 required for G (l)  cell cycle progression and 
4E-BP1 stimulates CAP-dependent translation (DeMarzo et al., 2003). LKB 1-mediated 
activation o f  AMPK negatively regulates the mTOR pathway (Shaw et al., 2004). AMPK 
phosphorylates TSC2 (tuberin) to block mTOR signalling in a Rheb-dependent manner, 
resulting in reduced growth and proliferation during low energy circumstances (Shaw et al.,
2004), (figure 1.12). In high energy conditions or in an LKB 1 deficient environment, the 
mTOR pathway is considered to be activated by extracellular stimulation o f  the PI3K/AKT 
pathway, ultimately activating TSC2. LKB 1-mediated regulation o f  AM PK also governs 
other AMPK controlled events, implicating that LKB1 can regulate the down-regulation o f  
fatty acid and cholesterol biosynthesis, as well as enhancing glucose uptake and glycolysis . 
Furthermore, LKB1 has been shown to regulate TGF0 signalling to prevent cell growth and 
proliferation by forming an LKB1 :LIP1 :SMAD4 ternary complex (Smith et al., 2001).
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Figure 1.12: LKBl-mediated signal transduction. The schematic illustrates LKBl signal 
transduction (violet arrows) and signalling networks deregulated upon loss of LKB 1 (black arrows). 
LKB1 phosphorylates ParlA to organise polarity events and bypass the Wnt pathway. Loss of LKB 1 
results in disrupted cell polarity and unphosphorylated ParlA can interact with Dishevelled (Dsh) to 
trigger Wnt signalling. LKBl-mediated AMPK phosphorylation during low ATP conditions results 
in TSC2 phosphorylation and inactivation. TSC2 inactivation inhibits mTOR by serving as a 
GTPase activating protein (GAP) for the Ras-like GTPase Rheb, which is required for mTOR 
activation. Loss of LKB1 is postulated to elevate mTOR signalling, inducing growth and 
proliferation. Growth factors stimulate PI3K, resulting in AKT phosphoiylation. Active AKT 
inhibits TSC2, allowing Rheb:GTP to activate mTOR and initiate growth and proliferation. LKB1 
can interact with and phosphorylate PTEN, which is speculated to prevent AKT activation (Song et 
al., 2007). This figure is adapted from Shaw et al (2004).
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1.3.2.3 LKB1 regulates Wnt signalling
LKB1 has also been implicated in regulating the Wnt pathway. Partitioning 
defective proteins (PARs) share sequence homology with LKB I and are considered LKB1 
signalling partners (Spicer et al., 2003). LKB1 has been shown to regulate the Ser/Thr 
kinase ParlA  (also termed cTAKl, MARK3 and p78) in the human cervical carcinoma cell 
line, HeLa S3 (Spicer et al., 2003). LKB1 phosphorylation of ParlA  is thought to regulate 
cell polarity events (Spicer et al., 2003). In its unphosphorylated form, ParlA  interacts with 
and phosphorylates Dishevelled (Dsh/Dvl) to stimulate the Wnt/p-catenin pathway (Spicer 
et al., 2003). Consequently, LKB1 may act as a pivot, competing with Dsh for ParlA, 
redirecting it from Wnt signalling to organise cell polarity and prevent growth and 
proliferation (figure 1.12). In addition, Lin-Marq et al (2005) reported mutations that impair 
kinase activity (K78I) or alter the cellular localisation of LKB1 in HeLa cells results in 
diminished upregulation of several genes involved in Wnt signalling, such as WNT5B and 
FZD2. Furthermore, LKB1 mutants fail to activate GSK3p required to phosphorylate p- 
catenin to target its ubiquitination and degradation, suggesting that loss of LKB1 may result 
in deregulated signalling following GSK3p suppression (Lin-Marq et al., 2005).
Controversially, LKB1 has also been shown to induce Wnt signalling in Xenopus 
laevis during embryonic development. Inhibition of LKB 1 (XEEK1) expression in Xenopus 
laevis embryos results in developmental abnormalities reminiscent of Wnt signalling 
defects, such as a shortened body axis and defective dorsoanterior patterning (Ossipova et 
al., 2003). XEEK1 has been shown to physically associate with glycogen synthase kinase- 
3p (GSK3p) and protein kinase C-£ (PKC-c;), a known GSK3p kinase (Ossipova et al.,
2003). PKC-£ mediated phosphorylation and inactivation of GSK3P at Ser9 results in 
stabilisation of P-catenin and is a well established mechanism of signal transduction induced 
by the insulin/IGF and PI3K/AKT pathways (Green, 2004). Generally, GSK3p inactivation 
is not considered sufficient to elevate p-catenin activity or Wnt signalling, however, under 
certain conditions it is speculated that Wnt signalling is potentiated (Ossipova et al., 2003). 
Indeed, two separate research groups have shown that a reduction in the affinity for GSK3p 
to bind to Axin may facilitate Wnt signalling in mammalian cell lines, as Axin facilitates p- 
catenin phosphorylation and degradation by bringing P-catenin and GSK3P together (Ding 
et a l, 2000; Yuan et al., 1999). The attenuation of the apparent affinity of GSK3P for Axin 
has also been shown to be mediated by activated Akt in the presence of Wnt ligands (Wntl 
or Frat) (Yuan et al., 1999). It is important to note that XEEK1 function may differ to that of
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hLKBl or mLkbl owing to the fact that XEEK1 is restricted to the cytoplasm, while the 
human and murine homologues have been detected in the cytoplasm and nucleus 
(Marignani et a l,  2001). Alternatively, LKB1/XEEK1 might positively regulate Wnt 
signalling in embryos, but negatively regulate it in adult tissues (Clements and Kimelman,
2003).
1.3.2.4 LKB1 regulates cell polarity
LKB1 plays a crucial role in organising cell polarity using several different signal 
transduction cascades. To coordinate the formation of the actin cytoskeleton and tight 
junctions, ParlA  activates Pari homologues (MARK 1-4), which phosphorylate Par3 to 
create binding sites for Par5 (14-3-3Q (Baas et al., 2004b). This suggests that LKB1 
regulation of ParlA  not only inhibits the Wnt cascade but also drives structural organisation 
of the cell (Spicer et al., 2003; Sun et al., 2001b). Interestingly, MARK3 mice manifest 
dwarfism, reduced fertility and autoimmune disease (Hurov et al., 2001) and LKB1- 
dependent activation o f AMPK is also documented to play a role in tight junction assembly 
(Alessi et al., 2006; Zhang et al., 2006). Activated AMPK can also phosphorylate the 
regulatory light chain o f myosin to coordinate the polarity o f several processes, including 
actin filaments (Wodarz and Nathke, 2007).
The important role LKB1 plays in regulating cellular polarity events is demonstrated 
by the fact that LKB1 deficient human intestinal epithelia displays abnormal polarisation in 
vitro (Spicer and Ashworth, 2004). This phenotype is rescued by over-expressing LKB1, 
causing the redistribution of ZO-1 and p i20 junctional proteins peripheral to the brush 
border (Baas et al., 2004a). Consistent with this, LKB1 has been shown to interact with 
several proteins involved in cell polarity, including the receptor-independent activator of G- 
protein signalling-3 (AGS-3), a homolog of PINS in Drosophila that is required for 
asymmetric neuroblast cell division (Baas et al., 2004a). Furthermore, mutational analysis in 
the HT1080 fibrosarcoma cell line has revealed that disrupting the LKB1 ATP-binding site 
(K78M) or N-terminal truncation (A88) hinders LKBl-mediated apoptosis by microtubule 
disrupting agents, not DNA-damaging agents. This is consistent with the notion that LKB1 
acts as a specific microtubule integrity sensor (Alessi et al., 2006; Baas et al., 2004b).
1.3.2.5 LKB1 regulates PI3K/AKT signalling
More recently, LKB1 has emerged as a regulator of PTEN stability (Mehenni et al.,
2005). LKB1 is speculated to bind to and phosphorylate the tumour suppressor PTEN,
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causing cytoplasmic relocalisation of LKB1 (Mehenni et al., 2005). In vitro studies have 
shown that LKB1 phosphorylates PTEN at S385, in combination with S380, T382 or T383 
to post-translationally regulate PTEN stability (Mehenni et al., 2005; Song et al., 2007). 
However, control mechanisms that mediate PTEN stability are not well understood and 
should be viewed with caution (Okahara et al., 2004). The fact that both LKB1 and PTEN 
are tumour suppressors suggests that LKBl-mediated phosphorylation o f PTEN may act to 
confer PTEN stability, resulting in PI3K/AKT pathway inhibition to prevent cell growth and 
proliferation (figure 1.12). In support, Song et al (2007) recently reported that LKB1 is 
capable of mediating PTEN activation/stability, which correlated to inactivation of the 
survival factor AKT in vitro and in vivo.
1.3.3 LKB1 and its role in cancer
The revelation that LKB1 is a key participant in several essential cellular pathways 
provides rationale for tumourigenesis in PJS patients and other LKB I deficient cancers 
(Alessi et al., 2006). Many o f these processes are major players in the homeostatic control 
of the adult epithelium and are commonly disrupted during tumourigenesis, including 
regulation of the cell-cycle, energy metabolism, Wnt signalling, cell polarity, and 
PI3K/AKT signalling (Mehenni et a l, 2005; Spicer and Ashworth, 2004; Spicer et a l,  
2003; Yoo et a l,  2002). The molecular events induced by LKB1 mutation predisposing to 
cancer represent potential therapeutic targets and are discussed below.
Lkbl null mice die in utero at stage E l l ,  with neural tube defects emerging at E8 
(Ylikorkala et al., 2001). L k b V ' mice are viable and are prone to hamartomatous polyps of 
the glandular stomach (93% incidence, >20 weeks o f age) and small intestinal hamartomas 
(31% incidence, > 50 weeks of age) (Miyoshi et al., 2002). These lesions retain both the 
wild-type and targeted Lkbl alleles, suggesting Lkbl haploinsufficiency is sufficient to 
initiate gastrointestinal hamartomas in mice. To date, conditional transgenic mouse models 
harbouring mutated Lkbl in targeted tissues have revealed that LKB1 plays a critical role in 
the murine heart (Thomson et a l,  2007), skeletal muscle (Sakamoto et al., 2005; Thomson 
et al., 2007) and lung (Ji et al., 2007). Inactivation of LKB1 has been found in 34% and 
19% of human lung adenomas and squamous cell carcinomas respectively and is associated 
with the upregulation o f metastasis-promoting genes (Ji et al., 2007).
The disruption of the homeostatic balance between proliferation and apoptosis 
underlines the basis for cancer development (Hanahan and Weinberg, 2000). Aberrant 
LKBl-mediated regulation of G(l)cell cycle progression may cause uncontrolled cell
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proliferation and induce tumour formation (Yoo et al., 2002). PJS polyps devoid of LKB1 
show reduced levels o f apoptosis compared to normal intestinal epithelium (Karuman et al., 
2001). This may reflect perturbation of two separate mechanisms regulated by LKB1, 
namely p53-mediated apoptosis and BRG1-mediated chromatin-remodelling. Loss of 
heterozygosity (LOH) at 17p as well as over-expression of p53, indicative of p53 gene 
mutation, has been detected in gastrointestinal adenocarcinomas associated with PJS 
(Gruber et al., 1998). Furthermore, a human lung cancer study has shown that p53 
expression is often lost concomitantly with LKB1 (Ji et al., 2007) and re-introducing LKB1 
into pancreatic adenocarcinomas deficient for LKB1 rescues the phenotype and elevates 
p5 3-dependent apoptosis, further demonstrating the tumour suppressive function o f LKB1 
(Qanungo et al., 2003).
Although p53 null mice do not develop hamartomatous polyps like LkbJ+/~ mice, 
they do exhibit a defect in intestinal epithelial apoptosis (Karuman et al., 2001). The fact 
that p53 null mice do not harbour an apoptosis defect in stem cells suggests that LKB1 may 
participate in stress kinase pathways mediated by ASK1, JNKK and JNK (Karuman et al., 
2001). This provides rationale for LKBl-mediated regulation of stem cell survival in a p53- 
independent manner, further associating LKB1 to malignant cancer formation in the later 
life of PJS patients (Karuman et al., 2001). In PJS patients that do not harbour an LKB1 
mutation, it is feasible that the mitochondrial translocation of LKB1 to amplify apoptotic 
signalling by means o f BCL2 family members is disrupted, ultimately reducing apoptosis 
(Yoo et al., 2002).
LKB1 typically acts to stimulate the ATPase function o f BRG1, necessary for both 
BRG1-dependent growth arrest and RB-induced cell cycle arrest in G (l) and S phase 
(Marignani et al., 2001; Yoo et a l,  2002). Loss of LKBl-mediated BRG1 activation is 
considered to disrupt chromatin-remodelling complex formation, resulting in unchecked cell 
proliferation and tumour formation. Disrupted BRG1 interactions with other proteins 
including steroid hormone receptors, BRCA1 and Cyclin E may further drive 
tumourigenesis (Marignani et al., 2001). To date, BRG1 is not known to be mutated in PJS 
patients (Alhopuro et al., 2005), however aberrant BRG1 expression is associated with 
prostate cancer (Sun et al., 2007), and B rg l+/' mice develop mammary carcinomas (Bultman 
et al., 2007).
LKB1 behaves as an energy sensor through interactions with AMPK during low 
energy states, redirecting cellular metabolism towards ATP generation instead of energy 
requiring macromolecular synthesis e.g. cell division (Spicer and Ashworth, 2004). This
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indicates that cells deficient for LKB1 might harbour a proliferative advantage. Consistent 
with this, PJS intestinal hamartomas express elevated levels o f S6K1 activity and p4EBPl, 
indicative of hyperactivation of mTOR signalling that promotes growth and proliferation 
(Corradetti et al., 2004; Shaw et al., 2004). Rapamycin, an mTOR inhibitor is currently in 
phase II clinical trials for prevention of PJS and sporadic LKB1 deficient tumours (Shaw et 
al., 2004).
Given that vascular endothelial growth factor (VEGF) mRNA recruitment to 
polyribosomes is governed by mTOR signalling (Ylikorkala et al., 2001), activation o f the 
mTOR pathway in an LKB1 deficient environment may elevate angiogenesis, further 
enhancing tumour growth and assisting metastasis. Consistent with this notion, Lkbl null 
mice that are embryonic lethal exhibit vascular defects associated with elevated Vegf 
expression (Ylikorkala et al., 2001). This evidence suggests that LKB1 plays a role in the 
development of the vasculature system and in the regulation o f VEGF signaling. In 
agreement with this hypothesis, enhanced expression of LKB1 in breast cancer cells 
attenuates angiogenesis, invasion, and metastatic potential (Zhuang et al., 2006). PJS and 
L k b l ' mouse tumours have also shown elevated COX-2 expression, further linking loss of 
LKB1 to elevated angiogenesis (Rossi et al., 2002; Wei et al., 2003). Consistent with this, 
LKB1 is speculated to interact with and phosphorylates PEA3 at Ser395, resulting in the 
ubiquitination and degradation of PEA3 and the transcriptional down-regulation of COX-2, 
ultimately preventing oncogenesis (Upadhyay et al., 2006).
The Wnt signalling cascade is commonly deregulated in a number o f human cancers, 
including PJS tumours (Miyaki et al., 2000; Polakis, 2000). Loss of LKB1 renders the 
AMPK-related kinase ParlA  (MARK3/cTAKl) in an unphosphorylated state and can 
elevate Wnt signalling (figure 1.12). Activated Wnt signalling results in an elevation o f Wnt 
target genes, such as c-Myc and CD44, which can further promote tumourigenesis (Clevers, 
2006; Polakis, 2000). In addition, loss o f LKBl-mediated phosphorylation o f ParlA  may 
also deregulate RAS signalling and cell polarity, which further drives neoplastic 
transformation of epithelial tissues (Baas et a l,  2004b; Wodarz and Nathke, 2007). For 
example, MARK3/cTAKl has been shown to phosphorylate and inactivate the kinase 
suppressor o f Ras (KSR) at Ser392 to suppress the MAPK pathway, which stimulates 
growth and proliferation (Muller et a l,  2001). It is speculated that loss of LKB1 might 
prevent MARK3/cTAKl-mediated KSR phosphorylation, leading to activated MAPK 
signalling and tumourigenesis.
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LKB1 regulation of cell polarity is conserved in humans (Boudeau et al., 2003) as 
well as worms and flies (Baas et al., 2004b). Consistent with this, PJS hamartomas have 
displayed depolarisation of intestinal cells, which leads to tumour formation (Boudeau et al., 
2003). This process is considered to be mediated through several distinct pathways. First, 
phosphorylation of ParlA  by LKB1 is deemed necessary for the maintenance of cell 
polarity (section 1.3.2.4) (Spicer and Ashworth, 2004; Spicer et al., 2003). Second, PKC-^ 
has been shown to elevate GSK3p phosphorylation during cell polarisation with Par-6 in an 
Lkbl dependent manner in Xenopus laevis (Ossipova et al., 2003). Connections between 
polarity and tumourigenesis are currently undefined, yet the location o f LKB 1 is believed to 
be important for GSK3P regulation (Ossipova et al., 2003). Furthermore, Baas et al (2004b) 
suggested that PJS tumourigenesis is likely to be a result o f impaired asymmetric division at 
the level of the epithelial stem cell.
Recently, LKB1 has been shown to interact with and phosphorylate PTEN in vitro 
and in vivo (Mehenni et al., 2005; Song et al., 2007). The implications of this event are not 
fully understood, although it has been speculated that LKB1 loss results in reduced PTEN 
function/stability, ensuing the constitutive activation of the PI3K/AKT pathway to promote 
tumourigenesis (section 1.3.2.5). The survival factor AKT has many downstream targets, 
which when activated (e.g. p-mTOR) or inactivated (e.g. p-GSK3p) stimulate cell division 
and differentiation (Jimenez et al., 2003). Moreover, approximately 70% of PJS patients 
also harbour a mutation in PTEN or display loss of at least one allele of PTEN, a common 
event in many cancers (Trotman et al., 2003). Lung cancer cells have also demonstrated that 
over-expressing LKB1 leads to cell growth suppression in a PI3K/AKT/PTEN dependent 
manner (Jimenez et al., 2003). This evidence further implicates LKB1 exerting its tumour 
suppressive role through the activation or stabilisation o f PTEN.
To conclude, there is currently no individual hypothesis to convincingly explain how 
LKB1 loss contributes to carcinogenesis. Nonetheless, LKB1 functions demonstrate clearly 
how morphological, biochemical and genetic events associated with LKB1 mutation may be 
applied to tumourigenesis and the high cancer risk associated with PJS.
1.4 The proto-oncogene P-catenin
P-catenin (CTNNB1) plays a central role in transmitting Wnt signals to regulate 
mammalian development and cellular responses, such as growth, proliferation, polarity,
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migration and differentiation. The normal cellular functions and implications o f  the gene in 
tumourigenesis are discussed in this section.
1.4.1 The structure and function of P-catenin
p-catenin is an 88kDa ubiquitous intracellular protein that maps to 3p22-p21.3 and 
consists o f  16 exons (Yardy and Brewster, 2005). p-catenin contains an N-terminal domain 
that comprises approximately 130 amino acids, a central region o f  550 amino acids and a C- 
terminal region o f  100 amino acids (figure 1.13), (Clevers, 2006). The N-terminal region 
harbours a conserved set o f  phosphorylation sites targeted by casein kinase l a  or le , 
C K la /e  (Ser45) and GSK-3p (Ser33/Ser37/Thr41), as well as an a-catenin binding site 
(K~lligs et al., 2002). The central region contains 12 armadillo repeats (42 amino acids 
each) that can form complexes with cadherin adhesion molecules, axin, APC and members 
o f  the LEF/TCF-family that induce the transcription o f  Wnt target genes (figure 1.13) 
(Clevers, 2006; Kolligs et al., 2002). The C-terminal carries the transactivating domain 
required for activation o f  Wnt target genes (Clevers, 2006; Kolligs et al., 2002).
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Figure 1.13: p-catenin protein structure. Both the N-terminal and C-terminal regions of p-catenin 
serve as transcriptional activators. The central part is made up of 12 highly homologous armadillo 
repeats (boxes 1-12), which mediate most interactions with other proteins, such as Axin, APC, 
Brgl, E-cadherin and Tcf/Lef. Residues Ser33, Ser37 and Thr41 are targeted by GSK3p for 
phosphorylation and Ser45 is phosphorylated by CKI. Mutation of one o f these residues prevents 
degradation of P-catenin. This figure was adapted from Kolligs et al (2002).
p-catenin exists in three cellular pools; (a) at the membrane associated with 
cadherins (e.g. E-cadherin), a-catenin and other molecules involved in cell adhesion, (b) in 
the cytoplasm where it accumulates and (c) in the nucleus, where it translocates in response 
to Wnt signalling, and behaves as a transcription factor (Nollet et al., 1996; Willert and 
Nusse, 1998; Yardy and Brewster, 2005). There are three known catenin molecules; a , p
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and y (or plakoglobin). p-catenin and y-catenin are members o f  the armadillo  family that 
harbour a 4 2 -a a  arm  m otif and are mammalian orthologues o f  Arm adillo (Arm) in 
Drosophila (Nollet et al., 1996). Both p-catenin and y-catenin have been shown to bind E- 
cadherin to form adherens junctions while a-catenin is a vinculin-related molecule that 
binds to p-catenin to link p-catenin:E-cadherin complexes to actin filaments (Niessen, 
2007). Adherens junctions (shown in figure 1.14) consist o f  two basic units, the nectin- 
afadin complex and the cadherin-catenin complex that are linked by interactions with actin 
(Niessen, 2007). Binding o f  p-catenin to cadherins is essential for functional adherens 
junctions, which are crucial for maintaining epithelial adhesion and regulation o f  cell 
growth and behaviour (Clevers, 2006).
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Figure 1.14: p-catenin forms adherens junctions. A schematic representation of the basic 
components of adherens junctions. P-catenin and a-catenin can bind to cadherins to link the 
membrane spanning cadherin to actin. Cadherin-catenin complexes can also interact with the nectin- 
afadin complex through actin to maintain cell-cell interactions. This figure was adapted from 
Niessen (2007).
P-catenin is also the central mediator o f  Wnt signalling. W nt molecules are secreted 
extracellular glycoproteins that have key roles in directing em bryonic growth and are 
involved in cellular processes such as migration, polarity, proliferation and cell fate 
specification (Yardy and Brewster, 2005). The Wnt pathway was originally described in 
Drosophila as the Wingless pathway and is highly conserved among flies, frogs, and 
mammals (Clevers, 2006). Currently, three different pathways are believed to be activated 
upon Wnt receptor activation; the canonical W nt/p-catenin cascade, the non-canonical 
planar cell polarity (PCP) pathway, and the W nt/Ca2+ pathway (Clevers, 2006). The 
canonical pathway is the best characterised o f  the three and is described in figure 1.15.
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Figure 1.15: The canonical Wnt signalling pathway, (a) In the absence of Wnt protein secretion, 
the cytoplasmic degradation complex of APC and axin provide a scaffold for GSK3(3 to 
phosphorylate P-catenin. Phosphorylated P-catenin is recognized by the F box/WD repeat protein p- 
TrCP, a component of the E3 ubiquitin ligase complex and is degraded. In the nucleus, transcription 
of TCF target genes is repressed by the co-repressor Groucho binding to TCF. (b) Following the 
secretion of Wnt, the ligand binds to the Frizzled cell-surface receptor causing its dimerisation with 
a co-receptor of the LRP family (Low Density Lipoprotein Receptor), either LRP-5 or LRP-6, 
triggering the phosphorylation of Dishevelled (Dsh) protein. Phospho-Dsh destabilises the 
degradation complex, resulting in the accumulation of stabilised P-catenin and its translocation to the 
nucleus. Nuclear p-catenin forms a transcription complex with TCF, displaces Groucho and recruits 
co-activators Lgs/BCL9 and pygopus. The transcription complex induces the transcription of Wnt 
target genes involved in proliferation and differentiation. This figure was adapted from Clevers
(2006).
Tight regulation o f  the free cytoplasmic pool o f  P-catenin is the central switch o f  the 
Wnt pathway (Kolligs et al., 2002). In the absence o f  a Wnt ligand, the degradation complex 
is formed, comprised primarily o f  APC, GSK3P and the scaffold protein axin (figure 1.15a). 
Diversin recruits casein kinase-1 a/e (CK1) to the degradation com plex where it can 
phosphorylate p-catenin at Ser45, priming p-catenin for GSK3P phosphorylation at Ser33, 
Ser37 and Thr41 (Hagen and Vidal-Puig, 2002). This in turn initiates binding o f the F-box 
protein h-TrCP, a component o f  a  dedicated E3 ubiquitin ligase complex. Consequently, P- 
catenin is ubiquitinated and targeted for rapid destruction by the proteosome (Clevers,
2006). GSK3p also phosphorylates other members o f  the W nt pathway, including Axin and 
APC, to regulate their stability and binding efficiency to p-catenin respectively (Kolligs et 
al., 2002). To ensure TCF-mediated transcription is not activated in Wnt deficient
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conditions, the co-repressor Groucho binds TCF and recruits histone deacetylases to 
condense chromatin (Clevers, 2006).
Wnt signalling is stimulated by the binding of an extracellular Wnt ligand to a 
seven-pass transmembrane receptor termed Frizzled (Fz). In binding Wnt, Fz receptors 
cooperate with a co-receptor of the LRP family (Low Density Lipoprotein Receptor) either 
LRP-5 or LRP-6 (Clevers, 2006). LRPs are single-pass transmembrane molecules (known 
as Arrow in Drosophila) (Glinka et al., 1998). Once activated, the Fz receptors in turn 
phosphorylate Dishevelled (Dsh), a cytosolic protein which dephosphorylates axin (Glinka 
et al., 1998). Axin then translocates to the membrane where it interacts with the LRP intra­
cellular tail, preventing its ability to form the degradation complex with APC and GSK3p 
and leading to p-catenin stabilisation (Clevers, 2006). In the nucleus, p-catenin displaces 
Groucho from TCF and forms a heterodimer with the T-cell factor (TCF)/lymphoid 
enhancer factor (LEF) family of DNA binding proteins (Glinka et al., 1998). Nuclear 
localisation of P-catenin is not currently understood and does not involve the exposure of an 
NLS sequence (Clevers, 2006). The P-catenin transcription factor complex drives the 
expression of numerous Wnt target genes including c-Myc, CD44, COX-2, c-Jun, Cyclin 
D l, Axin2 and SP5 (Clevers, 2006; Kolligs et al., 2002; Voeller et al., 1998; Yardy and 
Brewster, 2005). As deregulated Wnt signalling can cause cancer, it is very highly 
regulated. This regulation is only partially understood and additional signalling pathways 
and cellular factors regulating Wnt signalling are published very frequently. For example, 
Dickkopf (Dkk) has been shown to inhibit Wnt signaling by directly binding to LRP5/6, 
resulting in their internalisation and inactivation (Glinka et al., 1998).
1.4.2 P-catenin and its role in cancer
Previous work has shown that p-catenin mutations are occasionally present in 
several human malignancies (Kolligs et al., 2002), including the prostate (5% incidence) 
(Voeller et al., 1998), and is over-expressed in colon cancer (Korinek et al., 1997), 
hepatocellular cancer (Miyoshi et al., 1998) and ovarian cancer (Wright et a l,  1999). 
Human disease linked to P-catenin stabilising mutations result in the accumulation of p- 
catenin in the nucleus and transcription of Wnt target genes such as c-Myc, CyclinDl and 
CD44 that upregulate cell proliferation, survival and migration respectively (Clevers, 2006; 
Sansom et a l,  2004; Zhang et a l,  2005). Activated Wnt signalling has also been linked to
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the maintenance and activation of stem cells in intestinal, epidermal and haematopoietic 
systems (Reya and Clevers, 2005).
P-catenin null mice are embryonic lethal, highlighting the vital role the proto­
oncogene plays in development, particularly during axis formation (Haegel et al., 1995). 
Over-expression of a dominant stable form of p-catenin using Cre-LoxP technology to drive 
transgene expression in the intestine determined a direct link between p-catenin stabilisation 
and Wnt activation in intestinal tumourigenesis in vivo (Harada et al., 1999). Using the Cre 
recombinase transgene under the control of the cytokeratin 19 (CK19) or liver fatty acid 
binding protein (Fabpl) promoters, expression of a dominant stabilised from of p-catenin 
(CatnbWAex3) predisposed to intestinal adenomatous polyps, resembling an APC  deficiency 
(Bruxvoort et al., 2007; Harada et al., 1999). Mutations in components of the p-catenin 
degradation complex have also been identified, particularly inactivation o f APC, resulting in 
aberrant Wnt signalling and tumourigenesis. For example, germline inactivating mutations 
in the APC  gene are associated with Familiar Adenomatous Polyposis (FAP), a hereditary 
condition where patients show an increased risk to colon adenomas, which display elevated 
nuclear P-catenin expression (Miyaki et al., 2000). Using a novel inducible AhCre 
transgenic line in conjunction with a LoxP-flanked Ape allele to model FAP, AhCre+ Apd1^  
mice also demonstrate elevated p-catenin nuclear translocation, concomitant with intestinal 
tumourigenesis (Sansom et al., 2004). Furthermore, conditional transgenic mice that are 
deficient for Ape have been shown to predispose to prostate intra-epithelial neoplasia and 
adenocarcinoma in mice (Bierie et al., 2003; Bruxvoort et al., 2007; Gounari et al., 2002). 
Together, this evidence indicates that deregulation of the Wnt pathway is a common event 
in the development o f cancer in many tissues (Polakis, 2000).
1.5 The proto-oncogene Ras
Ras is a monomeric GTPase anchored at the membrane that transmits signals from 
the cell surface to modulate many cellular processes including transcription, translation, 
cell-cycle progression and apoptosis (Malumbres and Pellicer, 1998; Schubbert et al., 2007). 
The normal cellular functions and implications of the oncogenic transformation of Ras are 
discussed in this section.
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1.5.1 Structure and function of Ras
The Ras subfamily consists o f  three functional members: H-Ras (Harvey rat sarcoma 
viral oncogene homolog), N-Ras (neuroblastoma RAS viral oncogene homolog) and K-Ras 
(Kirsten rat sarcoma 2 viral oncogene homolog) (Schubbert et al., 2007), (figure 1.16). K- 
Ras exists as two isoforms, 4A and 4B owing to alternative splicing at the C-terminus 
(Schubbert et al., 2007). All four proteins are highly homologous and carry identical 
sequences for the first 85 amino acids where GTP and GDP bind. The y-phosphate o f 
GTP/GDP binds to Ras at the P-loop (phosphate binding domain, residues 10-16) and 
switch 1 and switch II regulate Ras regulator and effector binding (Schubbert et al., 2007).
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Figure 1.16: Ras protein structure. The four Ras isoforms HRAS, NRAS, KRAS4A and KRAS4B 
are highly homologous and residues 1-85 are identical, where GDP and GTP bind. The P loop 
(phosphate-binding loop) binds the y-phosphate of GTP, and switch I and II regulate binding to Ras 
regulators and effectors. Somatic RAS mutations found in cancer frequently introduce amino-acid 
substitutions at positions 12 and 13 (P-loop) and 61 (switch II). The C-terminal hypervariable 
domain specifies membrane localization through post-translational modifications that include the 
famesylation of each isoform on the C-terminal CAAX motif (CVLS, C W M , CIIM or CVIM) and 
palmitoylation of key cysteines (C) on HRAS, NRAS and KRAS4A. Membrane localization of 
KRAS4B is facilitated by a stretch of lysines (KKKKKK) proximal to the CVIM motif. To highlight 
the degree of homology, conserved residues are shown in magenta and the variable residues in pink. 
This figure is adapted from Schubbert et al (2007), figure 2.
Ras proteins are small GTPases whose biological activity is catalysed by a cycle 
between active (GTP bound) and inactive (GDP bound) conformations (Malumbres and 
Pellicer, 1998). This process is triggered by growth factors binding their respective 
membrane-spanning receptor tyrosine kinases (RTKs), initiating RTK complex formation 
and subsequent activation (Malumbres and Pellicer, 1998). Once stimulated, RTKs 
autophosphorylate themselves at tyrosine residues within the kinase domain that lies in the 
cytoplasm. This elevates RTK function and creates docking sites for intracellular proteins
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that carry an SH2 (Src homology 2) domain, or a PTB (phospho-tyrosine binding) domain 
(Schubbert et a l., 2007). Proteins that carry an SH2 domain include SHC (SH2-containing 
protein), GRB2 (growth-factor-receptor bound protein 2) and Gab (GRB2-associated 
binding) proteins, which when bound to an activated RTK can recruit additional proteins 
through their SH3 (Src homology 3) domains that bind proline-rich sequences (Malumbres 
and Pellicer, 1998). For example, GRB2 binds to SOS (son o f  sevenless), a guanidine 
exchange factor (GEF) that activates Ras by stimulating it to release bound GDP and 
exchange it for GTP (figure 1.17a). PI3K and phospholipase-Cy may also stimulate Ras 
signalling by interacting with the autophosphorylated RTKs (Schubbert et al., 2007).
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Figure 1.17: Ras activation and effector pathways, (a) Growth factor stimulation of a receptor 
tyrosine kinase results in autophosphorylation of its cytoplasmic tail at tyrosine residues that are 
recognised by adaptor proteins, such as Grb-2. These adaptors contain both SH2 and SH3 domains 
and can recruit guanine-nucleotide exchange factors (GEFs), such as SOS. SOS binds to and 
activates Ras by triggering a conformational change that facilitates the exchange of GDP for GTP. 
Ras signalling is switched off by GTPase-activating proteins (GAPs), such as NF1. The complexity 
of the Ras signalling is illustrated in (b). The well-characterised pathway through which Ras 
mediates signal transduction is the MAPK cascade. Here Ras-GTP activation of Raf, an MAPKKK, 
triggers MEK activation, an MAPKK that ultimately stimulates the MAPK ERK to upregulate 
transcription of target genes, resulting in proliferation. Figure (a) was adapted from Schubbert et al
(2007) and (b) was adapted from Malumbres et al (2003).
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Ras-GTP initiates numerous Ras effector pathways that ultimately drive cell growth 
and proliferation in response to growth factors (Malumbres and Pellicer, 1998), 
(figure 1.17b). A crucial response is potentiation of the mitogen-activated protein kinase 
(MAPK) cascade, a series of serine/threonine phosphorylations mediated by Ras activation 
of the MAP-kinase kinase kinase, Raf. Raf phosphorylates the MAP-kinase kinase MEK 
which in turn triggers phosphorylation and activation o f the MAP-kinase ERK, which has 
the ability to regulate many targets and induce cell growth, survival and proliferation 
(Schubbert et al., 2007). To negatively regulate the Ras signalling pathway, the GTPase- 
activating protein (GAP) neurofibromin (NF1) binds to Ras-GTP and accelerates the 
conversion of Ras-GTP to Ras-GDP (Schubbert et al., 2007).
1.5.2 Ras and its role in cancer
The pathways triggered by Ras play a vital role in cell survival and proliferation, and 
therefore mutations in Ras or Ras signalling components can promote tumourigenesis by 
continuously inducing Ras effector cascades (figure 1.17b). The pattern o f Ras oncogenic 
transformations in cancer is considered to reflect differences between isoforms and tissue 
types (Schubbert et al., 2007). Since the 1980’s, K-Ras has been recognised as being the 
most frequently mutated isoform in human cancers. Between 17-25% of all human cancers 
are said to harbour an activating K-Ras mutation (Kranenburg, 2005), where colon (50%) 
(Janssen et al., 2006), pancreatic (90%) (Smit et a l , 1988) and lung (25-50%) (Jackson et 
al., 2001) malignancies exhibit a high prevalence (Bos, 1989; Malumbres and Pellicer, 
1998). W-Ras mutations have been detected in bladder tumours, cutaneous squamous cell 
carcinomas and in squamous head and neck tumours (Schubbert et al., 2007). Germline H- 
Ras mutations in Costello syndrome predispose suffers to bladder cancers and 
ganglioneuroblastoma, while K-Ras germline mutations have been linked to Noonan and 
Cardio-faciocutaneous (CFC) syndromes that cause skeletal abnormalities and mental 
retardation (Schubbert et al., 2007). Finally, N-Ras mutations are frequent in acute 
leukemias (mainly of the myeloblastic cell type) and in the myelodysplastic syndromes 
(Malumbres and Pellicer, 1998).
Oncogenic Ras mutations typically cause resistance to GTPase-activating proteins 
(GAPs) by introducing an amino acid substitution at positions 12, 13 or 61 (Schubbert et al.,
2007). This results in hyperactivation of Ras, which is locked in its active (GTP bound) 
conformation. In general, the Ras:GAP interaction is maintained, but the ability o f GAPs to 
catalyse GTP hydrolysis has become compromised (Schubbert et a l , 2007). However, Ras
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mutations alone rarely progress towards a metastatic/invasive tumourigenic state, which is 
considered to require combinatorial genetic/epigenetic events (Janssen et al., 2006). 
Consistent with this, human prostate cancer seldom manifests activating Ras mutations 
(Papatsoris et al., 2007; Weber and Gioeli, 2004), while autocrine and paracrine factors are 
upregulated, suggesting that increased wild-type Ras activation can promote tumourigenesis 
through elevated stimulation of Ras effector pathways. In support, growth factors, such as 
EGF, TGFa, FGF, IGF and KGF, and their receptors, have all been found to be over­
expressed in human prostate cancer (Schubbert et al., 2007) and human prostate cancer cell 
lines (Maroni et al., 2004). Deregulation of two principle Ras effectors, Raf and PI3K (a 
phosphatidylinositol kinase) are also common to human prostate cancer (Malumbres and 
Pellicer, 1998). Raf triggers the MEK/ERK MAPK cascade (Gioeli et al., 1999) and PI3K 
regulates AKT signalling to initiate proliferation and survival and prevent apoptosis, thus 
driving tumourigenesis (Liao et al., 2003; Malumbres and Pellicer, 1998).
The importance o f K-ras mutations in the initiation phase of carcinogenesis has been 
demonstrated in vivo. For example, conditional transgenic mice harbouring a K-rasGI2v 
mutation using a CA/F-Cre * ^ -mediated knockin strategy develop lung adenocarcinomas 
(Guerra et al., 2003). K-ras oncogenic mutation has also been shown to participate in 
tumour progression in the intestine in vivo (Sansom et al., 2006). Sansom et al (2006) 
demonstrated using a Cre-LoxP approach that although AhCre-dnvsn expression of K- 
rasvu did not predispose to intestinal tumours, in Ape deficient conditions, K-rasGV12 
expression enhanced tumour progression, indicating synergy between the Ras and Wnt 
signalling pathways. These studies indicate Ras can play a role at the onset or during later 
stages of progression to drive tumourigenesis in a tissue dependent manner.
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1.6 Aims and objectives
This thesis aims to generate novel mouse models of prostate cancer using 
conditional transgenesis to characterise the molecular events underlying prostate 
tumourigenesis in vivo. The primary objectives to investigate the roles of Lkbl, p-catenin 
and K-ras in the prostate have been outlined below;
1. Use the Cre-LoxP system to develop a mouse model in which Lkbl is absent in the 
prostate.
2. Characterise the phenotype of Lkbl deficiency in the mouse prostate using 
immunohistochemistry and to confirm deregulation of Lkbl-mediated pathways.
3. Investigate the cooperativity between Lkbl loss and Wnt signalling activation by 
conditionally activating p-catenin and deleting Lkbl within the mouse prostate.
4. Study the synergistic relationship between Ras and Wnt signalling using Cre-LoxP 
technology to express activated K-ras and p-catenin in the mouse prostate.
A floxed Lkbl allele (Sakamoto et al., 2005), combined with a prostate-specific Cre- 
recombinase (Ireland et al., 2004; Wu et a l,  2001) will allow removal of Lkbl in the 
prostate epithelium. LKB1 plays a key role in suppressing the oncogenic nature of the 
mTOR, PI3K/AKT and Wnt signalling pathways that drive proliferation, cellular polarity 
and survival (Alessi et al., 2006; Hardie, 2005; Spicer et al., 2003). Deletion o f Lkbl should 
consequently deregulate these pathways to facilitate tumourigenesis by disrupting cellular 
polarity and elevating growth and proliferation of the prostate epithelial cells.
Spicer et al (2003) showed that LKB1 can phosphorylate PARI A in vitro to 
suppress Wnt signalling and coordinate cellular polarity. To investigate the effects of Lkbl 
loss and activated Wnt signalling in the mouse prostate I will use a prostate-specific Cre- 
recombinase to drive conditional deletion of Lkbl and dominant stabilisation of P-catenin 
simultaneously in the same mouse. Given L kbl’s role in suppressing the Wnt pathway, it is 
predicted that upregulated Wnt signalling and loss of cellular polarity in an Lkbl deficient 
environment will accelerate tumour progression. This experiment is designed to provide an 
insight into the molecular mechanisms employed by Lkbl to prevent tumour formation in 
the prostate.
The multi-step nature of tumourigenesis has been demonstrated in many mouse 
models, whereby the synergistic relationship between Ras and Wnt signalling facilitates
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tumour progression (Hanahan and Weinberg, 2000). Synchronous activation of Ras and Wnt 
signalling has been shown to cooperate in colorectal (Janssen et a l , 2006; Li et al., 2005), 
intestinal (Sansom et al., 2006), kidney (Sansom et a l , 2006), mammary (Jang et a l,  2006) 
and liver (Harada et a l , 2004) tumours in mice. Conditional activation o f p-catenin and K- 
ras in the murine prostate will be used to investigate the cooperativity o f Wnt and Ras 
signalling pathways in the development and progression of prostate tumourigenesis. Given 
the role of these pathways in cell survival, growth, proliferation and their convergence in 
upregulating Wnt target genes such as c-Myc and COX-2, compound mutants are expected 
to accelerate the progression of the disease (Araki et a l , 2003; He et a l , 1998; Kerkhoff et 
a l,  1998).
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Chapter 2: Experimental procedures
All laboratory reagents and supplier details are detailed in Appendix 1.
2.1. Mouse colonies
Mice harbouring the p450 C yplal Cre Recombinase (AhCre) transgene on the 
C57BL6 background were supplied by Doug Winton (Ireland et al., 2004) and the B6.D2- 
Tg(Pbsn-Cre)4Prb (PBCre) strain was supplied by MMHCC Repository (NCI Frederick) to 
direct transgene expression to the prostate. The Lkbl-fioxed deletion model was constructed 
and supplied by Alan Ashworth (Sakamoto et al., 2005) and the constitutively active fi- 
catenin strain was developed by Makoto M. Taketo (Harada et al., 1999). Transgenic mice
i/i y
carrying an activating mutation in K-ras (termed K-ras ) were derived via a knockin 
strategy by Mariano Barbacid (Guerra et al., 2003). All mice were fed the Harlan standard 
diet (scientific diet services) and water provided al libitum. All animal studies and breeding 
were carried out under a UK Home Office project licence.
2.1.1 Induction of th e  A h C re  promoter
AhCre activity was induced by 4 i.p. injections of 80 mg/kg p-naphthoflavone within 
24 hours and tissue harvested 7 days later, p-naphthoflavone was prepared by dissolving 1 g 
P-naphthoflavone in 100 ml com oil (Sigma) at 99°C in a water bath whilst stirring 
occasionally for 1 h. Aliquots were prepared and stored at -20°C. Prior to injection, aliquots 
were defrosted at 65°C for 10-15 min.
2.2 Genotyping
Mice were genotyped by PCR using DNA extracted from tail biopsies at weaning 
age (four weeks old), using anaesthetic. Genotypes were re-confirmed at death.
2.2.1 DNA isolation and purification
Using the PureGene DNA isolation system (Gentra), 2-3 mm tail biopsy was lysed 
with 10 pi Proteinase K and 500 pi cell lysis solution overnight at 37°C. 200 pi of protein 
precipitation buffer was added and samples spun (10 min, 14,000 rpm). The S/N was 
transferred to a fresh tube with 500 pi propan-2-ol and spun (15 min, 14,000 rpm). The S/N
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was removed and the pellet air-dried for 10 min before re-suspending in 500 pi nuclease- 
free water. Samples typically contained 50-100 ng/pl.
2.2.2 Genotyping PCR
Prim er design: Primer sequences were designed by ‘Primer 3’ software (Whitehead 
Institute), unless previously described (Table 2.1) and blast searched using ‘EnsembP to 
check the specificity. Oligonucleotides were ordered from ‘Sigma Aldrich’.
Table 2.1: Genotyping primers
Primer Name Sequence (5’-3’) Product size 
(bp)
AhCre
(Ireland et al., 2004)
CreB = ATTGCCCCTGTTTCACTATC 
AHC = CCTGACTAGCATGGCGATAC
1200
p-catenin 
(Primer 3)
Ctnnbl = CTGCGTGGACAATGGCTACT 
Ctnnb2 = TCCATCAGGTCAGCTGTAAAAA
WT = 324 
HOM = 500
p-catenin 
recombined 
(Harada et al., 1999)
AS5 = ACGTGTGGCAAGTTCCGTCATCC 
GF2 = GGT AGGT G AAGCTC AGCGC AG
WT =  900 
Rec = 700
Cre/LacZ 
(Ireland et al., 2004)
CreA = T G ACCGT AC ACC AAAATTT G 
CreB = ATTGCCCCTGTTTCACTATC 
LacZA = CTGGCGTTACCCAACTTAAT 
LacZB =  ATAACTGCCGTCACTCCAAC
Cre = 1000 
LacZ = 500
K-rasLSLV,J 
(Guerra et al., 2003)
510 = AGGGT AGGT GTT GGG AT AGC 
3Exl = CTCAGTCATTTTCAGCA 
103 rev-2 = CT GTCCTTT ACT G A AGGCT C
WT = 403 
Floxed = 621 
Rec = 669
Lkbl
(Primer 3)
Lkblf = GATTTCCGCC AGCT GATT GA 
Lkblr = AGT GT G ACCCC AGCTG ACC A
WT = 320 
Floxed = 280
Lkbl recombined 
(Primer 3)
Lkbl A = CAGAATCACATCCCCTGGTT 
LkblB = TTCCCCTCCTCCTGCTAGAT
Rec = 500
Pten
(Suzuki et al., 2001)
Ptenl =  CTCCTCTACTCCATTCTTCCC 
Pten2 = ACTCCCACCAATGAACAAAC
WT = 228 
HOM = 335
Genotyping PCR protocols: PCR reactions were performed in a 96-well plate with PicTaq 
(Cancer Research UK), PlatinumTaq (Invitrogen) or GoTaq (Promega) DNA polymerases, 
depending on the primer set (Table 2.2). Details for a single 50 pi reaction are provided 
below for each polymerase.
PicTaq: 2 pi DNA, 37 pi nuclease-free water, 5 pi 5x PicTaq PCR Buffer (1.21 g Tris and 
3.72 g KC1 in 100 ml nuclease-free water at pH 8.3 and filtered through a 0.2 pi filter prior 
to use), 5 pi 25 mM MgCl2, 0.4 pi 25 mM dNTPs, 0.4 pi PicTaq, 0.1 pi of each primer (100 
pM).
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PlatinumTaq: 2 pi DNA, 37.2 pi nuclease-free water, 5 pi lOx PlatinumTaq buffer, 5 pi 25 
mM MgCb, 0.4 pi 25 mM dNTPs, 0.2 pi PlatinumTaq, 0.1 pi of each primer (100 pM). 
GoTaq: 2 pi DNA, 32.2 pi nuclease-free water, 10 pi 5x GoTaq Flexi Buffer, 5 pi 25 mM 
MgCl2, 0.4 pi 25 mM dNTPs, 0.2 pi GoTaq, 0.1 pi of each primer (100 pM).
Standard PCR protocol:
(1) 94°C for 2.5 min, (2) 94°C for 30 sec, (3) 60°C for 30 sec, (4) 72°C for 1 min, (5) 
Repeat step 2 -  4 for 34 cycles, (6) 72°C for 5 min, (7) END (14°C hold).
Alterations for specific primers are outlined in Table 2.2.
Table 2.2 PCR protocols
Primer Name DNA Polymerase Alterations to PCR protocol steps
AhCre PicTaq Standard
p-catenin GoTaq (6) 72°C for 10 min
p-catenin recombined GoTaq (3) 60°C for 1.5 min
(4) 72°C for 5 min 
(6) 72°C for 10 min
Cre/LacZ Platinum Taq Standard
K-rasLSI'vu PicTaq Standard
Lkbl GoTaq Standard
Lkbl recombined GoTaq Standard
Pten PicTaq (1) 95°C for 2 min
(2) 95°C for 1 min
(3) 58°C for 1 min
Gel Electrophoresis: To detect PCR products, 5pi of loading dye was added to each 
sample and 20 pi run on a 2% agarose TBE gel containing 15 pi ethidium bromide/200 ml 
(except p-catenin recombined PCR which was run on a 1% agarose TBE gel). 
Electrophoresis was run at 100 V for 30 min in lx TBE running buffer and PCR fragments 
were detected using a UV light box.
2.3 Tissue preparations
2.3.1 Tissue harvesting
The genitourinary (GU) tract and liver, lung, stomach, kidney, spleen, pancreas, 
salivary gland and small intestine were harvested using a micro-dissection kit. Small
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intestine samples were prepared by removing waste from the gut by flushing it with water 
using a syringe. 3x 1 cm sections were cut 10 cm from proximal end, and wrapped together 
longitudinally and parallel to each other in surgical tape to form a bundle. All samples were 
fixed in neutral buffered 10% formalin fixative (Sigma) on ice for a maximum of 24 hours 
to allow cross-polymerisation to occur within the tissue. Samples were then embedded in 
paraffin wax immediately using an automated tissue processor (Leica TP 1050) or 
transferred to 70% ethanol at 4°C for short-term storage prior to processing. Sections were 
cut (5-10 pm thick) onto poly-L-lysine coated slides using a Leica RM2135 microtome. 
Samples adhered to the slides on a hot plate (15-30 min) and then in an oven at 45°C for a 
minimum of 24 hours prior to histological procedures. Frozen samples were snap frozen in 
liquid nitrogen in tubes which were stored at -80°C until use. Cryosections (10-15 pm thick) 
were prepared by embedding samples in OCT (Lamb) on cork discs and slides were stored 
at -80°C until use.
2.4 Immunohistochemistry
Before commencing immunohistochemistry (IHC) and staining procedures, 
formalin-fixed, paraffin-embedded sections were de-waxed and rehydrated in a fume hood 
in the following; 2x 5 min Xylene, 2x 2 min 100% EtOH, 1x2 min 95% EtOH, 1x2  min 
70% EtOH and a 5 min wash in dH20. Dehydration in preparation for mounting followed 
this protocol in reverse. For each antibody, tissue sections of known positive and negative 
control samples were included and the Lambda Phosphatase Kit (#P0753, NEB) was 
employed according to manufacturer’s instructions to confirm the specificity of 
phosphoiylated antibodies. Briefly 100 pi o f control solution (10 pi lOx buffer, 10 pi lOx 
MnCL in 80 pi nuclease-free water) or Lambda phosphatase solution (10 pi lOx buffer, 10 
pi lOx MnCb, 4 pi Lambda enzyme in 76 pi nuclease-free water) was applied to control 
slides following the peroxidase block. Slides were covered in paraffin to prevent 
evaporation, incubated at 37°C for 2 h and washed 3x 5 min in the wash buffer before 
resuming the original protocol. Treating sections with Lambda phosphatase removes all 
phosphate groups at serine, threonine and tyrosine residues.
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2.4.1 Primary antibodies
Primary antibodies employed are listed in Table 2.3 which indicates the supplier, 
concentration and protocol required. Primary (and secondary) antibody dilutions were 
prepared in 10% normal serum diluted in the wash buffer (unless stated otherwise).
Table 2.3 Primary antibodies
Antibody Host Supplier Dilution Method
p-Akt (Ser 473) Rabbit Cell Signalling Technology #9277 1 50 2
p-AMPK (Thr 172) Rabbit Cell Signalling Technology #2531 1 50 2
Androgen Receptor Rabbit Labvision NeoMarkers #RB-1358 1 100 1
(3-catenin Mouse Transduction Laboratories #C 19220 1 200 6
Caspase-3 Rabbit R&D #AF835 1 750 1
CD44 Rat Pharmingen #550538 1 50 4
Chromogranin A/B Rabbit Abeam #ab8205 1 100 1
CK2a Rabbit QED Bioscience Inc #11040-25 1 300 2
COX2 Rabbit Labvision Neomarkers #RB-9072 1 200 2
E-cadherin Mouse Transduction Laboratories #610182 1 100 4
p-ERKl/2
(Thr202/Tyr204)
Rabbit Cell Signalling Technology #4376 1 100 2
Foxal Mouse Seven Hills Bioreagents #2F83 1 800 4
p-Gsk3(3 (Ser9) Rabbit Cell Signalling Technology #9336 1 50 2
Keratin 5 Rabbit Covance #PRB-160P 1 1000 2
Keratin 8 Chicken Abeam #ab 14053 1 500 5
Keratin 14 Rabbit Covance #PRB-155P 1 500 2
Keratin 18 Mouse Progen, #61525 1 50 4
Ki-67 Mouse Vector Laboratories #VP-K452 1 20 4
p63 Mouse Neomarkers #MS-1081 1 50 3
p-MEKl/2 (Ser221) Rabbit Cell Signalling Technology #2338 1 75 2
p-mTOR (Ser2448) Rabbit Cell Signalling Technology #2976 1 100 2
c-Myc Rabbit Santa Cruz #SC-764 1 200 7
p-PDKl (Ser241) Rabbit Abeam #ab32800 1 100 2
Pten Rabbit Cell Signalling Technology #9559 1 100 2
p-PTEN
(S380/T382/383)
Rabbit Cell Signalling Technology #9554 1 25 2
p-Rps6 (Ser240/244) Rabbit Cell Signalling Technology #2215 1 200 2
P-S6K (Thr 421/424) Rabbit Cell Signalling Technology #9204 1 200 2
ZO-1 Rabbit Zymed, Invitrogen #40-2300 1 20 8
2.4.2 Immunohistochemistry protocols
Method 1: Rabbit polyclonal primary antibodies (Envision)
Antigen unmasking was achieved by microwaving for 10 min in lx  citrate buffer 
(pH 6.0) (#AP-9003-500, Labvision). Slides were cooled for 30 min, rinsed in dH20 and 
incubated for 20 min in H2O2 solution (Rabbit Envision Kit, DAKO #K4010) to block
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endogenous peroxidase activity. Slides were washed (3x 5 min) in TBS/Tween (0.1%) and 
incubated in 10% normal goat serum (DAKO) for 40 min to eliminate background staining. 
The rabbit polyclonal primary antibody was added for 2 h at room temperature and any 
excess washed off TBS/Tween (0.1%). Detection of the primary antibody was achieved by 
the horseradish peroxidase (HRP)-conjugated polymer (Rabbit Envision Kit, DAKO) for 1 
hour and washed in TBS/Tween (0.1%) to remove excess polymer. HRP was detected by 
applying Diaminobenzidine (DAB) solution (#K3467, DAKO) according to manufacturer’s 
instructions for 2-10 minutes until a brown product developed. Slides were counterstained 
with Meyer’s haematoxylin for 30-60 sec, rinsed in running water and dehydrated before 
being mounted with DPX.
Method 2: Rabbit polyclonal (Biotin)
Antigen unmasking was achieved by microwaving for 15 min in lx  citrate buffer 
(pH 6.0) (#AP-9003-500, Labvision). Slides were cooled for 30 min prior to blocking 
endogenous peroxidase activity with 1.5% H2O2 (Sigma) in dH20 for 20 min. Sections were 
washed in TBS/Tween (0.1%) and incubated in 10% normal goat serum (DAKO) for 40 min 
to eliminate background staining. The rabbit polyclonal primary antibody was applied o/n at 
4°C and slides washed thoroughly in TBS/Tween (0.1%) the next day. To detect the primary 
antibody, the goat-anti-rabbit biotin conjugated secondary antibody (#E0432, DAKO) was 
applied, 1:200 for 30 min. Slides were washed in TBS/Tween (0.1%) and Biotin-HRP 
labelled for 30 min using the Vectastain ABC-HRP conjugate (Standard Vectastain Kit, 
#PK6100). Sections were washed in TBS/Tween (0.1%) and stained with DAB solution 
(#K3467, DAKO) according to the manufacturer’s instructions to produce a brown product. 
Slides were counterstained with Meyer’s haematoxylin for 30-60 sec, rinsed in running 
water and dehydrated before being mounted with DPX.
Method 3: Mouse monoclonal (Envision)
Antigen unmasking was achieved by microwaving for 10 min in lx  citrate buffer 
(pH 6.0) (#AP-9003-500, Labvision). Slides were cooled for 30 min, rinsed in dH20 and 
incubated for 20 min using the Mouse Envision Kit H2O2 solution (DAKO #K4006) 
according to manufacturer’s instructions. Slides were washed (3x 5 min) in TBS/Tween 
(0.1%) and incubated in 10% normal rabbit serum for 40 min to eliminate background 
staining prior to incubating with the mouse monoclonal primary antibody for 2 h at room
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temperature. To detect the primary antibody, sections were incubated with the HRP- 
conjugated polymer (Mouse Envision Kit) for 1 h and washed in TBS/Tween (0.1%). 
Sections were stained with DAB solution (#K3467, DAKO) according to the manufacturer’s 
instructions to produce a brown product. Slides were counterstained with Meyer’s 
haematoxylin for 30-60 sec, rinsed in running water and dehydrated before being mounted 
with DPX.
Method 4: Mouse/Rat polyclonal (Biotin)
Antigen unmasking was achieved by microwaving for 15 min in lx  citrate buffer 
(pH 6.0) (#AP-9003-500, Labvision). Slides were cooled for 30 min prior to endogenous 
peroxidase activity blocking with 1.5% H2 O2 (Sigma) in dH20 for 20 min. Sections were 
washed in TBS/Tween (0.1%) and incubated in 10% normal rabbit serum (DAKO) for 40 
min to eliminate background staining. The mouse primary antibody (or Rat for anti-CD44) 
was applied o/n at 4°C and slides were washed thoroughly in TBS/Tween (0.1%) the next 
day. To detect the primary antibody, slides were incubated with the rabbit-anti-mouse biotin 
conjugated secondary antibody (#E0464, DAKO) or for CD44, the rabbit-anti-rat (#E0468, 
DAKO) biotin conjugated secondary antibody, 1:200 for 30 min. Sections were washed in 
TBS/Tween (0.1%) and Biotin-HRP labelled by incubating with the Vectastain ABC-HRP 
conjugate (Standard Vectastain Kit, #PK6100) for 30 min. Sections were washed in 
TBS/Tween (0.1%) and stained with DAB solution (#K3467, DAKO) according to the 
manufacturer’s instructions to produce a brown product. Slides were counterstained with 
Meyer’s haematoxylin for 30-60 sec, rinsed in running water and dehydrated before being 
mounted with DPX.
Method 5: Chicken polyclonal (Biotin)
Antigen unmasking was achieved by microwaving for 15 min in lx  citrate buffer 
(pH 6.0) (#AP-9003-500, Labvision). Slides were cooled for 30 min prior to endogenous 
peroxidase activity blocking with 1.5% H2O2 (Sigma) in dH20 for 20 min. Sections were 
washed in TBS/Tween (0.1%) and incubated in 10% normal rabbit serum (DAKO) for 40 
min to eliminate background staining. The chicken polyclonal primary antibody was applied 
o/n at 4°C and slides were washed thoroughly in TBS/Tween (0.1%) the next day. To detect 
the primary antibody, slides were incubated with the rabbit-anti-chicken (#12-341, Upstate) 
HRP-conjugated secondary antibody, 1:200 for 30 min prior washing in TBS/Tween (0.1%)
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and stained with DAB solution (#K3467, DAKO) according to the manufacturer’s 
instructions to produce a brown product. Slides were counterstained with Meyer’s 
haematoxylin for 30-60 sec, rinsed in running water and dehydrated before being mounted 
with DPX.
Method 6: P-catenin immunohistochemistry
To remove endogenous peroxidase activity, slides were incubated with fresh 1.5% 
H2O2 (Sigma) prepared in peroxidase block solution (2.08 g citric acid, 5.38 g DiSodium 
Hydrogen Phosphate-2-hydrate and 0.5 g Sodium Azide in 500 ml dH20) for 40 min and 
washed in PBS. Antigen unmasking was achieved by boiling for 50 min in 30 ml antigen 
retrieval solution (24.2 g Tris and 1.86 g EDTA in 100 ml dH20, pH 8) diluted in 1.5 L 
dH20. Slides were cooled for 1 h hour and washed in PBS. To prevent endogenous staining, 
sections were blocked for 30 min in 1% BSA (Sigma, #A4503) in PBS. Slides were 
incubated o/n at 4°C with the mouse monoclonal P-catenin antibody (diluted 1:300 in 1% 
BSA). Sections were washed in PBS and incubated with the HRP-conjugated polymer 
(Mouse Envision Kit, DAKO #K4006) for 1 h to detect the primary antibody, washed in 
PBS and DAB solution (#K3467, DAKO) applied for 1-2 min according to the 
manufacturer’s instructions to detect positive cells. Sections were counterstained with 
haematoxylin for 30-60 sec, rinsed in running water, dehydrated and mounted with DPX.
Method 7: c-Myc immunohistochemistry
To remove endogenous peroxidase activity, slides were incubated with fresh 1.5% 
H2O2 (Sigma) prepared in peroxidase block solution (2.08 g citric acid, 5.38 g DiSodium 
Hydrogen Phosphate-2-hydrate and 0.5 g Sodium Azide in 500 ml dH20) for 40 min and 
washed in tap water. Antigen unmasking was achieved by microwaving sections for 15 min 
in antigen retrieval buffer (1.21 g Tris and 0.186 g EDTA in I L dH20, pH 9). Slides were 
cooled for 1 h hour and washed in tap water. To prevent endogenous staining, sections were 
blocked for 30 min in 1% BSA (Sigma, #A4503) in PBS. Slides were incubated o/n at 4°C 
with the rabbit polyclonal c-Myc antibody (diluted 1:200 in 1% BSA/PBS). Sections were 
washed in tap water and incubated with the HRP-conjugated secondary antibody, anti-rabbit 
Powervision solution (Immunotech) for 30 min to detect the primary antibody, washed in 
tap water and DAB solution (#K3467, DAKO) applied for 1-2 min according to the
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manufacturer’s instructions to detect positive cells. Sections were counterstained with 
haematoxylin for 30-60 sec, rinsed in running water, dehydrated and mounted with DPX.
Method 8: ZO-1 immunofluorescence
Cryosections (10-15 pm thick) were warmed to room temperature and washed in 
PBS to remove the OCT embedding medium. Slides were treated with 3 drops of “Digest- 
All” pepsin solution (Zymed #00-3009) and covered with strips of paraffin to prevent 
evaporation during incubation at 37°C for 5-10 min. Slides were washed in PBS and 
incubated in 10% normal goat serum (DAKO) for 30 min to prevent endogenous staining. 
The ZO-1 (N-term) rabbit polyclonal primary antibody (Zymed, Invitrogen #40-2300) was 
applied at 1:20 dilution o/n at 4°C. Sections were washed in PBS and incubated with 1:200 
AlexaFluor-488 goat-anti-rabbit secondary antibody (Molecular probes #A24922) for 1 h in 
the dark. Sections were washed in PBS and mounted with Vectashield HardSet + DAPI 
mounting medium (Vector Laboratories #H-1500). Using a confocal microscope DAPI 
staining of nuclei appeared blue while ZO-1 positive tight-junctions were green.
2.4.3 Scoring
The percentage of p63, Ki-67, Foxal and AR positive cells (detected by 
immunohistochemistry) was calculated by counting the total positive and negative cells 
from 20 acini, or in tumours 20 random 2500 pm2 regions (determined by a grid using the 
“AnalySIS” software (Olympus Soft Imaging System GMBH) at 40x magnification). A 
minimum of 1000 cells/mouse were counted (n = 3). The average score for each genotype at 
each time point underwent statistical analysis using the non-parametric Mann Whitney test 
(95% confidence interval) to assess any significant difference between genotypes. P-values 
<0.05 represent a significant difference between data sets. Statistical analysis was carried 
out using MiniTab software.
A running mean is the ongoing calculation of a statistic, using progressively more of 
the available data values. This process starts with a single value and continues to include all 
data values in the order that they are supplied. An example of a running mean chart is 
shown in figure 2.1, where the percentage of proliferative cells has been determined by 
counting Ki-67 positive and negative cells in wild-type adult prostate acini (n = 20 per 
mouse). The chart indicates scoring 20 acini is sufficient to generate a stabilised estimate of 
the percentage of Ki-67 positive cells within the prostate.
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Figure 2.1: Running mean plot of Ki-67 positive cells in wild-type adult prostate epithelium.
Plot demonstrates the generation of a running mean where the percentage of proliferating cells 
labelled with Ki-67 were counted in 20 difference acini of an adult wild-type male. The running 
percentage of Ki-67 positive cells is shown in blue, while the average number of Ki-67 positive cells 
is in pink, representing 1.791%.
2.5 H istological tissue sta ins
Staining procedures were performed following de-waxing and rehydration of 
formalin-fixed, paraffin-embedded sections (unless stated otherwise). Once staining 
procedures were completed, slides were rinsed in running water for 5 min and dehydrated 
and cleared in xylene prior to mounting in DPX (see section 2.4).
2.5.1 Cresyl violet acetate stain
Cresyl violet acetate solution was prepared by dissolving cresyl violet powder 
(Sigma #C1791) 1% w/v in ACS grade 100% EtOH and left at room temperature under 
constant agitation for 3 hours or overnight. The solution was filtered through a 0.2 pM filter 
unit prior to use. Frozen sections were rinsed in nuclease-free water to remove OCT 
embedding medium and stained for 20 sec in cresyl violet acetate solution. Slides were 
dehydrated by rinsing for 1 min in 70% EtOH and 1 min in 100% EtOH. Stained sections 
were used immediately for LCMD where the nuclei appear blue/dark purple.
2.5.2 Haematoxylin and eosin stain
For histological analysis, slides were immersed in Meyer’s Haematoxylin (Lamb, 
#170-D) for 1 min and rinsed in water for 5 min, prior to being counterstained in 1% 
aqueous Eosin (Lamb, 100-D) for 30 sec.
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2.5.3 LacZ stain
Tissue was fixed for 6 hours on ice in fresh fixing reagent (2% formaldehyde, 0.2% 
glutaraldehyde, 250 ml 10% formalin and made up to 500 ml with PBS). As a 
cryoprotectant measure, tissue was then incubated in fresh 20% sucrose (w/v) solution for 
24-28 hours (changed 4 times). Sucrose favours the formation of amorphous ice (solid 
rather than crystals). Samples were then embedded in OCT on dry ice and cryosectioned 10- 
15 pm thick. To stain for P-galactosidase, cryosections were incubated at 37°C for 1-3 hours 
under agitation in the dark in fresh X-gal staining solution (0.1 g MgCk, 0.48 g potassium 
ferricyanide, 0.64 g potassium ferrocyanide in 500 ml PBS and 4 ml 5% X-gal in DMF 
(Promega) was added before use). Sections were washed in PBS and lightly counterstained 
with 0.1% nuclear fast red (see section 2.5.1) for 1 min.
2.6 Harvesting RNA and qRT-PCR
2.6.1 RNA isolation
Tissue was harvested, snap-frozen in liquid nitrogen and stored at -80°C for short­
term storage or placed in 3 ml RNA Later solution (Sigma #R0901) at -80°C for long-term 
storage. Samples were thawed in 2 ml lysing matrix tubes (Q-Biogene #6913-500) 
containing 1 ml TRIzol reagent (Invitrogen #15596-026). This reagent contains lysis buffer 
and phenol to destroy proteins. Tissue was homogenised at 5600 rpm for 2x 25 sec using the 
Stretton Scientific Homogeniser and then centrifuged (13,000 rpm for 10 min at 4°C). The 
S/N was transferred to 200 pi chloroform and incubated on ice for 15 min to remove the 
phenol. Samples were then centrifuged (13,000 rpm for 15 min at 4°C) and the S/N 
transferred to 600 pi propan-2-ol and incubated o/n at 4°C to precipitate the RNA. 
Following precipitation, samples were centrifuged (13,000 rpm for 15 min at 4°C) and the 
pellet washed with 500 pi chilled 100% EtOH. Samples were centrifuged (13,000 rpm for 
10 min at 4°C) and the S/N discarded. The pellet was air-dried for 5 min, re-suspended in 
50-100 pi nuclease-free water by heating at 65°C for 10 min. Samples were placed 
immediately on ice or at -80°C for long-term storage.
2.6.2 DNase treatment
To eliminate DNA contamination, DNAse treatment was carried out using the 
Ambion TURBO kit (#1907) according to the manufacturer’s instructions. Briefly, 20 pi of 
total RNA was mixed with 2 pi TURBO buffer and 1 pi DNase enzyme and incubated at
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37°C for 30 min. To terminate the reaction, 2 pi TURBO DNase Inactivator solution was 
added and incubated for 2  min at room temperature before being spun down ( 1 0 , 0 0 0  rpm for 
2 min). 20 pi of S/N was transferred to a fresh tube and placed on ice (or stored at 4°C).
2.6.3 RNA quality and quantification
RNA degradation was monitored by running 1 pi of DNase treated RNA on a 1 % 
agarose TAE gel (containing 1 pi Ethidium bromide/25 ml) at 50 V for 30 min in lx TAE 
running buffer (figure 2.2a). RNA quantification was determined by using the Nanodrop 
ND-1000 spectrophotometer (Labtech) according to the manufacturer’s instructions. 
Samples were discarded if the 260/280 ratio was not within the range 1.8-2.0 (figure 2.2b).
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Figure 2.2: Determining the quality of RNA samples. Samples were run on a 1% TAE gel to 
check for degradation (a). Lanes 1-3 represent good quality RNA while lanes 4 and 5 show degraded 
RNA. Mammalian 28S and 18S rRNAs are approximately 5 kb and 2kb in size. The 260/280 ratio 
was checked using the Nanodrop ND-1000 spectrophotometer (b). Any samples that were either 
degraded on the gel or were not within the 260/280 ratio range of 1.8-2.0 were discarded.
2.6.4 Reverse transcription
To convert RNA into cDNA (lpg/20pl) reverse transcription was carried out using 
the Invitrogen Superscript II Kit (#18064071, Invitrogen). Briefly, samples of 1 pg RNA in 
9 pi nuclease-free water (Sigma) were prepared and heated in a thermocycler at 70°C for 10 
min. Samples were cooled to 42°C before adding 10 pi of master mix (2 pi DNp6  (100 
ng/pl), 4 pi 5x Buffer, 2 pi 0.1 M DTT, 0.4 pi 25 mM dNTPs (Sigma), 0.5 pi RNaseIN Plus 
(Promega, #N2611), 1.1 pi dH20). Samples were incubated for 2-3 min at 42°C, placed on 
ice whilst adding 1 pi Superscript II and incubated at 42 °C for 1 h. To inactivate the 
reaction, samples were heated to 70°C for 15 min and placed on ice (or stored at -20°C) 
until use. Controls were prepared in a similar manner except the master mix added
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contained 2.1 pi H2O and no Superscript II was added. To check for contamination, controls 
underwent normal PCR and were run on a 2% TBE agarose gel.
2.6.5 qRT-PCR
Duplicate qRT-PCR reactions were performed using the Chromo4 real time detector 
(MJ Research) and the DyNAmo HS SYBR Green qPCR kit (#F-410L, GRI). Primers were 
designed to exon-exon boundaries (to eliminate DNA contamination) using “Primer 3” 
online software and their specificity was checked using an “Ensembl” blast search. 
Sequences are shown in Table 2.4.
Table 2.4: qRT-PCR primers
Primer Name Sequence (5’-3’) Product size 
(bp)
18s 18s-F = CAT GGCCGTT CTT AGTT GGT 
18s-R = CGCTGAGCC AGTCAGTGTAG
100-150
Lkbl Lkbl-F = CT CCG AGGG AT GTT GG AGT A 
Lkbl-R = GCTTGGTG GG AT AGGT ACG A
1 0 2
c-Myc cMyc-F = TGAGCCCCTAGTGCTGCAT 
cMyc-R = AGCCCGACTCCGACCTCTT
- 1 0 0
qRT-PCR specific for 18s mRNA was employed as an endogenous control to 
normalise for differences in RNA quantites between samples. 2.5 pi of forward and reverse 
primer mixes (10 pM each) were added into the 96-well plate (white) and 22.5 pi of the 
master-mix added (7 pi cDNA (1 pg/200 pi), 3 pi nuclease-free water and 12.5 pi DyNAmo 
Hot Start SYBR green (#F-410L, GRI). qRT-PCR was run at 95°C for 15 min, 40 cycles of 
95°C for 30 sec, 60°C for 30 sec, 72°C for 30 sec and 82°C for 30 sec. The 82°C step helps 
to eliminate primer-dimer formation. A melting curve was recorded at 53 - 95°C every 
0.5°C to check for the presence of primer dimers and to confirm all samples generated the 
same product (i.e. same Tm). Fold change between samples was calculated using the 2A'AACt 
method previously described (Livak and Schmittgen, 2001). To double-check for 
contamination and primer-dimers, 5 pi of the qRT-PCR product was also run on a 2% 
agarose TBE gel.
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2.7 Electron microscopy
2.7.1 Preparation of electron microscopy samples
Electron Microscopy was performed with the assistance of Antony Hann (Electron 
Microscopy Service, Cardiff University) as described previously (Maunsbach and Bjom, 
1999). Briefly, tissue was fixed for 2 h at 4°C in 2.5% (v/v) glutaraldehyde buffered with 
0.1 M Sorensen phosphate buffer (pH 7.4). Samples were washed 2x 10 minutes in PBS to 
remove excess glutaraldehyde and post-fixed for 1 h at 4°C in 1% osmium tetroxide 
solution (1% osmium tetroxide in 0.1 M phosphate buffer). Infiltration occurred o/n in 1:1 
mixture of propylene oxide and resin araldite CY212 and samples were embedded for 2 
days at 60°C in pure araldite. Samples were washed 5 min in PBS and 4x 15 min d d ^ O  to 
remove free osmium. To stain samples, they were incubated for 45 min in 0.5% uranyl 
acetate (1 ml 2% uranyl acetate in 3 ml dH2 0 ) and washed in ddH2 0  prior to dehydrating at 
4°C in a graded series of ethanol concentrations (30, 50, 70, 90 and 100%) for 15 min each 
and 2 x 1 0  min changes of pure propylene oxide.
2.7.2 Electron microscopy
The resin polymerised block was sectioned using the Reichert Ultracut E microtome 
(Leica, UK) to produce 1.5 pm thick sections and stained with toluidine blue (1 g toluidine 
blue and 1 g borax in 100 ml dH2 0 , filtered prior to use). Slides were rinsed with water, 
dried on a hot plate and viewed under a light microscope. If the section was of interest then 
samples were prepared for electron microscopy.
Sections were cut 0.9 pm thick using the Reichert Ultracut E microtome (Leica, UK) 
and collected on a pioloform-coated copper grid. Sections were stained with 2% uranyl 
acetate (2 g uranyl acetate in 100 ml dH2 0 ) for 10 min and then 5 min in Reynold lead 
citrate (prepared by shaking in 1.33 g lead nitrate and 1.76 g sodium citrate in 30 ml CO2- 
free dH2 0  for 30 minutes, adding 8  ml of 1M NaOH and 12 ml of dH2 0  and spinning down 
before use). Samples were then examined using a transmission electron microscope (Phillips 
EM 208).
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2.8 Laser Capture Microdissection (LCMD)
2.8.1 Tissue preparation for LCMD
Snap-frozen tissue was embedded in OCT on dry ice and cryosectioned (15 pm 
thick) onto polyethylene naphthol membrane-coated glass slides (PALM, #415101 -4401 - 
000) and air-dried before proceeding (or stored at -80°C). Slides were washed in nuclease- 
free water for 1 min to remove the OCT and stained for 15 sec with 1% cresyl violet acetate 
(section 2.5.2). Slides were quickly dehydrated in 75% EtOH and 100% EtOH for 1 min 
each.
2.8.2 DNA isolation of LCMD tissue
The total time taken to complete LCMD for each sample was restricted to no more 
than 30 min (to prevent heat degradation of the tissue) using the PALM laser capture 
microdissection equipment (PALM, Germany). Approximately 1-1.5 x 10 pm of target 
tissue was catapulted into a 0.2 ml PALM adhesive cap (#415101-4400-245) and visualised 
using a dissecting microscope before isolating DNA with the QIAamp DNA Micro Kit 
(#56304, Qiagen) according to manufacturer’s instructions. Briefly, samples were incubated 
o/n at room temperature upside down with 30 pi ATL lysis buffer and 10 pi Proteinase K. 
Samples were spun in a microcentrifuge (max. speed for 1 min) and 40 pi AL buffer and 40 
pi 100% EtOH added. Samples were spun (max. speed for 5-10 sec) and incubated at 65°C 
in a water bath for 10 min. Samples were spun (max. speed for 1 min) and transferred to a 
spin column and spun (13,000 rpm for 1 min), retaining the DNA on the column membrane. 
The column membrane was washed with 500 pi AW1 buffer and tubes spun (13,000 rpm 
for 1 min) and re-washed with 500 pi AW2 buffer. Samples were centrifuged twice more 
(13,000 rpm, 3 min) and DNA collected into a fresh 1.5 ml tube by incubating the 
membrane with 2 0  pi nuclease-free water for 1 0  min and centrifuging (13,000 rpm for 2  
min). DNA (2 pi) was quantified using the Nanodrop ND-1000 spectrophotometer 
(Labtech) and concentrations ranged between 5-25 ng/pl.
2.8.3 DNA amplification and ethanol precipitation
To amplify LCMD DNA to a quantity suitable for PCR, the Genomiphi DNA 
amplification kit from Amersham (#25-6600-00) was employed according to the 
manufacturer’s instructions. Briefly, 1-2 pi DNA and 9 pi sample buffer was incubated for 3 
min at 95°C in a water bath and placed on ice for 2 h. 1 pi enzyme and 9 pi reaction buffer
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was added to each sample and incubated in a thermocycler at 30°C for 16-18 hours followed 
by an inactivation step at 65 °C for 10 min. DNA was ethanol precipitated (recommended by 
Amersham) by adding 20 pi nuclease-free water, 4 pi clean up buffer (0.5 ml 1.5 M NaAc, 
pH 9.5 and 0.5 ml 0.5 M EDTA) and 100 pi 100% EtOH. Samples were spun (12,000 rpm 
for 15 min), the S/N discarded and the pellet washed with 400 pi 70% EtOH. Samples were 
spun (12,000 rpm for 2 min), the S/N removed and the pellet air-dried for 5 min before re- 
suspending in 2 0  pi nuclease-free water.
2.8.4 LCMD PCR
The log phase for each primer set was determined by running PCRs at 15, 20, 25, 30 
and 35 amplification cycles, running the products on a 2% agarose TBE gel and checking 
for band saturation. LCMD DNA was quantified using the Nanodrop ND-1000 
spectrophotometer (Labtech) and 50 ng/pl dilutions prepared. PCR reactions were carried 
out according to section 2 .2 .2 , except the cycle number for each primer set was reduced to 
25 cycles (confirmed to be within the log phase). To calculate the recombination percentage 
within the prostate, PCR products were run on a 2% gel and the intensity of the bands (n = 
6 ) were measured using densitometry software (Bio-Rad).
2.9 In situ hybridisation
2.9.1 Generation of the probe
The Lkbl full length cDNA clone inserted in the pYX-Asc vector (1.69 kb) was 
obtained from RZPD, Germany (#IRAVp968E05123D). The clone was cultured in E.coli 
strain DH10B TonA on selective agar containing 0.05 mg/ml ampicillin. DNA was purified 
using the QIAprep Spin Mini prep kit (Qiagen, #27104) according to manufacturer’s 
instructions. To confirm plasmid orientation and to verify construct validity DNA was 
sequenced from both T3 and T7 RNA polymerase binding sites by the DNA Sequencing 
Core (Molecular Biology Unit, Cardiff University. The T3 primer (5’- 
AARRAACCCTCACTAAAGGG-3’) and the T7 primer (5’-TAATACGACTCACTAA 
AGGG-3’) were provided by Dr. Rosalind John (Cardiff University). Sequencing 
determined the 5’-end of the Lkbl insert begins at T7 and confirmed 100% identity of the 
Lkbl insert with the NCBI Sequence (accession number BC052379). Single restriction 
digests using EcoRl (#R0101S, NEB) and Notl (#R0189S, NEB) determined the linear 
plasmid to be 3.2 kb and a double digest revealed the Lkbl insert was 1.6 kb by running the
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samples on a 1% agarose TBE gel. Restriction digests were carried out in a thermocycler 
according to the manufacturer’s instructions at 37°C o/n. Large quantities of the Lkbl insert 
were acquired by using the HiPure Plasmid DNA kit (#K2100-03, Invitrogen) according to 
the manufacturer’s instructions. To generate templates, 20 pg of the purified DNA was 
linearised with either EcoRl (Anti-sense) or Notl (Sense) and DNA phenol chloroform 
extracted and ethanol precipitated. To verify linearization, 0.5 pi was run on a 1% agarose 
TBE gel (expected size = 3.2 kb). Anti-sense and sense RNA probes were then obtained by 
in vitro transcription of the template (1 pg/pl) using T3 (anti-sense) and T7 (sense) RNA 
polymerases (#1031163 and #881767, Roche). Probes were DNase treated and labelled 
using the DIG RNA labelling kit (BM 1175025, Roche) according to the manufacturer’s 
instructions. Probes were run on a 1% agarose TBE gel to ensure the correct size and to 
check that degradation had not occurred. Aliquots of 10 pi were stored at -80°C in 
hybridisation buffer (2.5 ml 20x SSC (Sigma, S6639), 5 ml formamide (Sigma, #47671), 0.5 
ml 20% SDS, 50 pi 10 mg/ml Heparin (Sigma, #H4784), 50 pi 10 mg/ml calf liver tRNA 
(Sigma, R4752-100N) in 10 ml DEPC H20).
2.9.2 I n  s itu  hybridisation
In situ hybridisation was performed in glassware baked o/n at 175°C and using 
DEPC-treated H20  (RNase-free) for preparation of all solutions as described previously 
(Kikyo et al., 1997). Briefly, 5-10 pm thick sections from formalin-fixed, paraffin- 
embedded sections (stored at 4°C) were de-waxed in 2x 10 min fresh xylene and re­
hydrated in a graded series of ethanol (2x 100, 95, 85, 75, 50 and 30%) for 1 min each. 
Sections were washed with lx  saline and lx  PBS, 5 min each. To inactivate endogenous 
alkaline phosphatase activity, sections were incubated in 6 % hydrogen peroxidase block (25 
ml lOx PBS, 50 ml 30% H2 0 2 and 175 ml DEPC H2 0 )  for 30 min. Sections were then fixed 
on ice for 15 min in 4% paraformaldehyde, washed with lx  PBS and treated with Proteinase 
K solution (12.5 ml 1 M Tris pH 8 , 2.5 ml 0.5 M EDTA pH8 , 250 pi 20 mg/ml Proteinase K 
in 250 ml DEPC H2 0 ) for 5 min to increase the signal. Slides were post-fixed in 4% 
paraformaldehyde for 5 min and to prevent non-specific binding and incubated for 10 min in 
TEA HCl/acetic anhydride solution (25 ml 1 M Triethanolamine hydrochloride (Sigma), 
225 ml DEPC H20  and 0.63 ml acetic anhydride (Sigma)). Slides were washed in lx  PBS 
and lx  saline (5 min each) and de-hydrated in a graded series of EtOH (30, 50, 70, 85, 95 
and 2x 100%), 30 sec each. Hybridisation buffer was heated to 80°C and the probe added
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immediately before use (1:50). Slides were air-dried for 30 min and hybridized with 200 pi 
of probe solution per slide o/n at 65°C in a water bath. Slides were covered with parafilm to 
prevent evaporation and placed in an air-tight container to prevent them from drying out. 
Sections were washed 1x15 min in 5x SSC to remove excess probe and then washed 3x 30 
min at 65°C in solution 1 (200 ml formamide, 100 ml 20x SSC, 40 ml 10% SDS and 60 ml 
DEPC H2O). Slides were incubated at room temperature in solution II (200 ml formamide, 
10 ml 1 M TrisHCl, pH7.5, 1 ml Tween 20 made up to 1 L with DEPC H2 O) 3x 10 min, lx 
45 min at 37°C (containing 10 mg/ml RNase A) and 1x10 min at room temperature. Slides 
were washed with solution III (200 ml formamide, 40 ml 20x SSC and 160 ml DEPC H2 O) 
2x 30 min at 65°C and 2x 5 min PBS washes prior to blocking with 10% sheep serum 
(X0503, DAKO) at room temperature for 3 h. Meanwhile, the alkaline phosphatase- 
conjugated anti-digoxigenin (DIG) antibody (#11327723, Roche), 1:500, was pre-absorbed 
at 4°C for 3 h (in 500 pi lx  PBS containing 3 mg embryo powder and 10 pi 50% sheep 
serum) to prevent non-specific binding and spun at 4°C for 5 min, 14,000 rpm. The S/N was 
transferred to a fresh tube and made up to 2 ml with 1% sheep serum. Slides were incubated 
with 200 pi of the anti-DIG antibody overnight at 4°C in the dark. Slides were washed 3x 5 
min and 3x 30 min in PBT (lx  PBS in DEPC H2 O and 0.1% Tween 20) and then 
preconditioned with 3x 5 min washes in NTMT solution (5 ml 5 M NaCl, 25 ml 1 M 
TrisHCl, pH9.5, 12.5 ml 1 M MgCl2 , 0.25 ml Tween 20, 0.25 ml 2 M Levamisole (Sigma, 
#L9756) made up to 250 ml with DEPC H2 O). Levamisole acts to remove endogenous 
alkaline phosphatase activity. Alkaline phosphatase activity was detected by using BM 
purple AP (Roche) according to the manufacturer’s instructions (for 8-24 hrs in the dark) 
until a purple colour developed. Slides were then washed 3x 5 min in PBT, 30 min in DEPC 
H2O and lightly counterstained using Eosin. Sections were air-dried and mounted using the 
aqueous mounting medium VectaMount AQ (#H5501, Vector Labs).
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Chapter 3: Lkbl deficiency causes prostate neoplasia
3.1 Introduction
3.1.1 LKB1 is expressed at low levels in the prostate
LKB1 (STK11) is a 60 kDa serine threonine kinase that was originally identified as 
a tumour suppressor in Peutz-Jeghers Syndrome (PJS) (Alessi et a l, 2006). Multiple 
germline mutations of LKB1 that abrogate enzymatic function in PJS patients predispose 
hamartomas in the small intestine and a number of extra-intestinal cancers including those 
of the reproductive system (Yoo et a l,  2002). Collins et al (2000) documented the 
expression of Lkbl mRNA in the mouse, illustrating the importance of this gene in a variety 
of different tissues. High Lkbl expression was detected in the liver, testis, skeletal muscle 
and small intestine, while a moderate level of Lkbl mRNA transcript was also detected in 
the prostate (figure 3.1) (Collins et a l, 2000).
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Figure 3.1: Lkbl mRNA expression in mice. This figure demonstrates adult and foetal mRNA 
levels of Lkbl normalised to foetal liver tissue (100%). An RNA master blot was probed with the 
Lkbl anti-sense probe and hybridization was observed in all tissues and brain regions examined, 
with the highest levels in skeletal muscle, testis, small intestine and foetal liver. Moderate Lkbl 
mRNA levels in the prostate (red arrow head). This figure was adapted from Collins et al (2000).
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3.1.2 Derivation of AhCre+Lkbt/l^  mice to study Lkbl function in the small intestine
To investigate the role o f  Lkbl specifically within the small intestine, Shoming et al 
(2008, under review) exploited the p450 C yplal-driven Cre-Recombinase transgene 
(termed AhCre), controlled by xenobiotic promoter induction (Ireland et al., 2004), in 
conjunction with a LojcP-flanked (floxed) Lkbl construct (Sakamoto et a l, 2005) to 
generate AhCre+L k b l mice (figure 3.2). Importantly, this system allows Lkbl to be 
monitored at several expression levels owing to the hypomorphic nature o f  the Lkbl floxed 
construct. Sakamoto et al (2005) assessed the hypomorphic nature o f  un-induced Cre 
L k b l mice to show that Lkbl protein expression and activity is reduced 5-10 fold in the 
tissues analysed (testis, skeletal muscle, heart, liver and kidney). Cre'Lkbl+/^  mice showed a 
2-fold reduction in Lkbl expression and activity (Sakamoto et al., 2005). Shoming et al 
(2008, under review) determined that intestinal Lkbl transcript levels are 2-fold down in 
C r e 'L k b l mice and 30-fold down in AhCre ’ L k b l^  mice following xenobiotic induction 
o f the Ah (CyplAl)  promoter compared to wild-type mice.
Wild-type Lkbl allele
10
Floxed Lkbl construct
z m n z n Exon 5-7 cDNA NEOE
(3-naphthoflavone
10
Lkbl recombined allele
10
AhCre transgene
Ah Promoter Cre-Recombinase
Exon 5-7 cDNA NEOy
i
Degraded
Figure 3.2: Generation of the Z,A^/-floxed construct. The top schematic illustrates the wild-type 
Lkbl allele which carries 10 exons. The floxed Lkbl construct contains LoxP Cre-excision sites in 
introns 3-4 and 7-8 and exons 5-7 encoding the catalytic domain of Lkbl are replaced with a cDNA 
construct encoding the remainder of the Lkbl sequence, as well as a Neomycin (NEO) selection 
gene. The expression of NEO is driven by the Lkbl promoter and is fused with Lkbl mRNA. 
Translation is directed by an internal ribosome entry site. When Lkbl floxed mice are crossed to 
mice harbouring the AhCre transgene, exons 4-7 of the Lkbl gene are deleted through action of the 
Cre recombinase, thereby ablating functional expression of Lkbl. Activity of the AhCre-transgene 
can be induced by xenobiotics such as P-naphthoflavone or by endogenous activation of the Ah 
promoter(Ireland et a l,  2004). This figure is based on Sakamoto et al (2005).
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AhCre L k b l^ 1 mice induced with the xenobiotic p-naphthoflavone showed Cre- 
mediated deletion of Lkbl in the small intestine (Shoming et al., 2007). The pattern of 
recombination was confirmed using the surrogate marker LacZ in the Rosa26 reporter 
system (Soriano, 1999), detailed in Section 1.2.4. Induced AhCre+L k b l ^  mice 
demonstrated proliferation of absorptive enterocyte lineages in the small intestine, resulting 
in their apoptosis, in conjunction with expansion of the secretory cell population that 
manifested aberrant secretory functions (Shoming et al., 2007). It was during the course of 
these studies that a prostate phenotype became apparent in un-induced mice, suggesting 
spontaneous activation of the AhCre transgene occurs in prostate epithelium.
3.1.3 Lkbl plays a role in the prostate
There is currently little in the literature to directly link LKB1 mutation with human 
or murine prostate neoplasia. However, somatic LKB1 mutations have been observed in 
human lung cancer and inactivation of Lkbl has been shown to predispose to lung 
tumourigenesis in the mouse (Ji et al., 2007). This suggests that Lkbl may have a broad 
tumour suppressive role in epithelial tissues.
In the human prostate, LKB1 has been detected in the cytoplasm of luminal cells 
using immunohistochemistry (Conde et al., 2007) and low levels of Lkbl mRNA are 
detectable in mouse prostate (Collins et al., 2000). Sequencing studies have reported that 
LKB1 is mutated in one of five sequenced human prostate carcinoma cell lines, with a 
ffame-shift deletion within the kinase domain of DU 145 cells (p.K178fs*86) (Ikediobi et 
al., 2006). Further support for a tumour suppressive role for Lkbl comes from a whole- 
genome scan study that identified an association between chromosome segments 19ql2- 
ql3.11 and prostate cancer aggressiveness (Neville et al., 2003). The chromosome segment 
19pl3.3 harbours the LKB1 tumour suppressor gene (Neville et al., 2003). Deletions, 
amplifications and structural rearrangements of Chromosome 19 have also been reported in 
a variety of tumours including pancreatic adenocarcinomas, both benign and anaplastic 
thyroid tumours and stomach cancers (Neville et al., 2003). Interestingly, prostate cancer 
has also been anecdotally reported in a PJS patient ( 6 6  years old) following the development 
of colon cancer (Boardman et al., 1998). The presence of prostate cancer in PJS patients is 
not a frequent occurrence, possibly as a consequence of the normal age of onset of disease. 
Prostate cancer is typically diagnosed in the 7th decade of life, while PJS patients have an 
average life-span of 57 years (Yoo et a l, 2002).
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3.2 Aim
The objective of this chapter is to determine the expression pattern of the tumour 
suppressor Lkbl in the mouse GU tract and to investigate the possible link between loss of 
Lkbl and prostate tumourigenesis using the un-induced A hC re+ Lkbl^  conditional 
transgenic mouse model. Cohorts were analysed histologically and by 
immunohistochemistry. Un-induced AhCre-mediated recombination and excision of the 
Lkbl targeted allele in the prostate was determined by LacZ staining in mice harbouring 
both the AhCre transgene and the Rosa26 reporter locus. PCR amplification of the 
recombined allele on prostate DNA isolated by laser-capture microdissection and an in situ 
hybridisation that detects Lkbl mRNA transcripts was also employed to assay 
recombination and Lkbl expression in the mouse GU tract.
3.3 Results
3.3.1 Un-induced A h C r e +L k b l ^  mice have a reduced life-span
AhCre+ mice were inter-crossed with mice carrying the ZoxP-flanked Lkbl allele 
and the Rosa26 reporter allele. Cohorts of un-induced wild-type (AhCre+Lkbl f/+), 
AhCre" Lkbl C re 'L kb l^  and AhCre+Lkbl^  mice were generated and aged to 200 days.
Each cohort contained a minimum of 20 males which were monitored for signs of illness 
and killed when they became symptomatic of disease (figure 3.3). Un-induced Wild-type, 
AhCre " Lkbl and Cre'Lkbl^  cohorts all survived to 200 days and did not significantly
differ from each other (Chi-squared test). However, all un-induced AhC re+ Lkbl^ male 
mice became ill by 2 0 0  days, with a significantly reduced average survival of 83 days 
compared to all other cohorts.
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Figure 3 3 : Un-induced AhCre+Lkbl*1*1 male mice display reduced longevity. A Kaplan-Meier 
plot of the un-induced wild-type (n = 26), AhCre Lkbl *^  (n = 41), Cre'Lkbl*1*1 (n = 20) cohorts all 
represented in green and un-induced AhCre Lkbl*1*1 mice (n = 26) illustrated in purple. Un-induced 
AhCre ' Lkbl*1*1 mice show decreased longevity, with 100% of the cohort not surviving past 200 days. 
Chi-squared tests confirmed un-induced AhCre ' Lkbl*1*1 mice exhibit a significantly reduced average 
survival of 83 days compared to un-induced wild-type (p < 0.0001, %2 = 39.85), AhCre' L k b l /Jl (p < 
0.0001, x2 = 59.01) and Cre'Lkbl*1'*1 (p < 0.0001, x2 = 31.97) cohorts. Statistical analysis was carried 
out using a Chi-squared test using “MiniTab” software.
3.3.2 Un-induced AhCre+Lkbl*1**1 mice develop multiple GU tract phenotypes
Histological analysis o f  the genitourinary (GU) tract is summarised in Table 3.1. No 
gross phenotype was observed in un-induced wild-type (n = 21) and A hC re+L k b l+/*1 (n = 18) 
mice aged to 200 days. The un-induced AhCre+Lkbl*1**1 cohort (n =  18) was predisposed to a 
number o f GU tract phenotypes. The anterior prostate from un-induced AhCre+Lkbl*1**1 mice 
between 2-4 months o f  age revealed foci o f  atypical hyperplasia (AH) with 100% incidence. 
Progression to high-grade prostate intra-epithelial neoplasia (HG-PIN) was also observed 
(83% incidence), predominantly in the proximal region o f  the duct. Neoplastic lesions were 
observed as early as 8 weeks when mice became sick. Dorsolateral and ventral lobes 
displayed a less severe phenotype, where cells exhibited nuclear atypia associated with focal 
epithelial hyperplasia with 61% and 56% incidence respectively. These mice were also 
prone to an interstitial immune infiltrate throughout the GU tract (100% incidence), which 
in 33% o f the cohort obstructed the prostate lumen (resembling prostatitis). Additional male 
accessory glands other than the prostate also manifested aberrant architecture in the un-
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induced AhCre+Lkbl-^1 cohort. Hvpemlastic bulbourethral eland (BUG) cvsts were 
observed with 1 0 0 % incidence and a subset of the cohort also developed urethral 
hvperplasia (39%) and seminal vesicle squamous metaplasia (11%). Furthermore, both un- 
induced Cre L k b l^  (n = 19) and AhCre+L k b l^  cohorts were infertile with 100% 
incidence, corresponding to a previous studv (Sakamoto et al.. 2005).
Table 3.1 Phenotype incidence in un-induced /4/rOe-mediated L kbl deficient 
transgenic mice
^Genotype
Phenotype""--^
Wild-type
(n=21)
AhCre+Lkbli/JI
(n=18)
CreLkbljVJ1 
(n =19)
AhCre+LkblJIJI
(n=18)
Anterior AH 0 0 0 18(100%)
Anterior PIN 0 0 0 15 (83%)
Dorsolateral AH 0 0 0 11 (61%)
Ventral AH 0 0 0 10 (56%)
Inflammation 0 0 0 18(100%)
Prostatitis 0 0 0 6 (33%)
Bulbourethral 
gland cyst
0 0 0 18(100%)
Urethral
hyperplasia
0 0 0 7 (39%)
Seminal vesicle
squamous
metaplasia
0 0 0 2 ( 1 1 % )
Infertile 0 0 19(100%) 18(100%)
3.3.3 Un-induced AhCre+L k b l ^  mice are predisposed to prostate neoplasia
Histological analysis of the genitourinary (GU) tract was in accordance with the 
consensus report from the Bar Harbor meeting of the mouse models of human cancer 
consortium prostate pathology committee (Shappell et al., 2004) and confirmed by Prof. 
Collins (urology consultant histopathologist, Bristol Royal Infirmary).
Un-induced control anterior prostate (Cre'Lkbl^1) demonstrates normal single­
layered, ordered branching of the prostate epithelium that project into the lumen and show 
normal secretory function at 200 days (figure 3.4a-b). Un-induced AhCre+Lkbl^/J] 
demonstrated AH and PIN lesions at terminal end-points. Characteristic of hyperplasia, tufts 
of cells demonstrating aberrant architecture of the acini have accumulated within the lumen, 
displaying loss of cellular polarity, mitotic bodies and cytological atypia, including 
prominent nucleoli and nuclear enlargement (figure 3.4c-d).
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Figure 3.4: Un-induced A/rOe-mediated deletion of Lkbl predisposes to PIN. Histological 
analysis of H&E stained formalin-fixed, paraffin-embedded tissue from un-induced Cre'Lkb and 
AhCre Lkb f mice aged 2-7 months. Un-induced Cre Lkb lf l anterior prostate at low (a) and high 
magnification (b) shows ordered architecture of normal epithelium. Atypical hyperplasia in the un- 
induced AhCre Lkb 1 ^  mutants illustrates tufting of luminal cells and cytological atypia (c-d). 
Progression to PIN was observed in 83% of the cohort, demonstrating cribriform architecture (e), 
apoptosis (arrow) and cytological atypia, such as enlarged nuclei and mitosis (arrow head) (f). 
Dorsolateral (g-h) and ventral (i-j) prostate lobes exhibited hyperplasia in association with nuclear 
atypia in the un-induced AhCre L k b l^  cohort. Images were taken at low power (20x) or high power 
(40x) magnification and scale bars represent 50 pm.
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W ithin PIN lesions, solid and cribriform intra-luminal proliferation o f  markedly 
atypical epithelial cells was accompanied by cytological (nuclear) atypia such as nuclear 
enlargement, pleomorphism, chromatin abnormalities, an increased prom inence o f  nucleoli 
and mitotic bodies (figure 3.4e-f), (Brawer, 2005; Shappell et a l , 2004). This process was 
also coupled to thickened stroma surrounding the acini and a scattered interstitial infiltrate 
o f  lymphocytes and plasma cells. Sparse lymphocytes were also observed within some AH 
and PIN lesions, which in severe cases obstructed prostate acini resulting in gross tubular 
dilation. Dorsolateral and ventral lobes displayed a less severe phenotype, where cells 
exhibited nuclear atypia associated with focal epithelial hyperplasia (figure 3.4g-j).
3.3.4 Un-induced mice develop bulbourethral gland cysts, urethra
hyperplasia, seminal vesicle squamous metaplasia and inflammation of the GU tract
The un-induced AhC re+L k b l ^ 1 cohort could be identified visually from  6-8 weeks 
o f  age because 100% o f the mice developed swellings at the base o f  the tail (figure 3.5a-b). 
Histological analysis from this region revealed un-induced AhCre*Lkb 0 1 mice are prone to 
developing cystic bulbourethral glands associated with hyperplastic acini (figure 3.5c-f). 
The acinar mucosal epithelium o f the glands was characterised by a loss o f  cellular polarity 
and was composed primarily o f  ductal cells, consistent with reduced secretory function and 
depleted foamy cytoplasm, similar to an Nkx3.1 deficiency (Bhatia-Gaur et al., 1999).
Cre Lkb lm
AhCre* Lkb lm
Figure 3.5: Un-induced AhCre*Lkbmice develop bulbourethral gland cysts. Compared to 
control cohorts (a), un-induced AhCre'Lkb^mice developed bulbourethral gland cysts at the base 
of the tail (b) by 6-8 weeks of age. Histological analysis of formalin-fixed, paraffin-embedded H&E 
sections revealed ordered acini in control cohorts (c and e) while un-induced AhCre L k b mice 
demonstrated chronic infection (*) (d), reduced secretory function and over populated acini (f). 
Histology images were taken at 20x (low) and 40x (high) magnification and scale bars represent 50 
pm.
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The un-induced A hC re ' Lkb ^  cohort manifested urethral gland hyperplasia (39% 
incidence). Wild-type urethral glands typically form a narrow layer between the muscle and 
lamina propria o f the urethra (figure 3.6a), while un-induced AhC re Lkb lJlJ] mutants 
displayed nodular hyperplasia of the membranous urethra transitional epithelium within the 
lamina propria. In conjunction with this, cytological atypia and proliferation of the urethral 
glands was evident (figure 3.6b). Using the “Analysis” imaging software (Olympus Soft 
Imaging System, GMBH, demonstrated in figure 3.6c-d) the area of the urethral gland and 
transitional epithelium in un-induced wild-type , Cre'Lkb 1 ^ ,  AhCre L kb l :/7 and 
AhCre LkbIJ1 ^  mice was determined (average area 4.87 x 106 pm2). Compared to all other 
genotypes (total average area 1.27 x 106 pm2), the un-induced AhCre L k b l transgenic 
line showed a statistically significant 3-fold increase in the urethral gland and epithelium 
area (p = 0.001 compared to un-induced wild-type mice, Mann Whitney), (figure 3.6e).
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Figure 3.6: Un-induced AhCre*L k b mice develop hyperplasia of the urethra. Histological 
analysis of formalin-fixed, paraffin-embedded H&E sections aged 2-7 months revealed that un- 
induced AhCre Lkbl J1 and Cre Lkblflfl cohorts developed wild-type urethral transitional epithelium 
that lies above the lamina propria (LP) and faces the urethral lumen. The urethral glands (UG) also 
exhibit an ordered structure beneath the LP (a). Un-induced AhCre LkblflJI mice taken at end point 
demonstrated nodular urethral gland hyperplasia (circle) and proliferation o f the transitional 
epithelium (b). Measurements of the outside (c, red line) and inside (d, green line) of the transitional 
epithelium and urethral glands using “Analysis” imaging software (Olympus Soft Imaging System, 
GMBH) allowed semi-quantitative estimates of the area o f the urethra. Images were photographed at 
4x (low power) or 20x (high power) magnification and scale bars represent 50 pm. The area of the 
urethra for each genotype is plotted in (e), indicating a 3-fold increase in the un-induced 
AhCre L kb l"11 cohort (n = 8). Statistical analysis was performed using the non-parametric Mann 
Witney test (MiniTab Software, 95% confidence interval) revealing a significant difference between 
AhCre Lkbl fI mutants (*) compared to un-induced wild-type (p = 0.0011, n = 8), AhCre Lkbl ,l (p 
= 0.0029, n = 7) and Cre LkblJlJ] (p = 0.0019, n = 9) mice. Error bars represent standard deviation.
,
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A small proportion o f  the un-induced AhCre L kb lJlJ1 cohort also developed seminal 
vesicle squamous m etaplasia (11%  incidence). The seminal vesicle typically functions to 
store sperm in male adults. Un-induced Wild-type, AhCre L k b l ' 11 and C r e ' L k b r mice all 
displayed normal single-layered branched architecture (figure 3.7a). Seminal vesicle 
squamous metaplasia in un-induced AhCre L k b l,l,J deficient m ice com prised o f 
proliferation o f  the transitional epithelium  into the lumen and flattening o f  the epithelial 
cells (figure 3.7b).
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Figure 3.7: Un-induced ,4/rOe-mediated deletion of Lkbl predisposes to seminal vesicle 
squamous metaplasia. Histological analysis of H&E stained formalin-fixed, paraffin-embedded 
seminal vesicle tissue from un-induced Cre Lkbl1111 and AhCre Lkb l,ljl mice was carried out on 
cohorts aged 2-7 months. Control seminal vesicles display a single layered structure with regular 
infoldings into the lumen (a). Un-induced AhCre Lkbl1 ^  mice were predisposed to squamous 
metaplasia of the seminal vesicle that showed flattening of epithelial cells as they proliferated into 
the lumen, which contained scattered lymphocytes and cellular debris (b). Images were 
photographed at 40x magnification and scale bars represent 50 pm.
U n-induced AhCre L kb lAA mice displayed inflam m ation o f  the GU tract (figure 
3.8). Neutrophils and m ononuclear inflamm atory cells were present w ithin the prostate 
glandular epithelium, the lumen o f  the prostate gland (33%  incidence) and the prostatic 
strom a (100%  incidence). The infection resembled both chronic prostatitis and cystic lesions 
observed in the bulbourethral glands.
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Figure 3.8: Un-induced AhCre+Lkbt/ l male mice develop GU tract inflammation. Formalin- 
fixed, paraffin-embedded H&E sections from un-induced AhCre Lkblj],] anterior prostate aged 2-7 
months. Immune infiltrate was observed in the interstitium (a-b) and inside prostate acini, 
resembling prostatitis (c). Images were taken at 20x (low power) and 40x (high power) 
magnification and scale bars represent 50 pm. Arrowheads indicate immune cell infiltration.
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It is important to note that areas devoid of inflammation still exhibited hyperplasia 
and PIN (shown in figure 3.4). This indicates that PIN is not likely to be a consequence of 
reactive hyperplasia caused by inflammation (termed proliferative inflammatory atrophy or 
PIA), which occurs in approximately 20% of human prostate cancers (DeMarzo et al., 
1999). Indeed, the PIN lesions are considered to reflect Lkbl loss in the prostate epithelium 
and it is speculated that the development/disruption of cystic bulbourethral glands in un- 
induced AhCre+L k b 0 1 mice is the cause of an aggressive inflammatory response within the 
GU tract. The BUG lesions are also thought to be responsible for the reduced life-span, thus 
preventing progression to more advanced stages of prostate cancer, such as adenocarcinoma 
and metastasis, from its acknowledged precursor PIN in un-induced AhCre L k b l ^  mice 
(average survival was 83 days).
3.3.5 Un-induced C re 'L k b P ^  and A h C re +L k b l ^  male mice are infertile
Un-induced wild-type and AhC reLkbC ^1 mice are fertile while un-induced Cre' 
LkbP1^  and AhCre+L k b l ^  adult male mice are sterile (100% incidence). Male infertility 
has been reported previously in un-induced C re 'L kb l^  mice and is considered to reflect the 
hypomorphic nature of the Lkbl floxed allele (Sakamoto et al., 2005). Sakamoto et al 
(2005) reported that in addition to the 50 kDa protein corresponding to full length Lkbl, the 
LKB1 antibody employed in an immunoblot analysis of the mouse testis also recognised a 
48 kDa species. Interestingly, the faster migrating species was not detected in un-induced 
C re 'L kb l^  mice, while the 50 kDa species was reduced 10-fold (Sakamoto et al., 2005).
The testis consists of a coil of seminiferous tubules, the site of spermatogenesis 
(figure 3.9a). The epididymis is split into four compartments consisting of the initial 
segment, caput (head), corpus (body) and cauda (tail) (figure 3.9b) and forms a coiled 
structure that surrounds the testis. Sperm pass through the epididymis to complete the 
maturation process. Histological analysis revealed that un-induced Cre'Lkblm  and un- 
induced AhCre+L k b l ^  testes display hypospermatogenesis, where the seminiferous tubule 
epithelium and spermatogenesis is reduced (figure 3.9c-e). This phenotype was concomitant 
with aspermia in the epididymis (figure 3.9f-q). The lumen o f the epididymis in un-induced 
C re'Lkbf/Jl and AhCre+LkblM  mice contained cellular debris and the epididymal 
epithelium displayed several apoptotic bodies.
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Figure 3.9: Un-induced Cre L k b l ^  and AhCre+L k b ^  males are  infertile, (a) Illustrates the 
ultrastructure of the seminiferous tubules that comprise the mouse testis, (b) Depicts the four major 
compartments of the murine epididymis; initial segment, caput, corpus and cauda. Formalin-fixed, 
paraffin-embedded H&E stained sections from adult male mice aged 2-7 months were analysed. Un- 
induced wild-type testis (c) illustrates normal spermatogenesis and seminiferous tubule epithelium 
consisting of many layers of spermatogenesis. Un-induced C re 'L k b f11 and AhCre L k b r fl cohorts 
both demonstrated hypospermatogenesis and a decrease in the epithelial layer of the seminiferous 
tubule (d-e). Un-induced wild-type epididymis compartments all contain maturing sperm in the 
lumen while un-induced Cre L k b l^  and AhCre LkbClf] cohorts are devoid of sperm and cellular 
debris is present (f-q). All images were taken at 40x magnification and scale bars represent 50 pm. 
Figure (a) is adapted from “The Mouse Histology Atlas” (http://www.deltagen.com/ 
target/histologyatlas/HistologyAtlas.html) and (b) is adapted from “The Androgen Society” 
(http://www.andrologysociety.com).
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3.3.6 The un-induced A h C re  transgene mediates recombination in the male GU tract
Un-induced AhCre L k b l ^  male mice developed a number o f GU tract phenotypes, 
indicating that expression of the AhCre construct may occur in the absence of exogenous 
xenobiotics. To characterise the pattern of endogenous stimulation o f the AhCre transgene, 
double transgenics harbouring both the AhCre transgene and the Rosa26R reporter locus 
were utilised. Figure 3.10 shows X-gal staining of tissue sections, where recombination 
events are indicated by excision of the STOP cassette in the Rosa26 reporter construct, 
permitting P-galactosidase expression and resulting in a blue stain (detailed in section 
1.2.4).
LacZ staining of induced AhCre+Lkbl^  mice revealed that recombination takes 
place in the small intestine and liver, while un-induced AhCre'Lkblm  mice do not 
recombine in these tissues (figure 3.10a-d), corresponding to previous studies (Ireland et a l ,
2004). LacZ staining determined that endogenous activation o f the AhCre construct occurs 
without xenobiotic induction in all four lobes of the prostate in un-induced AhCre+Lkbl^ 
mice (figure 3.10e-j). Endogenous stimulation of the AhCre transgene was also identified in 
components of the GU tract including the bladder, seminal vesicle, urethral glands, 
bulbourethral glands, testis, vas deferens and all four compartments o f the epididymis. In all 
except the bladder, a phenotype was observed in these tissues, highlighting the widespread 
role of Lkbl in the mouse as a tumour suppressor. Given that the bladder was not prone to 
tumourigenesis in un-induced AhCre+Lkbl^ mice, it is possible that un-induced AhCre- 
mediated recombination in the transitional epithelium of the bladder occurs in cells that are 
not tumour initiating or that Lkbl does not act as a tumour suppressor in this tissue.
Un-induced A /zOe-mediated recombination was also detected in the stomach and 
kidney of un-induced AhCre+Lkbl^ mice (figure 3.10d, m and n). Indeed, un-induced 
AhCre+ transgenic mice homozygous for a conditional Ape allele (AhCre+Apc/1^ )  have 
previously been shown to develop renal carcinoma (Sansom et al., 2005). Here, histological 
analysis revealed no gross phenotype in the kidney or stomach in AhCre+Lkblfl/jl mice aged 
2-7 months.
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Figure 3.10: Un-induced /lACrc-mediated recombination of Lkbl occurs within the GU tract.
Tissue from adult transgenic mice (aged 2-4 months) was harvested for the detection of Ah driven 
Cre recombinase activity using X-gal staining (blue stain). AhCre L k b l^  positive controls were 
exposed to four daily i.p injections of P-naphthoflavone (80 mg/kg) and harvested 6 days later. This 
strategy of induction has been reported to be sufficient for near 100% recombination in the small 
intestine (a) and liver (b), (Ireland et a l, 2004). Un-induced controls were negative (c-d). Cross- 
sections from un-induced Cre L k b l and un-induced AhCre L k b l^  anterior (e-f) lateral (g-h), 
dorsal (i-j) and ventral (k-1) prostate lobes revealed that endogenous activation of the AhCre 
construct occurs in all four lobes. Punctate staining shown in (e) is attributable to endogenous P- 
lactamase activity. AhCre-mediated recombination was also detected in un-induced AhCre L k b l^  
kidney (m), stomach (n), seminal vesicle (o), bladder (p), urethral glands (q), bulbourethral glands 
(r), testis (s), vas deferens (t), and the epididymis initial segment (u), caput (head) (v), corpus (body) 
(w) and cauda (tail) (x). This indicates that a wide variety of tissues are capable of activating 
expression of the AhCre construct without xenobiotic stimulation. Images were photographed at 20x 
(a and c) or 40x magnification (b, d-x) and scale bars represent 50 pm.
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3.3.7 Un-induced AhCre+Lkbl^  PIN lesions are recombined
To confirm that the Lkbl kinase domain had been deleted in the neoplastic prostate 
tissue, PCR was performed on DNA extracted from laser capture microdissected (LCMD)
tissue. This approach was taken as insufficient tissue was available for western blots, and
immunohistochemistry using anti-Lkbl antibodies did not detect a product in control tissue 
and was therefore inappropriate to demonstrate loss of function. This is likely to reflect the 
low expression level of Lkbl within prostate epithelium.
For PCR amplification, positive controls were derived from AhCre+L k b l^  mice 
which had been exposed to P-naphthoflavone (induced). This protocol delivers near 100% 
recombination of the target allele in the liver (Ireland et al., 2004). LCMD extracted DNA 
from the anterior prostate epithelia of normal (N) regions from un-induced AhCre+Lkb f 11 
and C r e ' L k b mice served as a negative control for a PCR specific for the recombined 
Lkbl allele (figure 3.11).
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Figure 3.11: Un-induced AhCre+Lkbl™1 PIN lesions are recombined. Using laser capture 
microdissection, DNA was isolated from anterior prostate lobes of un-induced C r e 'L k b ^  and both 
normal (N) and PIN (P) lesions from un-induced AhCre" Lkb I™1 mice and underwent PCR analysis 
(a). Induced AhCre LkbI™1 liver was used as a positive control, where mice were exposed to four 
daily i.p injections of p-naphthoflavone (80 mg/kg) and harvested 6 days later, reported to be 
sufficient for near 100% recombination (Ireland et al., 2004). LCMD extracted DNA from 2 mice 
was run on a gel (although n = 6 for each genotype). The top gel shows the product for the un­
recombined LojcP-flanked Lkbl allele (280 bp), revealing none in the induced positive control, a 
strong band in Cre LkbI*1*1 and AhCre Lkbl™1 normal (N) un-induced samples and reduced levels in 
un-induced AhCre" Lkb I™1 PIN lesions (P). Densitometry suggested that compared to material from 
un-induced Cre'LkbI*1*1 mice there was an 87% reduction in the level o f the un-recombined allele in 
PIN material. The middle gel shows results for the Lkbl recombined allele (500 bp), with a strong 
band in the positive control and a weaker band in the PIN material, reflecting 64% recombination 
compared to the control. Un-induced Cre'LkbI™1 negative controls showed no recombination. The 
lower gel shows a PCR for Pten, employed as a loading control (230 bp).
Lkbl™1
Lkbl recombined
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Densitometry of anterior PIN lesions from un-induced AhCre+L k b l ^  mice showed 
64% of Lkbl alleles to be recombined (when compared to fully recombined liver controls). 
This correlated with a marked reduction in the level of the un-recombined ToxP-flanked 
Lkbl allele (87%). The fact that recombination was below 100% presumably reflects the 
observed stromal content in the PIN lesions. These observations establish that 
recombination of the ZojcP-flanked Lkbl allele is associated with PIN, but cannot 
discriminate between the hypomorphism and haploinsufficiency of Lkbl.
3.3.8 I n  s itu  hybridisation determined L k b l  is deficient in un-induced A h C re +L k b ^  
prostate
To further validate if Lkbl is present in wild-type murine prostate and that 
AhCre L k b l ^  PIN lesions are deficient for Lkbl, an in situ hybridisation was carried out. 
This procedure requires a labelled complementary strand, termed a probe, o f either DNA or 
RNA that hybridises to the target sequence within a tissue section. The pYX-Asc vector 
(figure 3.12a) containing a sequence verified full length Lkbl clone (PUBMED ID: 
BC052379) was ordered from RZPD (#IRAVp968ED, Germany) in E. coli, strain DH10B 
TonA. The vector is selected for using ampicillin resistance and contained both T3 and T7 
PCR promoters. To synthesise the probe, the Lkbl containing cells were grown on 
ampicillin agar, cultured and large quantities of DNA isolated using a Midi-prep kit 
(Qiagen). To prepare anti-sense (hybridisation) and sense (control) single-stranded RNA 
probes it is necessary to determine the orientation of the Lkbl insert. To this end, 
linearization of the vector was carried out by either EcoRX or Not\ restriction digest and 
primers to T3 or T7 promoters within the vector were used to initiate sequencing (figure 
3.12b-c). Sequencing analysis (carried out by the DNA sequencing core, Cardiff University) 
determined that the T7 primer is at the 3’-end of the Lkbl insert, allowing the insert to be 
transcribed from linearised DNA using the appropriate polymerase (i.e. T7 for anti-sense 
and T3 for sense probes) and DIG labelled. A double restriction digest using EcoK\ and 
Notl confirmed the size of the insert as 1.7 kb and only fully digested samples were chosen 
for RNA probe generation and DIG labelling (figure 3.12d-e).
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Figure 3.12: Probe preparation for Lkbl specific in situ hybridisation. The Qiagen Midi-prep kit 
was used to prepare large scale production of the pYX-Asc vector, 1.69 kb (a) carrying a full length 
Lkbl clone (1.7 kb, PubMed ID: BC052379) ordered from RZPD (IRAVp968E05123D, Germany). 
The vector was successfully linearised using EcoKl (b, top) or Not] (b, bottom) restriction enzymes 
and samples were run on a 1% agarose gel producing a band 3.4 kb in size. UE and UN represent 
undigested controls for EcoR\ and Notl digests respectively (c). A double restriction digest using 
EcoRl and Notl restriction enzymes determined the insert size to be 1.7 kb, the same as the vector, 
where U represents an undigested sample and lanes 1-6 represent double digest samples (d). The 1 
kb ladder shown in (c) is the 1 kb Plus DNA Ladder (Invitrogen) and the Standard 1 kb Ladder 
(Promega) is shown in (d). Linearised DNA was sequenced using PCR primers specific to the T3 
promoter for EcoRl digested DNA and the T7 promoter for Notl digested DNA (carried out by the 
DNA Sequencing Core, Cardiff University) to confirm sequence orientation and identity. The 
orientation of the insert determined the anti-sense and sense templates (e). The pYX-Asc vector map 
in (a) was adapted from the RZPD website.
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In situ hybridisation revealed that Lkbl mRNA transcripts are present in all four 
lobes of the prostate of un-induced wild-type mice and that Lkbl transcript levels were 
undetectable in un-induced AhCre' Lkb lJl 11 mice (figure 3.13). A sense RNA probe 
determined that no non-specific binding occurred.
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Figure 3.13: Reduced Lkbl mRNA in un-induced AhCre+Lkblfl/fl prostate. In situ hybridisation 
using formalin-fixed, paraffin-embedded sections was performed to detect Lkbl mRNA in un- 
induced wild-type anterior, ventral and dorsolateral prostate lobes. The sense RNA probe determined 
there was no non-specific staining (a-c) and the anti-sense probe to Lkbl revealed that Lkbl is 
expressed in un-induced wild-type prostate epithelia (d-f)- Un-induced AhCre Lkb f  J1 prostate did 
not express the Lkbl mRNA transcript (g-i). Images were taken at 40x magnification and scale bars 
represent 50 pm.
3.3.9 Analysing the un-induced AhCre+L k b l ^  prostate phenotype
To further characterise the anterior prostate lesions at a molecular level, 
immunohistochemistry was performed. The proliferation marker, Ki-67, was rarely 
expressed in un-induced control {Cre'Lkb l ,Vfl) anterior prostate epithelium, however it was 
significantly elevated in epithelial cells throughout the acini of un-induced AhCre' Lkb 1 ^  
mice (figure 3.14a-b). Basal cells were detected using antibodies against p63 and Keratin-5 
in the epithelial lining of anterior acini (Shappell et al., 2004), indicating a marked 
accumulation and clustering of these cells within PIN foci (figure 3.14c-f). Keratin-18, an 
epithelial tumour marker (Shappell et al., 2004), is not highly expressed in control anterior 
acini epithelium while PIN lesions showed elevated expression, mimicking human prostate
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cancer (Shappell et al., 2004), (figure 3.14g-h). AR is a pivotal mediator of prostate 
carcinogenesis (Isaacs and Isaacs, 2004). AR activation and downstream signalling in 
response to engaging androgens is required for prostate growth, particularly within the 
epithelial population (Prins et al., 1991). In agreement, Lkbl deficient PIN showed an 
increase in the number of cells expressing AR in the nucleus, suggesting that loss of Lkbl is 
deregulating androgen signalling, thus promoting tumourigenesis (figure 3.14i-j).
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Figure 3.14: Characterisation of Lkbl deficient prostate intra-epithelial neoplasia.
Immunohistochemical analysis of the anterior prostate of un-induced control {Cre Lkb7 ^ )  and un- 
induced AhCre L k b l^  mice (aged 2-7 months) revealed an increase in proliferation using an anti- 
Ki-67 antibody (a-b), arrow head indicates a homeostatic level of proliferation in normal anterior 
prostate epithelium. Basal cell clustering was determined by monitoring p63 (c-d) and Keratin-5 (e- 
f) expression, which were over-expressed in neoplastic lesions. The luminal cell marker Keratin-18 
is elevated in PIN foci (g-h) as is the androgen receptor (AR), suggesting deregulation of androgen 
signalling within neoplastic lesions (i-j). Images were taken at 40x magnification and the scale bars 
represent 50 pm.
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Analysis of dorsolateral and ventral lobe atypical hyperplasia (AH) revealed that the 
proliferation marker, Ki-67 (Shappell et al., 2004) was elevated in hyperplastic foci 
compared to control sections (figure 3.15a-d). Using an anti-Keratin-5 antibody, basal cell 
clustering in hyperplastic lesions was detected, particularly in the dorsolateral lobe (figure 
3.15e-h). Immunohistochemistry to detect Keratin-18 determined the luminal cell 
population has become disorganised in un-induced AhCre+L k b l^  dorsolateral and ventral 
prostate epithelium, where layers of cells have arisen in AH foci that contain enlarged, 
centrally located nuclei (figure 3.15i-l). The number of cells expressing AR was also 
increased in AH lesions (figure 3.15m-p), indicating that Lkbl deletion in the dorsolateral 
and ventral prostatic epithelium parallels that of the anterior prostate and may promote 
androgen-induced tumourigenesis.
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Figure 3.15: Characterisation of atypical hyperplasia in the dorsolateral and ventral lobes of
Lkbl deficient mice. Immunohistochemistry of 10% formalin-fixed, paraffin-embedded sections 
from un-induced control (CreLkb 1 ^ )  and un-induced A h C r e " L k b mice aged 2-7 months 
revealed an increase in proliferation using an anti-Ki-67 antibody in both the dorsolateral (DLP) and 
ventral (VP) lobes (a-d). Arrowheads indicate a basal level of proliferation in normal epithelium. 
Basal cell clustering was detected in hyperplastic foci by monitoring Keratin-5 expression (e-h). The 
luminal cell marker Keratin-18 was expressed in control prostate epithelium and was upregulated in 
Lkbl deficient AH foci (i-1). AR was upregulated in hyperplastic lesions, suggesting deregulation of 
androgen signalling (m-p). Images were taken at 40x magnification and scale bars represent 50 pm.
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3.3.10 Characterisation of un-induced A h C re ^ L k b P 1^  bulbourethral gland, urethra 
and seminal vesicle lesions
Un-induced ^4/*Oe-mediated recombination of the floxed Lkbl transgene also 
occurred in the bulbourethral gland (BUG), urethra and seminal vesicle (figure 3.10). These 
tissues displayed abnormalities that were characterised further by means of 
immunohistochemistry. Firstly, un-induced AhCre'Lkb !m  mice were predisposed to 
hyperplasia of the BUG in association with the development o f cystic lesions. 
Immunohistochemistry determined that un-induced AhCre+Lkbl^fl BUGs exhibited elevated 
Ki-67 staining within the hyperplastic ductal cells and immune infiltrate, indicating these 
lesions are highly proliferative (figure 3.16a-b). Keratin-5 and Keratin-18 were also 
upregulated in un-induced AhCre L k b l^ 1 BUG lesions, consistent with transdifferentiation 
of the ductal cells (figure 3.16c-f). In addition, AR was highly expressed in un-induced 
AhCre 'Lkb 1 ^  BUG lesions, suggesting aberrant androgen signalling within the androgen- 
dependent tissue (figure 3.16g-h).
The BUG phenotype mimics that of a recently published transgenic mouse model 
bearing an Ape deficiency (Bruxvoort et al., 2007) and in P-catenin dominant stable mice 
described in chapter 5. Subsequently, immunohistochemistry for p-catenin and two Wnt 
transcriptional target genes, CD44 (a migration marker) (Clevers, 2006; Sansom et a l ,
2004) and Foxal (required for prostate development) (Sinner et a l , 2004) was performed. 
Nuclear p-catenin expression is upregulated in the cystic BUG, while normal BUGs only 
express P-catenin on the cell surface, where it participates in forming adherens junctions 
(figure 3.16i-j). Enhanced CD44 and Foxal expression in cystic BUGs further implies 
activated Wnt signalling (figure 3.12k-n). Taken together, these results demonstrate that 
Wnt signalling is deregulated in Lkbl deficient BUG lesions. Wnt signalling increases 
survival and proliferation as well as stimulating androgen signalling (Yardy and Brewster,
2005), further promoting tumourigenesis and providing a direct mechanism whereby loss of 
Lkbl deregulates Wnt and AR signalling to drive tumour growth.
108
Cre'Lkblm  AhCre+LkbJJI/JI
Ki-67
K5
K18
AR
Figure 3.16: Characterisation of un-induced AhCre+LkbI/I/J1 bulbourethral gland cystic lesions.
Immunohistochemistry of 10% formalin-fixed, paraffin-embedded sections from un-induced control 
(<Cre'Lkb1 ^ )  and un-induced AhCre L k b l^  mice (aged 2-7 months). An increase in proliferation, 
using an anti-Ki-67 antibody (a-b) and Keratin-5 (K5) (c-d) was detected in the BUG ductal cells of 
un-induced AhCre Lkb 1 ^  mice. Arrowheads indicate a basal level of proliferation and K5 
expression. Keratin-18 (K18) (e-f), AR (g-h), and Wnt signalling components, P-catenin (i-j), CD44 
(k-1) and Foxal (m-n) were also upregulated in Lkbl deficient BUGs. This evidence suggests that 
BUG tumourigenesis might be driven by aberrant Wnt and AR signalling. Images were taken at 40x 
magnification and the scale bars represent 50 pm.
Un-induced AhCre+L k b l^  mice were predisposed to urethral gland and transitional 
epithelium hyperplasia. Analysis of this phenotype by immunohistochemistry determined 
that the proliferation marker Ki-67 (figure 3.17a-b) and Keratin-5 (figure 3.17c-d) 
expression is elevated in urethral lesions while Keratin-18 expression was not altered (figure 
3.17e-f). Androgen receptor is highly expressed in un-induced Cre'Lkbl^1 control urethral 
transitional epithelium and this level of expression was maintained in the un-induced 
AhCre+L k b l^  hyperplastic lesions (figure 3.17g-h). Further investigation determined that 
urethral tumourigenesis is associated with an increase in the nuclear localisation of p- 
catenin, suggesting Wnt signalling is active in this tissue (figure 3.17i-j). Consistent with 
this, Wnt transcriptional targets CD44 (figure 3.17k-l) and Foxal were also over expressed
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(figure 3.13m-n). As shown for the BUG cysts, loss of Lkbl deregulates Wnt signalling and 
AR signalling to drive tumour growth.
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Figure 3.17: Characterisation of un-induced AhCre+LkbIfl//l urethral gland and transitional 
epithelium hyperplasia. Immunohistochemistry of 10% formalin-fixed, paraffin-embedded sections 
from un-induced control (Cre L kb l^1) and un-induced AhCre LkbF^1 mice aged 2-7 months 
revealed an increase in proliferation of the un-induced AhCre L k b urethral glands and 
transitional epithelium using an anti-Ki-67 antibody (a-b). The arrow in (a) indicates a basal level of 
proliferation in the urethra. Keratin-5 (K5) is located in the basal layer o f the transitional epithelium 
that is 1-2 cells thick in control tissue (c). In un-induced AhCre Lkb I*1*1 hyperplastic foci, K5 is 
expressed continuously throughout hyperplastic foci, some 4-8 cells thick (d). Keratin-18 (K18) is 
expressed within the urethral glands (e) and expression was not altered in un-induced AhCre+Lkbl^fl 
urethral lesions (f). AR is highly expressed in control transitional epithelium, and the number of 
cells expressing AR in hyperplastic lesions was increased (g-h). Wnt signalling components, (3- 
catenin (i-j), CD44 (k-1) and Foxal (m-n) were all upregulated in urethral tumours. Images were 
taken at 40x magnification and scale bars represent 50 pm.
Seminal vesicle squamous metaplasia occurred with 11% incidence in un-induced 
AhCre+L k b l^  mice. Immunohistochemistry determined that tumours over-expressed the 
proliferation marker Ki-67 (figure 3.18a-b) as well as Keratin-5 and Keratin-18 (figure 
3.18c-f). Nuclear AR was also upregulated in control and tumour tissue (figure 3.18g-h), 
possibly reflecting the fact that seminal vesicle growth is regulated by androgens.
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Immunohistochemistry for p-catenin revealed that nuclear translocation is increased in the 
lesions compared to control tissue, where p-catenin is only expressed on the cell surface 
(figure 3.18i-j). Activation of the Wnt cascade was further validated by detecting the over­
expression of the Wnt target genes CD44 and Foxal (figure 3.18k-n). These results suggest 
that androgen signalling may not play a role in Lkbl deficient metaplasia of the seminal 
vesicle. However, loss of Lkbl has been shown to deregulate the Wnt pathway in this tissue, 
revealing a potential mechanism for tumourigenesis.
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Figure 3.18: Characterisation of seminal vesicle squamous metaplasia in un-induced
AhCre+LkblfI/fl mice. Immunohistochemistry of 10% formalin-fixed, paraffin-embedded sections 
from un-induced mice aged 2-7 months revealed that cells expressing Ki-67 (a-b), Keratin-5 (K5) (c- 
d), Keratin-18 (K18) (e-f), and AR (g-h) were all elevated in seminal vesicle squamous metaplasia. 
Increased expression of nuclear p-catenin (i-j) indicated aberrant Wnt signalling in lesions. 
Downstream transcriptional targets of the Wnt pathway were also upregulated, namely CD44 (k-1) 
and Foxal (m-n), indicating that the Wnt cascade is activated in Lkbl deficient seminal vesicle 
squamous metaplasia. Images were taken at 40x magnification and scale bars represent 50 pm.
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33.11 Characterising male sterility in un-induced C re'Lkb^1 mice
Histology studies o f  the testis and epididymis from male cohorts determined 
infertility to be associated with reduced Lkbl expression in both un-induced Cre'Lkb 1 ^  and 
un-induced AhC re'Lkbl^1 male mice (figure 3.9). In situ hybridisation specific for Lkbl 
mRNA determined that Lkbl is expressed in all four compartments o f  the epididymis and in 
the seminiferous tubules o f the testis in wild-type mice (figure 3.19). Interestingly, the 
spermatozoa also highly express the Lkbl transcript, correlating to an immunohistochemical 
study in humans (Conde et al., 2007). Un-induced Cre'Lkb!fl/jl mice displayed a marked 
reduction in the level o f  Lkbl mRNA expression, in the testis, spermatozoa and epididymis. 
The sense probe served as a negative control.
Initial segment
Caput
Corpus
Cauda
Seminiferous tubule
Figure 3.19: Un-induced Cre'Lkb1?® testis and epididymis have reduced Lkbl mRNA 
transcripts. In situ hybridisation was carried out using probes described in section 3.3.8 on 
formalin-fixed, paraffin embedded sections (aged 5 months). Un-induced wild-type prostate 
displayed Lkbl mRNA in all four compartments of the epididymis, seminiferous tubule epithelium, 
Leydig cells and spermatozoa, which was markedly reduced in un-induced Cre L k b l^  mice. The 
sense probe confirmed no un-specific binding occurred. Images were taken at 40x magnification and 
scale bars represent 50 pm.
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A reduction in Lkbl mRNA transcript levels in un-induced Cre Lkbl-*1**1 and un- 
induced AhCre+Lkbl^1*1 testis and epididymis was further confirmed by means o f qRT-PCR 
(figure 3.20). Lkbl mRNA levels in the testis were significantly decreased in Cre'Lkb l*1*1 
hypomorphic mice and AhCre' Lkbl*1*1 mice (70% and 82% respectively) compared to wild- 
type and AhCre+Lkbl+ / testis (p = 0.0404, Mann Whitney), (figure 3.20a-b). The 
epididymis also demonstrated a significant reduction in Lkbl mRNA levels in Cre'Lkb I*1*1 
and AhCreLkbl*1*1 mice (82% and 81% respectively) compared to control cohorts (p = 
0.0404, Mann Whitney test), (figure 3.20c-d).
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Figure 3.20: Un-induced Cre'LkbI*1'*1 and AhCre+Lkbl11*1 mice express reduced levels of Lkbl 
mRNA in the testis and epididymis. qRT-PCR was carried out using RNA isolated from un- 
induced wild-type, Cre'Lkbl*111, AhCre' L k b l /fi and AhCre Lkb l*^ *1 mice (aged 5 months), revealing a 
reduction in the testis (a-b) and epididymis (c-d) within Cre Lkb I*1*1 and AhCre'Lkbl*1*1 mice (n = 3). 
Normalised Ct (ACt) values confirmed that Cre'Lkbl/ljr and AhCre Lkbl*1*1 mice display a significant 
reduction in Lkbl mRNA levels in the testis (a) and epididymis (c) compared to wild-type and 
AhCre' L kb l'/fl cohorts (p = 0.0404 and p = 0.0404 respectively). The level of Lkbl mRNA in the 
hypomorph testis and epididymis was not significantly different to AhCre 'Lkbl*1*1 mice (p = 0.0952 
and p = 0.065 respectively). Error bars represent standard deviation and statistical analysis was 
carried out using a non-parametric Mann Whitney testl using “MiniTab” software (95% confidence 
interval).
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To further characterise male sterility, sperm production in the testis was determined 
by scoring fully developed spermatozoa within the seminiferous tubules (figure 3.21a). Un- 
induced wild-type and un-induced AhCre* Lkb 1*/J1 mice displayed >30 spermatozoa in 100% 
of the seminiferous tubules scored (25 per mouse, n = 3). Scoring un-induced Cre'Lkb 1 ^  
and AhCre* L k b l ^  cohorts revealed that 62% and 75% of the seminiferous tubules 
contained less than 30 spermatozoa respectively, indicative of hypospermatogenesis and 
infertility. Analysis of testis weight determined that atrophy of the organ had not occurred in 
un-induced C re 'L k b l^ 1 mice (average testis weight = 0.096 g, p = 0.3176, Mann Whitney), 
which was not significantly different to wild-types (average testis weight = 0.108 g). 
Atrophy was demonstrated in un-induced A h C re* L kb l^1 mice that were 27% lighter in 
weight compared to wild-type mice (average testis weight = 0.079 g, p = 0.004, Mann 
Whitney), (figure 3.21b).
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Figure 3.21: Un-induced ,4/rOe-inediated Lkbl deficiency in the testis causes
hypospermatogenesis. (a) Fully developed sperm in seminiferous tubules were counted in un- 
induced wild-type, AhCre Lkbl ffl, Cre LkbI*1*1 and AhCre LkbC1*1 adult mice aged 150-200 days (n 
= 3 and 25 tubules were counted per mouse). Both wild-type and AhCre LkbC/fl mice showed 
normal spermatogenesis, where all seminiferous tubules scored contained >30 spermatozoa. Sperm 
counts in un-induced Cre Lkb P1*1 and AhCre Lkb 1 ^  cohorts revealed hypospermatogenesis with 
<30 spermatozoa in 62% and 75% of the seminiferous tubules respectively, (b) Testicle weights 
revealed AhCre Lkb 1 ^  deficient testes (n = 5) were 27% lighter compared to wild-types (n = 12, p = 
0.004), but not the hypomorphs (p = 0.0603). This indicates acute testicular atrophy in the 
conditional knockouts. Error bars represent standard deviation and statistical analysis was carried 
out using a non-parametric Mann Whitney test using “MiniTab” software (95% confidence interval).
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Hypospermatogenesis was investigated further by means of electron microscopy 
(figure 3.22). Micrographs revealed that control seminiferous epithelium displays ordered 
architecture (figure 3.22a-b) and normal spermatozoa production (figure 3.22c). Un-induced 
Cre L k b ^  mice demonstrate loss of cell polarity and apoptosis during spermatogenesis 
(figure 3.22d), along with phagocytosis of dysfunctional sperm (figure 3.22e). Abnormal 
sperm development (figures 3.22f and g) is considered to reflect the hypomorphic nature of 
the Lkbl floxed allele.
Control Cre Lkb ^
Figure 3.22: Morphology of Lkbl deficient testis. Micrographs of un-induced control 
(AhCre' Lkb C /fl) and un-induced Cre'Lkb 1 ^  seminiferous tubule epithelium (aged 5 months) show 
ordered spermatogenesis in control tissue (a-b) and normal spermatozoa (c). In Cre L k b 0 1 testis, 
cell architecture is disrupted indicating loss of cell polarity and many apoptotic cells are present 
(arrow) (d). Cre L k b ^  abnormal sperm appear to be undergoing phagocytosis (e). Abnormal sperm 
are depicted at high power in (f) and (g) where the tail has not formed properly (f) or the head is bent 
(g). Micrographs were taken using the transmission electron microscope (Phillips EM 208).
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Transport of spermatozoa through the coils of the epididymis is necessary for sperm 
maturation and motility (Rankin et al., 1992). The fact that the epididymis tubules were not 
dilated indicates that the epididymis is not obstructed in un-induced C r e 'L k b ^  or un- 
induced A h C re* L kb ^  mice. Spermatozoa debris and macrophages are present in the lumen 
of the tubules and apoptotic bodies were evident in epididymis epithelium. Detection of the 
apoptosis marker, Caspase-3 (apoptosis-related cysteine peptidase, CP322) revealed a 
dramatic increase in the number of apoptotic cells in Cre Lkb lm  epididymis (figure 3.23).
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Figure 3.23: Lkbl deficient epididymis is highly apoptotic. Immunohistochemistry of 10% 
formalin-fixed, paraffin-embedded sections from mice aged 2-7 months to detect the apoptosis 
marker Caspase-3. Un-induced wild-type epididymis (initial segment, caput, corpus and cauda) all 
demonstrated a negligible level of apoptosis while un-induced C re'Lkbrfl and AhCre L k b l^  mice 
showed elevated levels of Caspase-3 positive cells. Images were taken at 40x magnification and 
scale bars represent 50 pm.
Hypospermatogenesis in Lkbl deficient testes does not fully explain the lack of 
spermatozoa in the epididymis. There are several potential scenarios currently 
acknowledged to cause infertility (Rankin et al., 1992), these include; (a) loss of polarity of 
the stereocilia lining the epididymis, thus preventing normal passage of the sperm through 
the lumen, (b) abnormal sperm maturation, (c) deregulated hormone secretion from 
stereocilia required for sperm maturation or (d) loss of motility. Loss of motility is highly 
probable considering Lkbl plays a role in both energy metabolism and cell polarity (Yoo et 
al., 2002) and that Lkbl mRNA is expressed in spermatozoa in mice (figure 3.19) and
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humans (Conde et al., 2007). Nonetheless, mature sperm were not detected in the 
epididymis where the spermatozoa complete the maturation process and gain the ability to 
become motile. Preliminary sperm motility assays did not detect mature sperm in the 
epididymis, only cellular debris (data not shown). To further investigate the cause of 
aspermia in the epididymis, a morphological investigation using electron microscopy was 
carried out. Control epididymis displayed ordered architecture of the epithelium and 
stereocilia (figure 3.24a-b). Micrographs of the un-induced Cre'Lkbl deficient epididymis 
revealed that the principle cells that project stereocilia into the lumen are disorganised and 
show depleted numbers of mitochondria and clumped stereocilia (figure 3.24c-d). This 
suggests that loss of Lkbl might cause infertility in males, owing to a cytoskeletal 
abnormality in the epididymal stereocilia.
Control Cre'Lkb l ^ 1
Figure 3.24: Morphology of Lkbl deficient epididymis. Electron micrographs were taken from 
un-induced control {AhCre'Lkbl+/fl) and un-induced Cre L k b caput epididymis (aged 5 months). 
Control epididymal epithelium demonstrated ordered architecture with a smooth apical surface 
which projects stereocilia (arrow) into the lumen (a). The stereocilia are supported by many 
mitochondria (arrow heads) to provide energy for their movement (b). Lkbl deficient epididymis 
manifested aberrant architecture where the apical surface appears to have lost cellular polarity and 
the stereocilia appear clumped together (c). High magnification of the stereocilia revealed a 
reduction in mitochondria and a disruption in the coordination of the stereocilia from the apical 
surface of the principle cells o f the epididymal epithelium (d). Arrowheads indicate mitochondria 
and arrows point to stereocilia. Micrographs were taken using the transmission electron microscope 
(Phillips EM 208).
117
Together, these data suggest that infertility in Lkbl deficient mice is likely to be 
caused by hypospermatogenesis, abnormal development of sperm in the testis, as well as 
loss of cellular polarity, apoptosis and aberrant stereocilia formation in the epididymis 
epithelium (figure 3.22-3.24). This is in keeping with Lkbl being responsible for 
microtubule integrity (Karuman et a l , 2001). Disruption of stereocilia might prevent sperm 
transport through the coils and could disrupt secretion and absorption o f epididymal proteins 
required for maturation, such as MEP7-10 (Rankin et a l,  1992).
3.3.12 Derivation of L k b l  deficient mice using the P B C re  transgene
The development of bulbourethral gland cysts and interstitial infection of the GU 
tract is believed to be the primary cause of reduced longevity in AhC re+ Lkbl^  male mice, 
which die before advanced lesions have time to develop. To this end, a novel transgenic line 
termed PBCre (described in section 1.2.5) was employed to target the LoxP-flanked Lkbl 
construct to the prostate. This line carries the Cre gene under the control of the composite 
PB promoter, ARR2PB, a derivative of the rat prostate-specific PB promoter, which drives 
Cre recombinase expression in the prostate (Wu et a l,  2001). This promoter is thought to be 
more efficient than the original minimal PB promoter or the large PB promoter and is 
spontaneously activated by androgens (Maddison et a l,  2000; Wu et a l ,  2001).
3.3.13 P B C r e + L k b l^  mice do not show reduced survival
Cohorts of male wild-type {PBCre Lkbl /+ or Cre~Lkbl v ) (n = 21), PBCre Lkbl 1^ 
(n = 14), C r e 'L k b ^  (n = 12), and PBCre+Lkbl^ (n = 8) transgenic mice were generated 
and aged to 500 days or sacrificed owing to ill health (or tumour burden >1 cm). The 
Kaplan-Meier survival plot shown in figure 3.25 compares the survival rates of PBCre 
cohorts harbouring the LoxP-flanked Lkbl allele with aged, un-induced AhCre+Lkb 1+^ and 
AhCre+Lkbl^ cohorts. Only un-induced AhCre+Lkbl^1 mice show a statistically 
significant decrease in longevity compared to all other cohorts (determined using a Chi- 
squared test) and the aged Cre'Lkb 1 ^ ,  PBCre+Lkbl+/fl and P B C r e + L k b lcohorts 
exhibited survival rates similar to the wild-type mice.
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Figure 3.25: Un-induced AhCre*Lkbl11*1 male mice display reduced longevity compared to 
PBCre*Lkbl™1 mice, (a) Kaplan-Meier plot of wild-type (n = 14), un-induced AhCre Lkbl /fl (n = 
13), un-induced AhCre Lkb lm  (n = 26), Cre Lkb ft*1 (n = 12), PBCre L kb l'/Jl (n = 14) and 
PBCre'Lkb (n = 8) mice aged to 500 days or sacrificed when sick. Only un-induced 
A h C reL kb l^  mice demonstrate decreased longevity, with 100% of the cohort not surviving past 
200 days. Chi-squared tests confirmed un-induced AhCre Lkb I*1*1 mice exhibit a significantly 
reduced average survival of 83 days compared to wild-types (p = 0.000, %2 = 65.42), Cre L k b (p = 
0.000, x2 = 29.43) and PBCre' Lkb ^  (p = 0.000, x2 = 20.46) cohorts. Chi-squared tests were 
performed using MiniTab software and the Kaplan-Meier survival curve was generated using 
‘MedCalc’ software.
3.3.14 P B C re + L k b lmice develop multiple GU tract phenotypes
Histological analysis o f H&E sections from all cohorts aged 500 days determined 
several GU tract phenotypes were predisposed in Cre and PBCre+ L kbl deficient mice 
(Table 3.2). Inflammation o f  the GU tract was only observed in a single mouse o f the 
PBCre+Lkblm  cohort that also harboured a BUG cyst, further linking the co-incident 
development o f these two phenotypes that were frequently observed in un-induced 
AhCre*Lkb0 *  mice.
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Table 3.2: Phenotype incidence in PBCre-mediated L kbl deficient transgenic mice at 
500 days
^ '' ' ' '" - - ^ ( j e n o ty p e
Phenotype
Wild-type
(n=21)
PBCre* Lkb 1+/Jl 
(n=14)
PBCre Lkb 1J,JI 
(n=12)
PBCre+Lkblm  
(n=8)
Anterior AH 0 0 9 (75%) 7 (88%)
Dorsolateral/ 
Ventral AH
0 0 3 (25%) 4 (50%)
Anterior LG-PIN 0 0 4 (33%) 0
Inflammation of GU tract 0 0 0 1 (13%)
Bulbourethral gland cyst 0 0 0 1 (13%)
Preputial gland 
keratinised squamous 
metaplasia
0 1 (7%) 6 (50%) 1 (13%)
Seminal vesicle squamous 
metaplasia
0 0 0 1 (13%)
Infertile 0 0 12(100%) 8 (100%)
Stomach hamartoma 0 3 (21%) 4 (33%) 3 (38%)
Kidney abnormalities 0 6 (42%) 4 (33%) 8(100%)
3.3.15 PBCre+Lkbl^  mice develop prostate atypical hyperplasia
Histological analysis of PBCre cohorts aged to 500 days determined that both Cre 
L kbl^  and PBCre Lkb 1 ^  mice were predisposed to a prostate phenotype, while control 
{PBCre Lkb 1 ^ )  prostate showed normal duct architecture (figure 3.26a-c). Cre'Lkb 1 ^  
mice aged to 500 days displayed atypical hyperplasia (AH) in the anterior, dorsolateral and 
ventral lobes of the prostate (75%, 25% and 25% incidence respectively), which progressed 
to LG-PIN in the anterior prostate with 33% incidence. LG-PIN foci displayed cribriform 
structures and cytological atypia, resembling the AhC re L kb lfl/fl model (figure 3.26d-f). 
This phenotype was not observed in Cre'Lkb 1 ^  mice that were only aged to 200 days 
however, differences in strain, background and cellular stress levels may also play a role.
PBCre* Lkb 1 ^  mice developed anterior, dorsolateral and ventral AH foci with 88%, 
50% and 50% incidence respectively and progression to PIN was not observed (figure 
3.26g-i). AH lesions in PB C re+ L kbZ/7/7 mice also demonstrated a high number of apoptotic 
bodies. Interestingly, epithelium of the anterior lobe also exhibited large cytoplasmic 
vacuoles that contained basal and compressed nuclei (figure 3.26g). This phenotype 
resembles mucinous metaplasia observed in PBCre mice bearing an H-/?as activating
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mutation (Scherl et a l , 2004), suggesting that aberrant Ras signalling may play a role in the 
development of these lesions. Consistent with this, concomitant K-Ras activation and LKB1 
inactivation has been demonstrated in human lung adenocarcinomas (Sanchez-Cespedes et 
al., 2002), and a recent mouse lung cancer model has shown cooperativity between K-ras 
activation and Lkbl loss (Ji et al., 2007).
Further investigations are required to determine the nature of the mucinous-like cells 
observed in P B C r e * L k b mice, such as a mucin stain and immunohistochemistry of Ras 
effectors, such as MEK and ERK. In addition, p63 staining might also help to define the 
observed mucinous-like cells, as a similar phenotype was observed in p 6 3 v~ mice. Kurita et 
al (2004) speculated that these cells in p63~ ~ mice indicate impaired differentiation of the 
basal cells and previous work has also reported mucinous adenocarcinoma in humans 
(Odom et a l ,  1986), suggesting that the PBCre Lkb I1111 model resembles human prostate 
pathology.
PBCre+L k b l+/Jl CreL kb lm  PBCre* Lkb lm
Anterior
Dorsolateral
Ventral
Figure 3.26: PBCre-mediated deletion of Lkbl causes prostate atypical hyperplasia.
Histological analysis of formalin-fixed, paraffin-embedded H&E stained prostate sections from 
control (PBCre L k b l /fl) (a-c), Cre Lkb (d-f) and PBCre L k b (g-i) mice (aged 500 days). Cre 
L k b l^  anterior prostate developed LG-PIN (d) while the dorsolateral and ventral lobes developed 
AH (e-f). PBCre L k b ^  mice were predisposed to AH of all four prostate lobes (g-i) and cells 
containing large cytoplasmic vacuoles (mucinous-like cells) were observed in the anterior lobe 
(arrowheads). Images were taken at 40x magnification and scale bars represent 50 pm.
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3.3.16 PBCre* L k b male mice are infertile
Histological analysis of PBCre' Lkbl /fl testis (aged 500 days) revealed normal 
seminiferous tubule epithelium architecture and spermatogenesis (figure 3.27a-b). Cre' 
L k b l^  and PBCre' Lkb 1 ^  male cohorts were infertile (100% incidence), resembling the 
AhCre transgenic line (section 3.3.5). Hypospermatogenesis was observed in C re 'L kb l^  
mice at 500 days (figure 3.27c-d), consistent with that described for C re'L kb l^1 testis at 200 
days and un-induced AhCre Lkblfl/fl mice (figure 3.9). PBCre Lkb 1JVI1 mice demonstrated 
Sertoli-cell-only syndrome (SCOS) with 100% incidence, where the seminiferous tubule 
epithelium is comprised solely from the Sertoli cells (figure 3.27e-f). Interestingly, PJS 
patients develop testicular tumours of Sertoli-cell origin, providing a direct link between the 
transgenic model and the human disease (Westerman and Wilson, 1999). PBCre Lkbl ^  
mice displayed normal epididymis epithelium with abundant sperm in the lumen undergoing 
maturation (figure 3.27g-h). Cre'Lkb P1^1 and PBCre Lkb 1 ^  mice aged to 500 days 
demonstrated aspermia and cellular debris in the lumen of the epididymis and focal 
hyperplasia, enlarged vacuoles and apoptosis of the epididymis epithelium (figure 3.27g-l).
_______________ Testis____________________________ Epididymis
PBCre+
Lkbl*/fl
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Figure 3.27: Lkbl deficient mice are infertile and P/JCr^-mediated recombination predisposes 
to Sertoli-cell-only syndrome. Histological analysis of formalin-fixed, paraffin-embedded 
H&E stained sections of PBCre*LkbV®, Cre'Lkb 1 ^  and PBCre Lkb 1 ^  testis and 
epididymis (caput shown) aged 500 days. Arrows indicate Sertoli cells, showing the 
enlarged, circular nuclei in SCOS lesions compared to the smaller, triangular nuclei of 
normal testis. Images were taken at 40x magnification and scale bars represent 50 pm.
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3.3.17 PBCre+ Lkbl deficient mice develop kidney lesions, stomach hamartomas and 
preputial gland squamous metaplasia
Histological analysis o f PBCre cohorts aged to 500 days determined that 
PBCre ' Lkbl Cre'Lkb^  and P B C r e * L k b mice were predisposed to several non-
prostatic lesions (figure 3.28). PBCre LkbV'fl, Cre Lkb 1™ and PBCre*Lkb^  mice 
developed kidney abnormalities (42%, 33% and 100% incidence respectively) that consisted 
o f gross fatty deposits and epithelial neoplasms (figure 3.28b). In the small neoplasms, 
dilated tubules contained epithelial cells that varied in size and showed enlarged nuclei. This 
phenotype resembled oncocytomas in humans and preneoplastic tubuli in p53 null mice that 
were also heterozygous for Wilms’ Tumour 1 ( Wtl) (Menke et al., 2003). Further renal 
analysis (such as urine and plasma albumin levels to detect renal failure) is required to 
define the aberrant kidney physiology observed in Lkbl deficient mice. The presence o f  the 
fatty deposits has been observed previously in long-term AhCre*Lkb 1+/^  mice (induced with 
(3-naphthoflavone) and is reported to share similarities with glycogen storage diseases (J 
Zabkiewicz, Ph.D. thesis, In vivo modelling o f tumour suppressor gene function, 2005, 
Cardiff University).
Figure 3.28: Lkbl deficient mice develop kidney lesions, stomach hamartomas and preputial 
gland keratinised squamous metaplasia. Histological analysis of formalin-fixed, paraffin- 
embedded H&E stained sections of wild-type and Lkbl deficient (PBCre Lkbl+/fl, C r e L k b ^  or 
PBCre' Lkb l^*1) mice aged 500 days. Compared to wild-type kidneys, P B C r e L k b l^ ,  Cre'Lkb 1 ^  
and PBCre'Lkblflfl mice developed lesions that demonstrated small epithelial neoplasms (arrow) 
and deposits resembling fat (arrowhead) (b). In addition hamartomas in the stomach and pyloric 
region were also observed with a relatively high frequency (c-f). In comparison to wild-type mice, 
Lkbl deficient cohorts manifested keratin pearl formation in association with squamous metaplasia 
within the preputial gland, which also appeared dilated (g-h). Images were taken at 40x 
magnification and scale bars represent 50 pm.
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Hamartomas of the stomach and pyloric region were detected in PBCre^Lkbl+/ 
Cre LkbpW  and PBCre+LkbPl/Jl mice (21%, 33% and 38% incidence respectively) aged to 
500 days (figure 3.28c-f). This is consistent with PJS patients that are predisposed to 
hamartomatous polyps and carcinomas throughout the gastrointestinal tract with a 93% risk 
(Giardiello et al., 1987). In addition, heterozygous, L kb l+/' knockout mice also develop PJS 
symptoms, predominantly gastrointestinal hamartomatous polyposis, directly resembling the 
human disorder (Miyoshi et al., 2002).
The preputial gland is androgen regulated and functions to produce olfactory 
substances. PBCre+L kb l+/fl, Cre'LkbP1*1 and PBCre LkbP1^  mice aged to 500 days were 
also predisposed to keratinised squamous metaplasia of the preputial gland (7%, 50% and 
13% respectively), shown in figure 3.28g-h. Preputial gland keratinised squamous 
metaplasia has been previously demonstrated in mice expressing a dominant stable form of 
p-catenin (Gounari et a l,  2002). This data suggests that Lkbl plays a role in preventing 
tumourigenesis in the preputial gland and that Lkbl loss in this gland results in deregulated 
Wnt signalling, which ultimately drives tumourigenesis by upregulating oncogenic Wnt 
target genes, such as c-Myc and CD44 (Clevers, 2006; Sansom et al., 2004).
3.3.18 PBCre-mediskted recombination
To determine the pattern of endogenous PBCre-mediated recombination within the 
GU tract, mice harbouring both the PBCre transgene and the Rosa26 reporter locus 
underwent X-gal staining. Expression of p-galactosidase, a positive marker of 
recombination at the surrogate Rosa26 reporter locus was detected in many components of 
the PBCre" GU tract, paralleling published data (Wu et al., 2001). Recombination occurred 
in all four lobes of the prostate (figure 3.29a-c), testis interstitial (Leydig) cells (figure 
3.29d), epididymis epithelium (figure 3.29e-h), vas deferens epithelium (figure 3.29i), 
urethral gland (figure 3.29j) and the stomach (figure 3.29k). Notably, no recombination was 
detected in the kidney, bladder, liver or transitional epithelium of the urethra, in contrast to 
un-induced mice expressing the AhCre transgene (figure 3.10).
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Figure 3.29: The PBCre construct mediates recombination within the GU tract. Tissue from 
adult male PBCre Rosa26R transgenic mice (aged 12 months) underwent LacZ staining to 
determine the profile of PBCre-mediated recombination, where recombination events are 
represented by a blue stain. Recombination was detected in the anterior (a), dorsolateral (b) and 
ventral (c) prostate lobes as well as the interstitial (Leydig) cells o f the testis (d) and the epithelium 
of epididymal compartments; initial segment (e), caput (f), corpus (g), and cauda (h). The epithelium 
of the vas deferens (i), urethral gland (j) and the stomach (k) were also positive for recombination. 
Images were photographed at 40x magnification and scale bars represent 50 jam.
3.4 D iscussion
3.4.1 Un-induced A h C r e ^ L k b ^  mice develop prostate neoplasia, mimicking aspects of 
human prostate cancer
In this chapter, I have shown that the tum our suppressor L kbl plays a role in the 
onset and progression o f  prostate cancer using a conditional transgenic approach. Loss o f 
Lkbl in un-induced AhCre L k b l ^  mice significantly reduced m ale longevity and 
predisposed to prostate AH that progressed to PIN in the anterior lobe (w ithin 2-4 months), 
which resembled aspects o f  human prostate cancer. Im m unohistochem ical analysis o f  Lkbl 
deficient PIN showed that the proliferation marker K i-67 is upregulated in PIN lesions, 
correlating with both human and mouse PIN studies (Chin and Reiter, 2004). PIN lesions 
also displayed elevated levels o f  Keratin-18, suggesting that Lkbl deficient PIN parallels 
human prostate cancer in the expression o f  a clinically relevant biom arker (Bostwick et al., 
1996; Shappell et al., 2004). K eratin-18 is widely used to aid detection and identification o f  
tumours owing to the fact that it is persistently expressed in tum our cells derived from 
simple (single-layered) epithelia (Oshima et al., 1996). Continual K eratin-18 expression in
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lesions is thought to be linked to oncogenes that activate ras signal transduction pathways. 
Ras signalling stimulates members of the AP-1 (jun and fos) and ETS families that 
upregulate Keratin-18 transcription (Oshima et a l, 1996).
It has been suggested that the p63+/K5+ basal cell lineage harbours the stem cell 
population in prostate epithelium (Collins et a l,  2001; Foster et a l,  2002; Uzgare et a l, 
2004). Basal cells were detected using antibodies to anti-p63 and anti-K5 to reveal 
expansion of this lineage. p63+ cells formed tufting patterns in un-induced AhCre+L k b l^  
PIN lesions, in conjunction with aberrant cellular architecture. Typical triangular shaped 
basal cells were replaced by larger, circular cells that, which in some cases were not 
adjacent to the basement membrane. Consistent with this, Pten deficient conditional 
transgenic mice have also displayed an increase in basal cell density and altered basal cell 
morphology and localisation, believed to represent expansion o f the transit-amplifying zone 
(Wang et a l, 2006b). This may be confirmed by carrying out double-labelling of p63 and a 
transit-amplifying cell marker such as PSCA (Tran et a l,  2002) or c-MET (Van-Leenders et 
a l, 2002). Wang et al (2006) reported that the expansion of a prostate stem/progenitor-like 
subpopulation in PBCre * PterJ1^  mice is concomitant with basal cell proliferation and these 
cells expressed p63, Sca-1 and Bcl-2. Furthermore, qRT-PCR analysis of Sca-1+ cells sorted 
by FACS displayed elevated ANp63, AR and keratin 5 transcript levels, while TAp63 
mRNA levels were reduced (Wang et al., 2006b). This suggests that expression levels of the 
p63 isoforms may direct the differentiation status of the basal cell population and that Pten 
loss can promote stem cell self renewal in the prostate, which has been shown previously in 
neural stem cells (Groszer et a l,  2006).
The trans-activating TAp63 form is considered to inhibit terminal differentiation 
while the non-trans-activating form ANp63a/p isoforms are common to adult prostate 
epithelium and stimulate terminal differentiation (Kurita et a l ,  2004). Consequently, the 
phenotype observed in Lkbl deficient prostate may reflect differential regulation of p63 
isoforms in oncogenesis, as TAp63 and ANp63 are transcribed from different promoters 
(Park et a l,  2000). Interestingly, elevated p63 expression has also recently been observed in 
lung tumours from mice bearing Lkbl inactivation (Ji et a l ,  2007). Taken together, this 
evidence suggests that Lkbl may regulate basal cell differentiation and that loss of Lkbl in 
un-induced AhCre * L k b l ^  mice may result in the expansion of the prostate stem/progenitor 
cell population.
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In an attempt to identify tumour initiating cells within un-induced AhCre+LkblJI/JI 
PIN lesions, immunohistochemistry to detect the stem cell marker CD 133 was carried out 
(Tsujimura et al., 2007). Positive nuclear CD 133 staining was widely observed throughout 
malignant prostate epithelium, suggestive of non-specific staining. To address this 
hypothesis further, FACS analysis of AhC re*Lkbl^  PIN lesions to detect stem cell 
markers, such as Sca-1 and CD 133, along with subsequent in vitro and in vivo analysis 
would be necessary (Tsujimura et al., 2007; Xin et al., 2005).
Anti-androgen hormone therapy is commonly undertaken to treat prostate cancer 
patients (Isaacs and Isaacs, 2004). Un-induced AhCre+L k b l ^  mice exhibited elevated 
levels of AR in PIN foci, suggesting tumourigenesis is probably androgen-dependent, 
especially considering the early stage of progression. However, this cannot be unequivocally 
determined without modifying the circulating level of androgens either chemically or by 
castration. It is speculated that these lesions would regress following androgen ablation, 
demonstrating androgen-dependent prostate neoplasia.
A human prostate cancer study using a tissue microarray was not possible during the 
time course of this project. Preliminary analysis of human prostate RNA revealed that Lkbl 
mRNA transcript levels are not significantly altered in benign prostatic hyperplasia (BPH) 
compared to adenocarcinomas, irrespective of tumour grade (figure 3.30). However, this 
might reflect the fact that Lkbl loss is considered to play a role in cancer initiation or the 
cellular heterogeneity of prostate cancer. To address this, qRT-PCR to detect the level of 
Lkbl in normal prostate samples is required, 
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Figure 3.30: LKB1 mRNA expression in human prostate cancer, (a) qRT-PCR was performed on 
LCMD human RNA using Lkbl specific primers to amplify the Lkbl transcript. Figure (a) was 
prepared by Caroline Pennington (University of East Anglia, UK), (b) Comparing benign samples (n 
= 16) with Gleason grades 3+4 (n=19), 4+3 (n=4), 5+4 (n=5) and 5+5 (n=5) determined there was 
no statistical significant difference associated with tumour aggression (p = 0.0621, p = 0.1444, p = 
0.5, p = 0.4756 respectively) (b). Statistical analysis was carried out using the non-parametric Mann 
Whitney test (95% confidence interval) using “MiniTab” software.
127
3.4.2 The A h C re  transgene drives spontaneous recombination events in the prostate
In un-induced mice, LacZ staining revealed that AhCre mediates recombination in 
all four lobes of the prostate, reflecting endogenous activity of the Ah promoter, p- 
galactosidase expression identified a mosaic recombination pattern, suggesting the AhCre 
transgene might target a subpopulation of cells residing in the prostate epithelium. The 
pattern of recombination may also reflect the differences in the genetic background of the 
mice, cellular stress levels or the extent of GU tract infection. Considering that 
recombination was observed in all four lobes of the prostate, it is surprising that the 
advanced lesions (HG-PIN) were restricted to the anterior prostate. The biochemical 
properties of each lobe are not completely understood and may play a role in determining 
the penetrance of the phenotype. The fact that Lkbl deficiency did not result in PIN with 
100% incidence suggests that PIN lesions were not observed owing to the plane of 
sectioning. Furthermore, factors additional to Lkbl loss may be required to facilitate 
tumourigenic progression from hyperplasia to neoplasia, such as cellular stress or the 
genetic background. Spontaneous activity of the C yplal {Ah) promoter within the prostate 
may be a result of endogenous Ah receptor transcription factors and the receptors co-factor 
ARNT (Campbell et a l,  1996). Furthermore, pervious work has shown that Wnt signalling 
may regulate C yplal expression, following the discovery of three consensus TCF binding 
sites in the Ah receptor promoter (Chesire et al., 2004).
Un-induced AhCrePter/1^1 mice also developed HG-PIN, with similar phenotypic 
elements to that of the AhCre L k b l ^  mice. Pten deficiency in the prostate has been well 
documented using various transgenic models, recapitulating the full spectrum of human 
disease progression (Abate-Shen et al., 2003; Wang et a l,  2003). Consequently, a large 
cohort of mice was not generated. Figure 3.31 demonstrates HG-PIN development observed 
in un-induced AhCre+Pter/1^1 mice (n = 3, 100% incidence) aged between 300-400 days. 
Progression to advanced stages of the disease, common to Pten deficient prostate cancer 
models (Abate-Shen et a l, 2003; Wang et al., 2003), was not observed between 300-400 
days. This may reflect several possible scenarios; (a) the AhCre transgenic line may reduce 
or limit disease progression (b) AhCre" P terf^  mice may develop advanced prostate tumours 
upon aging or (c) differences in genetic background, strain and cellular stress play a role in 
generating invasive prostate lesions.
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Figure 331: AhCre+Pter/1/fl mice develop neoplasia. Histological analysis of formalin-fixed, 
paraffin-embedded H&E sections revealed AhCre-mediated recombination in un-induced 
AhCre Pter/1 mice results in HG-PIN (n = 3, aged 300-400 days). Images were taken at (a) 20x 
(low power) and (b) 40x (high power) magnification and the scale bars represent 50 pm.
It remains possible that the prostate phenotype and additional GU tract disorders 
observed in AhCre* Lkbl^  mice might be a consequence o f  un-induced AhCre-mediated 
recombination in a non-GU tract organ. Un-induced ,4/tO e-m ediated recombination has 
been reported previously in the kidney (Sansom et al., 2005), in accordance with previous 
AhCre studies (Ireland et al., 2004). Consistent with this, the Rosa26 reporter identified a 
low level o f ,4/iOe-mediated recombination in the kidney, stomach and bladder o f un- 
induced AhCre*Lkb J ^ 1 mice (figure 3.10). However, histological analysis o f  these organs 
did not detect any gross phenotype, suggesting that endogenous spontaneous recombination 
o f the AhCre construct in non-prostatic organs (except the BUG cyst) is not responsible for 
prostate tumourigenesis in this model.
3.4.3 Un-induced A hC re*L kb l^  mice develop multiple GU tract phenotypes
It seems unlikely that PIN is the direct cause o f  the observed reduced longevity in 
un-induced AhCre*Lkb iP® mice. Health o f the un-induced AhCre* Lkb 1 ^  male cohort 
deteriorated owing to a combination o f phenotypes. Ultimately, progression o f  PIN to more 
advanced stages o f  prostate cancer, such as adenocarcinoma and metastasis is probably 
inhibited owing to the reduced life-span. It is speculated that the generation o f BUG cysts 
and their susceptibility to rupture and lead to GU tract infection is the primary cause o f 
decreased longevity. Immune infiltration was observed in the interstitium and in some cases 
obstructing prostate acini, resembling prostatitis. Consistent with this, not all PIN lesions 
were associated with infection (figure 3.4). Bulbourethral disorders in association with GU 
tract infection have also been demonstrated in other murine prostate models, indicating that 
prostate tumourigenesis may predispose to cystic BUG hyperplasia (Abate-Shen et al., 
2003; Bhatia-Gaur et al., 1999; Dunker and Aumuller, 2002).
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In addition to BUG cysts, un-induced AhCre' Lkb mice were also predisposed to 
urethral gland hyperplasia (39%) and seminal vesicle squamous metaplasia (11%). This 
suggests that the AhCre transgene is spontaneously activated within these androgen- 
dependent organs and this hypothesis is supported by LacZ staining. Un-induced 
AhCre'Lkb 1 ^  mice demonstrated A /zOe-mediated recombination of the Rosa26 reporter in 
the BUG, urethral gland and seminal vesicle epithelium (figure 3.10). Immunohistochemical 
characterisation of these lesions showed an increased level of proliferation and Wnt 
signalling, which is frequently deregulated in many organs to drive tumour formation and 
progression (Clevers, 2006). This presents a direct mechanism whereby Lkbl loss 
deregulates the Wnt pathway to promote tumourigenesis (refer to section 1.3.3). Consistent 
with this, mice expressing a dominant stable form of P-catenin under the control of the 
MMTV-LTR-Cre construct resulted in proliferation of the urethral glands in association with 
inflammation (Bierie et a l , 2003), closely resembling the AhCre Lkb 1 ^  phenotype. 
Furthermore, BUG cysts also demonstrated AR over-expression which may be linked to 
elevated p-catenin nuclear translocation (Yardy and Brewster, 2005). As detailed in Chapter 
5, BUG lesions are frequent in mice bearing an activating P-catenin mutation, using the 
PBCre transgenic line to drive transgene expression.
3.4.4 L k b l  deficiency leads to male sterility
Lkbl has been implicated in proliferation, cell cycle regulation and polarity events 
(Alessi et al., 2006). All these are required for the homeostasis o f adult epithelium and 
spermatogenesis. High levels of Lkbl mRNA have been detected in human seminiferous 
tubules using in situ hybridisation (Rowan et al., 2000) and Conde et al (2007) have 
demonstrated that LKB1 is present in the cytoplasm of Sertoli cells, spermatids and 
spermatozoa and its expression mimics phospho-Acetyl CoA carboxylase, p-ACC (an 
AMPK target). Together, this suggests that Lkbl may play a tumour suppressive role within 
the testis. Interestingly, PJS patients are predisposed to testicular cancer, particularly a rare 
disorder termed Sertoli cell only syndrome (SCOC), (Rowan et al., 2000). Mutational 
screening of 28 testicular tumours by single-strand conformation polymorphism analysis 
revealed 4% of tumours carried a heterozygous LKB1 missense type variant, in which 
glycine 163 was changed to aspartic acid (within exon 4 of the kinase domain), (Rowan et 
al., 2000). This change was absent in the DNA of normal tissue. Together, these findings 
suggest that somatic mutations of LKB1 are not frequent in colorectal and testicular cancer
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(Avizienyte et al., 1998). However, this study does not account for any possible epigenetic 
inactivation of the gene.
Male un-induced C re 'L kb 0 1 and AhCre* Lkb 1 ^  mice were sterile and demonstrated 
hypospermatogenesis and abnormal sperm production. In situ hybridisation and qRT-PCR 
to detect mRNA showed a dramatic decrease in testicular and epipdidymal Lkbl transcript 
levels in Cre'Lkb 1 ^  mice (70% and 81% respectively). This reflects the hypomorphic 
nature of the LoxP-flanked Lkbl allele and suggests a role for Lkbl within these tissues. 
PBCre-mediated Lkbl deficiency in the testis predisposed to non-obstructive Sertoli-cell- 
only syndrome (SCOS) in PBCre* Lkb 1 ^  mice at 500 days, resembling PJS patients. The 
fact that SCOS was not observed in un-induced AhCre+L k b l ^  or hypomorphic Cre L k b l^  
mice (at 200 and 500 days), suggests that SCOS observed in PBCre L k b l ^  mice could 
reflect a further reduction in the level of Lkbl mRNA in PBCre L k b l^ 1 testis or that AhCre 
and PBCre transgenes target different cells within the testis. However, we cannot rule out 
the possibility that PBCre-mediated recombination results in Lkbl loss in an unidentified 
tissue or that the genetic background and cellular stress levels, which could also predispose 
to SCOS.
The fact that un-induced Cre'Lkb 1 ^ ,  AhCre* Lkb 1 ^  and PBCre ' L k b l^ 1 mice 
demonstrated mature spermatids in some normally composed seminiferous tubules indicates 
that the observed phenotype is likely to be caused by impairment of early germ cell 
proliferation or survival, and not a specific block during sperm maturation (i.e. maturation 
arrest) (Behr et al., 2007).
There is little in the literature to link Lkbl loss to male infertility however, several 
potential scenarios exist and are discussed below. First, Lkbl plays a role in regulating both 
the PI3K and mTOR signalling pathways (Alessi et al., 2006) and previous work has shown 
that the stem cell factor (SCF)/c-kit system can regulate germ cell proliferation, meiosis, and 
apoptosis through the PI3K/AKT/p70S6K pathway, which is inhibited by the mTOR 
inhibitor Rapamycin (Feng et al., 2000). Immunohistochemistry do detect active Akt and 
mTOR would determine whether deregulation of the PI3K/AKT and mTOR pathways plays 
a part in Lkbl deficient hypospermatogenesis. Preliminary analysis determined a decrease in 
p-mTOR expression in L k b l^  seminiferous tubules (not shown).
Second, Lkbl loss in PBCre Lkb 1 ^  testis may predispose to infertility by 
deregulating the paracrine-mediated production of inhibin in Sertoli cells. Inhibin (a  or p) is 
a gonadal glycoprotein hormone that is stimulated by FSH and functions to negatively
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regulate the release of FSH in the pituitary (Pineau et al., 1990). Loss of Lkbl has been 
shown to play a role in Sertoli cell tumours in PJS patients, where inhibin-a is upregulated 
in parallel with a reduction in FSH, LH and testosterone levels in the blood (Lefevre et al.,
2006). Detecting FSH, LH and testosterone serum levels and determining whether PBCre 
recombination occurs in the hypothalamus, anterior pituitary or adrenal cortex may provide 
insights into the mechanisms leading to male infertility in the PBCre+Lkb ^  model.
Third, Lkbl is known to mediate cellular polarity events (Alessi et al., 2006; Baas et 
al., 2004b) (section 1.3.2), subsequently loss of Lkbl may disrupt the adhesion of proteins 
participating in adherens (cadherin-catenin), tight (zonula occludens) and gap (connexins) 
junctions required during spermatogenesis (Pointisa et a l,  2005). In particular, Connexin 43 
(Cx43) has been identified to play a key role in specific spermatogenic steps and Cx43 null 
mice (which are embryonic lethal) display a 50% reduction in primordial germ cells and 
exhibit abnormal proliferation and differentiation of germ cells derived from the foetal testis 
(Pointisa et al., 2005).
Immunohistochemical analysis showed that expression of the tight junction protein 
ZO-1, which coincidentally binds Cx43 (Fink et a l, 2006), is decreased in Cre'Lkb l ^ 1 testis 
compared to wild-type mice (figure 3.32a-b). This suggests that Lkbl regulates ZO-1 
expression in the testis, which could account for the observed defect in spermatogenesis in 
Lkbl deficient mice. Consistent with this notion, LKB1 expression has been shown to 
rescue depolarisation of LKB 1 deficient intestinal cells by redistributing ZO-1 to the brush 
border (Baas et al., 2004a).
Aberrant ZO-1 expression in human testicular carcinoma in situ (CIS), the non- 
invasive precursor of most human testicular germ cell tumours, has been shown to disrupt 
the blood-testis barrier (Fink et al., 2006), (figure 3.32c). The blood-testis barrier divides the 
seminiferous epithelium into a basal compartment and an adluminal compartment and this 
barrier is regulated by an array of signalling networks including TGFp, occluding, PKA and 
PKC (Lui et al., 2003). The basal compartment contains spermatogonial and preleptotene 
spermatocytes, which can access blood-borne circulating molecules (Fink et a l, 2006). All 
other germ cells are contained in the adluminal compartment, an immune-free environment 
maintained by the Sertoli cells that is required to protect post-meiotic germ cells and is 
essential for spermatogenesis (Fink et al., 2006). Preleptotene and leptotene spermatocytes 
must translocate from the basal to the adluminal compartment to develop into spermatids 
(Lui et al., 2003). Together, this evidence suggests that Lkbl loss disrupts the formation of
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ZO-1 tight-j unctions, which may result in disruption of the blood-testis barrier to predispose 
to impaired maturation of the Sertoli cells and hypospermatogenesis.
Wild-type Cre'Lkbl^1
ZO-1
_  -----------
r* ■, ■ if X '
b
ft
A
%
4#
c
Tight junction
A
Actin filament
Lumen of seminiferous t tb tlu s
ZOI
S erto li cell Adluminal
'compartment
SC SC
Sertoli 3e»
Basal
compartment
3G
Basal amlraTight junctions
Figure 332: Cellular polarity is lost in un-induced C reL k b l^  seminiferous tubules.
Immunohistochemistry of formalin-fixed, paraffin-embedded testis sections (aged 2-7 months) 
revealed ZO-1 is expressed in wild-type seminiferous tubules undergoing spermatogenesis (a) and 
shows a marked in un-induced Cre L k b l  mice (b). Images were taken at 40x magnification and the 
scale bars represent 50 pm. (c) Schematic of the tight-j unction structure in the seminiferous 
epithelium. ZO-1 forms tight junctions between adjacent Sertoli cells (SC) near the basal lamina, 
constituting the blood-testis barrier and separating the seminiferous epithelium into the basal and 
adluminal compartments. SG, spermatogonium; pSP, preleptotene/leptotene spermatocyte; SP, 
pachytene spermatocyte; rSp, round spermatid; Sp, elongated spermatid; JAM, junctional adhesion 
molecules. Figure (c) was adapted from Fink et al (2006).
Finally, previous work has shown that haploinsufficiency of Foxa3 predisposes to 
SCOS, resembling PBCre+L k b l mice (Behr et al., 2007). Foxa3 is a forkhead box 
transcription factor that is expressed in the liver and testis and plays a vital role in organ 
development and metabolism (Behr et a l , 2007; Friedman and Kaestner, 2006). Foxa3 
deficient SCOS displays aberrant Sertoli cell maintenance, which might be a consequence of 
increased testicular kallikrein proteases that are capable of disrupting the local
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communication between the Leydig cells and the cells of the seminiferous tubules. 
Importantly, paracrine hormone signalling was not altered in Foxa3 deficient mice, as 
circulating FSH, LH and testosterone levels and AR expression were normal (Behr et a l,
2007). Immunohistochemistry to detect Foxa3 and kallikrein protease in Lkbl deficient 
mice may reveal a mechanism whereby Lkbl loss results in male infertility.
To conclude, Lkbl loss is associated with testicular tumours and male infertility in 
PJS patients and the Lkbl deficient mouse models described in this chapter may provide a 
useful tool for investigating the mechanisms that underlie hypospermatogenesis and SCOS. 
The direct cause of male infertility in un-induced Cre'LkbT^7, AhCre L k b l^ 1 and 
PBCre L k b ^  mice is unknown. It is speculated that reduced Lkbl expression in the 
seminiferous epithelium is likely to cause loss of cellular polarity by disrupting ZO-1 tight 
junctions required for spermatogenesis. Further investigation of known markers of male 
infertility, such as inhibit-a, Foxa3 and kallikrein proteases may assist in elucidating the 
mechanisms involved.
Aberrant epididymis architecture in Cre'Lkb 1 ^  mice was characterised by high 
levels of apoptosis and lumen cellular debris (probably apoptotic sperm). Electron 
micrographs showed abnormal clustering of stereocilia and cytoskeletal abnormalities in the 
principle cells (figure 3.24), probably linked to the fact that Lkbl loss has been shown to 
deregulate cellular polarity events (Alessi et a l , 2006; Baas et a l , 2004a). These 
architectural abnormalities may further predispose to infertility in Lkbl deficient mice by 
preventing any mature sperm that are produced in the testes from passing through the 
epididymal coils or leading to defective secretion of hormones/factors required for 
maturation of spermatozoa (Taboga et a l , 1999).
3.4.5 P B C re-mediated L k b l  loss causes prostate hyperplasia
Lkbl deletion at the onset of prostate tumourigenesis and progression to PIN was 
driven using the AhCre transgene to mediate recombination of Lkbl-Woxzd alleles. 
However, as a consequence of the reduced longevity, it was not possible to age the animals 
beyond 200 days to determine whether Lkbl loss could drive progression to advanced 
stages of the disease. In an attempt to overcome this difficulty, the well characterised PBCre 
transgenic line was exploited. Indeed, PBCre "Lkbl C r e ' L k b and PBCre ' Lkb 1 ^
cohorts displayed survival rates comparable to wild-type mice of 500 days.
Un-induced Cre L k b l^  mice developed LG-PIN lesions demonstrating that 
hypomorphic deletion of Lkbl induces PIN in the prostate at 500 days. This phenotype was
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enhanced to HG-PIN in un-induced AhCre*Lkb 1 ^  mice, in which endogenous expression 
of Cre drives recombination, resulting in additional loss of Lkbl in the prostate. The level 
of Lkbl is critical for this phenotype as AhCre+ L kb l+/^  and PBCre Lkbl ^  mice do not 
develop prostate lesions.
PBCre ' Lkb 1 ^  mice exhibited a reduced phenotype (atypical hyperplasia at 500 
days) compared to LG-PIN observed in C r e ' L k b mice. This suggests that PBCre targets 
recombination to cells in which deficiency of Lkbl does not induce PIN, or cells in which 
Lkbl deficiency actually inhibits tumourigenesis. It is also important to note that cohort 
numbers of PBCre' Lkb l ^ 1 mice are relatively low compared to other cohorts, which may 
reflect the phenotype incidence observed.
PBCreYLkb 1 ^  mice will have loss of Lkbl in the tumour initiating cells in common 
with the C re'Lkb}^  mice, as well as additional cells mediated by endogenous PBCre. 
Therefore the loss of Lkbl in these additional cells must inhibit the tumourigenic effects of 
Lkbl deficiency in the prostate.
A potential mechanism for this is PSCre-mediated deletion of LKB1 in a non­
prostate tissue that regulates androgen production/synthesis. This would result in reduced 
testosterone levels in the blood, subsequently preventing androgen-dependent prostate 
tumourigenesis in PBCre^Lkb}^1 mice.
Consistent with this notion, PBCre-mediated recombination was detected in the 
Leydig cells of PBCre+Lkb 1 ^  mice, that produce androgen in response to luteinising 
hormone (LH) and follicle stimulating hormone (FSH), predisposing to Sertoli-cell-only 
syndrome (SCOS). In support of this model, SCOS has been shown to reduce testosterone 
levels in humans (Kim and Lee, 1987), however, assays of circulating levels of LH, FSH 
and testosterone in PBCre L k b l  mice are required to validate this hypothesis.
Importantly, PPCre-mediated deletion of other genes, such as Pten, have been 
shown to predispose to prostate cancer (Kasper, 2005; Wang et al., 2003; Wang et a l , 
2006b). This suggests two potential mechanisms, either that Lkbl deficiency causes 
tumourigenesis in a different subset of cancer initiating cells to Pten, or alternatively, that 
loss of Pten in the PBCre targeted cells does not have the same tumour suppressing effect 
that loss of Lkbl does in the same cells.
To conclude, deficiency of Lkbl either by hypomorphic deletion or endogenous 
AhCre activity results in PIN. However, loss of Lkbl by endogenous PBCre does not result 
in PIN, suggesting that loss of Lkbl in some cells can actually inhibit tumourigenesis.
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3.4.6 / ’ffOe-mediated Lkbl loss causes multiple phenotypes
The fact that the un-induced AhCre+LkbPUJl cohort showed a significantly reduced 
life-span compared to the PBCre+LkbPl/Jl cohort is considered to reflect the lack of BUG 
cyst development in PBCre' Lkb 1 ^  transgenic mice. A single mouse in the PBCre+Lkb 1 ^  
cohort that developed a small BUG cyst (< 1 cm) also displayed infection of the GU tract 
interstitium and prostate acini (at 500 days), providing evidence to link the two phenotypes. 
Infection was not observed in any other members of the PBCre+Lkb 1 ^  cohort.
A number of other non-prostatic tumours were also observed in PBCre+Lkbl 
deficient mice. Preputial keratinised squamous metaplasia developed in PBCre' Lkbl 
PBCre'Lkb ^  and PBCre+Lkbl^ cohorts (7%, 50% and 13% respectively), indicating that 
the PB promoter drives recombination in this sebaceous, androgen-regulated gland. A 
similar phenotype has been observed in mice expressing a dominant stable form of 0- 
catenin under control of the MMTV-LTR-Cre construct (Bierie et a l , 2003), suggesting that 
aberrant Wnt signalling may play a role.
PBCre+L kbl+/fl mice displayed keratinised squamous metaplasia of the preputial 
gland, stomach hamartomas and kidney abnormalities, despite no evidence for PBCre- 
mediated recombination in these tissues. This implicates the hypomorphic nature of the 
LoxP-flanked Lkbl allele in the predisposition to these unexpected phenotypes. Consistent 
with this, the frequency of these lesions increased in mice homozygous for the Lkbl 
transgene (displayed in Table 3.2).
In parallel with un-induced AhCre' Lkb 1 ^  mice, seminal vesicle squamous 
metaplasia was observed in the PBCre' Lkb ^  cohort (13% incidence). However, LacZ 
staining showed that the PBCre construct does not drive recombination in the seminal 
vesicle epithelium, unlike un-induced A /zCre-mediated recombination (figure 3.10o). 
Consequently, in a PBCre setting, development of seminal vesicle squamous metaplasia 
might not be directly associated with loss of Lkbl, but could reflect alterations in the stroma 
and paracrine signalling molecules caused by adjacent prostate lesions. Alternatively, 
seminal vesicle tumours observed in PBCre+LkbP1^  mice may simply arise as a 
consequence of the hypomorphic nature of the Lkbl transgene.
P B C re L k b l^1, PBCre'Lkb l ^ 1 and PBCre L k b cohorts aged to 500 days were 
also predisposed to kidney lesions (42%, 33% and 100% incidence) and stomach 
hamartomas (21%, 33% and 38%). No recombination was detected in the kidney and 
although LacZ staining did reveal recombination in the forestomach, this region of the
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stomach was not predisposed to tumourigenesis and could in fact reflect endogenous p- 
lactamase activity causing a false-positive. This evidence suggests that the hypomorphic 
f\oxed-Lkbl allele might be sufficient to drive the formation of kidney lesions and stomach 
hamartomas. To address this, qRT-PCR would determine whether there is a reduction in the 
level of Lkbl mRNA transcription in these tissues.
Interestingly, the phenotypes observed in aged PBCre Lkbl PBCre Lkb and 
PBCre L k b l ^  cohorts resemble that of PJS patients (Giardiello et al., 1987), namely 
stomach and pyloric hamartomas and Sertoli-cell-only syndrome. Consistent with this 
model, a similar phenotype has been shown in L kb l+/~ mice (>20 weeks) considered to be 
linked to Lkbl gene haploinsufficiency, that is, without LOH (Miyoshi et a l , 2002). These 
data suggest a link between loss of Lkbl and PJS.
3.5 Summary
Despite the high incidence of prostate cancer in the Western World, the paucity of 
animal models has constrained details of the molecular events predisposing the initiation 
and progression to carcinoma and metastasis of the disease. To address this, I have 
developed a mouse model in which the prostate is deficient in the tumour suppressor Lkbl. 
Loss of this gene in the mouse prostate predisposes to PIN. This is the first demonstration of 
a link between Lkbl deficiency and prostate neoplasia. Furthermore, Lkbl may also 
function to suppress tumourigenesis in a variety of male accessory organs including the 
bulbourethral glands, urethral glands, seminal vesicle, epididymis and testis. Importantly, 
this model may also provide insights into the development of male infertility associated with 
Sertoli-cell-only syndrome. Chapter 4 shall explore the deregulated molecular mechanisms 
incurred by an Lkbl functional mutation in prostate epithelium.
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Chapter 4: Investigating the molecular mechanisms underlying 
L k b l  deficient PIN
4.1 Introduction
To further investigate the mechanism underlying the predisposition to prostate 
neoplasia in un-induced AhCre+L k b l^ 1 mice, three Lkbl-mediated pathways will be 
investigated; (a) the AMPK/mTOR pathway, (b) Wnt signalling and (c) the PI3K/Pten/Akt 
cascade (detailed in section 1.3). To date, there is little published data to support a direct 
role for AMPK deregulation in prostate tumourigenesis (Lee et a l,  2006). However, 
aberrant Wnt signalling and deregulated PI3K/Pten/Akt signalling are common events in 
human prostate cancer (Sun et a l, 2001a; Yardy and Brewster, 2005). All Lkbl deficient 
mice in this chapter are aged, un-induced AhCre+Lkb 1 ^  mice. Wild-type or un-induced Cre' 
L k b l^  mice, that displayed normal prostate tissue at 200 days, were used as controls.
4.2 Aim
The objective of this chapter is to carry out immunohistochemical analysis of un- 
induced AhCre L k b l ^  deficient PIN lesions to determine whether Lkbl related signalling 
pathways have been deregulated to drive prostate tumourigenesis, such as the 
AMPK/mTOR pathway, Wnt signalling and the PI3K/PTEN/AKT cascade.
4.3 Results
4.3.1 mTOR signalling is suppressed in un-induced A h C re +L k b l ^  PIN
To establish on a molecular level whether loss of Lkbl deregulates mTOR signalling 
in AhCre+ Lkb 1 ^  PIN foci, immunohistochemistry was performed to detect active p- 
AMPKa, p-mTOR, p-S6K (ribosomal protein S6 kinase, 70kDa, RSK), a p-mTOR 
downstream target and its substrate p-Rps6 (ribosomal protein S6) (figure 4.1). Compared to 
control mice (wild-type and C re 'L kb 0 1 mice, 200 days old), cytoplasmic p-AMPKa 
expression increased significantly in AhCre L k b l^ 1 PIN foci (figure 4.1a-c). Lambda 
phosphatase treatment (that dephosphorylates proteins) was used to determine the extent of 
any non-specific staining following anti-p-AMPKa immunohistochemistry, which was 
observed weakly at the apical surface of the epithelium (figure 4 .Id). Similar controls for 
other antibodies used did not identify any non-specific staining (figure 4.1h, 1 and p).
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Figure 4.1: The mTOR pathway is suppressed in Lkbl deficient PIN. Formalin-fixed, paraffin- 
embedded anterior prostate tissue sections from wild-type, Cre Lkbl11 jl and AhCre Lkblj]j] mice aged 
2-7 months underwent immunohistochemistry to detect p-AMPKa (a-d), p-mTOR (e-h), p-S6K (i-1) 
and p-Rps6 (m-p). Lkbl deficient PIN lesions displayed elevated p-AMPKa throughout the 
cytoplasm while p-mTOR nuclear expression is lost. The mTOR downstream target p-S6K and its 
substrate p-Rps6 were depleted in PIN foci. Lambda phosphatase was used as a control to detect 
non-specific phosphate binding of each antibody (d, h, 1 and p) according to the Cell Signalling 
Technology protocol. Images were taken at 40x magnification and scale bars represent 50 pm.
AMPK activation stimulates TSC2 to prevent m TOR phosphorylation and activation 
by restricting Rheb to its GDP conformation (Alessi et al., 2006). Nuclear p-mTOR 
expression is lost in PIN foci while control mice displayed nuclear p-m TOR in a subset o f 
basal and luminal cells (figure 4.1e-g). Inconsistent w ith a decrease in m TOR expression, 
the mTOR target p-S6K (figure 4.1 i-k) and its substrate p-Rps6 (figure 4.1m-o) were 
elevated in PIN lesions. This data suggests that S6K is activated via an mTOR independent 
mechanism in PIN lesions.
Further investigation into the mTOR pathway in A h C re fLkb 1 ^  dorsolateral and 
ventral prostate atypical hyperplasia (AH) revealed p-A M PK a was highly expressed in the 
cytoplasm o f  dorsolateral and ventral prostate lobes in control and Lkbl deficient mice 
(figure 4.2a-d). However, nuclear expression o f  p-m TOR was detected at a low level in Cre' 
L kblfljl dorsolateral and ventral lobes and was absent in A h C r e * L k b AH lesions (figure
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4.2e-h) and p-S6K and p-Rps6 expression was not m arkedly altered in L kb l deficient AH 
lesions com pared to control prostate (figure 4.2i-p). This data suggests that the mTOR 
pathway is not active in dorsolateral and ventral AH, but S6K activation is m aintained by an 
mTOR independent pathway.
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Figure 4.2: The mTOR pathway is suppressed in Lkbl deficient AH lesions. Formalin-fixed, 
paraffin-embedded dorsolateral (DLP) and ventral (VP) prostate tissue sections from Cre LkblJ1)1 and 
AhCre Lkb 1 ^  mice (aged 2-7 months) were stained for p-AMPKa (a-d), p-mTOR (e-h), p-S6K (i-1) 
and p-Rps6 (m-p) to reveal no marked changes in p-AMPKa expression, while p-mTOR nuclear 
expression was lost. p-S6K and p-Rps6 expression was not altered in Lkbl deficient lesions. Images 
were photographed at 40x magnification and scale bars represent 50 pm.
4.3.2 W nt signalling is deregulated in un-induced AhC re+L k b l ^  PIN
To investigate w hether W nt signalling was deregulated in L kbl deficient PIN 
lesions, the expression o f  a num ber o f  W nt signalling com ponents and downstream 
transcriptional targets were m onitored using im m unohistochem istry (figure 4.3). Lkbl has 
previously been shown to mediate Pari A to regulate both the W nt cascade and cellular 
polarity (Spicer et a l., 2003). Wild-type and Cre'Lkb 1 ^  prostate epithelial cells 
predom inantly express p-catenin at the cell surface m em brane w here it binds catenins to 
form adherens junctions (figure 4.3a). P-catenin w as rarely observed in the nucleus where it 
associates w ith transcription factors to regulate W nt target genes. However, P-catenin
140
nuclear translocalisation was highly elevated in Lkbl deficient neoplastic cells indicating 
activation of the Wnt pathway (figure 4.3b). Recently, E-cadherin cytoplasmic relocation 
from the membrane has been linked to p-catenin switching from its structural role to a 
transcription factor that transmits Wnt signals (Li et al., 2007b). Consistent with this, Lkbl 
deficient PIN displayed increased cytoplasmic expression of E-cadherin compared to 
control prostate epithelial cells (figure 4.3c-d).
Aberrant Wnt signalling was further demonstrated by monitoring a number of p- 
catenin transcriptional targets. The cell surface migration marker CD44 is an immediate 
transcriptional target of Wnt signalling (Wielenga et a l , 1999) that is over-expressed in 
advanced human prostate cancer (Wissmann et al., 2003). Immunohistochemistry 
determined CD44 is absent in control prostate epithelium, while AhCre+Lkbl^ PIN foci 
demonstrated an elevation in CD44 expression on the cell surface of neoplastic cells (figure 
4.3e-f). The absence of CD44 staining in wild-type prostate was unexpected, considering 
human prostate basal cells are CD44 positive (Collins et al., 2005). This was initially 
thought to reflect the quality of the antibody used to detect CD44, however previous work in 
the mouse has shown that CD44 immunoreactivity undergoes transition from mesenchyme 
to epithelium during the course of development and is absent in adult prostate (Gakunga et 
al., 1997). Newborns display staining in the mesenchymal tissue and between 10-15 days, 
strong staining was detected in the epithelial membrane while staining in the mesenchyme 
was reduced. At 30 days no CD44 immunostaining was evident (Gakunga et al., 1997). 
These results are suggestive of the significant role played by hyaluronan-CD44 interactions 
in mediating androgen-induced prostatic growth and morphogenesis (Gakunga et a l , 1997).
Activation of the Wnt pathway was further demonstrated by immunohistochemistry 
to detect Foxal, a Forkhead box factor involved in prostate development that acts as AR co­
activator (Gao et a l , 2003). Wnt signalling drives transcription of Sox 17, which in turn 
induces Foxal transcription (Sinner et a l , 2004). Foxal was markedly elevated in Lkbl 
deficient PIN lesions compared to control prostate epithelium. Counting the percentage of 
positive Foxal nuclei in prostate epithelium revealed a significant increase in Foxal 
staining in Lkbl deficient PIN lesions (92% positivity) compared to control epithelium 
(39% positivity) (figure 4.3e). This data supports the LADY model system (described in 
section 1.2.3) where PIN lesions over-expressed Foxal (Mirosevich et al., 2005).
Upregulated Wnt signalling was also demonstrated by detecting inactivation of 
glycogen synthase kinase 3p (GSK3p). GSK3p phosphorylates P-catenin at Ser33, Ser37
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Foxal
and Thr41 to target it for ubiquitin-mediated degradation (section 1.4.1). Inactivation o f 
Gsk3p at Ser9 subsequently results in p-catenin nuclear translocation and upregulation o f 
Wnt target genes (Clevers, 2006). Immunohistochemistry to detect inactive p-Gsk3p (Ser9) 
revealed that it is expressed at a low level in the cytoplasm o f control epithelium and is 
highly elevated in PIN lesions (figure 4.3j-k). Together, this evidence further implies Lkbl 
loss results in activated Wnt signalling.
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Figure 4.3: Wnt signalling is activated in Lkbl deficient PIN. Formalin-fixed, paraffin-embedded 
anterior prostate tissue sections from Cre L k b and AhCre L k b mice (aged 2-7 months) were 
stained for Wnt signalling components; p-catenin (a-b), E-cadherin (c-d), CD44 (e-f), Foxal (g-h) 
and p-Gsk3p (j-k). All components were all elevated in AhCre L k b PIN, indicating Wnt 
signalling is deregulated. Photographs were taken at 40x magnification and scale bars represent 50 
pm. (i) Scoring positive Foxal nuclear expression within control (WT) and AhCre Lkb 1 ^  prostate 
epithelium revealed a 53% increase in Foxal nuclear expression levels in PIN foci (p = 0.001, n = 
3). Error bars represent standard deviation and statistical analysis was carried out using the non- 
parametric Mann Whitney test using “MiniTab” software. Immunofluorescence to detect the tight 
junction protein ZO-1 revealed control prostate epithelium exhibits ordered cellular polarity, while 
AhCre L k b f fl PIN lesions display aberrant ZO-1 surface expression and punctate nuclear 
accumulation, suggesting loss of polarity (1-m). Confocal images were taken at 63x magnification 
and scale bars represent 10 pm.
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In addition to activating the Wnt pathway, loss of Lkbl-mediated Pari A 
phosphorylation is speculated to disrupt cellular polarity (Spicer et al., 2003). Cell polarity 
is critical for epithelial formation and function and loss of cellular polarity is a hallmark of 
cancer, where decreased cell-cell attachments lead to abnormal architecture of the tissue and 
facilitates malignant progression (Wodarz and Nathke, 2007). Potential loss of cellular 
polarity in Lkbl deficient tumours was assessed by staining for zona-occludens-1 (ZO-1) 
using immunofluorescence. ZO-1 is a luminal cell marker that functions to construct tight 
junctions (Baas et a l , 2004a; Gottardi et al., 1996). Control prostate epithelium 
demonstrated tight junctions on the cell surface membrane of ordered prostate epithelium, 
while AhCre+LkbP1^1 PIN lesions showed irregular ZO-1 expression, being either lost 
completely or perturbed in a subset of cells (figure 4.31-m). In addition, neoplastic cells 
demonstrated punctate nuclear expression of ZO-1, a phenomenon hypothesised to reflect 
altered regulation of cell polarity events (Gottardi et al., 1996). Consistent with the notion 
that Lkbl loss disrupts cellular polarity, intestinal studies have shown that LKB1 expression 
can rescue depolarisation of LKB 1 deficient cells by redistributing ZO-1 to a diffuse circle 
around the brush border (Baas et al., 2004a).
Immunohistochemical analysis of AhCre+L k b l^ 1 dorsolateral and ventral AH foci 
also revealed Lkbl loss in prostate epithelium causes elevated Wnt signalling. Nuclear 
translocation of P-catenin was detected in dorsolateral and ventral AhCre' Lkb l ^ 1 AH 
lesions (figure 4.4a-d) and correlated to the upregulation of Wnt cascade downstream 
targets; CD44 (figure 4.4e-h) and Foxal (figure 4.4i-l).
Taken together, this data strongly suggests that Lkbl deficiency in the mouse 
prostate results in deregulated Wnt signalling and concomitant loss of cellular polarity, 
which is considered to reflect dephosphorylation of Pari A (MARK3/cTAK) (Spicer et al., 
2003). As Wnt signalling is implicated in many forms o f cancer, including the prostate 
(Yardy and Brewster, 2005), this data provides a model in which Lkbl loss stimulates the 
oncogenic effects of the Wnt signalling pathway, which includes elevated AR signalling 
(Yardy and Brewster, 2005).
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Figure 4.4: Wnt signalling is activated in Lkbl deficient AH foci. Formalin-fixed, paraffin- 
embedded sections from C re 'L k b ^  and AhCre Lkb 1 ^  dorsolateral and ventral prostate lobes (aged 
2-7 months) were stained with antibodies to anti-J3-catenin (a-d), anti-CD44 (e-h) and anti-Foxal (i-
1) revealing aberrant Wnt signalling. Images were taken at 40x magnification and the scale bars 
represent 50 pm.
4.3.3 PI3K/Akt signalling is activated in un-induced A h C r e ^ L k b ^  PIN
Lkbl has been shown to regulate the PI3K/AKT pathway by directly interacting 
with and phosphorylating PTEN (Mehenni et a l ,  2005; Song et al., 2007). PTEN functions 
to prevent PI3K/AKT signalling, which drives growth, differentiation, proliferation and 
recently, PTEN has been shown to interact with AR to promote A R degradation (Lin et al., 
2004b). To determine whether the PI3K/Akt pathway is deregulated upon loss o f Lkbl, 
immunohistochemistry was carried out using an antibody directed against total Pten (figure 
4.5a-b) and one that only recognises inactive/phosphorylated (Ser380/385 and Thr382) p- 
Pten (figure 4.5c-d). Total and inactive Pten are over-expressed in Lkbl deficient PIN 
(figure 4.5a-d). This data implicates that although total Pten expression is elevated, it is 
phosphorylated at sites known to reduce Pten function/stability. Consistent with reduced 
Pten activity, AhCre+L k b J ^  mice also exhibited increased activation o f p-Akt (figure 4.5e- 
f) and p-PDKl (figure 4.5g-h) within PIN foci, demonstrating activation o f  the PI3K/Akt 
pathway in Lkbl deficient PIN.
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Figure 4.5: PI3K/Akt signalling is stimulated in Lkbl deficient PIN. Immunohistochemistry of 
formalin-fixed, paraffin-embedded anterior prostate sections from C r e L k b ffl and AhCre'Lkb f 11 
mice (aged 2-7 months) revealed total Pten (a-b), inactive p-Pten (Ser380/Thr382/383) (c-d), p-Akt 
(Ser473) (e-f), and p-PDKl (Ser241) (g-h) are over-expressed in PIN lesions. Images were taken at 
40x magnification and scale bars represent 50 |Lim.
Analysis o f the dorsolateral and ventral prostate lobes determined that PI3K/Akt 
signalling was also dysregulated in Lkbl deficient hyperplastic foci. Total Pten (figure 4.6a- 
d), inactive p-Pten (figure 4.6e-h) and p-Akt (figure 4.6i-l) were all over-expressed in the 
cytoplasm o f Lkbl deficient dorsolateral and ventral prostate epithelium and activated p- 
PDK1 expression was increased in the nucleus and cytoplasm (figure 4.6m-p).
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Figure 4.6: The P13K/Akt signalling cascade is stimulated in Lkbl deficient AH foci.
Immunohistochemistry of formalin-fixed, paraffin-embedded dorsolateral (DLP) and ventral (VP) 
prostate sections from control {Cre'Lkb I™1) and AhCre Lkblfl/jl mice (aged 2-7 months) revealed 
total Pten (a-d), inactive p-Pten (Ser380/Thr382/383) (e-h), p-Akt (Ser473) (i-1), and p-PDKl 
(Ser241) (m-p) are all over-expressed in DLP and VP hyperplastic foci. Images were taken at 40x 
magnification and scale bars represent 50 gm.
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Together this data suggests that Lkbl deficiency in the mouse prostate results in 
deregulated PI3K/Akt signalling via reduced Pten activity. PI3K/Akt signalling is frequently 
deregulated and PTEN is commonly lost in many forms o f cancer, including the prostate 
(Le-Page et al., 2006; Wang et al., 2003). This data provides a direct mechanism whereby 
Lkbl loss promotes tumourigenesis through the inhibition o f Pten function, which results in 
elevated AR signalling (Lin et al., 2004b) and activation o f  the oncogenic PI3K/Akt 
pathway (Pommery and Henichart, 2005).
4.3.4 Insights into the molecular mechanism that causes PIN upon Lkbl loss
Figure 4.7 illustrates a speculative schematic for signalling events mediated by Lkbl 
(top) and those under Lkbl deficient conditions (bottom) within prostatic epithelia.
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Figure 4.7: Postulated schematic of Lkbl-mediated signalling in prostate epithelium. A
speculative schematic for signalling events mediated by Lkbl (top) and those under Lkbl deficient 
conditions (bottom) within prostatic epithelia. Firstly, Lkbl typically acts to phosphorylate AMPK 
to suppress mTOR signalling. Once Lkbl is lost, mTOR signalling may proceed. Our investigations 
indicate an alternative AMPK kinase acts on behalf of Lkbl (e.g. p-PDKl, which stimulates S6K), 
to sustain mTOR signalling inhibition. Secondly, Lkbl phosphorylates Pari A to maintain cellular 
polarity and prevent Wnt signalling. Upon loss of Lkbl function, the role of Pari A is redirected 
from cellular polarity to stimulate Dishevelled (Dsh) to inhibit the APC:Axin:Gsk3(3 complex, 
allowing P-catenin to translocate into the nucleus. Here it stimulates transcription of downstream 
Wnt target genes and induces growth and proliferation as well as androgen signalling (Yardy and 
Brewster, 2005). Finally, although the role of Lkbl interaction and phosphorylation of Pten is still 
undefined, our data suggests that Lkbl maintains Pten stability, inhibiting Akt activation. In the 
absence of Lkbl, we observed inactivation of Pten function, a common precursor to prostate cancer. 
Pten loss results in activated Akt and ultimately results in p-Gsk3p expression, which can act to 
maintain Wnt signalling and drive tumourigenesis.
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4.4 D iscussion
AhCre+L k b 0 1 anterior PIN exhibited elevated Wnt and PI3K/Akt signalling, loss of 
cell polarity and suppression of the mTOR pathway within the neoplastic epithelial cells. A 
speculative schematic of events occurring in the presence and absence of Lkbl in prostate 
epithelium is depicted in figure 4.7.
4.4.1 Suppression of mTOR signalling in Lkbl deficient PIN
Suppression of mTOR signalling coincides with an unexpected elevation of p- 
AMPKa in PIN and AH lesions. It is feasible that either Lkbl does not regulate AMPK 
within adult prostate tissue or that an alternative AMPKK compensates for the loss of Lkbl, 
resulting in suppression of the mTOR pathway. Our data suggests PDK1 as a likely 
candidate for such a role (Zou et al., 2003) and consistent with this, others have shown that 
active p-PDKl can also stimulate S6K (Bayascas et al., 2005; Pullen et a l 1998). This is 
consistent with the observed elevation in both p-S6K and its substrate p-Rps6. However, it 
is important to note that S6K is activated by several converging pathways, namely the PI3K, 
Ras/MAPK and mTOR signalling cascades (Martin and Blenis, 2002). AMPK may also be 
regulated by Ca /calmodulin protein kinase kinase (CaMKK), indicating additional routes 
of AMPK activation are feasible following the loss of Lkbl (Woods et a l , 2005). The 
mTOR pathway has also been linked to inhibition of AR (Cinar et al., 2005), thereby 
providing a rationale for the observed feedback mechanism resulting in AMPK activation 
and suppression of the mTOR pathway, to promote androgen-dependent neoplastic growth 
in Lkbl deficient PIN.
4.4.2 Upregulation of Wnt signalling in Lkbl deficient PIN
Our results from the AhCre+ L k b l ^  mice parallel those o f previous studies which 
have monitored the effects of aberrant Wnt signalling in the prostate, demonstrating an 
association with prostate tumourigenesis (Bierie et al., 2003; Bruxvoort et al., 2007; 
Gounari et al., 2002). Lkbl loss of function has been reported to reduce phosphorylation of 
a microtubule-associated protein for tau termed Pari A (cTAKl, MARK3), (Spicer et al., 
2003). Unphosphorylated Pari A results in phosphorylation of Dishevelled (Dsh), 
propagating the translocation of p-catenin into the nucleus to initiate transcription of Wnt 
target genes, concomitant with the disruption of ParlA-mediated cellular polarity events 
(Spicer et al., 2003). This gives a direct mechanism whereby Lkbl loss may lead to 
activated Wnt signalling and disrupt cellular polarity. Furthermore, Lkbl loss was shown to
147
deregulate E-cadherin expression (figure 4.3d), which may further promote the loss of 
cellular polarity in AhCre L k b t ^  PIN lesions.
Lkbl deficient tissues have been previously shown to lose cell polarity, particularly 
in the intestine (Spicer and Ashworth, 2004) and the Lkbl C-terminus exerts an essential 
function in the control of cell polarity (and AMPK regulation) (Forcet et al., 2005). Lkbl 
has been shown to regulate the cell polarity of intestinal epithelial cells, which display 
aberrant expression of the tight-junctional protein ZO-1 in Lkbl deficient conditions (Baas 
et a l , 2004a; Baas et al., 2004b). Consistent with this, ZO-1 expression is depleted in 
AhCre'L k b l^  neoplastic cells, suggesting that loss of cellular polarity in Lkbl deficient 
PIN is a consequence of disrupted tight junctions (figure 4.3m). This evidence also parallels 
that observed in Lkbl deficient murine testicles (described in section 3.4.4). Unfortunately, 
attempts to determine whether the observed loss of cellular polarity in Lkbl deficient 
prostate epithelium involves loss of Pari A (cTAK, MARK3) phosphorylation, using 
immunohistochemistry to detect p-cTAK have not been successful.
Over-expression of a number of Wnt signalling downstream targets (CD44 and 
Foxal) and components (p-GSK3p) was determined in Lkbl deficient PIN foci, facilitating 
tumour formation and progression. CD44 is a type-1 transmembrane glycoprotein known to 
be a be elevated in human prostate cancer (Wissmann et al., 2003). Wielenga et al (1999) 
showed that CD44 transcription is regulated by |3-eatenin/Tcf4 signalling in the intestine 
and is speculated to participate in the generation and turn-over o f epithelial cells. Foxal 
(HNF-3a) has recently emerged as an indirect transcriptional target o f p-catenin. Animal 
cap assays in Xenopus laevis have revealed p-catenin physically interacts with Sox 17 to 
induce transcription of the Foxal gene (Sinner et al., 2004). Foxal has been detected in the 
UGS and adult prostatic epithelial cells (particularly the anterior and ventral prostate lobes) 
where it is speculated to direct morphogenesis and cell differentiation, further establishing a 
potential role in prostate tumourigenesis (Besnard et al., 2004). Foxal may also govern 
androgen signalling by binding regions adjacent to androgen response elements (AREs) to 
facilitate androgen-regulated prostatic gene expression (Gao et al., 2003; Mirosevich et a l , 
2005; Yu et a l , 2005). Consistent with this, in vitro studies have documented P-catenin can 
interact directly with AR (Truica et a l, 2000) and P-catenin accumulation during prostate 
cancer has been shown to permit P-catenin to behave as a transcriptional co-regulator of AR 
(Yardy and Brewster, 2005). Consequently, AR over-expression in AhCre+L k b l^  PIN may 
be a direct consequence of activated Wnt signalling.
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AhCre+L k b l ^  PIN resembles aspects of transgenic mice expressing either a 
dominant form of p-catenin or Ape loss in the prostate, under the control of the MMTV- 
LTR-Cre or PBCre constructs respectively (Bierie et al., 2003; Bruxvoort et al., 2007; 
Gounari et al., 2002), although the overall phenotype is significantly less severe in the 
AhCre+ L k b l^  model. The discrepancy in severity probably reflects differences in gene 
function (between Lkbl and Ape/p-catenin) within the prostate; but may also reflect 
differences in the experimental approaches used, such as the pattern of Oe-mediated 
recombination. It is also important to note that elevated p-catenin/Wnt signalling has also 
been shown to increase Ah receptor transcript and protein expression, which regulates 
Cyplal p450 {Ah) expression (Chesire et al., 2004). This suggests that activation of Wnt 
signalling could further enhance Cre-mediated recombination events.
Taken together, these results suggest that Lkbl loss predisposes to prostate neoplasia 
in the mouse through the deregulation of cellular polarity events (as determined by aberrant 
ZO-1 expression) and concomitant with elevated p-catenin nuclear translocation, which 
upregulates Wnt targets to further promote tumourigenesis.
4.4.3 Elevated PI3K/Akt signalling in L k b l  deficient PIN
The observed progression of AH to PIN in AhCre+LkbP1^  shares phenotypic 
characteristics with Pten deficient mice (Di Cristofano et al., 2001; Di Cristofano et al., 
1998; Wang et al., 2003), although again being somewhat less severe. Loss of Pten results 
in AH which predisposes to PIN that has been shown to progress into carcinoma and 
metastasis in PBCre"PterP^1 mice (Wang et al., 2003). Pten deficient tumourigenesis is 
positively correlated with the over-expression of p-PDKl, p-Akt and its downstream targets, 
such as p-Gsk3p (Wang et al., 2003). Lkbl mutant mice mimic this pattern and the elevation 
of both total Pten and inactive Pten was previously observed in the TRAMP model (detailed 
in section 1.2.3) (Shukla et al., 2005). Together, this suggests that loss of Lkbl impairs Pten 
function, possibly as a consequence of directly interacting with and regulating Pten stability 
(Mehenni et al., 2005), leading to enhanced PDK-1 and Akt activity and ultimately 
predisposing to PIN. This is consistent with recent in vitro studies that have shown LKB1- 
mediated phosphorylation of PTEN results in PTEN stabilisation (Mehenni et al., 2005; 
Song et al., 2007). In addition, an in vitro study in LNCaP cells has reported that PTEN can 
repress androgen signalling through the PI3K/Akt pathway and can directly interact with 
AR to sequester it in the cytoplasm, thus preventing AR protein degradation and
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suppression of AR transactivation and apoptosis (Lin et al., 2004b). Consequently, in the 
absence of PTEN function, AR signalling is considered to be deregulated and can contribute 
to androgen-dependent tumour formation. However, it is important to note that elevated 
PTEN expression induces cell death, indicating that the results from these experiments 
(carried out using dying LNCaP cells) should be viewed with caution. Furthermore, 
PI3K/Akt signalling is reported to stimulate androgen signalling through Gsk3p inhibition 
and p-catenin accumulation (Sharma et al., 2002). Aberrant PI3K/Akt signalling also 
provides a direct mechanism for deregulation of the Wnt pathway. Active p-Akt can 
phosphorylate and inactivate Gsk3p, which maintains Wnt signalling by inhibiting 
ubiquitin-mediated degradation of p-catenin (Al-Khouri et al., 2005; Green, 2004). Had 
more time been available it would have been interesting to see whether downstream AR 
signalling targets (such as PSA) are upregulated and to confirm that PIN lesions are 
androgen dependent by carrying out an androgen ablation study.
Casein kinase II (CK2) is a protein kinase frequently upregulated in human prostate 
cancer and plays key roles in cell growth, proliferation and survival (Laramas et al., 2007). 
Among its many cellular activities (including Nkx3.1 activation) it functions to regulate 
PTEN stability (Laramas et al., 2007). Post-translational modifications of PTEN are not 
well understood and should be viewed with caution, however CK2 has been shown by 
independent research groups to phosphorylate residues S380, T382 and T383 and 
predominantly S370 and S385 to regulate PTEN stability/activity (Al-Khouri et a l , 2005; 
Mehenni et al., 2005). To further investigate the inactivation o f Pten in Lkbl deficient PIN 
lesions, expression levels of CK2 were monitored (figure 4.8). Immunohistochemistry 
demonstrated that CK2 is not expressed in control prostate epithelium but is significantly 
elevated in Lkbl deficient tumours, consistent with the observed inactivation of Pten. This 
presents an additional mechanism whereby PTEN might be phosphorylated and 
subsequently inactivated by upregulated CK2, leading to PDK1 and Akt activation.
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C re L k b l"  AhCre'Lkblm '
Figure 4.8: Analysis of CK2 expression in Lkbl deficient PIN. Immunohistochemistry of 
formalin-fixed, paraffin-embedded dorsolateral and ventral prostate sections from Cre Lkblflfl and 
AhCre L k b ^  mice (aged 2-7 months) revealed that CK2 is absent in control tissue (a) and over­
expressed in the nuclei of Lkbl deficient neoplastic cells (b). Images were taken at 40x 
magnification and scale bars represent 50 pm.
To conclude, these data suggest that loss of Lkbl in the prostate causes neoplastic 
transformation, owing to the loss of Pten activity, which ultimately results in tumourigenesis 
by stimulating the oncogenic effects of the PI3K/Akt signalling pathway. It is speculated 
that elevated CK2 expression may play a role in mediating this process by phosphorylating 
and inactivating Pten. The fact that p-PDKl is upregulated, provides a direct mechanism for 
the observed suppression of the mTOR pathway and elevated levels of p-S6K.
4.5 Summary
To conclude, Lkbl deficiency predisposes to anterior prostate neoplasia by 
deregulating Lkbl-mediated signalling pathways. PIN lesions demonstrated aberrant Wnt 
and PI3K/Akt pathways that may cooperate to modulate apoptosis, loss of cell polarity, 
migration, proliferation and androgen signalling, the combined consequence of which is to 
facilitate neoplastic tumour formation. Consistent with this phenotype, Lkbl deficiency 
mirrors aspects of both PTEN loss and hyperactivation of the Wnt pathway. Although 
AMPK is activated by Lkbl, an unexpected increase in p-AMPK was detected in Lkbl 
deficient neoplastic prostate epithelial cells in parallel with suppression of the mTOR 
pathway. It is speculated that inhibition of the mTOR pathway may be the direct result of a 
negative feedback mechanism whereby AMPK is activated by an alternate AMPKK to 
Lkbl, such as PDK1 or CaMKK. In agreement with this hypothesis, p-PDKl expression 
was elevated in PIN lesions and corresponds to the observed S6K activation. Mechanisms 
for such deregulation and pathway cross-talk have been illustrated in figure 4.7.
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Chapter 5: P-catenin stabilisation predisposes to prostate 
adenocarcinoma
5.1 Introduction
P-catenin (CTNNB1) is an 88kDa proto-oncogene that participates in adherens 
junctions and Wnt signalling (discussed in section 1.4). Aberrant Wnt signalling is 
emerging as a key event in the development of prostate cancer, possibly as a direct 
consequence of its role in regulating AR transcriptional activity (Yardy and Brewster, 
2005). Consistent with this, AhCre+LkbPl prostate intra-epithelial neoplasia demonstrated 
elevated Wnt signalling (chapter 4). To address the genetic basis for prostate cancer in 
Lkbl deficient mice, a novel model of prostate cancer was generated where the PBCre 
transgenic line was used to drive recombination of both the Lkbl floxed transgene 
(Sakamoto et al., 2005) and a dominant stabilised form o f P-catenin (Harada et al., 1999).
5.1.1 P-catenin and prostate cancer
Approximately 5-7% of human prostate cancers harbour an activating P-catenin 
mutation within the regulatory region (Voeller et al., 1998) and inactivating mutations in 
A PC and hTRCPl (also known as BTRC), which prevent the degradation of p-catenin, have 
also been detected in human prostate cancer (Gerstein et al., 2002). In addition, human 
tissue microarray studies have shown that 50% of early and 80% of metastatic prostate 
cancer samples display p-catenin nuclear localisation, indicating active Wnt signalling 
(DeLaTaille et al., 2003).
p-catenin is known to stimulate the transcription of AR target genes and androgen 
ablation/regeneration experiments have shown that P-catenin accumulates in the nuclei of 
testosterone-restored animals, suggesting that P-catenin may play a role in androgen- 
induced prostate regeneration (Chesire et al., 2002). In addition, Cheshire et al (2002) also 
observed that transient p-catenin over-expression enhances AR-mediated transcription of 
two natural target gene promoters in six prostate cancer cell lines in vitro (Chesire et al.,
2002). AR co-activators and co-repressors contain LXXLL motifs that mediate their 
binding to AR (Truica et al., 2000). P-catenin harbours five LXXLL motifs within the 
armadillo repeat region that are postulated to facilitate p-catenin:AR interactions (Truica et 
al., 2000). Evidence for p-catenin as an AR receptor co-activator has been demonstrated in
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vitro, where p-catenin nuclear accumulation leads to enhanced AR-dependent transcription, 
including transcriptional activity of the AR gene itself (Terry et al., 2006; Truica et al., 
2000; Yang et al., 2006). Furthermore, p-catenin may alter the ligand specificity of the AR 
and has been shown to relieve the repression of anti-androgens, thus contributing to the 
progression of prostate cancer (Truica et al., 2000; Verras and Sim, 2006).
Regulation of the Wnt signalling pathway, and therefore AR signalling, is a 
complex process that to date is not well defined. GSK3P plays a dual role in cells, linking 
the regulation of Wnt pathway to AR signalling and is itself regulated by PI3K/AKT 
signalling (Terry et al., 2006). Gsk3p has recently been shown to act as a negative 
regulator of AR-mediated transcription through direct interactions with AR (Wang et al., 
2004a). PI3K/AKT signalling has also been shown to be mediated by androgen signalling 
via GSK3P phosphorylation, permitting nuclear translocation of p-catenin and augmenting 
AR activity (Sharma et a l,  2002). An indirect mechanism for p-catenin activation of AR 
signalling involves p-catenin-mediated transcription of Sox-17, a HMG box transcription 
factor that directly triggers Foxal mRNA expression (Sinner et a l,  2004). Foxal is required 
during prostate development (Mirosevich et a l, 2005) and has recently emerged as an AR 
signalling component (Gao et a l, 2003; Yu et a l, 2005).
p-catenin can also down-regulate the metastasis suppressor gene KAI1, whose 
expression is frequently decreased in metastatic prostate cancer (Kim et a l,  2005; Reya 
and Clevers, 2005). p-catenin and the reptin chromatin remodelling complex are thought to 
act in concert with histone deacetylases to antagonise the Tip60-pontin co-activator 
complex, which is required to activate transcription of NF-tcB genes, including KAIL 
Ultimately, p-catenin-reptin complexes prevent the Tip60-pontin co-activator complex 
from binding to the KAI1 promoter, suppressing KAIl expression and promoting 
tumourigenesis (Kim et a l, 2005).
5.1.2 Wnt signalling and mouse models of prostate cancer
Mouse models have demonstrated that aberrant Wnt signalling causes prostate 
tumourigenesis but have been limited in terms of progression. Gounari et al (2002) derived 
mice bearing a dominant stabilised form of p-catenin in the prostate, using the MMTV- 
LTR-Cre construct to drive transgene expression (detailed in section 5.1.3). PIN-like 
lesions manifested keratinised squamous metaplasia by 10 weeks of age and demonstrated 
upregulation of AR and the Wnt target c-Myc (Gounari et a l,  2002). These mice also
153
displayed hair follicle cysts, urethral hyperplasia, odontomas and keratinised squamous 
metaplasia of the salivary, preputial, hardarian and mammary glands indicating P-catenin 
plays a role in widespread epithelial tumours (Gounari et al., 2002). Mice were aged to 5 
months and no evidence for further disease progression, invasion or metastasis was 
observed. Bierie et al (2003) also characterised the dominant stabilised p-catenin model in 
MMTV-LTR-Cre transgenic mice, determining epithelial hyperplasia and extensive trans­
differentiation into epidermal-like structures that expressed keratin 1 and 6, filaggrin, 
loricrin and involucrin. These mice were not viable past 3 months, which hindered studies 
of late stage progression. Ventral prostate transplants to mammary fat pads were necessary 
for further progression to squamous metaplasia and neoplastic transformation (Bierie et a l ,
2003). Discrepancies in the phenotype observed in these two transgenic models are thought 
to reflect subtleties in strain background.
More recently, Bruxvoort et al (2007) derived mice bearing biallelic inactivation of 
the Ape gene using the PBCre transgenic line to drive activation of the Wnt pathway in the 
prostate. Ape loss was coupled with increased p-catenin expression in the nucleus, 
suggesting deregulation of the Wnt signalling pathway. Hyperplasia was observed at 4.5 
weeks and progressed to prostate carcinoma by 7 months, which castration experiments 
revealed were androgen independent (Bruxvoort et a l , 2007). No evidence for metastasis 
was observed, despite 30% of the mice developing hepatomas and tumour derived 
lymphadenopathy of the lumbar lymph nodes (Bruxvoort et a l,  2007).
5.1.3 Derivation of a dominant stable P -ca ten in  isoform
Using Cre-LoxP technology, Harada et al (1999) developed a conditional, activated 
form of p-catenin to study the role of deregulated Wnt signalling within the intestine 
during tumourigenesis and progression in vivo. Here, exon 3 (amino acids 5-80) of the p- 
catenin gene is followed by a PGK-NEO cassette and is sandwiched between two LoxP 
sites, termed Catnblox(ex3) (Harada et a l,  1999), (figure 5.1). Following Cre-mediated 
recombination, exon 3 is excised resulting in the loss of the highly conserved Ser33, Ser37 
and Thr41 residues that are phosphorylated by GSK3p to target p-catenin for ubiquitin- 
mediated degradation (Harada et a l, 1999). This ultimately generates a dominant stable 
form of the gene that is constitutively active.
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Figure 5.1: Construction of dominant stabilised form of p-catenin using the Cre-LoxP system. 
From top to bottom, structures show p-catenin protein (phosphorylation sites in red), the wild-type 
allele (Catnb \  the targeting vector, targeted allele (Catnb,ox(ex3)) and the recombined allele 
(Catnb*™) respectively. Red arrows indicate the LoxP sites flanking exon 3 that carries the GSK3p 
phosphorylation site. Figure is adapted from Harada et al (1999).
Using the promoter regions of either cytokeratin 19 (CK19) or rat liver fatty acid 
binding protein (Fabpl) to drive Cre-recombinase expression, Harada et al (1999) targeted 
transgene expression to intestinal and colonic epithelia. Mice were predisposed to 
numerous intestinal adenomatous polyps and some colonic microadenomas (emerging ~2 
weeks after birth), demonstrating that activation of the Wnt pathway in the gut results in 
tumourigenesis (Harada et a l, 1999). To date, the dominant stable P-catenin transgene has 
been widely exploited in several different tissues to reveal direct experimental evidence for 
elevated Wnt signalling in cancer. These include colorectal neoplasms, 
hepatocarcinogenesis, hair follicle tumours, mammary carcinomas and keratinised 
squamous metaplasia of the prostate and preputial gland (Bierie et a l,  2003; Gounari et a l, 
2002; Harada et a l,  2004; Harada et a l, 1999).
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5.2 Aim
Having previously established that the Wnt cascade is stimulated in AhCre LkbP1^1 
PIN (chapter 4), the objective of this chapter is to investigate the possibility of a synergistic 
relationship between Lkbl loss and activated Wnt signalling. It is hypothesised that Lkbl 
deficiency and P-catenin hyperactivation will cooperate to facilitate tumour formation. 
This process may be facilitated solely by activation of the Wnt pathway if the all the effects 
of Lkbl loss are mediated through the Wnt pathway. To determine whether Lkbl 
inactivation and p-catenin activation are independent or dependent events, the PBCre 
transgenic line was used to drive recombination in the prostate of a targeted dominant 
stable p-catenin transgene, in combination with the floxed Lkbl construct. Single and 
double mutant cohorts were analysed histologically and the underlying molecular events 
that led to prostate adenocarcinomas were investigated using immunohistochemistry.
5.3 Results
5.3.1 PBCre+Catnb+/lox(ex3) male mice have a reduced life-span
PBCre transgenic mice were inter-crossed with mice bearing one LoxP-flanked fi- 
catenin allele (shown in figure 5.1) and one wild-type P-catenin allele. Male cohorts of 
wild-type (PBCre+Catnb+l+ or Cre'Catnb+l+), control (<Cre~Catnb+Aox3(ex3)) and mutant 
(PBCre C atnb/lox(ex3)) mice were aged and monitored for signs of disease. Mice were 
harvested when they became symptomatic of disease or at specified time points (100, 200 
and 500 days). Each long-term cohort contained a minimum of 15 males while earlier time 
points allocated to monitor progression were smaller (n = 6). All members of the wild-type 
and Cre~Catnb+/lox(ex3) cohorts survived to 500 days while a Chi-squared test determined the 
average survival of the PBCre+Catnb+/lox(ex3) cohort was significantly reduced to 417 days 
as mice became sick (%2 = 34.56, p = 0.000). Only 22% of the mutant males survived to the 
500 day endpoint.
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Figure 5.2: PBCre+Catnb+/lox(ex3> male mice display reduced longevity. A Kaplan-Meier survival 
curve where wild-type (n = 32) and Cre C atnb/lox3(ex3) (n = 15) cohorts are represented in green and 
the PBCre Catnb{/lox(ex3) cohort (n = 18) is in blue. PBCre C atnb/lox(ex3) mice show decreased 
longevity, with only 22% of the cohort living till the endpoint of 500 days. Chi-squared tests 
confirmed PBCre Catnby/lox(ex3) mice exhibit a significantly reduced average survival of 417 days 
compared to wild-type and PBCre'Catnb+/lox3(ex3) cohorts (%2 = 34.56, p = 0.000). Statistical analysis 
was carried out by a Chi-squared test using ‘MiniTab’ software and the Kaplan-Meier plot was 
generated using ‘MedCalc’ software.
5.3.2 PBCre+Catnb+/u>x(ex3) mice are predisposed to multiple GU tract phenotypes
Histological analysis o f H&E sections from all cohorts aged to 100 (n = 6), 200 (n 
= 6) and 500 days (or end point, n = 18) determined PBCre Catnb ^ /lox(ex3) mice were
predisposed to multiple GU tract tumours, while wild-type (n = 32) and control (n = 15) 
cohorts were normal (Table 5.1).
Table 5.1 Phenotype incidence in PBCre+Catnb+/lox(ex3) mice
Genotype
Phenotype
Wild-type 
(500 d)
Cre' 
Catnb+ ,ox(ex3) 
(500 d)
PBCre 
Catnb+lox(ex3) 
(100 d)
PBCre 
Catnb* h,x(ex3) 
(200 d)
PBCre
Catnb+lox(ex3) 
(End point)
Prostate HG-PIN and 
keratinised squam ous 
metaplasia
0% 0% 100% 100% 0%
Prostate adenocarcinoma 0% 0% 0% 100% 100%
Bulbourethral gland  
keratinised squam ous 
metaplasia
0% 0% 100% 100% 100%
Preputial gland  
keratinised squam ous 
metaplasia
0% 0% 67%
(4 mice)
100% 100%
Urethra keratinised 
squamous metaplasia
0% 0% 0% 17%
(1 mouse)
28%
(5 mice)
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5.3.3 PBCre-mediated recombination drives expression of the dominant stabilised p- 
catenin transgene in the prostate
LacZ staining carried out in chapter 3 revealed that PBCre-mediated recombination 
occurs in all four lobes o f the prostate (figure 3.29) and correlated to published reports (Wu 
et al., 2001). To confirm recombination occurred within PBCre* Catnb+/lox(ex3) prostate 
tumours, a PCR specific for the P-catenin recombined allele (Catnb+/Aex3) was carried out. 
Monoallelic deletion o f exon 3 o f  the p-catenin  gene (amino acids 5-80) was confirmed in 
both keratinised squamous metaplasia and adenocarcinoma lesions (figure 5.3a). In wild- 
type prostate epithelium, p-catenin expression is predominantly found at the cell surface to 
form adherens junctions and is rarely detected in the nucleus (figure 5.3b). All PBCre* p- 
catenin*//>ex3 lesions (squamous metaplasia and adenocarcinoma) demonstrated increased p- 
catenin nuclear localisation where it can regulate transcription o f  Wnt target genes (figure 
5.3c-e). Together this data indicates P-catenin oncogenic transformation occurred in 
PBCre v Catnb*/Aex3 prostate lesions.
a WT SqM Ad H20
PBCre~Catnb~
Endpoint100 davs
Figure 5.3: p-catenin is constitutively active in PBCre*Catnb*//Sex5 prostate tumours. DNA
isolated from anterior prostate lobes of wild-type mice (aged 500 days) and squamous metaplasia 
and adenocarcinoma lesions of PBCre Catnb /lox(ex3) mice underwent P-catenin recombined PCR 
analysis (a). Wild-type (WT) prostate displayed the wild-type P-catenin allele (1 kb) while 
squamous metaplasia (SqM) and adenocarcinomas (Ad) expressed one WT allele and one P-catenin 
recombined allele (0.7kb). Immunohistochemistry to detect P-catenin in wild-type (b) and 
PBCre Catnb /lox(ex3) mice aged 100 days (c), 200 days (d) and at end point (e) revealed elevated 
nuclear p-catenin expression in prostate lesions. Images were taken at 40x magnification and scale 
bars represent 50 pm.
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5.3.4 PBCre*Catnb+/U>x(ex3) mice manifest prostate keratinised squamous metaplasia 
that progressed to adenocarcinoma
Wild-type {PBCre*Catnb*/+) and control {Cre'Catnb*/lox(ex3)) mice demonstrated 
normal architecture o f all four prostate lobes (anterior lobe shown in figure 5.4a). By day 
100, all four prostate lobes in PBCre*Catnb*/lox(ex3) mice developed a diffuse, aggressive 
HG-PIN that exhibited keratinised squamous metaplasia with 100% incidence (figure 
5.4b).
JVtld-npe HG-PIN" and keratinised squamous metaplasia (100 days)
HG-PIN and adenocarcinoma Adenocarcinoma
(200 days) (end point)
Figure 5.4: Dominant stabilisation of B-catenin causes prostate cancer. Histological analysis of 
formalin-fixed, paraffin-embedded H&E stained sections from wild-type mice aged 500 days and 
PBCre Catnbr/AexS mice aged 100, 200 and 500 days (or end point). Wild-type prostate shows 
ordered single-layered branched intra-luminal projections (a). Dominant stabilisation of (3-catenin 
resulted in HG-PIN-like lesions that manifested keratinised squamous metaplasia at 100 days (b). 
The insert in (b) indicates apoptotic cells (arrow head) within metaplastic foci. Keratin pearl 
formations stained positively for Keratin-5 and the arrow represents a positively stained 
keratinocyte (c). At day 200, HG-PIN lesions and keratinised squamous metaplastic foci were 
present in addition to the development of adenocarcinoma that formed rosette (*) structures (d). 
End point mice manifested diffuse and locally invasive adenocarcinomas associated with mitosis 
(white arrow) and apoptosis (black arrow head). All images were taken at 40x magnification and 
scale bars represent 50 pm.
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Lesions demonstrated nuclear atypia, apoptotic bodies, mitosis, angiogenesis, 
keratin pearl formation, extensive over-crowding of the lumen as multi-cellular 
disorganised layers form and metaplastic foci, surrounded by thick muscle walls. Keratin 
was detected by anti-keratin-5 immunohistochemistry staining that also labels the basal cell 
population (figure 5.4c). Staining for epidermal differentiation markers, such as loricrin, 
involucrin and fillagrin would further validate keratinisation and squamous metaplasia.
At 200 days, the PBCre' Catnb+/lox(ex3) cohort (n = 6) was predisposed to lesions of 
keratinised squamous metaplasia and adenocarcinoma with 100% incidence (figure 5.3d). 
Cells formed rosette-like structures indicating glandular differentiation is maintained and 
lesions were associated with nuclear atypia (figure 5.4d insert). At 500 days, 
hyperactivation of p-catenin led to diffuse and locally invasive adenocarcinomas with 
100% incidence in PBCre+Catnb+/lox(ex3) mice (n = 18). Adenocarcinomas at 500 days 
showed increased severity compared to those at 200 days and keratinised squamous 
metaplasia was not detected (figure 5.4e). Prostate cancer progression in the 
PBCre Catnb ^ /lox(ex3) model closely mirrors that of Ape deficient mice (Bruxvoort et a l , 
2007).
5.3.5 P B C re+C atnb  /lox(ex3) male mice develop multiple GU tract squamous metaplasias
Male accessory glands were also predisposed to tumourigenesis in the 
PBCre+Catnb+/lox(ex2) cohort. Bulbourethral gland (BUG) keratinised squamous metaplasia 
was observed with 100% incidence by 100 days. BUGs consist of tall secretory cells with 
basally located nuclei that form acini in the tubular coiled gland (figure 5.5a). Dominant 
stabilisation of p-catenin caused BUG tumours that were dramatically increased in size 
compared to controls and showed elevated angiogenesis (figure 5.5b). Histological analysis 
revealed keratinised squamous metaplasia and aberrant acini architecture that displayed 
reduced secretion and enlarged basal nuclei (figure 5.5c-d). It is important to note that 
these lesions did not demonstrate any immune cell infiltrate and were histologically distinct 
to the hyperplastic BUG cysts predisposed in AhCre+L k b l ^  mice (section 3.3.4).
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Figure 5.5: PBCre+Catnb+/lox<ex3) mice develop keratinised squamous metaplasia of the
bulbourethral gland. H&E staining was performed on formalin-fixed, paraffin-embedded wild- 
type tissue sections at 100 days illustrating normal duct architecture and secretory function (a). 
PBCre Catnb+/,ox(ex3) mice displayed enlarged bulbourethral glands (arrows), adjacent to the distal 
urethra (U) where it joins the penis (P) (b), taken at 500 days and the ruler indicates 1 mm. H&E 
staining of PBCre C atnb/lox(ex J bulbourethral gland at low (c) and high magnifications (d) revealed 
squamous metaplasia and aberrant ductal cells and secretory function at 100 days. Images were 
taken at 20x (low power) and 40x (high power) magnification and scale bars represent 50 pm.
Keratinised squamous metaplasia of the preputial gland and urethra was observed at 
100 days (67% and 0% incidence respectively), 200 days (100% and 17% incidence 
respectively) and at end point (100% and 28% incidence respectively). Wild-type preputial 
glands displayed normal sebaceous gland function (figure 5.6a), while P-catenin activation 
resulted in keratin pearl formation in the lumen and squamous metaplasia of the ductal 
cells (figure 5.6b). A similar phenotype was observed in the urethra transitional epithelium, 
where acini developed squamous metaplasia and the lumen contained keratin (figure 5.6d).
Wild-type PBCre* Catnb*/lox<ex3>
Preputial gland
Urethra
Figure 5.6: PBCre+Catnb+/lox(ac3} mice develop preputial gland and urethra keratinised 
squamous metaplasia. Wild-type preputial gland exhibits normal ductal architecture and secretory 
function (a) while PBCre C atnb/lox(ex3) mice display keratinised squamous metaplasia (b). 
Flattening of cells is clearly seen in (b). Wild-type urethra is shown in (c) and keratinised squamous 
metaplasia of PBCre ' C atnb/lox(ex3) urethra is illustrated in (d). Keratin is clearly identifiable in acini 
formed within the urethral transitional epithelium. Images were taken at 20x (low power) and 40x 
(high power) magnification and scale bars represent 50 pm. All mice were 200 days old.
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5.3.6 Molecular characterisation of PBCre+Catnb+/Aex3 prostate lesions
To characterise the prostate lesions at a molecular level, immunohistochemistry was 
performed to detect the proliferation marker, Ki-67. A basal level o f Ki-67 positive cells 
was observed in control prostate epithelium, however dominant stabilised p-catenin 
prostate tumours demonstrated a significant increase in the number o f proliferating cells 
(figure 5.7a-b). Scoring the percentage o f  Ki-67 positive cells per acinus revealed that 
proliferation in PBCre+Catnb+/AexS lesions (57%) was significantly different compared to 
wild-type and control cohorts (4%), throughout the course o f  tumour progression (p = 
0.0404, Mann Whitney). Furthermore, Ki-67 staining remained constant during disease 
progression from PIN-like squamous metaplasia to adenocarcinoma (figure 5.7c).
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Figure 5.7: PBCre+Catnb+/**3 prostate lesions are highly proliferative. Immunohistochemistry 
of formalin-fixed, paraffin-embedded end point anterior prostate sections to detect the proliferation 
marker Ki-67 in wild-type (a) and PBCre Catnb ‘/Aex3 adenocarcinoma revealed a dramatic increase 
in the rate of proliferation (b). Images were taken at 40x magnification and scale bars represent 50 
pm. The chart in (c) shows the percentage of proliferating cells in prostate epithelium (20 acini 
were scored per mouse, n = 3 for each genotype). PBCre Catnb **3 prostate showed a significant 
increase in proliferation compared to wild-type and control tissue at all time points (p = 0.0404). 
Error bars represent standard deviation and statistical analysis was carried out using a non- 
parametric Mann Whitney test using “MiniTab” software (95% confidence interval). Counting was 
carried out by Jennifer Howard (Undergraduate student, Cardiff University).
Basal cells were detected by immunohistochemistry using an anti-p63 antibody 
(Shappell et a l ,  2004). The basal cell population was reduced in prostate lesions 
expressing activated p-catenin compared to control tissue at each time point (figure 5.8a-f). 
Control prostate demonstrated the basal cell population comprised -11%  o f the prostatic
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epithelium at all time points (figure 5.8g), consistent with the literature (Collins et al., 
2001). Squamous metaplasia and adenocarcinoma at 100 days and 200 days respectively 
showed a significant reduction in p63 positive cells (8-9%, p = 0.0404, Mann Whitney). 
Interestingly, end point adenocarcinomas showed a further reduction in p63 (2.7%, p = 
0.0404, Mann Whitney). In parallel with this data, depletion o f the basal cell population 
has been demonstrated during the progression o f human prostate cancer and p63 expression 
has been deemed necessary for the development o f  squamous metaplasia (Bruxvoort et a l ,  
2007). Similarly, bladder tumours show a progressive reduction in p63 with progression 
(Urist et al., 2002).
Wild-type PBCre Catnb" * x3
100 days
200 days
End 
(500 days)
Figure 5.8: Loss of the basal cell population is associated with PBCre+Catnb+/AexS prostate 
cancer progression. Immunohistochemical analysis of formalin-fixed, paraffin-embedded wild- 
type (a-c) and PBCre Catnb" zkyri (d-f) prostate from mice aged 100 days, 200 days and end point 
(up to 500 days) revealed a reduction in the expression of the basal cell marker p63. Images were 
taken at 40x magnification and the scale bars represent 50 pm. The chart in (g) demonstrates the 
percentage of basal cells per acinus (20 acini were scored per mouse, n = 3 for each genotype). The 
basal cell population is significantly decreased in prostate tumours (p = 0.0404). Furthermore, p63 
expression does not change with age in control prostate tissue (p = 0.6625). Error bars represent 
standard deviation and statistical analysis was carried out using a non-parametric Mann Whitney 
test using “MiniTab” software (95% confidence interval). Counting and immunohistochemistry was 
carried out by Jennifer Howard (Undergraduate student, Cardiff University).
Immunohistochemistry to detect AR revealed that dominant stabilisation o f p- 
catenin results in an increase in the number o f cells expressing nuclear AR compared to 
control prostate tissue (figure 5.9a-b). AR was present in 5.3% o f the control prostate 
epithelium and was elevated 10-fold in adenocarcinomas (52.6%, p = 0.0404, Mann 
Whitney) (figure 5.9c). This suggests that P-catenin-mediated AR transcription and
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signalling may further facilitate tumour progression in PBCre+Catnb+/lox(ex3) mice (Terry et 
a l , 2006; Truica et al., 2000; Yang et a l ,  2006).
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Figure 5.9: PBCre+Catnb+//Sex3 prostate tumours over-express AR. lmmunohistochemical 
analysis of control {Cre Catnb ,ax3(ex3)) (a) and PBCre*Catnb* ^ x3 (b) prostate from mice aged 500 
days revealed upregulated AR expression in tumours. Images were taken at 40x magnification and 
the scale bars represent 50 pm. Plot demonstrates the percentage of AR positive cells (counted from 
20 acini per mouse, n = 3 for each genotype) at end point (c). Compared to control acini, the 
number if AR expressing cells was significantly increased in adenocarcinomas (p = 0.0404). Error 
bars represent standard deviation and statistical analysis was carried out using a non-parametric 
Mann Whitney test using “MiniTab” software (95% confidence interval). Counting and IHC was 
carried out by Jennifer Howard (Undergraduate student, Cardiff University).
5.3.7 Wnt targets are upregulated in PBCre+Catnb+//3ex3 prostate lesions
Dominant stabilisation o f P-catenin is predicted to stimulate the transcription o f 
Wnt target genes that drive tumour progression. To confirm that elevated nuclear 
accumulation o f p-catenin in prostate lesions results in the expression o f Wnt target genes, 
immunohistochemistry was employed to analyse the expression o f  the migration marker 
CD44 and the proto-oncogene Foxal (figure 5.10). CD44 was not detected in wild-type 
prostate (figure 5.10a) while mutant PIN-like squamous metaplasia lesions and 
adenocarcinomas both showed over-expression o f CD44 (figure 5.10b-c). Foxal was also 
upregulated in PBCre+Catnb+//3ex3 squamous metaplasia and adenocarcinoma compared to 
wild-type tissue (figure 5.10d-f). Together, this indicates that hyperactivation o f p-catenin 
in prostate epithelium stimulates the transcription o f  Wnt target genes, which potentially 
act to drive tumour progression. This is consistent with other studies which have strongly 
implicated deregulated Wnt signalling in cancer (Polakis, 2000; Yardy and Brewster, 
2005).
Cre'Catnb+/lox(ex3)
PBCre+Catnb+/Jex3
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CD44
Foxal
Figure 5.10: PBCre+Catnb+//lex3 prostate tumours demonstrate activated Wnt signalling.
Immunohistochemical analysis of wild-type and PBCre Catnb + 3 prostate from mice aged 100 
and 500 days revealed CD44 (a-c) and Foxal (d-f) expression is induced in both squamous 
metaplasia and adenocarcinoma lesions (a-c) compared to wild-type prostate epithelium. Images 
were taken at 40x magnification and the scale bars represent 50 pm.
5.3.8 PBCre3L kb l+/^ :Catnb+/lox^ex3* mice do not show decreased longevity compared to
PBCre+Catnb+/U)x(ex3) mice
PBCre3 L k b l '^ 1 transgenic male mice were inter-crossed with Cre'
L k b l3/Jl;Catnb+/lox(ex3) females. A male cohort o f PBCre3L k b l+/fi;Catnb+/lox(ex3) mice (n =
10) was generated and aged to 500 days or harvested when they became symptomatic o f 
disease. Unfortunately, sufficient numbers o f male PBCre3L k b ^ ; C a tn b +/lox(ex3) mice were 
not generated within the time course o f  the project (n = 2). Chi-squared analysis 
determined that the observed Mendelian frequencies did not fit the expected ratios (%2 = 
19.785, p = 0.0484, n = 135). This suggests that there is some lethality in a number o f the 
genotypes. Expected ratios shown in Table 5.2 indicate that the number o f  LkblM  mice is 
lower than expected, however the cohort size o f this genotype is relatively small. 
Consistent with this data, Sakamoto et al (2005) have reported that L kb lm  mice are bom at 
a frequency -30%  lower than the expected Mendelian ratio, suggesting partial embryonic 
lethality o f this genotype. Mice carrying the dominant stable /3-catenin transgene did not 
demonstrate partial lethality, although it is not clear from our data whether this construct 
may further enhance the partial embryonic lethality in L kb lm  mice.
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Table 5.2 Partial embryonic lethality in L k b ^  mice
Cross: PBCre+L k b l+/JI (<?) x Cre L k b l+/J1;Catnb+/lox(ex3) (2 )
Genotype Observed Expected
Cre 14 8.43
PBCre+ 6 8.43
Cre Lkb r  " 19 16.88
PBCre Lkbl ’' 19 16.88
CreLkblW 4 8.43
PBCre'Lkb f " 2 8.43
Cre Catnb' 11 8.43
PBCre'Catnb* 9 8.43
Cre'L kbV ", Catnb* 24 16.88
PBCre'Lkbl'"tCatnb' 18 16.88
CreLkbl" ".Catnb' 4 8.43
PBCre' Lkbl" " ,Catnb5 8.43
Total 135 135
A Kaplan-Meier survival plot (shown in figure 5.11) and Chi-squared analysis 
revealed double heterozygous transgenic mice (PBCre+L k b l+/fi;Catnb+/lox(ex3)) showed a 
significant reduction in lifespan (average survival 453 days, %2 = 26.07, p = 0.000 
compared to wild-type mice), but this did not differ from the PBCre+Catnb+/lox(ex3) cohort
Genotype
  PBCre+ Catnb liet
 PBCre-*- Lkbl liet
PBCre-t- Lkbl liet, Catnb liet
  PBCre- Lkbl hom
  Wild-type
Figure 5.11: PBCre+Lkbl+/J!:Catnb+/lox<ex3> male mice display reduced longevity. A Kaplan-Meier
plot of wild-type (n = 32), PBCre Catnb',ox(ex3) (n = 18), PBCre L k b l '11 {n = 16), Cre Lkbl11(n = 
12)and PBCre Lkb1 ' ; Catnb',ox(ex3) (n = 10) mice. PBCre L k b l'fl;Catnb',ox(ex3) mice displayed a 
small yet significant decrease in survival compared to wild-type mice (average survival 453 days, 
X2 =  26.07, p = 0.000). This reduction was similar to PBCre Catnb /lox(ex3) m jce (average survival 
417 days, % = 2.825, p = 0.093). Statistical analysis was carried out using a Chi-squared test using 
“MiniTab” software and the Kaplan-Meier plot was generated using “MedCalc” software.
(average survival 417 days, y 2 = 2.825, p = 0.093).
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5.3.9 Investigating the cooperativity of Lkbl loss and P-catenin activation in the 
prostate
Histological analysis o f H&E sections from PBCre+Lkb 1*^; C a tn b /lox(ex3) mice 
displayed prostate adenocarcinoma with 100% incidence, resembling PBCre+Catnb /lox<ex3) 
mice (figure 5.12a). This probably reflects the fact that PBCre+L k b l+ / mice did not 
develop a prostate phenotype. Compound mutants were also predisposed to bulbourethral, 
preputial and urethral gland squamous metaplasia with 100%, 100% and 30% incidence 
respectively (as shown in figures 5.5 and 5.6). In addition, seminal vesicle squamous 
metaplasia (50% incidence) was observed in the double transgenic line which was not 
detected in single transgenics, suggesting heterozygous inactivation o f  the L kb l gene may 
cause prostate cancer invasion into the adjacent male accessory organ (figure 5.12b-e).
PBCre*Lkbl tCatnb*'**3 Seminal vesicle
Prostate Adenocarcinoma
Figure 5.12: Monoallelic Lkbl loss and p-catenin dominant stabilisation do not synergise in 
the prostate. Histological analysis of formalin-fixed, paraffin-embedded H&E stained sections 
from PBCre Lkbl 11 ;Catnb^ ^ 3 mice aged 500 days displayed diffuse adenocarcinoma (a). 
PBCre+Lkbl f,;Catnb+Mx:> mice also developed seminal vesicle squamous metaplasia (b-e). All 
images were taken at 40x magnification and scale bars represent 50 pm.
The Cre L k b l^ ;C a tn b +/lox(ex3) cohort (n = 8) demonstrated atypical hyperplasia 
(AH) o f  the anterior lobe (63% incidence) and the dorsolateral and ventral lobes (25% 
incidence) as well as anterior LG-PIN (25% incidence), correlating to Cre L kblm  mice 
(shown previously in Table 3.2) and reflecting the hypomorphic nature o f  the L kbl floxed 
construct (figure 3.28d-f).
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To date, only two male PBCre"Lkb1 ^ ; Catnbwlox(ex3) mice have been generated. 
Histological analysis o f these mice at 100 days revealed that these mice were predisposed 
to PIN-like keratinised squamous metaplasia o f  all four prostate lobes, concomitant with 
epithelial cells that contained large cytoplasmic vacuoles with basal and compressed nuclei 
(figure 5.13), reminiscent o f mucinous metaplasia observed in p63 null prostate (Kurita et 
a l ,  2004) and PB-H-rasvn  mice (Scherl et al., 2004). The PBCre" LkblM ;Catnb"/Iox(ex3) 
phenotype resembles aspects o f both PBCre+Catnb+/lox(ex3) mice at this time point (figure 
5.3b) and PBCre" L k b ^  mice aged to 500 days (figure 3.28), suggesting an acceleration 
o f the L kb l deficient phenotype. In addition, both PBCre"Lkb 1 ^ ; Catnb"/lox(ex3) mice 
analysed were sterile (hypospermatogenesis) and developed preputial gland, bulbourethral 
gland and urethra keratinised squamous metaplasia. Together, this data implicates a 
synergistic relationship between Lkbl loss and dominant stabilisation o f P-catenin in 
prostate tumourigenesis in the mouse, although more double mutant mice are necessary to 
support this notion.
Figure 5.13: Potential synergy in PBCre"Lkb ^ tC a tn b ^ * * 3 prostate. Histological analysis of 
formalin-fixed, paraffin-embedded H&E stained sections from PBCre4L k b f fl;Catnb+lox(ex3) mice 
aged 100 days revealed all four prostate lobes were predisposed to several distinct lesions. PIN-like 
lesions (a-b) displayed tall columnar cells (arrow), nuclear atypia and mitotic and apoptotic figures 
shown in (b), mucinous-like epithelial cells that contained large vacuoles with compressed, basally 
located nuclei (arrow heads) shown in (c) and at high power in (d) and (f). Keratinised squamous 
metaplasia (*) was also observed (d), displaying flattened epithelial cells and nuclear atypia, shown 
at high power in (e). All images were taken at 40x magnification and scale bars represent 50 pm.
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5.4 Discussion
5.4.1 Dominant stabilisation of p-catenin is sufficient to cause prostate 
adenocarcinoma
In this chapter, the role of Wnt/p-catenin signalling in prostate tumourigenesis was 
investigated using a conditional transgenic approach that led to dominant stabilisation of P- 
catenin in prostate epithelial cells and subsequent oncogenic transformation. Male 
PBCre+Catnb+/,ox(ex3) mice showed reduced longevity owing to tumour burden (>1 cm) 
and displayed an average survival of 417 days. Hyperactivation of P-catenin led to the 
development of squamous metaplasia at 100 days which progressed to adenocarcinoma by 
200 days which became locally invasive at 500 days. This phenotype was characterised by 
P-catenin nuclear translocalisation and increased transcription of Wnt target genes (CD44 
and Foxal). These results support previous work that showed p-catenin dominant 
stabilisation causes prostate neoplasia (Bierie et a l,  2003; Gounari et a l, 2002) and 
demonstrates for the first time that hyperactivation of P-catenin can drive progression to 
late stage adenocarcinoma in vivo, resembling a PBC reApd1^1 mice (Bruxvoort et a l, 
2007).
It is highly probable that the upregulated expression of Wnt target genes facilitates 
tumour progression in PBCrei Catnbwlox(ex3) mice. Consistent with this, Sansom et al 
(2004) have shown that MMP-7, FGF-4 and its receptor and TIAM1 may interact with 
CD44 or are targets of CD44. Of particular interest, TIAM1 has been shown to mediate 
Ras signaling, as mice deficient in TIAM1 are resistant to Ras-induced skin tumours 
(Malliri et a l, 2002). Furthermore, breast cancer cell lines that over-express Foxal have 
demonstrated that Foxal can directly regulate p27K,pl transcription, indicating that elevated 
Foxal expression in PBCre'Catnb '/AexS prostate lesions might play a role in deregulating 
the cell cycle (Williamson et a l, 2006). Taken together, this evidence provides rational for 
prostate tumourigenesis in PBCre+Catnb+/lox(ex3) mice via activation of the Wnt pathway, 
which leads to the upregulation of oncogenic Wnt target genes.
5.4.2 P B C re C atnb+/Aex3 prostate tumours show a progressive reduction in p63 
expression with progression
Previous work has demonstrated that a reduction in p63 staining correlated directly 
with human prostate disease progression (Kwabi-Addo et a l,  2001; Parsons et a l, 2001;
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Signoretti et a l , 2000) and more recently has been correlated with tumour stage in bladder 
cancer (Urist et al., 2002). The human p63 gene is located on chromosome 3, within a 
region which is frequently amplified in squamous cell carcinomas (Moll et a l , 2001). 
Squamous metaplasia of the lung (Ji et a l,  2007), breast (Koker and Kleer, 2004) and 
prostate (Bruxvoort et a l,  2007) display a decrease in p63 expression upon progression to 
advanced stages of the disease, strongly resembling the PBCref Catnb 'VAexS prostate 
phenotype. Clusters of p63 cells with altered morphology and localisation observed in the 
PBCre ' Catnb */Aex3 metaplastic lesions may represent expansion of the transit-amplifying 
cells, suggesting that PBCre-mediated dominant stabilisation of p-catenin may result in the 
activation of prostate stem cells (Wang et a l,  2006b). The reduction in p63 expression in 
advanced lesions may reflect the fact that basal cells of normal epithelium, including the 
epidermis, strongly express p63 proteins (predominantly the ANp63a isotype) and lose 
them as soon as these cells withdraw from the stem cell compartment (Moll et al., 2001). 
Alternatively, trans-differentiation of the p63+ cells may also account for the reduction in 
p63 expression within the tumours. In addition, Notch signalling activation could be 
investigated, since keratinocytes have been shown to down-regulate p63 expression in 
response to Notch signalling (Nguyen et a l,  2006).
Human prostate cancer does not typically demonstrate squamous metaplasia 
(Melissari et a l, 2006) however, squamous metaplasia initiation has been linked to 
estrogen receptor (ER) signalling (Chang and Prins, 1999; Cunha et a l,  2004). Long-term 
exposure to exogenous or endogenous estrogen, in addition to studies using ERa knockout 
mice, have revealed squamous metaplasia initiation is mediated by ERa signalling and is 
usually reversible by removal of the estrogen stimulus (Chang and Prins, 1999; Cunha et 
a l, 2004). ER signalling has been directly linked to elevated Wnt signalling by rapidly 
upregulating the expression of Wnt4 and Wnt5a of the Wnt family and frizzled-2 of the 
Wnt receptor family in the mouse uterus to promote uterine growth (Hou et a l ,  2004). 
Both ERa and ERp have been detected in the adult rat reproductive tissues, and ERp was 
prominent in the prostate (Chang and Prins, 1999) and together, this evidence suggests that 
squamous metaplasia in PBCre C atnb/Iox^ex3^  mice may be a consequence of disrupted 
balance between AR and ER signalling in prostate epithelium (Risbridger et a l, 2007). To 
address this, immunohistochemistry to detect ER is necessary.
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5.4.3 Dominant stabilisation of P-catenin drives androgen-independent 
tumourigenesis
Prostate cells require androgens for growth and survival and their effects are 
mediated by AR, which translocates into the nucleus in its ligand bound form to stimulate 
the upregulation of genes that promote proliferation and survival (detailed in section 1.1.8). 
p-catenin has been shown to bind AR to mediate androgen signalling and drive 
transcription of the AR gene and may provide a direct mechanism for prostate 
tumourigenesis (Yardy and Brewster, 2005). The interaction o f p-catenin and the ligand- 
bound AR has also been shown to introduce a steroid-specific response, possibly linking 
aberrant Wnt signalling to hormone-refractory disease that maintains high levels of the AR 
protein (Truica et al., 2000; Verras and Sun, 2005). Consistent with this, androgen ablation 
experiments in P B C re* A p ^  mice revealed that adenocarcinoma lesions were androgen- 
independent (Bruxvoort et al., 2007). Given that AR is significantly over-expressed in 
PBCre4 CatnbWAex3 adenocarcinomas that were phenotypically similar to androgen- 
independent PBCre*Apc/1^1 adenocarcinomas, it is hypothesised that PBCre Catnb'/lox(ex3) 
mice could also provide a model for hormone refractory prostate cancer.
5.4.4 Potential synergy between L k b l loss and dominant stabilisation of P-catenin
A synergistic relationship between Lkbl loss and constitutive activation of p~ 
catenin was not demonstrated in PBCre * Lkb 1+/^ ; Catnb */lox(ex3) mice. Given that
PBCre*Lkb 1*^ mice were not predisposed to prostate tumourigenesis, only a very strong 
synergy between the mutations would be detectable in PBCre* Lkb 1*^;Catnb*/lox(ex3) mice. 
The phenotype of PBCre*Lkbl^;Catnb*//>ex3 mice at 100 days suggests that Lkbl loss and 
P-catenin activation may cooperate in the prostate to drive tumourigenesis, however cohort 
numbers are not sufficient to confirm this and aging (>100 days) may be required to 
demonstrate further acceleration of the disease. In support of this hypothesis, Miyaki et al 
(2000) reported that PJS hamartomatous polyps that display LKB1 loss of heterozygosity 
can progress to form adenomatous and carcinomatous lesions, which contain p-catenin 
mutations (and occasional p53 mutation). This evidence suggests that a synergistic 
relationship may exist between P-catenin hyperactivation and Lkbl inactivation to promote 
gastrointestinal tumour progression (Miyaki et a l, 2000).
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5.5 Summary
Using a Cre-LoxP approach, the expression of a constitutively active dominant 
form of p-catenin confirmed a link between activation of the Wnt pathway and prostate 
tumourigenesis. This supports the molecular analysis of AhCre L k b l ^  mice, which 
implicated a role for Wnt in the development of prostate neoplasia (chapter 4). No evidence 
for synergy was determined between Lkbl loss and activation of the Wnt pathway, 
although investigations were limited to PBCre Lkbl +/^ :Catnb '/lox(ex3) mice and preliminary 
analysis of PBCre ' LkbP1^1 :Catnb /lox(ex3) mice did not rule out this possibility.
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Chapter 6: Wnt and Ras signalling synergise to accelerate
prostate tumourigenesis
6.1 Introduction
Activating mutations in Ras and /3-catenin have been shown to synergise in 
colorectal (Janssen et al., 2006; Li et a l, 2005), kidney (Sansom et al., 2006), mammary 
(Jang et a l , 2006) and liver (Harada et al., 2004) tumours, resulting in accelerated tumour 
progression. Furthermore, aberrant Ras and Wnt signalling are emerging as key events in 
the multi-step nature of prostate tumourigenesis and progression (Weber and Gioeli, 2004; 
Yardy and Brewster, 2005). To address whether synergy between Ras and Wnt occurs in the 
prostate, the PBCre transgenic line was used to drive expression of a dominant stabilised 
form of P-catenin (Catnb+/lox(ex3)) and an activating mutant form of K-ras (K-ras+/V12).
6.1.1 Alterations in Ras signalling promotes prostate tumourigenesis
Although Ras activating mutations are infrequent in human prostate cancer, aberrant 
Ras signalling is emerging as a common event in prostate tumour formation and progression 
(discussed in section 1.5). Raf, a mitogen-activated protein kinase kinase kinase 
(MAPKKK) and PI3K, a phosphatidyloinositol kinase, two principle Ras effectors, are also 
common to human prostate cancer (Carey et al., 2007; Papatsoris et a l,  2007). Raf triggers 
the MEK/ERK MAPK cascade (Gioeli et a l, 1999) and PI3K regulates AKT signalling 
(Liao et a l, 2003), which stimulate proliferation and survival, thus driving tumourigenesis 
(Malumbres and Pellicer, 1998). Ras signalling can also stimulate AR, further facilitating 
prostate growth or tumourigenesis (Carey et a l, 2007; Papatsoris et a l,  2007).
To date, in vivo prostate cancer models expressing activating mutations in Ras have 
not generated consistent prostate phenotypes. This is considered to reflect differences in the 
transgenes and the genetic background employed (Scherl et a l,  2004). Ha-RasT24 is an 
endogenous H-ras mutation from the T24 human bladder carcinoma cell line (Cohen and 
Levinson, 1988). This is an oncogenic form of the gene, which contains a point mutation at 
position 12 (replacing glycine with valine) and a second point mutation in intron 4 that 
causes a 10-fold increase in H-Ras protein expression (Cohen and Levinson, 1988). 
Transgenic mice expressing Ha-RasT24 under control of the PB promoter (the initial 454 bp 
of the flanking sequence of the probasin gene) developed atypical hyperplasia (AH) in the 
dorsolateral and ventral lobes of the prostate between 6-12 months of age (Barrios et a l,
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1996). This model also reported epithelial hyperplasia of the epididymis and focal 
destruction of the seminiferous tubules. Conversely, the same group reported that Ha- 
RasT24 expression mediated by the PSA promoter predisposed to salivary gland and 
gastrointestinal tract neoplasms, but no prostate phenotype was observed. Consistent with 
this study, rats expressing both the SV40 T antigen and c-Ha-ras (H-rasl28) under minimal 
probasin promoter control did not develop any additional prostate phenotype compared to 
the PB-SV40 T-Ag single transgenic line that develops prostate adenocarcinoma 
(Hokaiwado et al., 2003). The human c-Ha-ras 128 also has an activating mutation at 
position 12 (128 refers to the transgenic rat strain) (Hokaiwado et a l , 2003).
More recently, Scherl et al (2004) showed that mice expressing Ha-RasT24 (termed 
H-Rasvn) expression under the control of the minimal PB promoter (-426/+28 bp of the
probasin gene), displayed LG-PIN that exhibits a high incidence of intestinal metaplasia by
1/1 *23 months. It is important to note that the H-RAS transgene was not detected in this model 
>12 months, resulting in a decrease in PIN incidence with age. This evidence suggests that 
PB expression decreases with reduced androgen levels in older mice and that aberrant Ras 
signalling might be required to maintain the phenotype (Scherl et al., 2004).
v-H-ras activating mutations have also been shown to promote prostate tumour 
progression. Subcutaneous injections of the AT2.1 Dunning rat prostate adenocarcinoma 
cell line transfected with v-H -ras DNA developed metastasis with 80% incidence, compared 
to just 10% in AT2.1 inoculated mice (Treiger and Isaacs, 1988).
6.1.2 Derivation of mice expressing activated K-ras
The cancer prone K-ras+/v12 mouse (detailed in figure 6.1) has been employed to 
investigate the role of aberrant Ras signalling within many tissues, including the intestine, 
kidney and pancreas (Guerra et a l, 2003). This transgene allows conditional activation of 
K-ras via Cre mediated deletion of a STOP codon upstream of Exonl (Guerra et a l,  2003; 
Sansom et a l,  2006). CMV-Cre+/T mediated recombination throughout the body revealed 
that only a percentage of K-ras F/2-expressing lung bronchiolo-alveolar cells undergo 
malignant transformation, leading to the formation of multiple adenomas and 
adenocarcinomas by eight months (Guerra et al., 2003). These results indicate that 
tumourigenesis induced by the K-ras*72 oncogene depends upon cellular context.
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Figure 6.1: Schematic representation of wild-type and activated K-rasVI2 alleles. To generate the 
conditional K-ras112 transgene the wild-type (WT) K-ras allele (top) was manipulated by 
homologous recombination to replace the endogenous first exon with sequences carrying a mutant 
codon 12, encoding a valine residue, common to human tumours (*). In addition, a transcriptional 
STOP sequence was targeted to the first intron together with a PKG-Hygro cassette (Hyg) flanked 
by LoxP sites (arrow heads), middle panel. CVe-recombinase excises the STOP codon and the 
activated K-rasvn allele is expressed, bottom panel. The construct also harbours an internal 
ribosome entry site-/2-geo cassette (IRES-geo) in the untranslated region allowing bicistronic 
translation of (3-geo sequences driven by the endogenous K-ras promoter, which may be detected by 
X-gal staining. This figure is adapted from Guerra et al (2003).
Although the Ras isoforms show similar structural and functional properties, Ras 
gene mutations in cancer are dependent on both the tissue type and oncogenic Ras isoform 
(detailed in section 1.5). This is considered to relate to their differential expression within 
subcellular compartments and separate post-translational modification events (Schubbert et 
al., 2007). In addition, sequence differences have dem onstrated that K-ras (and not H-ras or 
N -ras) is susceptible to protein kinase C (PKC) phosphorylation (M alumbres and Pellicer, 
1998) and only K-ras null mice are embryonic lethal, indicating this isoform plays a distinct 
role in embryonic development, possibly owing to stem /progenitor cell expression 
(Schubbert et al., 2007). Consistent with this, activating K-ras m utations are predominant in 
somatic human diseases (30%) and H -ras activating mutations are less abundant (< 1%) 
(Schubbert et al., 2007).
6.1.3 Activated Ras and Wnt signalling synergise to drive tum our progression
Cancer development is a multi-step process through which cells accumulate genetic 
mutations (Hanahan and Weinberg, 2000). Investigations that further our understanding o f 
the cooperativity o f these genetic transformations provide an insight into the aetiology o f  the 
disease and present targets for chemotherapeutic intervention. Synchronous activation o f  K- 
ras and activated Wnt signalling has been dem onstrated in many transgenic models and the 
convergence o f these pathways have been shown to upregulate the expression o f  genes that
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function to promote tumourigenesis and progression, such as COX-2, c-Myc, AR and VEGF 
(Araki et al., 2003; Janssen et a l, 2006). Compared to single oncogenic K-ras or (3- 
catenin/Apc mutations, the combinatorial effects of these oncogenes in accelerating tumour 
progression has been shown in mouse models of colorectal cancer (Janssen et al., 2006; Li 
et al., 2005), intestinal tumours (Sansom et al., 2006), kidney lesions (Sansom et al., 2006), 
mammary tumours (Jang et al., 2006) and hepatocarcinogenesis (Harada et al., 2004).
Previous experiments using the mouse prostate reconstitution (MPR) model 
(described in section 1.2.2) have demonstrated synergy between vHa-itas and c-Myc 
activating mutations. UGS transfected with activated vHa-Ras and c-Myc mutations and 
transplanted under the renal capsule of a male host revealed accelerated progression to a 
more advanced phenotype, highlighting the multi-step nature of prostate cancer and 
synergism between Wnt and Ras signalling (Thompson et a l,  1989).
6.2 Aim
Elevated Ras signalling has been linked to prostate tumourigenesis, but to date 
murine models that express oncogenic H-Ras have only developed hyperplastic foci or LG- 
PIN. Activating mutations of K-RAS in human prostate cancer are more common than any 
other isoform (Schubbert et al., 2007). Therefore, activation of K-Ras in the mouse prostate 
is predicted to drive tumour progression. To test this hypothesis, the PBCre transgenic line 
was used to drive monoallelic K-rasvu expression in prostate epithelium. This model was 
examined for signs of neoplasia and characterised by means o f immunohistochemistry and 
PCR.
To address whether synergy between Ras and Wnt signalling occurs in the prostate, 
the PBCre transgenic line was used to drive expression of a dominant stabilised form of P- 
catenin and an activating mutation in K-ras simultaneously in the mouse prostate. The 
phenotype of double mutants was characterised using immunohistochemistry and qRT-PCR.
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6.3 Results
6.3.1 PBCre*K-ras+/VI2 mice are predisposed to prostate cancer
To investigate the role o f activated Ras signalling within the prostate, K-ras+/vl2 
mice (see figure 6.1) that harbour a conditional oncogenic K-rasVI2 allele (Guerra et a l ,
2003) were inter-crossed with the PBCre mice (Wu et a l ,  2001). Cre-LoxP technology 
permits the expression o f  the K-rasvl2 allele within the prostate following endogenous 
PBCre-mediated excision o f a floxed transcriptional inhibitory STOP sequence situated 
upstream from Exon 1 (Guerra et a l , 2003), shown in figure 6.1. Male cohorts o f control 
(PBCre+K-ras+/+ and Cre'K-ras+/lox) and mutant {PBCre+K -ras+/v12) mice were generated 
and observed for signs o f  illness. To monitor disease progression we examined mice at 100 
days (n = 6) and 200 days (n = 6), while the majority o f  histological analysis was carried out 
on cohorts aged to 500 days (n > 15). All mice survived until the specified end point 
(average survival was 500 days). PBCre+K -ras+/vl2 mice were predisposed to atypical 
hyperplasia (AH) that demonstrated progression to LG-PIN in all four lobes o f the prostate 
(Table 6.1). No additional phenotypes were observed in non-prostate tissues.
Table 6.1 Phenotype incidence in PBCre+K -ras+/V12 mice
Genotype
Phenotype
Controls 
(500 d)
PBCre+ 
K -ras+VI2 
(100 d)
PBCre+
K -ras+/vl2 
(200 d)
PBCre+
K -ras+/VI2 
(500 d)
Prostate AH 0% 100% 100% 93%
Prostate LG-PIN 0% 0% 67% 60%
Prostate adenocarcinoma 0% 0% 0% 7%
(1 mouse)
At 100 days, PBCre+K-ras+/v12 mice displayed low severity focal atypical 
hyperplasia (AH), predominantly in the anterior prostate (100% incidence), when compared 
to control mice {wild-type or Cre~K-ras+/lox mice) (figure 6.2a-b). AH comprised o f focal 
tufting with nuclear abnormalities, including enlargement and the increased prominence o f 
nucleoli. At 200 days, discrete AH foci were observed (100% incidence), which 
demonstrated progression to small LG-PIN foci (67% incidence), predominantly within the 
anterior prostate (data not shown as same phenotype as figure 6.2c). AH and LG-PIN 
lesions were both observed at 500 days with 93% and 60% incidence. LG-PIN foci 
comprised 2-3 cell layers within luminal epithelial cell compartments that demonstrated
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nuclear atypia (figure 6.2c). In addition to LG-PIN, one PBCre+K - r a s [ 12 mouse also 
displayed diffuse adenocarcinoma that showed elevated angiogenesis at 500 days (figure 
6.2d).
Figure 6.2: PBCre*K-ras+A 12 mice are predisposed to prostate neoplasia. Histological analysis of 
10% formalin-fixed, paraffin-embedded GU sections determined that compared to wild-type or Cre 
K -ras/lox prostate shown in (a), PBCre'K-ras+/VI2 mice were predisposed to focal AH at 100 days 
(b) which progressed to LG-PIN at 200-500 days (c) and in one case, adenocarcinoma (d). All 
images were taken at 40x magnification and scale bars represent 50 pm. (e) PCR analysis of tail 
biopsies determined wild-type (WT) mice were not recombined and only expressed the wild-type K- 
ras allele (403 bp). PBCre K-ras +/v12 tail DNA expressed one wild-type and one K-rasV12 allele (621 
bp) and was not recombined. Recombined prostate lesions (Rec) expressed wild-type, K-rasvn 
floxed and the recombined (621 bp) K-rasyn alleles (e).
To confirm the PBCre transgene successfully targeted recombination and 
hyperactivation o f K -ras in prostate epithelium, DNA was extracted from PBCre+K-ras+/V12 
anterior prostate (at 500 days) and a PCR specific for the recombined, floxed and wild-type 
K-ras alleles was performed as described previously (Guerra et al., 2003). PCR analysis 
determined excision o f  the transcriptional STOP cassette within the K -ras+/v12 transgene is 
specific to prostate lesions. Wild-type and P BC re+K -ras+/v12 tail DNA served as negative 
controls (figure 6.2e).
6.3.2 Activated Ras signalling in PBCre+K-ras+/VI2 prostate neoplasia
To validate the hyperactivation o f  K -ras, we monitored the expression o f  two 
proteins that participate in the M APK cascade stimulated by Ras using 
immunohistochemistry. Nuclear and cytoplasmic levels o f  activated p-Erkl/2 
(Thr202/Tyr204) and its upstream kinase p-M ekl/2  (Ser 221) were significantly elevated in
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K-ras+/v12 prostate lesions compared to wild-type controls (figure 6.3). Indeed, upregulation 
o f the Ras signalling components corresponded to increased severity o f  the lesions, 
suggesting that sustained activation o f the MAPK pathway might be required for tumour 
progression (Scherl et al. , 2004). Furthermore, PBCre ' Catnb /Aex3 adenocarcinomas did not 
display elevated p-E rkl/2  or p-M ekl/2 expression (figure 6.3g-h), suggesting that 
heterozygous dominant stabilisation o f  (}-eatenin (described in chapter 5) does not facilitate 
prostate tumourigenesis by deregulating the MAPK cascade.
p-Erkl/2
p-M ekl/2
Figure 6.3: The MAPK cascade is activated in PBCre*K-ras+/VI2 mutant prostate lesions.
Histological analysis of 10% formalin-fixed, paraffin-embedded prostate sections (at 500 days) 
determined that wild-type prostate (anterior shown) expresses low levels of p-Erkl/2 
(Thr202/Tyr204) (a), which was over-expressed in PBCre K -ras/vn LG-PIN (b) and 
adenocarcinoma (c) lesions. A similar pattern of expression was observed for p-Mekl/2 (Ser221) (d- 
f). Over-expression of p-Erkl/2 and p-Mekl/2 was not demonstrated in PBCre Catnb ^ 3 
adenocarcinomas at 500 days. All images were taken at 40x magnification and scale bars represent 
50 pm.
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To determine whether aberrant Ras signalling deregulated the Wnt pathway we 
monitored the expression of p-catenin and the downstream Wnt signalling target CD44 
using immunohistochemistry (figure 6.4). No difference in p-catenin expression was 
observed in K-ras+/V12 LG-PIN lesions compared to control prostate epithelium (figure 6.4a- 
c). Accordingly we detected negligible levels of the migration marker CD44 in wild-type 
and K-ras mutants (figure 6.4d-f). These data demonstrate that active Ras signalling does 
not deregulate Wnt signalling in the prostate.
PBCre*K-ras+/vn 
Wild-type LG-PIN Adenocarcinoma
p-catenin
CD44
Figure 6.4: PBCre^K-ras+/VI2 prostate lesions do not show activated Wnt signalling.
Immunohistological analysis of 10% formalin-fixed, paraffin-embedded prostate sections (at 500 
days) determined that wild-type prostate (anterior shown) expresses p-catenin at the cell surface 
where it forms adherens junctions (a). The pattern of p-catenin expression in PBCre+K -ras/V12 
lesions mirrored wild-type prostate epithelium (b-c). Consistent with this, the Wnt target CD44 was 
not induced in lesions (d-f). Images were taken at 40x magnification and scale bars represent 50 pm.
6.3.3 PBCre+Catnb+/lox(ex3):K-ras+/VI2 mice show reduced longevity
To investigate the potential cooperative role between K-ras and p-catenin, we 
generated a cohort o f  male mice heterozygous for both activated K-ras112 and the dominant 
stable form o f p-catenin, using PBCre to drive expression in prostate epithelium (n = 6). 
Mice were aged until they became symptomatic o f disease and sacrificed accordingly 
(figure 6.5). Chi-squared tests determined PBCre ‘ Catnbf/lox(ex3)•K -rasf/VI2 longevity was 
significantly reduced (average survival time 211 days) compared to wild-type, K-ras+/VI2 
and Catnb+/lox(ex3) single transgenic mice (x2 = 48.66, p = 0.000, x2 = 48.66, p = 0.000 and x2 
= 31.89, p = 0.000 respectively). Wild-type and PBCre+K-ras+/VI2 cohorts showed normal 
survival (at 500 days) while PBCre+Catnb+/lox(ex3) mutants showed a significant reduction in
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survival (average 417 days, x2 = 34.56, p = 0.000). These data suggest that activation o f K- 
ras and p-catenin cooperate to accelerate tumourigenesis in the prostate.
Wild-type (n = 32) 
K -ras+/VI2 (n = 17)
l  o o
8 0
2.0 +/,ox(ex3)(n=\S)Catnb
Catnb+/,ox(ex3):K-ras+/VI2 (n = 6)
1  o o 200 300 400 5 00
Time (days)
Figure 6.5: Activation of p-catenin and K-ras reduces longevity. Kaplan-Meier survival curve 
shows synergism between (3-catenin and K-ras activating mutations results in decreased longevity. 
Compared to wild-type (green), K-ras" 112 (orange) and Catnb+ ,ox(ex3) (blue) cohorts, 
PBCre'Catnbk/lox(ex3):K-ras m 2 mice (brown) showed a significant reduction in longevity (x2 = 
48.66, p = 0.000, %2 = 48.66, p = 0.000 and = 31.89, p = 0.000 respectively). Statistical analysis 
was carried out by a Chi-squared test using ‘MiniTab’ software and the Kaplan-Meier plot was 
generated using ‘MedCalc’ software.
6.3.4 PBCre+Catnb+/Iox(ex3):K-ras /VI2 mice are predisposed to multiple phenotypes
Histological analysis o f  PBCre+K-ras+/v12 and PBCre+Catnb+/lox(ex3) single
transgenic lines and PBCre+Catnb+/lox(ex3):K -ras+/VI2 double transgenic cohorts aged to 500 
days determined a predisposition to multiple phenotypes (Table 6.2). Wild-type mice did not 
develop any phenotypes during the time course o f the experiment. At terminal end points K- 
ras+/V12 mutants were predisposed to AH, LG-PIN and (in one case) adenocarcinoma, while 
dominant stabilisation o f  P-catenin led to diffuse adenocarcinoma in all four lobes o f the 
prostate. Double mutants showed accelerated prostate cancer progression to invasive 
carcinoma with 100% incidence.
The PBCre Catnb /Aex3 cohort also developed BUG, preputial gland and urethral 
keratinised squamous metaplasias (100%, 100% and 28% incidence respectively), which 
were also identified in the PBCre+Catnb+/lox(ex3):K-ras+/V12 cohort (100%, 67% and 17% 
incidence respectively). In addition, 83% o f the PBCre+Catnb+/lox(ex3):K -ras+/VI2 cohort 
were infertile.
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Table 6.2 Phenotype incidence in PBCre+C atnb/lox(ex3):K-ras+A 12 mice compared to 
single transgenic lines (at end point)
Genotype
Phenotype
Wild-type 
(500 d)
PBCre+
V  +/VJ2K-ras 
(500 d)
PBCre+ 
Catnb*'**3 
(End point)
PBC re+ 
Catnb*" W ®  
(End point)
Prostate AH 0% 93% 0% 0%
Prostate LG-PIN and 
keratinised squam ous 
m etaplasia
0% 60% 0% 0%
Prostate adenocarcinom a 0% 7%
(1 mouse)
100% 0%
Prostate carcinom a 0% 0% 0% 100%
Bulbourethral gland  
keratinised squam ous 
m etaplasia
0% 0% 100% 100%
Preputial gland  
keratinised squam ous 
metaplasia
0% 0% 100% 67%
Urethra keratinised  
squam ous m etaplasia
0% 0% 28%  (5 mice) 17%
Infertile 0% 0% 0% 83%
6.3.5 Activated K-ras and p-catenin synergise to accelerate prostate tumour 
progression
Histological analysis o f  the prostate from each cohort was carried out at terminal end 
points or 500 days. PBCre Catnb lox(ex3J:K-ras u 2 mice dem onstrated accelerated tumour 
progression compared to single transgenic lines, predisposing to invasive carcinoma that 
developed from solid or sheet-like proliferations w ith frequent rosette structures, nuclear 
atypia, apoptotic bodies and mitosis (figure 6.6a-f). PBCre C a tn b ' lox(ex3):K-ras+/V12 
carcinomas also demonstrated elevated angiogenesis w hich facilitates tum our progression. 
PCR analysis o f  DNA isolated from PBC re+C atnb+/lox(ex3);K -ras44 /2 carcinomas revealed 
that these tumours expressed one wild-type and one recom bined allele o f  the dominant 
stabilised /3-catenin (figure 6.6g) and K -ras112 (figure 6.6h) transgenes.
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Figure 6.6: PBCre+Catnb+/h>x(ex3):K-ras+/VI2 mice develop invasive prostate carcinoma.
Histological analysis of 10% formalin-fixed, paraffin-embedded GU sections from end point mice 
determined that compared to PBCre" K-ras¥/VI2 LG-PIN (a-b) and PBCre Catnb" 
adenocarcinoma (c-d), PBCre Catnb ^ :K -ra s" m2 mice are predisposed to invasive carcinoma (e- 
f). All images were taken at 40x magnification and scale bars represent 50 pm. PCR analysis of 
wild-type (Wt) and PBCre+Catnb +/lox^ex3^ K -ra s+/VI2 (Het) tail biopsies and prostate lesions (Rec) 
determined that invasive carcinoma lesions express both the recombined P-catenin allele (g) and the 
recombined K-ras allele (h).
Invasive carcinoma frequently predisposes to metastasis (Shappell et a l ,  2004). 
Histological analysis of the liver in PBCre+Catnb+/lox(ex3):K -ras+/VI2 mice revealed that 83% 
of the cohort developed an infiltration of immune cells in the liver, concomitant with mitotic 
figures (figure 6.7a-b). To address the possibility that these deposits were in fact metastatic, 
immunohistochemistry to detect AR was carried out. Normal liver tissue does not express 
AR while a subset of the potential metastatic liver deposits stained positively for the AR in 
the cytoplasm, suggesting that these cells might be derived from the prostate tumours 
(figure 6.7c). However, PCR analysis of PBCre+Catnb+/lox(ex3>K-ras+/V12 liver DNA did not 
detect recombination of the K-rasV12 or Catnb+/lox(ex3) alleles (figure 6.7d), indicating that the 
observed liver abnormality is more likely to be a consequence of an immune infiltration, 
reflecting the deterioration of health in these mice following the development of prostate 
carcinoma. Tail DNA from wild-type and PBCre+Catnb +/lox<ex3); K -ras+/V12 mice served as a 
negative control for recombination and PBCre+Catnb+/Aex3:K-ras+/VI2 carcinoma served as a 
positive control.
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Figure 6.7: Analysis of PBCre+Catnb+/lox(ex3) :K-ras+/yi2 mice to detect any metastasis. Formalin- 
fixed, paraffin-embedded H&E stained sections from end point mice were analysed. Wild-type (a) 
and Catnb/lox(ex3\'K-ras+/V12 (b) liver determined the presence of mitotic cells and inflammation in 
double mutants, which were not observed in single transgenic lines. Immunohistochemistry to detect 
AR revealed that some of the aberrant cells in the fiver of compound mutants expressed AR (c). All 
images were taken at 40x magnification and scale bars represent 50 pm. To address the possibility of 
metastasis, K-ras and /3-catenin recombined specific PCR analysis was carried out (d). The top gel 
indicates that anterior prostate carcinoma (AP), the epididymis (E) and the BUG all express a 
recombined K-rasyi2 allele while the testis (T), preputial gland (PG), fiver (L), lymph node (Ly) and 
kidney (K) were heterozygous for the K-rasVI2 transgene, but not recombined. A similar pattern of 
recombination was determined for the (d-catenin dominant stable allele (bottom gel) indicating the 
fiver is not recombined.
Interestingly, DNA isolated from the epididymis and bulbourethral glands was 
recombined, correlating to the TTfCVe-mediated pattern o f  recombination determined by 
LacZ staining (figure 3.31). In addition, no recombination o f  the K -rasvn  or Catnb+/lox(ex3) 
alleles was detected in the testis, preputial gland, lymph node or kidney (figure 6.7d).
6.3.6 PBCre+Catnb+/lox(ex3):K-ras+/V12 transgenic mice are infertile
Wild-type and K-ras+/VI2 cohorts were fertile and showed normal seminiferous 
tubule, epididymal and ductus deferens histology (figure 6.8a-f). Although
PBCre+Catnb+/lox(ex3) mice show normal spermatogenesis, sperm maturation and no 
abnormalities o f  the seminiferous tubule, epididymis and ductus deferens epithelia (figure 
6.8g-i). It was noted that aging PBCre+Catnb+/lox(ex3) males became sterile, concomitant with 
disease progression. Sterility is hypothesised to reflect prostate growth constricting the
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urethra as no phenotype was observed in the testis or epididymis which displayed normal 
spermatogenesis and sperm maturation. Histological analysis of the aged 
PBCre+Catnb+/lox(ex3):K-ras+/v12 cohort revealed that 83% of these mice were infertile. 
Seminiferous tubules were degenerated and devoid of spermatids (figure 6.8j). The 
epididymis and ductus deferens epithelia displayed hyperplasia and apoptotic bodies and the 
lumen contained cellular debris (figure 6.8k and 1). The remaining 27% of the double 
transgenic cohort showed normal spermatogenesis and maturation in one testis and 
epididymis, while the second set demonstrated testicular degeneration, aspermia and 
hyperplasia of the epididymis.
Wild-type
PBCre+K-ras+/v12
PBCre+Catnb +/lox(ex3)
PBCre+
Catnb+/lox(ex3): K-ras+/V12
Figure 6.8: PBCre+Catnb+/lox(ex3) :K-ras+/VI2 male mice are infertile. Formalin-fixed, paraffin- 
embedded H&E stained sections from end point mice were analysed. Wild-type (a-c), K-ras+/VI2 (d-f) 
and Catnbwlox(ex3) (g-i) cohorts display normal seminiferous tubule, epididymal and ductus deferens 
epithelium respectively and sperm was present in all organs. PBCre Catnb /lox(ex3):K-rasi/V]2 males 
were infertile. Seminiferous tubules were degenerated (j) and the epididymal (k) and ductus deferens 
(1) epithelium showed hyperplastic foci and apoptosis and the lumen contained cellular debris. All 
images were taken at 40x magnification and scale bars represent 50 pm.
This evidence suggests a synergistic relationship between activating K-rasv12 and 
dominant stable P-catenin mutations in the testis and epididymis, given that single 
transgenics were fertile. Although recombination was not detected in testis using PCR 
(figure 6.7), the pattern of recombination driven by the PBCre construct indicates that the 
Leydig cells are recombined (figure 3.9a).
Eptdidymis
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6.3.7 Ras and W nt signalling pathways are upregulated in PBCre+Catnb+/AexS:K-ras+/[ 12 
invasive prostate carcinoma
K -ras+/VI2 mice have been shown to upregulate the MAPK cascade but do not 
deregulate the Wnt pathway, as p-catenin was localised to the cell membrane, resembling 
wild-type prostate epithelial cells (section 6.2.3). In addition, PBCre Catnb4/Aex3 
adenocarcinomas did not demonstrate upregulated MAPK signalling (figure 6.3g-h). It was 
predicted that oncogenic transformation o f both K-ras and P-catenin will result in 
hyperactivation o f  both Ras-mediated and Wnt-mediated signalling pathways to accelerate 
prostate tumourigenesis. To address this, immunohistochemistry was performed to detect 
both activated MAPK signal transduction molecules (p-Erkl/2 and p-M ekl/2) and activated 
Wnt signalling components (p-catenin and CD44). PB C re ' Catnb /Aex3:K-ras4/VI2 invasive 
carcinomas over-expressed activated MAPK signalling proteins p-Erkl/2 and p-M ekl/2 
(figure 6.9a-b), suggesting that Ras signalling is active in these lesions. The double mutants 
also displayed nuclear localisation o f  p-catenin and elevated expression o f the canonical 
Wnt transcriptional target gene, CD44 (figure 6.9c-d). Together, this evidence demonstrates 
that Ras signalling and W nt signalling is elevated in invasive carcinomas o f  double mutants, 
ultimately facilitating tumour progression.
Ras signalling Wnt signalling
p-Erkl/2
p-M ekl/2
P-catenin
CD44
Figure 6.9: PBCre+Catnb+/Aex3:K-ras+/VI2 carcinomas demonstrate elevated MAPK and Wnt 
signalling cascades. Histological analysis of 10% formalin-fixed, paraffin-embedded prostate 
sections at end point determined that PBCre Catnb /kx3:K-ras ~/VI2 prostate carcinoma displays 
upregulated MAPK cascade molecules p-Erkl/2 (Thr202/Tyr204) (a) and p-Mekl/2 (Ser221) (b). 
Activation of the Wnt pathway was also detected in carcinomas as p-catenin was highly expressed in 
the nucleus (c) and the downstream Wnt target CD44 was over-expressed (d). All images were taken 
at 40x magnification and scale bars represent 50 pm.
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6.3.8 Activated P-catenin and K-ras synergise to accelerate prostate cancer progression
To characterise the synergistic relationship between dominant stabilisation of P~ 
catenin and K-rasVI2 oncogenic transformations, immunohistochemistry was performed on 
lesions from PBCre*K-ras*'VI2, PBCre Catnb*'**3 and PBCre*Catnb*'**3:K-ras*'m  mice 
to monitor the expression of the proliferation marker Ki-67, the basal cell marker p63 and 
AR. Ki-67, was rarely expressed in control prostate epithelium, however it was significantly 
elevated in epithelial cells throughout prostate tumours in PBCre+K-ras+/V]2 (LG-PIN), 
PBCre' Catnb+/AexS (adenocarcinoma) and double heterozygous (invasive carcinoma) mice 
(figure 6.10a-d). Basal cells were detected using an antibody against p63, revealing a 
marked reduction in the presence of this lineage, concomitant with disease progression 
(figure 6.10e-h). Notably, all prostate lesions contained small clusters of p63+ cells that 
displayed altered cytological morphology. Detection of AR showed that as the tumour stage 
progresses, nuclear AR accumulates in the neoplastic cells (figure 6.10i-l).
Scoring the percentage o f cells expressing Ki-67, p63 and the AR determined a 
significant difference between wild-type prostate epithelium and PBO*e+K -ras /F/2, 
PBCre*Catnb*'**3 and PBCre*Catnb*'**3.K-ras+/TO mice (at end point), (figure 6.10m-o). 
Notably, the number of cells expressing Ki-67 and AR increased with disease progression 
and p63+ cells negatively correlated with tumour grade. This suggests impaired 
differentiation of the prostate epithelium in the lesions.
Wild-type prostate demonstrated a basal level of proliferation of the adult gland at 
500 days (1.8%) which elevated slightly in PBCre+K-ras+/V]2 LG-PIN (3.7%) and increased 
significantly in PBCre+Catnb+//lex3 adenocarcinoma (19.5%) and PBCre1 Catnb+/AexS:K- 
ras+/v12 invasive carcinoma (18.3%, p = 0.0404, Mann Whitney). A slight reduction in Ki- 
67 positive cells in PBCre+Catnb i/Aex3:K-raswv12 mice compared to PBCre Catnb /^Aex3 
mice was significant (p = 0.0404, Mann Whitney) and probably reflects the increased 
incidence of necrosis associated with invasive carcinomas (figure 6.10m).
The basal cell population was detected using the p63 marker and the number of 
positive prostate epithelial cells counted. In wild-type mice, 10.8% of the prostate epithelial 
cells were p63+ (figure 6.1 On), corresponding to previous work (Signoretti et a l , 2000). 
Analysis of K-ras and P-catenin mutant mice revealed that p63 expression decreases with 
advancing prostate tumour progression. LG-PIN lesions in PBCre K-ras4 /VI2 mice at 500 
days were reduced to 7.1% and PBCref Catnb+/AexS adenocarcinomas demonstrated a further 
reduction (2.9%). Interestingly, invasive carcinoma tumours in double transgenics rarely
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expressed p63 positive cells (0.1%), mimicking human prostate cancer (Parsons et a l, 2001) 
and bladder tumours (Urist et al., 2002). The observed loss of p63 expression may reflect 
the withdrawal of the basal cells or transit-amplifying cells from the stem cell compartment 
(Moll et al., 2001), as discussed in section 5.4.2.
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Figure 6.10: Characterisation of activated P-catenin and K-ras synergy in the prostate.
Histological analysis of 10% formalin-fixed, paraffin-embedded (anterior) prostate sections 
determined an increase in the proliferation marker Ki-67 (a-d), a decrease in p63 (e-h) and elevated 
AR expression (i-1) in PBCre K-ras v12, PBCre Catnb ^  and PBCre+Catnb //Sex3:K-ras+/VI2 
prostate tumours (at end time points), which correlated with disease progression. All images were 
taken at 40x magnification and scale bars represent 50 pm. The percentage of Ki-67 (m), p63 (n) and 
AR (n) positive neoplastic cells at end point was counted (20 acini were scored per mouse, n = 3 for 
each genotype). K-ras and P-catenin single and double mutant prostates showed a significant 
difference in Ki-67, p63 and AR expression compared to wild-type mice (p = 0.0404) and to each 
other (p = 0.0404). Error bars represent standard deviation and statistical analysis was carried out 
using a non-parametric Mann Whitney test using “MiniTab” software (95% confidence interval).
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Counting AR positive cells revealed that AR is not highly expressed in wild-type 
anterior prostate at 500 days (5.3%). Transgenic mice displayed a significant elevation in 
the level of AR expression with tumour aggression; K-ras mutant LG-PIN (35.8%), p- 
catenin mutant adenocarcinoma (52.6%) and double mutant invasive carcinoma (63.9%), 
(figure 6.10o). This coincides with human prostate cancer studies that have observed a 
similar elevation in AR expression, thus providing the basis for anti-androgen hormone 
therapy which kills AR+ cells (Chang and Heinlein, 2004). The fact that 
PBCref Catnb+/Aex3 :K-ras ' /V12 mice show the highest level of AR expression may reflect 
cooperativity between these two oncogenes and may be a consequence of MAPK and Wnt 
signalling mediated regulation of AR (Weber and Gioeli, 2004; Yardy and Brewster, 2005).
To further confirm that accelerated tumour progression in PBCre+Catnb+/Aex3; K- 
ras+/v12 mice reflects the cooperation of activating mutations in P-catenin and K-ras, 
immunohistochemistry was carried out using antibodies to detect c-Myc (figure 6.11a-e) 
and COX-2 (figure 6.11f-j). The Ras/MAPK and Wnt signalling pathways are known to 
drive transcription of both c-Myc (He et a l,  1998; Kerkhoff et al., 1998) and COX-2 (Araki 
et a l, 2003). Furthermore, K-ras has been shown to stabilise COX-2 mRNA expression 
(Araki et a l, 2003). Immunohistochemistry revealed a slight increase in c-Myc and COX-2 
protein expression in PBCre+K-ras1 /v 12 and PBCref Catnb1 /AexS prostate lesions while 
PBCre Catnb /Aex3:K-rasY/VI2 invasive carcinoma demonstrated a dramatic increase in c- 
Myc and COX-2 expression. Interestingly, nuclear COX-2 expression was observed in 
double mutants (figure 6.1 Ij), which previous work has shown to increase cell cycle 
progression, proliferation and angiogenesis (Parfenova et a l,  2001).
Synergy was further verified using qRT-PCR to detect the mRNA levels of c-Myc in 
the prostate (figure 6.1 lk  and 1). Using the 2A'AACt method (Livak and Schmittgen, 2001) to 
determine fold change, PBCre CatnbWAex3 mice showed a 2-fold increase in c-Myc 
expression and PBCre Catnb{/Aex3:K-ras^/VI2 mice revealed a 17-fold increase (p = 0.0404, 
Mann Whitney). This evidence suggests synergy between activation of the Ras and Wnt 
pathways in the prostate, ultimately accelerating tumour progression beyond that observed 
in the single transgenic lines.
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Figure 6.11: Activating P-catenin and K-ras mutations synergise in the prostate.
Immunohistochemistry of 10% formalin-fixed, paraffin-embedded wild-type, PBCre K-ras m2, 
PBCre Catnb **3 and PBCre Catnb **s;K-ras VI2 prostate sections at end point revealed a 
significant increase in the expression level of c-Myc (a-e) and COX-2 (f-j) in double transgenic 
tumours. All images were taken at 40x magnification and scale bars represent 50 pm. Transcript 
levels of c-Myc were detected using qRT-PCR revealing a statistically significant increase in the 
level of c-Myc in PBCre Catnb * xS ;K-ras*/vl2 and PBCre *Catnb* **3 mice compared to wild-type 
prostate (p = 0.0404), and between single and double transgenic tumours (p = 0.0404), (k). Plotting 
the fold change revealed a 2-fold and 17-fold increase in c-Myc mRNA in PBCre Catnb * **3 
adenocarcinoma and PBCre*Catnb **3;K-ras+/V12 carcinoma respectively (1). Statistical analysis 
was carried out using a non-parametric Mann Whitney test using “MiniTab” software (95% 
confidence interval) on the original ACt values. qRT-PCR analysis was carried out by Dr. Toby 
Phesse (Cardiff University).
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6.4 Discussion
6.4.1 PBCre+K-ras+/VI2 mice are predisposed to LG-PIN
In this chapter, the oncogene K-ras+/VI2 has been shown to play a role in the onset 
and progression of prostate cancer predisposing to LG-PIN (and in one case 
adenocarcinoma) using a conditional activation approach. Activation of K-ras did not 
decrease longevity, and AH and LG-PIN were evident at 100 and 200-500 days
Vi 2respectively. Consistent with this model, mice expressing Ha-RasT24 (termed H-Jtas ) 
driven by the minimal PB promoter also developed LG-PIN by 3 months, albeit in 
conjunction with intestinal metaplasia (Scherl et al., 2004). Given that the PBCre+K-ras'/VI2 
model did not exhibit intestinal metaplasia, it is possible that the Ras isoform, genetic 
background and the level of cellular stress may play a role in determining the observed
phenotype (discussed in section 6.1.1). The fact that PBCre+K-ras+/VI2 mice demonstrated
1/1 0recombination of the targeted K-ras allele at 500 days, while Scherl et al (2004) reported
the H-Rasv12 transgene was not detected in PB-H-rasv12 mice >12 months, suggests that the 
method of driving transgene expression may also reflect the phenotypic differences 
observed. Furthermore, the lack o f advanced progression in both the PBCre+K-ras+/V12 and
i/1 y t
PB-H-ras models correlates with the literature, whereby activating Ras mutations alone 
rarely progress to a metastatic/invasive tumourigenic state, which typically requires 
combinatorial genetic/epigenetic events (Janssen et a l,  2006). Together, these data
i/ 1  y
implicate that K-ras mutation and concomitant upregulation of Ras effector pathways can 
promote tumour formation and early stage neoplasia in vivo.
The PBCre+K-ras+/v12 model also mimics aspects of human prostate cancer. Firstly, 
immunohistochemistry to detect p-Erkl/2 and p-Mekl/2 expression determined K-ras 
activation stimulates the RafTMek/Erk MAPK pathway in PBCre+K-ras+/v12 prostate lesions 
(figure 6.3). The majority of human studies have reported that p-ERK upregulation 
correlates with tumour grade (Bakin et a l,  2003; Gioeli et al., 1999; Price et a l, 1999), 
although one study has demonstrated that ERK is down-regulated in advanced tumours 
(Malik SN, 2002). Consistent with this, the TRAMP transgenic prostate cancer model 
(described in section 1.2.3) has also demonstrated elevated MAPK signalling during tumour 
initiation and progression, while poorly differentiated, advanced adenocarcinomas and 
androgen-independent tumours showed reduced Erkl/2 and Mekl/2 expression (Uzgare et 
a l, 2003). It is possible that discrepancy in the literature regarding MAPK activation in
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prostate cancer may correspond to differential expression of the Raf kinase inhibitor protein 
RKIP (Fu et a l,  2003).
Secondly, an increase in AR expression in PBCre+K-ras+/VI2 AH and LG-PIN 
lesions also mimics human prostate cancer progression and may reflect previous reports that 
have shown Ras activation can play a causal role in driving prostate cancer cells towards 
decreased hormone dependence (Weber and Gioeli, 2004).
Thirdly, a reduction in p63 expression was observed, correlating to human prostate 
adenocarcinomas that usually express markers for secretory cells (Bruxvoort et a l, 2007; 
Signoretti et a l,  2000). Consistent with this, the reduction in p63 expression has been 
speculated to reflect the fact that the neoplastic cells have withdrawn from the stem cell 
compartment (Moll et a l,  2001). Furthermore, p63 is also down-regulated in head and neck 
squamous carcinoma cells in vitro (Matheny et a l,  2003) and previous work has shown that 
a progressive decrease in p63 correlates with progression in bladder carcinomas (Park et a l, 
2000; Urist et a l,  2002).
Signoretti et al (2000) reported that secretory cells originate from the p63+ basal 
cells, suggesting that p63+ cells may also represent the transit-amplifying population. This 
suggests that expression of the dominant stabilised P-catenin and activated K-rasvu 
transgenes may result in the activation of prostate stem cells. Previous work has shown that 
activation of H-ras in the mouse results in mucinous metaplasia (Scherl et a l, 2004), 
resembling impaired basal cell differentiation (Kurita et a l,  2004). It is possible that 
activation of the MAPK cascade may regulate p63 expression through Src (Kurita et a l,
2004). Src is typically active in a proportion o f the basal cells in the proliferation-quiescent 
state of the adult prostate, indicating its presence in normal adult prostate. Kurita et al 
(2004) grafted UGS from p63 null mice into adult nude male mice revealing that prostate 
development can occur in the absence of basal cells. In this model, luminal cells show 
upregulated Ras signalling following expression of c-Src in the luminal cells in an 
androgen-dependent manner (Kurita et a l,  2004). Additionally, ANp63 has been shown to 
block p-catenin phosphorylation and nuclear accumulation in squamous cell carcinoma cell 
lines, suggesting that down-regulation of the ANp63 isoform may play a role in further 
enhancing Wnt signalling (Reis-Filho et a l,  2003).
Interestingly, p63 expression is suppressed by Notch 1 activation in human and 
mouse keratinocytes (Nguyen et al., 2006). This suggests that aberrant Notch signalling may 
also play a role in prostate tumourigenesis in PBCre' K-ras'/V12, PBCref Catnb1 /Aex3 and
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PBCre+Catnb+//3ex3;K-ras+/V12 mice. To address whether Notch regulation o f  p63 is 
deregulated within these models, immunohistochemistry to detect Notch and Notch 
signalling components, such as y-secretase, could be carried out to determine whether 
prostate lesions display reduced Notch signalling, providing a direct mechanism for the loss 
o f p63 expression and stem cell activation (Nguyen et al., 2006).
6.4.2 Dominant stabilised P-catenin and K-rasV12 mutations synergise to accelerate 
prostate cancer progression
The life-span o f  PBC re+Catnb+/Aex3;K-ras+/VI2 transgenic mice was significantly 
reduced compared to wild-type and single transgenic lines (figure 6.5). Histological analysis 
revealed the development o f  invasive carcinoma as the primary cause o f  reduced longevity, 
demonstrating that activating mutations o f  P-catenin and K-ras are synergistic in promoting 
prostate tumourigenesis and progression. Consistent with this, tumours displayed elevated 
proliferation concomitant with a decrease in p63 expression and elevated Wnt/(3-catenin and 
MAPK signalling, ultimately facilitating tumour progression by stimulating AR, c-Myc and 
COX-2 expression beyond that observed in single transgenic neoplastic prostate epithelium. 
The findings o f  this investigation have been summarised in (figure 6.12).
Kras* ‘ 2
Catnb*
Adenocarcinoma
Kras*'v'2: Catnb*ie*3 Ki-67
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COX2
c-M yc
V E G F ?
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Figure 6.12: Schematic diagram illustrating synergy between activated Ras and Wnt/f3-catenin 
signalling in the prostate. PBCre'K-ras+/vl mice were predisposed to LG-PIN at 500 days while 
end-point PBCre' Catnb'/lox(ex3) mice displayed adenocarcinoma. Synergy between Ras and Wnt 
signalling was demonstrated in PBCre Catnb'/lox(ex3);K-ras'm2 mice that showed accelerated tumour 
progression to invasive carcinoma concomitant with a reduction in p63 expression and upregulation 
of the proliferation marker Ki-67, AR, COX-2, c-Myc and angiogenesis (suggesting upregulated 
VEGF transcription).
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Wild-type mice displayed the highest level of p63 expression, while LG-PIN in 
PBCre "K-ras /V12 mice, PBCre+Catnb{/Aex3 adenocarcinomas and invasive carcinomas in 
PBCre+Catnb+/lox(exS);K-ras+/v12 mice demonstrated a marked reduction in p63 expression 
that correlated with tumour progression. This evidence suggests that both the Wnt and 
MAPK cascades may regulate p63 expression, and that the p63 positive cells observed in 
the PBCre' Catnb*/Aex3:K-ras*/VI2 lesions are likely to be androgen-independent, as both 
these pathways regulate androgen signalling (Carey et al., 2007; Weber and Gioeli, 2004; 
Yardy and Brewster, 2005). The ramifications of these cells are unclear but it is speculated 
that this evidence may reflect both the activation of prostate stem cells and the development 
of androgen-independent prostate growth.
Recent publications have demonstrated that AR regulation by Ras and Wnt 
signalling is a complex process (Weber and Gioeli, 2004; Yardy and Brewster, 2005). 
Upregulation of AR in PBCre * Catnb1 /AexS: K-ras /K/2 carcinomas provides a direct 
mechanism whereby synergism occurs following activation of both K-ras and p-catenin. 
The role Wnt/p-catenin signalling plays in elevating AR expression is detailed in section 
5.1.1. The MAPK pathway has been shown to regulate an AR element-inducible reporter in 
human prostate cancer cell lines (Carey et al., 2007) and p-ERK can mediate androgen 
signalling by phosphorylating AR coactivators including the steroid receptor co-activator 
(SRC-1) and ARA70 (Heinlein and Chang, 2002; Ueda et al., 2002). c-Src also activates the 
MAPK cascade by stimulating She, providing a positive feedback mechanism to facilitate 
tumour progression (Heinlein and Chang, 2002). It has also become apparent that Ras 
signalling may play a role in regulating androgen sensitivity, as K-ras expression is also 
reported to decrease the concentration of androgens required to culture LNCaP cells, 
increasing their cancerous growth potential (Bakin et a l, 2003).
Chen et al. (2004) documented that the 2-5 fold increase in AR mRNA was both 
necessary and sufficient for hormone-refractory progression in animal models. As a result, 
cells can become supersensitive to androgens rather than independent of them (Isaacs and 
Isaacs, 2004). This evidence suggests that the upregulation of the AR in the 
PBCre*Catnb*/Aex3 and PBCre*CatnbWAex3;K-ras'/V12 adenocarcinomas and invasive 
carcinomas respectively may be sufficient to promote androgen-independent prostate 
growth, correlating to human disease progression. Consistent with this, castration revealed 
that PBCre* A p c^1 prostate tumours demonstrated androgen independence (Bruxvoort et al., 
2007). It would be interesting to investigate this possibility further by carrying out anti­
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androgen therapy or castration experiments to determine whether tumour regression occurs 
in PBCre' Catnb hlox(ex3J;K-ras+/v12 mice. Additionally, analysis of co-regulators and co­
repressors of the AR that are mediated by the MAPK and Wnt signalling pathways might 
further our understanding of the molecular events underlying the cooperativity of these 
pathways in accelerating tumour progression, which is hypothesised to be androgen- 
independent. To address this, hormone ablation therapy, castration or qRT-PCR analysis to 
detect androgen independence, such as Anxa7, is required.
Importantly, the Wnt pathway did not appear to be upregulated in PBCre ' K-ras /v 12 
lesions, as P-catenin expression was not nuclear and the Wnt target CD44 was undetected. 
This suggests that the augmented tumour multiplicity and malignant behaviour in compound 
transgenic mutants is not related to a K-ras-induced increase in Wnt/p-catenin signalling, as
shown previously in intestinal studies (Janssen et a l, 2006). Expression of activated K-ras
1/ /(pVillin-K-ray ) was reported to upregulate p-catenin nuclear translocation in intestinal 
tumours, which was further increased in combination with an Ape deficiency (Apc+/1638N) 
(Janssen et a l , 2006). The fact that activation of K-ras did not induce Wnt signalling in the 
PBCre+K-ras+/V12 prostate cancer model suggests that this may be a tissue specific event, or 
could reflect differences in genetic background and stress levels.
The synergistic relationship between activated K-ras+/v12 expression and the 
dominant stabilised form of p-catenin in prostate epithelium was demonstrated by 
immunohistochemistry to detect c-Myc and COX-2. Given that c-Myc and COX-2 are 
regulated by both Ras and Wnt/p-catenin signalling, this provides rationale for accelerated 
tumour progression in PBCre+Catnbwlox(ex3);K-ras '/V12 mice. The oncogene c-Myc is a 
regulator of cell growth and mutations in this gene are common in a wide variety of human 
cancers (Bernard et al., 2003). Recently, the conditional deletion of c-Myc from the murine 
intestine was shown to rescue all the phenotypes of induced AhCre ' A p c ^  mice (Sansom et 
a l, 2007). These results strongly suggest that c-Myc is required for Wnt-induced 
tumourigenesis in the intestine. Furthermore, c-Myc expression has also been shown to 
confer androgen-independence in human prostate cancer cells in vitro (Bernard et a l, 2003). 
The Raf/Mek/Erk cascade has also been shown to stimulate transcription of c-Myc 
transcription in vitro, however c-Myc activation was dependent on TCF sites in its promoter 
region, demonstrating that activation was via the canonical Wnt pathway (Kerkhoff et a l, 
1998).
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These data are consistent with previous work in vitro studies and activated c-Myc 
and v-H-ras expression in rats has been shown to drive prostate cancer progression (Lehr et 
a l, 1998; Lu et a l,  1992). Compound mouse prostate reconstitution (MPR) models 
harbouring activating vHa-Ras and Myc mutations have also showed progression to 
carcinoma, illustrating the cooperativity of these oncogenes in prostate carcinogenesis 
(Thompson et a l,  1989). Together, these models demonstrate synergy between activation of 
Ras and c-Myc to drive prostate tumourigenesis and demonstrate the multi-step nature of 
tumourigenesis.
COX-2 is a regulatory factor in aracidonate metabolism that is undetectable in 
normal tissues and participates in proliferation, differentiation and tumourigenesis 
(Narayanan et a l,  2006). Previous studies have shown that COX-2 can be regulated by Wnt 
and Ras signalling (Araki et a l,  2003). COX-2 contains a TCF-4 binding element and its 
expression elevates following P-catenin nuclear localisation (Araki et a l, 2003). In addition, 
activated K-ras has been shown to increase COX-2 expression and stabilise COX-2 mRNA 
(Araki et a l, 2003). The PBCre ' CatnbWAex3:K-ras'/V12 mice demonstrate cooperativity 
between these pathways and their convergence at the level of COX-2 in vivo. To address the 
role that COX-2 upregulation plays during prostate tumourigenesis, it would be interesting 
to determine how tumour formation and progression is effected upon treating 
PBCre' Catnb'/AexS:K-ras+/VI2 mice with a COX-2 inhibitor, such as Aspirin or Colecoxib 
(non-steroidal anti-inflammatory drugs). Narayanan et al (2006) reported that Celecoxib 
inhibits adenocarcinoma of the TRAMP model in a dose-dependent manner, and thus limits 
the growth of metastatic prostate cancer and men that take Aspirin regularly, over a long 
period of time, have been reported to reduce the risk of developing prostate cancer (Jacobs 
et a l, 2005).
PBCre1 Catnb1 /lox(ex3): K -ras '/Vl2 carcinomas demonstrated elevated angiogenesis. 
Consistent with this, in vitro studies in colon cancer cells have shown that both Wnt and Ras 
signalling pathways can regulate VEGF expression, a key regulator of angiogenesis, via a 
TCF-4 binding element in the VEGF promoter (Araki et a l, 2003). Angiogenesis is 
modulated through cross-talk between the tumour and stroma and COX-2 has been linked to 
this process, providing an additional route for enhanced angiogenesis that drives tumour 
progression (Baneijee et a l, 2003). Taken together, this evidence implies that activation of 
Ras and Wnt signalling may cooperate in PBCre+Catnb+/lox(exS^ :K-ras+/V12 mice to further 
promote prostate cancer progression by stimulating angiogenesis via VEGF.
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6.4.3 PBCre+Catnb+/u,x(ex3):Krras+/VI2 mice are predisposed to multiple GU tract 
phenotypes
In addition to invasive carcinoma of the prostate, PBCre Catnb /lox^exS^ :K-ras /VI2 
mice developed squamous metaplasia of the preputial gland, bulbourethral gland and 
urethra, reminiscent of PBCre+Catnb+/lox(exS) mice. The fact that dominant stabilisation of p- 
catenin also predisposed to these lesions (discussed in chapter 5), indicates that oncogenic 
transformation of K-ras does not accelerate tumour growth in these lesions. This is 
consistent with the lack o f these tumours in the PBCre+K-ras+/v12 transgenic line.
The PBCre+Catnb+/lox(ex3):K-ras+/VI2 cohort was predisposed to testis degeneration 
(83% incidence), resulting in infertility. Mice harbouring single activating mutations were 
not prone to infertility, suggesting combinatorial effects of activated K-ras and P-catenin. 
This phenotype may be a consequence of several potential scenarios. Firstly, LacZ 
expression showed that PBCre-mediated recombination occurs in the Leydig cells of the 
testis, which function to produce testosterone in response to luteinising hormone (LH) and 
follicle stimulating hormone (FSH) (section 1.1.8). This suggests that recombination and 
subsequent activation of K-ras and P-catenin may occur in the Leydig cells, predisposing to 
the observed testis degeneration in PBCre ' Catnb /lox(ex3):¥^-ras+/VI2 mice. Consistent with 
this, activation of Ras signalling by Src has been shown to cause loss of LH responsiveness 
in MA10 Leydig cells (Taylor, 2002). This suggests that elevated Ras signalling in 
PBCre4 K-rasi/vl2 mice may desensitise the Leydig cells to hormone regulation, leading to 
testis degeneration. The fact that PBCre+K-ras+/V]2 male mice were fertile indicates that the 
combined activation of the Ras and Wnt pathways is required to cause male infertility in this 
model.
Ras and Wnt pathways have been shown to regulate AR expression, suggesting that 
disturbed paracrine communication between testicular cells may cause the observed testis 
degeneration/hypospermatogenesis, rather than an endocrine defect. This is consistent with 
PROe-mediated recombination taking place in the interstitial cells of the testis (figure 
3.29d). However, it is also possible that the PBCre construct drives recombination at an 
alternative site such as the hypothalamus or anterior pituitary, resulting in reduced levels of 
FSH, LH or testosterone. The fact that mature spermatids were observed in occasional 
hypospermatogenic seminiferous tubules in PBCre+Catnb+/lox(ex3):K-ras+/vl2 mice suggests 
impairment of early germ cell proliferation or survival and not a specific block during sperm 
maturation (Behr et ah, 2007), as postulated for C re 'L kb l^  mice (section 3.4.4).
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It is clear that further analysis of this phenotype is required to establish the cause of 
male infertility in PBCre+Catnb+/lox^ex3^ :K-ras+/VI2 mice. Detecting FSH, LH and 
testosterone serum levels and determining whether PBCre recombination occurs in the 
hypothalamus, anterior pituitary or adrenal cortex may provide insights into the mechanism 
leading to male sterility. In addition, laser capture microdissection of the Leydig cells would 
confirm whether they have undergone recombination in PBCre+Catnb+/lox^ex3^ :K-ras+/v12 
mice.
6.5 Summary
Using a Cre-LoxP approach, the expression of activated K-ras demonstrated that 
elevated Ras signalling is sufficient to predispose to AH and LG-PIN in the mouse prostate. 
Expression of activated K-ras in combination with the dominant stabilised form of p-catenin 
was shown to accelerate tumourigenesis and cause invasive prostate carcinoma, 
demonstrating synergy between activation of the Ras and Wnt/p-catenin signalling 
pathways, which cooperate to stimulate AR, c-Myc and COX-2 to facilitate tumour 
formation. PBCre+Catnb+/AexS;K-ras4/V12 carcinomas also mimicked aspects of human 
prostate cancer, demonstrating a reduction in p63 and an increase in AR expressing cells, 
suggestive of androgen-independent growth. To conclude, the PBCre+Catnb+/lox(ex3); K- 
ras+/VI2 model further establishes the link between aberrant Ras and Wnt signalling in the 
multistep nature of prostate tumourigenesis and progression correlating to colorectal cancer 
(Janssen et a l, 2006; Li et al., 2005), intestinal (Sansom et a l , 2006), kidney (Sansom et 
al., 2006), mammary (Jang et al., 2006) and liver (Harada et a l , 2004) cancers.
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Chapter 7: Summary
The development of novel models of prostate cancer is crucial to increasing our 
understanding of the molecular events underlying prostate tumourigenesis and progression, 
as well as providing novel therapeutic targets. To this end, this thesis has investigated the 
role of Lkbl, p-catenin and K-ras in prostate cancer with the aim of identifying potential 
therapeutic targets.
7.1 Loss of Lkbl predisposes to prostate neoplasia
Germ-line mutation of LKB1 is the key molecular event underlying Peutz-Jegher’s 
syndrome (PJS), a dominantly inherited condition characterised by a predisposition to a 
range of malignancies, including those of the reproductive system (Boardman et a l, 1998). 
Recently, somatic deletion of LKB1 has been linked to lung (Ji et al., 2007), pancreatic and 
biliary tumourigenesis (Su et al., 1999) and malignant melanomas (Guldberg et al., 1999), 
further implicating LKB1 as a tumour suppressor. This evidence raises the possibility that 
LKB1 may function as a tumour suppressor in several organs.
This thesis has investigated the role of Lkbl in the murine prostate using a 
conditional transgenic approach. Deletion of Lkbl in prostate epithelium predisposed to 
prostate intra-epithelial neoplasia in vivo, indicating that the tumour suppressive functions 
of Lkbl extend to the murine prostate and raises the possibility of a similar association in 
man.
Lkbl regulates numerous signalling pathways to exert its tumour suppressive 
function (Alessi et al., 2006). It is clear from this thesis that Lkbl loss deregulates both the 
Wnt pathway and PI3K/AKT signalling to promote tumourigenesis in the murine prostate. 
This is consistent with loss of Lkbl-mediated phosphorylation of Pari A, resulting in Wnt 
signalling and loss of cell polarity (Spicer et al., 2003) and loss of Lkbl:Pten interactions, 
speculated to cause Pten inactivation, which ultimately leads to Akt activation, promoting 
cell growth and proliferation (Mehenni et al., 2005; Song et a l, 2007). This evidence 
suggests that the Wnt and PI3K/Akt pathways are potential therapeutic targets in prostate 
tumours that display reduced Lkbl expression or inactivating Lkbl mutations. However, 
before therapies against inhibition of Wnt/PI3K signalling in the prostate are considered, it 
is essential to establish the role of endogenous Wnt and PI3K signalling in both the murine 
and human prostate.
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In the mouse, we have detected a low level of nuclear p-catenin expression in normal 
prostate epithelium, together with a high level of membrane immunoreactivity. This data is 
consistent with a human study, where nuclear and membrane p-catenin expression was 
detected in 0-5% and 100% of the prostate epithelial cells respectively (Horvath et a l , 
2005). The fact that Wnt signalling is known to regulate stem cell self-renewal in many 
tissues (Reya and Clevers, 2005), suggests that nuclear P-catenin expression may be specific 
to the prostate stem/progenitor cells. A definitive answer to this question could be 
determined by over-expressing the Wnt inhibitor Dickkopf-1 (DKK1) in the murine prostate 
using the PBCre transgenic line to determine whether normal tissue homeostasis altered. 
This experiment has been performed previously in adult murine intestine and colon, where 
adenoviral expression of DKK1 inhibited proliferation and resulted in the failure of crypts, 
villi and glandular structures to develop within 7 days (Kuhnert et al., 2004). Decreased 
DKK1 expression (>10 days) resulted in regeneration of the crypts and villi, highlighting 
the important role of Wnt signaling in intestinal homeostasis (Kuhnert et al., 2004).
Given that Lkbl is considered to suppress the Wnt pathway to prevent 
tumourigenesis (Spicer et al., 2003), a synergistic relationship between Lkbl loss and the 
activation of Wnt signalling oncogenic targets is predicted to promote tumourigenesis. 
Owing to partial embryonic lethality of mice expressing biallelic LoxP-flanked Lkbl alleles, 
it was not possible to generate a cohort of PBCre* Lkbl^Catnb*/lox(ex3) mice to address 
whether synergy occurred. Preliminary data from this thesis suggests that Lkbl loss and 
activated Wnt signalling accelerates tumour progression, following histological analysis of 
two PBCre+Lkbl^C atnb  '/lox(ex3) mice aged 100 days. The development of an aged cohort of 
PBCre*Lkbl^lCatnb+/lox(ex3) mice is necessary to confirm the synergy between loss of Lkbl 
and induction of the Wnt pathway.
Lkbl has also been shown to negatively regulate AMPK/mTOR signalling under 
low energy conditions, to decrease cell growth and proliferation (Alessi et al., 2006). Lkbl 
loss in prostate epithelium is subsequently predicted to decrease p-AMPK expression and 
elevate mTOR signalling. However, data from this thesis suggested that mTOR signalling 
was not upregulated in Lkbl deficient prostate epithelium. Indeed, the expression of active 
p-mTOR was markedly reduced, concomitant with increased p-AMPK expression (figure 
4.1), suggesting that a feedback mechanism compensates for Lkbl loss and prevents mTOR 
signalling by phosphorylating AMPK. Further investigation revealed that p-PDKl, 
postulated to be an AMPK kinase (Zou et al., 2003), may fulfil this task as p-PDKl 
expression was upregulated in Lkbl deficient PIN lesions. Taken together, this evidence
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indicates that treatment of prostate cancer with the mTOR inhibitor Rapamycin, may not be 
beneficial in Lkbl deficient prostate lesions. To validate the observed down-regulation of 
mTOR signalling, staining for additional AMPK and mTOR downstream targets, such as p- 
ACC (phospo-Acetyl CoA Carboxylase), an AMPK target (Conde et al., 2007), PKC (an 
mTORC2 target), and targets of mTORCl, such as CLIP-170, LIPIN, and STAT3 (Guertin 
and Sabatini, 2007) could be carried out. Unfortunately, attempts to obtain protein samples 
by laser capture were not successful, preventing western blot analysis of PIN lesions.
To date, the mechanisms employed by Rapamycin to inhibit tumour growth are not 
fully understood, which is in part owing to our lack of knowledge regarding the role of the 
mTORCl (mTOR:Raptor) and mTORC2 (mTOR:Rictor) complexes and the intricate series 
of feedback mechanisms that regulate their activity (Guertin and Sabatini, 2007). 
Rapamycin typically inhibits the mTORCl complex and has been shown to inhibit the Akt 
activating mTORC2 complex in a handful of cell types, including endothelial cells (Guertin 
and Sabatini, 2007). Since mTORC2 activates Akt, many studies have shown that PI3K 
inhibitors in combination with Rapamycin derivatives (e.g. RAD001) prevent cell growth, 
more so than Rapamycin alone (Sun et al., 2005; Van-Der-Poel et al., 2003).
An elevation in p-AMPK and subsequent reduction in p-mTORSer2448 expression in 
AhCre+L k b l^  PIN lesions does not correspond to previous work. Shaw et al (2004) 
reported elevated mTOR signalling in gastrointestinal hamartomas from heterozygous Lkbl 
knockout mice, suggesting that Lkbl negatively regulates mTOR signalling in the intestine. 
Moreover, Rapamycin, which is proposed to inhibit mTOR, has been shown to inhibit the 
growth of PC-3 and LNCaP prostate cancer cells lines, which is further inhibited in 
combination with the PI3K inhibitor LY294002 (Van-Der-Poel et al., 2003). Combined use 
of Rapamycin and PI3K inhibitors is thought to further inhibit cell growth by targeting both 
the mTORCl complex and mTORC2-mediated activation of Akt respectively (Van-Der- 
Poel et al., 2003), since Rapamycin does not target the mTORC2 complex in all tissues 
(Guertin and Sabatini, 2007). In addition, the MPAKT mouse prostate model in, which 
ventral prostate expresses human AKT1, has shown regression of neoplastic lesions upon 
Rapamycin treatment (Majumder et al., 2003).
Together, these data suggest that mTOR signalling is elevated in prostate cancer, 
indicating Rapamycin treatment is beneficial in reducing prostate cancer growth. However, 
one caveat of these studies is that the method employed to detect elevated mTOR signalling 
was an increase in p-S6K and its substrate p-Rsp6, instead of directly observing activated p- 
mTORSer2448 levels. S6K is also regulated by mTOR-independent pathways, such as
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PI3K/PDK1 signalling (Pullen et al., 1998) and the MAPK pathway (Martin and Blenis, 
2002), indicating that these studies have not specifically demonstrated elevated mTOR 
signalling.
Convincing evidence for elevated mTOR signalling in human prostate cancer has 
been demonstrated recently by a morphoproteomic approach that assessed p-mTORSer2448 
expression in HG-PIN and prostate cancer biopsies (Brown et al., 2008). Near to 100% of 
samples analysed displayed activated mTOR in prostate lesions compared to normal tissue 
(Brown et al., 2008). This presents several scenarios; (a) the lack of p-mTORSer2448 staining 
in AhCre+L k b l^ 1 mice is a false negative, (b) p-mTORSer2448 staining in the human prostate 
samples analysed by Brown et al (2008) is a false positive, (c) Lkbl is not lost in the human 
lesions analysed by Brown et al (2008) or (d) Lkbl-mediated regulation of AMPK/mTOR 
signalling in human and mouse prostate is distinct. To address this, p-mTORSer2448 
immunohistochemistry would need to be carried out on LKB1 deficient human prostate 
cancer, in combination with downstream targets specific to mTOR signalling. The lack of 
LKB1 deficient human prostate tissue clearly presents a problem, although it has not yet 
been determined whether LKB1 loss is a common event in human prostate cancer. The 
development of human prostate glands in culture from ES cells (Risbridger et al., 2007), 
may provide a useful tool for generating LKB1 deficient human prostate tissue in the future.
7.2 Does Lkbl loss drive prostate cancer progression?
Progression to advanced prostate lesions was not observed in Lkbl deficient mice, 
suggesting that Lkbl loss may only be sufficient to initiate early stages of the disease. 
However, progression may have been hindered by Cre-mediated recombination taking place 
in non-prostate tissue compartments or in a subset of prostate epithelial cells that either 
prevent tumourigenesis or are not tumour initiating. However, the development of 
bulbourethral gland cysts in the AhCre+L k b l ^  model resulted in death at around 2-4 
months, and therefore progression from PIN to later stages of disease could not be studied.
Interestingly, disrupted ZO-1 expression revealed Lkbl deficient PIN lesions had 
lost cellular polarity (figure 4.3m), an event not typically associated with initiation of the 
disease (Wodarz and Nathke, 2007). In addition, loss of E-cadherin was observed at the 
surface membrane (figure 4.3d), which is commonly associated with a more invasive 
phenotype (Wodarz and Nathke, 2007). Taken together, this evidence suggests that Lkbl 
loss is capable of initiating prostate cancer and shows elements of early disease progression, 
from atypical hyperplasia to HG-PIN. Subsequently, it is speculated that derivation of a
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model that drives Lkbl loss specifically in the prostate may permit disease progression. 
PSP94 (prostate specific secretory protein of 94 amino acids) has been shown to be 
specifically expressed in the murine prostate (Thorta et al., 2003). It is hypothesised that the 
by employing the PSP94 promoter to drive Cre recombinase expression, it may be possible 
to deleting Lkbl specifically within the murine prostate, allowing us to determine whether 
Lkbl loss can facilitate tumour progression to the later stages of the disease, avoiding 
complicated phenotypes owing to Lkbl loss in non-prostate tissues.
To confirm whether the PBCre and AhCre L k b l^  models demonstrate androgen- 
dependent prostate tumourigenesis, castration and androgen ablation studies could be 
carried out.
7.3 Lkbl loss mediated by the PBCre transgene may alter differentiation of prostate 
lineages
The notion that the basal cell lineage (p63 positive) contains the prostate stem cells 
is widely accepted, although not definitively demonstrated. Consistent with this notion, 
Signoretti et al (2000) have shown that p63 null mice develop defects in prostatic bud 
development, suggesting that the basal cells are required to restrict UGS endodermal cells to 
a prostate lineage and that p63 positive cells are required for luminal cell maintenance. 
Experiments grafting p63 null UGS into adult nude male hosts revealed that p63 deficient 
grafts developed ducts where basal cells were absent, preventing maintenance of normal 
luminal cell differentiation (Kurita et al., 2004). The PBCre L k b l^  prostate lesions 
displayed luminal cell mucinous-like metaplasia foci, resembling the phenotype observed in 
p63 null prostate. This suggests that loss of Lkbl might also impair basal cell 
differentiation, providing rationale for occasional luminal cell metaplasia. To verify whether 
Lkbl loss in prostate epithelial cells (targeted by the PBCre construct) results in impaired 
basal cell differentiation, immunohistochemistry to detect basal cell markers, such as p63, 
could be carried out. Furthermore, it would be interesting to determine the consequence of 
Lkbl deletion specifically within the basal cell population (as oppose to the luminal cell 
population targeted by the PBCre construct) by applying the keratin-5 promoter to drive 
Cre-recombinase expression. The data from this thesis suggests that these mice are likely to 
display loss of basal cell differentiation markers, concomitant with metaplastic 
transformation of the luminal lineage to mucinous-like cells, similar to the p63 null prostate 
described by Kurita et al, 2004.
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Interestingly, mucinous metaplasia was also observed in PB-W-ras mice that express 
an activated form of H-ras in the prostate (Scherl et a l, 2004). To address whether Lkbl 
loss results in mucinous metaplasia by deregulating Ras signalling, components of Ras 
effector pathways in Lkbl deficient prostate lesions could be detected using 
immunohistochemistry. Also, P B C re L k b l^  mice could be inter-crossed to mice 
expressing activated Ras, where double mutants are expected to demonstrate synergy and 
promote the development of prostate mucinous metaplasia, should Lkbl loss lead to 
elevated Ras signalling.
In contrast to the PBCre ' L k b l^  model that displayed hyperplasia and mucinous 
metaplasia, AhCre+L k b l ^  mice were predisposed to HG-PIN, concomitant with clusters of 
p63+ cells that exhibited altered morphology. Clustering of p63+ cell has been associated 
with expansion of the transit-amplifying cells and co-staining for p63 and transit-amplifying 
cell markers, such as PSCA or c-MET might provide an insight into the function of these 
cells (Tran et a l,  2002; Van-Leenders et a l,  2002). Furthermore, staining to detect prominin 
(CD133) may also determine whether the loss of Lkbl results in activation of the proposed 
prostate stem cells (Tsujimura et a l,  2007).
7.4 Lkbl plays a role in male fertility
It is clear from this thesis that Lkbl also plays a role in fertility, as all male mice 
bearing biallelic Lox-P-flanked Lkbl alleles were sterile, consistent with previous work 
(Sakamoto et a l, 2005). Histological analysis revealed hypospermatogenesis and Sertoli­
cell only syndrome in AhCre+ and PBCre' LkbP1^  mice respectively (figure 3.9 and 3.27). 
Previous work has shown that loss of Lkbl disrupts cellular polarity, by switching the role 
of Pari A in HeLa cells in vitro (Spicer et al., 2003) and by disrupting expression of the tight 
junction protein ZO-1 in intestinal cells in vitro (Baas et a l,  2004b).
Maintenance of cellular polarity is critical during spermatogenesis. Closing and 
opening of Sertoli cell tight junctions that constitute the blood-testis barrier is necessary to 
allow preleptotene and leptotene spermatocytes in the basal compartment to translocate to 
the adluminal compartment of seminiferous epithelium (figure 3.32), so that fully developed 
spermatids (spermatozoa) may be released into the tubular lumen at spermiation (Fink et a l, 
2006; Liu et a l, 2003). The regulation of this process is not yet fully understood, but has 
been linked to TGFp, PKA and PKC (Liu et a l, 2003). This thesis reports that ZO-1 
expression is disrupted in Lkbl deficient testis, providing rationale for male infertility. To 
further investigate the potential role of LKB1 in male fertility, it would be interesting to
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determine whether human testicular cancers frequently display reduced Lkbl expression or 
Lkbl inactivating mutations and to establish if ZO-1 deficient seminiferous tubules display a 
similar phenotype to Lkbl deficient mice. In addition, ZO-1 is known to be phosphorylated 
and regulated at tyrosine residues by kinases such as c-Src (Toyofuku et al., 2001). It is not 
thought that LKB1 directly regulates ZO-1 owing to the fact that it is a serine/threonine 
kinase. Of particular interest, TGFp has been shown to regulate tight junctions, although the 
mechanism involved is not fully established (Liu et al., 2003). Lkbl has been shown to 
regulate TGFp signalling by forming a heterotrimeric complex together with LIP1 and 
SMAD4 (Smith et al., 2001). Taken together, this evidence suggests that Lkbl loss may 
cause sterility in male mice by deregulating tight junctions through TGFp. Consequently, 
immunohistochemistry to detect TGFp deregulation in Lkbl deficient testes may provide a 
further insight into the role of Lkbl in male fertility.
In humans, male infertility is frequently associated with Karatagener’s syndrome, 
where the dynein arms that are normally attached to the nine microtubule doublets of cilia 
and flagella are lacking, causing immotility and sterility (Guichard et al., 2001). It is 
speculated that L kbl’s role as a microtubule sensor (Yoo et a l , 2002) may be important for 
sperm motility and further analysis of sperm in Lkbl deficient mice by electron microscopy 
may determine whether Lkbl loss disrupts microtubule arrangements in the flagella, causing 
male infertility.
7.5 Synchronous activation of Ras and Wnt signalling synergise to drive prostate 
cancer progression
Cancer development is a multi-step process through which cells accumulate genetic 
mutations (Hanahan and Weinberg, 2000). Investigations that further our understanding of 
the cooperativity of these genetic transformations provide an insight into the aetiology of the 
disease and present targets for chemotherapeutic intervention. Synchronous activation of K- 
ras and p-catenin has been demonstrated in many transgenic models illustrating their 
cooperation during intestinal, colorectal and liver tumourigenesis (Harada et a l , 2004; 
Janssen et al., 2006; Sansom et a l , 2006). This evidence suggests a similar cooperativity in 
other tissues.
This thesis also investigated the synergistic relationship between the Wnt and Ras 
signalling pathways in prostate cancer, revealing that conditional activation of p-catenin and 
K-ras in the murine prostate also demonstrate cooperativity between activated Ras and Wnt 
signalling, raising the possibility of a similar association in humans. Convergence of the Ras
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and Wnt pathways has been shown to upregulate the expression of genes that function to 
promote tumourigenesis and progression, such as COX-2, c-Myc, AR and VEGF (Araki et 
al., 2003; He et al., 1998; Kerkhoff et al., 1998; Terry et al., 2006; Weber and Gioeli, 
2004). Immunohistochemical analysis of PBCre1 K-ras /VI2;Catnb /Aex3 prostate carcinomas 
determined Ras and Wnt signalling synergise to promote tumour progression by 
upregulating c-Myc and COX-2 via the canonical Wnt pathway, presenting a target for 
chemotherapeutic intervention. It is speculated that treating double mutant mice with a 
COX-2 inhibitor, such as Aspirin or Colecoxib, would drastically repress tumourigenesis 
(Narayanan et a l , 2006). Additionally, it is predicted that crossing the compound mutant 
mice to mice harbouring a conditional inactivating cMyc transgene would rescue the 
phenotype, as demonstrated previously in Ape deficient murine intestine (Sansom et al., 
2007).
Interestingly, Lkbl is also known to play a role in regulating COX-2 expression by 
interacting with and phosphorylating PEA3 (Upadhyay et a l , 2006). Investigations into the 
phosphorylation status of PEA3 and COX-2 expression in LkblJ prostate might provide an 
insight into whether COX-2 inhibitors would also be beneficial in preventing 
tumourigenesis in prostate lesions deficient in Lkbl.
Elevated Ras and Wnt signalling revealed an increase in the number of cells 
expressing AR. This indicates that these neoplastic cells are likely to be hypersensitive to 
androgen levels. It is predicted that these lesions are androgen-independent, as demonstrated 
in Ape deficient mice that displayed a similar phenotype (Bruxvoort et a l , 2007). To 
address whether activated K-ras and/or P-catenin results in androgen-independent 
tumourigenesis, androgen ablation experiments could be performed. It is predicted that 
androgen ablation in PBCre+Catnb+/lox(exS) and PBCre K-ras+/vl2; Catnb+/lox(ex3) mice will 
not cause tumour regression, confirming androgen-independent prostate cancer growth.
An elevation in AR expression is thought to represent aberrant differentiation of the 
basal and luminal cells and to address this, double staining for basal/luminal cell markers 
could be carried out to determine whether they are co-expressed. Cells expressing both 
luminal and basal cell markers are considered to be transit-amplifying cells, representing 
activation of the stem cells (Tran et a l , 2002).
7.5 Reduced p63 expression correlates with prostate cancer progression
A reduction in p63 expression has been observed to correlate to tumour progression 
in the human prostate (Parsons et a l , 2001), bladder (Urist et a l , 2002) and head and neck
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cancer (Matheny et al., 2003). Immunohistochemistry revealed a reduction in the basal cell 
marker p63 in association with tumour progression in K-ras and P-catenin mutants. Previous 
work has shown that p63 expression in keratinocytes is mediated by Notch signalling 
(Nguyen et al., 2006). To establish whether this mechanism exists in prostate epithelium, 
immunohistochemistry to detect Notch signalling activity is required, in conjunction with 
p63 staining.
In addition, further investigation into the mechanism resulting in the loss of p63 
expression may present a new route for chemotherapeutic intervention, as PBCre+K- 
ras+/VI2;Catnb+/lox(ex3) mice demonstrated loss of p63 in parallel with elevated AR (figure 
6.10). Double staining for AR and p63 or Ki-67 might determine the role of AR expression 
and whether the few remaining p63 positive cells are proliferating. This staining would also 
provide an insight into whether the lesions are heterogeneous, resembling human prostate 
cancer.
7.5 Conclusions
Much of the challenge that remains lies in interpreting the molecular events 
underlying the predisposition to prostate cancer and androgen-independent prostate 
tumourigenesis. This thesis goes some way to addressing some of these questions by 
establishing the first correlation between Lkbl loss and prostate neoplasia and by 
demonstrating the cooperativity between activated Ras and Wnt signalling. These models 
provide a valuable resource for genetic based studies that recapitulate the nature of human 
prostate cancer.
Mice have become the primary model organism for studying human diseases as they 
are easy to manipulate genetically, they are prone to several diseases and cancers and they 
display similar genetics and physiology to humans. However, there are still some crucial 
differences, preventing a direct comparison and one central limitation is the lack of common 
human and mouse prostate stem/progenitor cell and prostate specific markers. 
Consequently, it is important to be cautious when translating the outcomes of murine studies 
into the clinic. In the future, it is hoped that deriving human prostate in culture from 
embryonic stem cells may provide a powerful tool for studying the genetic and biochemical 
events that take place during prostate tumourigenesis. It is also hoped that gene therapy will 
hold the key to inhibiting prostate cancer.
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Appendix 1: Laboratory reagents, enzymes and suppliers
Product
Proteinase K (14-22 mg/ml)
Cell lysis solution
Protein precipitation buffer
Nuclease-free water
PicTaq
25mM MgCl2
lOx Platinum Taq buffer
Platinum Taq
5x GoTaq Flexi Buffer
GoTaq
25 mM dNTPs
10% formalin
lOx citrate buffer (pH 6.0)
Standard Vectastain Kit
Rabbit Envision Kit
Mouse Envision Kit
Diaminobenzidine (DAB) kit
Invitrogen Superscript II Kit
RNA Later solution
TRIzol reagent
DNase TURBO kit
DyNAmo HS SYBR Green qPCR kit
Polyethylene naphthol membrane-coated slides
QIAamp DNA Micro Kit
Adhesive capped tubes (0.2 ml)
Genomiphi DNA amplification kit 
DIG Labelling kit 
RNA polymerase T3, 20 units/jul 
RNA polymerase T7, 20 units/pl 
DIG RNA Labelling mix lOx solution 
RNase inhibitor, 10-50 units/pi 
Anti-digoxigenin Fab fragments 
DNase 1, RNase free 20-50 units/pl 
Paraformaldehyde 
BM purple substrate 
20x SSC (pH 5)
Formamide
Heparin
Calf liver tRNA 
Triethanolamine hydrochloride
Supplier
#03115844001, Roche
Gentra
Gentra
Sigma
Cancer Research UK
Sigma
Invitrogen
#10966-034, Invitrogen 
#M890A, Promega 
#M830B, Promega 
Sigma 
Sigma
#AP-9003-500, Labvision 
#PK6100, Vectastain 
#K4010, DAKO 
#K4006, DAKO 
#K3467, DAKO 
#18064071, Invitrogen 
#R0901, Sigma 
#15596-026, Invitrogen 
#1907, Ambion 
#F-410L, GRI 
#415101-4401-000, PALM 
#56304, Qiagen 
#415101-4400-245, PALM 
#25-6600-00, Amersham 
#BM 1175025, Roche 
#1031163, Roche 
#881767, Roche 
#1277073, Roche 
#799017, Roche 
#11327723, Roche 
#776785, Roche 
#P6148, Sigma 
#11442074001, Roche 
#S6639, Sigma 
#47671, Sigma 
#H4784, Sigma 
#R4752-100N, Sigma 
#T1377, Sigma
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Lkbl Deficiency Causes Prostate Neoplasia in the Mouse
Helen B. Pearson,' Afshan McCarthy/ Christopher M.P. Collins/
Alan Ashworth/ and Alan R. Clarke'
'Cardiff University, School o f Biosciences, Cardiff, Wales, United Kingdom; -’Breakthrough Breast C ancer Research Center, The Institu te of 
Cancer Research, Ixrndon, United Kingdom; and ’Bristol Royal Infirmary, D epartm ent o f Pathology, Bristol, U nited Kingdom
Abstract
M utation o f  LKB1 is the key m olecu lar event underlying  
Peutz-Jeghers syndrom e, a  dom inan tly  inherited  con d ition  
characterized  by a  p red isp o sitio n  to  a range o f  m alignancies, 
includ ing th o se  o f  th e  reproductive system . We report here  
the use o f  a  Cre-LoxP  strategy  to  d irectly  address the role o f  
Lkbl in prosta te  n eop lasia . R ecom bination  o f  a L atP-flanked  
L k b l  a lle le  w ith in  a ll four m urine p ro sta te  lo b es  w as  
m ediated  by sp o n ta n eo u s activa tion  o f  a p 4 5 0  CYP1A1 -driven  
Cre recom h in ase  tra n sg en e  (term ed  AhC re). H om ozygous  
m u ta tio n  o f  L k b l  in  m a les  ex p ressin g  A hC re  red u ced  
longevity, w ith  100% m anifesting  atypical hyperplasia and  
83% develop in g  p ro sta te  in traep ith elia l n eop lasia  (PIN) o f  the  
anterior p ro sta te  w ith in  2 to  4 m onths. We also  observed  
focal hyperp lasia  o f  th e  d orso latera l and ventral lobes (61% 
and 56% in cid en ce , respectively), bulbourethral gland cysts  
associa ted  w ith  atyp ical hyperplasia  (100% incidence), hyper­
plasia  o f  the urethra (39% incid en ce), and sem inal vesicle  
squam ous m etap lasia  (11% incid en ce). PIN foci overexpressed  
nuclear (3-catenin, p-Gsk3(3, and  dow nstream  W nt targets. 
Im m u noh istoch em ical analysis o f  foci a lso  show ed a reduc­
tion  in P ten activation  and  up -regulation  o f  both  p-PDK l (an  
AMPK k in a se) a n d  p h o sp h o r y la te d  Akt. Our d a ta  are  
therefore co n sisten t w ith deregu lation  o f  W nt and  ph ospho- 
inositide 3-k inase/A kt sign a lin g  cascades after lo ss o f  Lkbl 
function. For th e  first tim e, th is m odel estab lishes a link  
betw een the tum or su ppressor Lkbl and  p rosta te  neoplasia , 
high lighting a tum or suppressive role w ith in  the m ouse and  
raising th e  p ossib ility  o f  a  sim ilar asso cia tio n  in the hum an. 
[Cancer Res 2008^8(7): 1-10]
Introduction
Prostate cancer is the second m ost com m on malignancy next to 
lung cancer in m en (1). A central limitation to studying prostate 
cancer has been the lack o f  suitable animal m odels that 
recapitulate all the stages o f  human disease progression. This has 
at least in part been alleviated by the generation o f a range o f  
mouse strains with prostate phenotypes, including those mutant 
for RB, PTEN, AR, AKT, and, more recently, (3-catenin (2). However, 
it remains o f paramount importance to develop novel m odels of 
prostate cancer to further our understanding o f the molecular 
mechanisms and genetic events underlying prostate cancer.
LKB1 encodes a serine-threonine kinase that was first identified 
as a gene whose multiple germ line mutations abrogate enzymatic
R equests fo r r e p r in ts : Alan Clarke, University o f Cardiff, M useum Avenue, Cardiff 
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function and are associated with familial Peutz-Jeghers syndrome 
(PJS; ref. 3). The disorder is characterized by melanin deposits on 
the buccal m ucosa, lips, and digits and the risk o f intestinal 
ham artom as and extraintestinal cancers, such as stom ach, 
pancreas, thyroid, and those o f the reproductive organs is at least 
10-fold higher than the general population (4). The molecular 
m echanism s underlying this enhanced tum or predisposition  
remain to  be fully elucidated, but LKB1 has been implicated in 
the regulation o f m ultiple pathways associated with tumor 
prevention (3-7). These include chromatin rem odeling angiogen- 
esis, p53-dependent apoptosis, cell cycle arrest, energy metabolism, 
fatty acid biosynthesis, W nt signaling proliferation, polarity, and 
differentiation (4, 8-11). Recently, som atic deletion of Lkbl has 
been linked to lung tum origenesis and mutation screening of 
human lung cancer patients revealed LKB1 inactivation is a 
com m on event in lung adenocarcinom as (34%) and squamous cell 
carcinom as (19%), further implicating Lkbl as a tumor suppressor 
(12). In addition, som atic m utation of L kbl has been reported in 
pancreatic and biliary cancers (13), as w ell as m alignant 
m elanom as (14).
LKB1 is a m em ber o f  the Snfl family o f kinases and has been 
shown to  phosphorylate at least 13 members o f the AMPK subfamily, 
many o f  which play a fundamental role in metabolic regulation (7). 
In particular, Lkbl can activate AMPK by phosphorylating Thr172 
within the T-loop (11, 15). This leads to mTOR inhibition via TSC2 
(tuberin) to  suppress cell growth and proliferation (16), as well as 
dow n-regulating fatty acid and cholesterol biosynthesis and 
enhancing glucose uptake and glycolysis (17, 18). However, to date, 
there is little published data to  support a direct role for AMPK 
deregulation in prostate tum origenesis (19).
With respect to  the W nt pathway, it has been reported that 
loss o f function o f LKB1 elevates Wnt signaling via its regulation 
o f  MARK3 (ParlA, cTAK). In the absence o f Lkbl, ParlA is 
unphosphorylated and available to participate in the Wnt cascade, 
instigating translocation o f (3-catenin into the nucleus where it 
instructs transcription o f  target genes to stimulate proliferation 
(8). This gives a direct mechanism, whereby mutation o f LKB1 
may lead to  activated W nt signaling The potential relevance of 
such deregulation to  prostate cancer has been indicated through 
studies o f human prostate cancer that have identified both muta­
tions in fi-catenin  and aberrant (3-catenin expression (20). Further 
evidence in support o f  such a link is derived from Cre-Lox-based 
models, which develop high-grade PIN and squamous metaplasia 
after Cre-mediated activation o f a constitutive (3-catenin mutation 
(20, 21). Most recently, the rat probasin promoter (PB-Cre4) has 
been used to drive Cre-mediated deletion of Ape in the prostate, 
and this has been shown to predispose to adenocarcinoma o f the 
prostate (22).
LKB1 has also been shown to interact with the tumor suppressor 
PTEN and thereby the phosphoinositide 3-kinase (PI3K)/Akt and 
mTOR pathways. The m ost direct evidence for this interaction was
www.aacrjournals.org 1 Cancer Res 2008; 68: (7). April 1, 2008
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derived from in vitro studies that have shown LKB1 to bind and 
phosphorylate PTFN (3, 23). This interaction has been speculated  
to result in PTFN stabilization and activation (23). Further indirect 
evidence for an interaction com es from the observation that ~  70% 
of PJS patients also harbor m utation or display loss o f at least one  
allele o f PTEN (24). Any potential interaction between PTF.N and 
LKB1 is o f particular relevance to prostate neoplasia, as PTF.N is 
well established as a tum or suppressor within this tissue. In 
humans, PTEN has been reported to be frequently deleted in 
prostate adenocarcinom as (24). In mice, hom ozygous inactivation  
o f Pten leads to  em bryonic lethality (25), whereas heterozygosity  
predisposes to prostate carcinom a within 9 to 16 m onths (50%). 
This phenotype can be accelerated by additional hom ozygous 
deletion o f C dknlb, with carcinom as occurring within 3 m onths on  
this background (26). Prostate-specific deletion o f Pten  has also 
been achieved using the PB-Cre4 construct to drive recom bination  
of a LoxP-flanked Pten  allele. This m odel recapitulates the full 
spectrum  of human prostate cancer progression from hyperplasia, 
low-grade PIN, high-grade PIN, carcinoma, and m etastasis (27). 
Finally, it has also been argued that progressive depletion o f Pten 
levels correlates with a more aggressive prostate phenotype and  
elevated Akt signaling (24), frequently associated with human  
prostate cancer (28).
There is currently little in the literature to directly link LKB1 
mutation with hum an or murine prostate neoplasia. However, the  
fact that som atic I.KB1 m utations have been observed in hum an  
lung cancer and the observation o f Lkbl-driven lung tum origenesis 
in the m ouse suggests that Lkbl may have a broad tum or  
suppressive role in epithelial tissues (12).
In the prostate, I.KB1 protein has been detected in the cytoplasm  
o f luminal cells using im m unohistochem istry (29) and low levels o f  
Lkbl mRNA are detectable (30). Sequencing studies have reported 
that LKB1 is m utated in one o f five sequenced hum an prostate  
carcinom a cell lines, with a frame-shift deletion (p.K178fs*86) 
within the kinase dom ain o f DU145 cells (31). Further support for a 
tumor suppressive role for Lkbl com es from a w hole-genom e scan  
study that identified an association between chrom osom e seg­
m ents 19ql2-ql3.11 and prostate cancer aggressiveness (32). The 
chrom osom e segm ent 19pl3.3 harbors the I.KB1 tum or suppressor 
gene and also contains m em bers o f the kalikrein family (such as 
KLK3, PSA) and the MUC16 gene that encodes the ovarian cancer  
antigen CA125 (32). Deletions, am plifications, and structural 
rearrangements o f  chrom osom e 19 have also been reported in a 
variety of tum ors, including pancreatic adenocarcinom as, both  
benign and anaplastic thyroid tum ors and stom ach cancers 
(reviewed in ref. 32). Interestingly, prostate cancer has also been  
anecdotally reported in a PJS patient (66 years old) after the  
developm ent o f  colon cancer (6). The presence o f prostate cancer  
in PJS patients is not a frequent occurrence, possibly as a con­
sequence o f the norm al age o f onset o f  disease. Prostate cancer is 
typically diagnosed in the seventh decade o f life, whereas PJS 
patients have an average life span o f 57 years (4).
Together with the biochem ical evidence o f pathway interaction, 
these observations suggest a potential role for deregulated I.KB1 
signaling in prostate cancer. To directly assess this possibility  
in vivo, we have characterized the phenotype o f m ice deficient for 
Lkbl within the prostate. Mice engineered to carry floxed (fl) L kbl 
alleles (L k b l ref. 33), where the kinase domain has been replaced 
by a cDNA cassette encoding exons 5 to 7, enabled Lkbl deletion  
within the prostate by using the AhCre prom oter to  drive 
expression o f Cre recom binase (34). By applying this strategy, we
show that loss o f L kbl predisposes to  atypical hyperplasia (AH) 
that progressed to PIN in the anterior lobe and focal hyperplasia 
associated with nuclear atypia o f the dorsolateral and ventral lobes 
within 2 to 4 m onths. W ithin PIN lesions, we observe elevation o f  
both the PI3K/Akt and W nt signaling pathways, supporting the  
concept that loss o f L kbl prom otes neoplasia through deregulation  
o f  these pathways.
Materials and Methods
G eneration o f  A hC re'L kblfl/Jt m ice. All anim al studies and breeding 
were carried ou t under a  UK Home Office project license. L k b ^ 1 mice and 
the AhCre transgenic mice have been described previously (33, 34). The 
Lkbl and  AhCre alleles were backcrossed six tim es onto a C57BL/6 
background. Mice containing one wild-type Lkbl allele and one floxed allele 
(LkbE /Jl) were m ated with AhCre-positive mice carrying the Rosa26 
repo rter allele (35). The Lkbl heterozygous progeny from this cross was 
in tercrossed  to  generate AhCre'L k b mice (as LkbT1^  males are sterile; 
ref. 33). Cohorts were aged, and the male genitourinary (GU) tract was 
harvested  w hen mice developed symptoms. Mice were genotyped by PCR 
using DNA isolated from tail biopsies. The wild-type and LoxP-flanked Lkbl 
alleles were detected  using the prim ers Lkbljwd, 5'-GATTTCCGCCAGCT- 
GATTGA-3' and Lkblrev, 3-AGTGTGACCCCAGCTGACCA-5' producing 
320-bp (wild-type) and 280-bp (floxed) PCR fragments. Recombined Lkbl 
was d e tec ted  using L kblrecl 5'-CAGAATCACATCCCCTGGTT-3' and 
Lkblrec2, 3'-TTCCCCTCCTCCTGCTAGAT-5', producing a PCR product of 
500 bp. Cre recombinase activity was induced in control mice by four i.p. 
injections o f 80 m g/kg (Vnaphthoflavone within 24 h. Recombined liver 
tissue was harvested 7 d later.
(3-G alactosidase analysis. To determ ine the pattern  of recom bination at 
the Rosa26R reporter locus, sectioned m aterial was analyzed as previously 
described, except X-gal staining w as reduced to 1 h a t 37°C (34).
T issue iso la tion . Tissue was harvested as described previously (36) and 
fixed for no longer th an  24 h in 10% neutral buffered formaldehyde at 4°C 
before being em bedded in paraffin and sectioned at 5 pm . Frozen sections 
were p repared  by snap-freezing in liquid nitrogen, em bedded in OCT on dry 
ice, and sectioned a t 10 pm.
H istology, im m unohistochem istry, and im m unofluorescence. For 
histology, sections were stained with H&E. For im m unohistochem istry, 
antigen retrieval was perform ed by incubating the slides in 1 x citrate buffer 
(pH 6.0) in the  microwave on full power for 15 min, and endogenous 
peroxidase activity was inactivated in a  solution containing 1.5% H20 2 in 
deionized w ater. D etection and visualization was carried out using the 3,3 - 
d iam inobenzid ine  chrom agen (DAKO Cytom ation) according to  the 
m anufactu rer’s protocol. Images were taken at 40 x m agnification using 
“AnalySIS” softw are (Olympus Soft Imaging System GMBH)”, and scale bars 
were added to  represent 50 pm. C ontrol slides known to  be positive for each 
antibody were incorporated. Prim ary antibodies were obtained from the 
following sources: an ti-androgen receptor 1:100 dilution (Lab Vision 
Corporation), an ti-(V caten in  1:50 dilution (Transduction Laboratories), 
CD44 1:50 dilution (PharM ingen), anti-Foxal 1:800 dilution (Clone 2F83, 
Seven Hills Bioreagents), anti-pG sk3|i (Ser9) 1:50 dilution (Cell Signaling 
Technology), an ti-K era tin-5  1:1000 dilution (Covance), anti-Ki-67 1:200 
dilution (Vector Laboratories), anti-p63 1:50 dilution (Lab Vision Corpora­
tion), an ti-p-PT EN  (S e r^ /T h r 3827383) 1:25 dilution (Cell Signaling Technol­
ogy), anti-PTEN 1:100 dilution (Cell Signaling Technology), anti-p-AKT 
(Ser171) 1:50 dilution (Cell Signaling Technology), anti-PDKl (Ser 241) 1:50 
dilution (Abeam), anti-K eratin-18 1:20 dilution (Progen), anti-p-AM PK 
(T h r1' 2) 1:50 dilution (Cell Signaling Technology), anti-p-m TO R (Ser2448) 
1:100 dilution (Cell Signaling Technology), anti-p-p70-S6K (Thr421 /Ser424) 
1:100 dilution (Cell signaling Technology), and anti-p-S6 ribosom al protein 
(p-Rps6; Ser240/244) 1:100 dilution (Cell Signaling Technology).
For im m unofluorescence, the frozen sections were treated with pepsin 
solution (Zymed) and incubated with the prim ary rabbit polyclonal a n ti-  
zona occludens 1 (ZO-1) antibody 1:20 dilution (Zymed). The prim ary was 
detected  using the AlexaFluor-488 Nanogold Fab fragm ent of goat anti-rabbit
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IgG (Molecular Probes) 1:200 dilution. Slides were m ounted with Vectashield 
HardSet + 4',6-diamidino-2-phenylindole m ounting medium (Vector Labo­
ratories), and fluorescence was detected  using the Leica TCS SP2 AOBS 
confocal microscope.
In situ  hybridization. The Qiagen midi-prep kit was used to  produce 
large-scale preparation o f the Lkbl insert, an Lkbl full-length cDNA clone 
inserted in the pYX-Asc vector (IRAVp968E05123D, RZPD). Templates were 
prepared by linearization w ith EcoRl o r Not I (Promega): DNA phenol 
chloroform was extracted, and ethanol was precipitated. The plasmid 
sequence was checked by au tom ated  sequencing, confirming 100% identity 
of the Lkbl clone with the National Center for Biotechnology Inform ation 
Sequence (accession num ber BC052379). Anti-sense and sense RNA probes 
were then obtained by in vitro transcrip tion  using T3 and T7 RNA 
polymerases (Roche) and labeled using the DIG RNA labeling kit (BM 
1175025, Roche). In situ hybridization was carried out as described 
previously on  10% formalin-fixed paraffin-embedded sections (37). Briefly, 
sections were fixed in 4% paraform aldehyde a t 4°C for 15 min, treated  with 
proteinase K (20 mg/mL), and hybridized with the probes overnight at 
65°C. The sections were w ashed a t 65°C and adsorbed with alkaline 
phosphatase-conjugated anti-DIG antibody (Roche) overnight a t 4°C. 
Alkaline phosphatase activity w as detected  by using BM purple AP solution 
(Roche).
Laser capture microdissection and DNA isolation and amplifica­
tion. Frozen tissue was sectioned (at 15-20 pm) onto polyethylene naphthol 
m em brane-coated glass slides (PALM Microlaser Technologies) and lightly 
stained with 1% cresyl violet acetate. Laser capture microdissection (LCMD) 
was perform ed im m ediately and  did n o t exceed 30 min. DNA was isolated 
with the  QIAamp DNA m icrokit (Qiagen) and amplified using the 
Genom iphi DNA am plification k it (Amersham). PCR reactions were 
performed in the log phase o f amplification using 100 ng of LCMD- 
amplified DNA in a  50-pi, reaction.
R e s u l t s
AhCre+L k b ln/nm ice  h ave a  reduced  life  span. AhCre* m ice  
were intercrossed with m ice carrying a LoxP-flanked L kbl allele 
and the Rosa26 reporter allele. Cohorts o f wild-type (AhCre* - 
L kbl*1'*), AhCre* Lkbl*/Jl A h C re L k b f/Jl, and AhCre* L k b ^  m ice  
were generated and aged. Each cohort contained a m inimum o f  
20 males. Animals were then monitored for signs o f illness and 
killed w hen they becam e sym ptom atic o f disease (Fig. L4). Wild- 
type, AhCre* Lkbl*/fl, and A hC reLkblfl/fl cohorts showed average 
survival tim es exceeding 450 days and did not significantly differ 
from each other ( x 2 test). However, all AhCre*LkbP1^  m ice becam e  
ill by 200 d, with a significantly reduced average survival o f 83 d 
compared with wild-type (P  < 0.0001, x 2 = 39.85).
A hC re*L kbl*1'*1 m ic e  d e v e lo p  m u ltip le  GU p h en o ty p e s ,  
inclu d ing  PIN. H istologic analysis o f the GU tract was performed 
in accordance with the consensus report from the Bar Harbor 
m eeting o f the m ouse m odels o f human cancer consortium prostate 
pathology com m ittee (36). No gross phenotype was observed in 
wild-type (n = 21), A h C re * L k b l* (n  = 18), and AhCre L /c b l^  (n = 
19) m ice, w hereas the AhCre*Lkbl^1^ 1 cohort (n = 20) w as 
predisposed to  a num ber o f GU phenotypes.
The anterior prostate from A h C re * L k b ^  mice between 2 to 4 
months o f age revealed atypical hyperplastic foci (100% incidence) 
and progression to prostate neoplasia predominantly in the  
proximal region o f the duct (Fig. 2/4). PIN was observed as early 
as 8 weeks when m ice becam e sick (83% incidence). Within these  
lesions, solid and cribriform intraluminal proliferation of markedly 
atypical epithelial cells was accom panied by cytologic (nuclear) 
atypia, such as nuclear enlargement, pleomorphism, chromatin 
abnormalities, and an increased prom inence of nucleoli, along with 
apparent focal rosetting that contained m itotic bodies (38). This
process was also coupled to thickened stroma surrounding the 
acini and scattered interstitial infiltrate o f lym phocytes and plasm a 
cells. Sparse lym phocytes were also observed within som e AH and 
PIN lesions and in severe cases obstructing prostate acini, resulting 
in gross tubular dilation. Dorsolateral and ventral lobes displayed a 
less severe phenotype, where cells exhibited nuclear atypia 
associated with focal epithelial hyperplasia with 61% and 56% 
incidence, respectively (Fig. 2B).
In addition to PIN, A h C re* L k b l^  mice displayed other GU 
phenotypes. The cohort could be identified visually from 6 to  
8 weeks o f age because 100% o f the m ice developed swellings at the 
base o f the tail. H istologic analysis from this region revealed 
bulbourethral gland (BUG) cysts associated with atypical hyper­
plasia (Fig. 2C). The acinar m ucosal epithelium  o f these cysts was 
characterized by a loss o f cell polarity and was com posed primarily 
o f  ductal cells, co n sisten t w ith  reduced secretory function  
indicative o f the depleted foam y cytoplasm, similar to an Nkx3.1 
deficiency (39, 40). The presence o f interstitial, AH, and PIN 
inflam m atory cells is probably linked to  disruption of the cystic 
BUGs. It is unlikely that the inflammation predisposes to the  
prostate phenotype, because lesions were not regenerative. We also 
identified urethral gland hyperplasia in 39% o f AhCre* Lkbf^fi mice 
(Fig. 2Di,ii). Nodular hyperplasia o f the membranous urethra 
transitional epithelium  (UGH) within the lamina propria and a 
predisposition to cytologic atypia was apparent. There were also 
tw o cases (11%) o f sem inal vesicle squam ous m etaplasia (SV SqM; 
Fig. 2Diii-iv). Interestingly, som atic m utation o f Lkbl in the lung 
has been show n to predispose to squam ous m etaplasia (12). Finally, 
all L k b ^  m ice were sterile, correlating with previous reports (33). 
PIN is not a likely cause o f  our observed reduced longevity. Health 
o f  the A hC re*L kb^/ft m ale cohort deteriorated, owing to a 
com bination o f  phenotypes. These include the developm ent of  
both cystic BUGs (susceptible to rupture) and subsequent infection
100
so -
60 -
40 -
20  -
Time (d)
Figure 1. AhCre*Lkb1m  male mice display reduced longevity. Kaplan-Meier 
plot of the AhCre'LkbC* (n = 26), AhCre'Lkbl** (n = 4 1 ), AhCre Lkb1mi 
(n = 20) cohorts were all represented in green, and AhCre* Lkb1m  mice (n = 26) 
were illustrated in purple. AhCre*Lkb1 mice show decreased longevity, 
where 100% of the cohort did not survive past 200 d. x 2 tests confirmed 
AhCre* Lkb1m  mice exhibit a significantly reduced average survival of 83 d 
compared with wild-type (P  < 0.0001, x 2 = 39.85), AhCre* Lkb1*m (P  < 0.0001, 
X2 = 59.01), and AhCre Lkb1m  (P  < 0.0001, x 2 = 31.97) cohorts.
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Figure 2. AhCre-mediated deletion of Lkbl predisposes to multiple GU phenotypes, including PIN. Histologic analysis of H&E sections from AhCre'Lkb1m  and 
AhCre* Lkb1m  cohorts aged 2 to 7 mo. A, AhCre Lkb1mi anterior prostate developed normally (/). AhCre* Lkb1m  anterior prostate developed atypical hyperplasia 
(//'), which progressed to PIN and showed solid and cribriform patterned lesions (///). High power magnification reveals mitotic cells present (arrow heads) and 
nuclear atypia (arrows), characteristic of PIN (hr). B, AhCre*Lkb1m  dorsolateral and ventral prostate lobes exhibited low-grade hyperplasia in association with 
nuclear atypia. C, the BUG displayed aberrant ductal architecture and chronic infection, suggesting cystic hyperplasia in AhCre*Lkbl mice compared with 
control cohorts (/—//), which were identified by swellings near the base of the tail that developed between 6 and 8 wk (iif-hr). D, urethral gland and transitional 
epithelial hyperplasia developed in Lkbl mutants, where the lamina propria (LP) and urethral glands (UG) seem  to have proliferated (/' and ;/). SV SqM was also 
observed in AhCre*Lkb1m  mice (Hi and hr). Images were photographed at 20x magnification (low power) or 40x magnification (high power), and scale bars 
represent 50 |xm.
of the GU tract. We assume these other phenotypes prevent 
progression of PEN to more advanced stages o f prostate cancer, 
such as adenocarcinoma and metastasis. The fact that the  
A hC re*Lkbl^  lesions are not regenerative and also that not all 
PIN lesions were associated with inflammation strongly suggests 
that infection does not drive the development of PIN in this model.
The AhCre transgene m ed ia tes recom bination in the GU. The 
observation o f a GU phenotype in the AhCre* L k b ^  mice implied 
recombination was occurring within these tissues, with subsequent 
loss o f Lkbl function. To characterize this pattern, we used mice 
bearing both the AhCre transgene and the Rosa26R reporter locus 
(35). Using this approach, AhCre-mediated  excision, as reported by 
LacZ expression, was observed in all four lobes o f the prostate and 
} in a mosaic pattern in the urethral glands (Fig. 3d). Further LacZ 
analysis revealed that uninduced AhCre-mediated recombination 
also occurred in the kidney (41), as well as in the BUG, seminal 
vesicle, testis, epididymis, and vas deferens (not shown). Histologic
analysis of the kidney from the A h C re* L k b ^  cohort determined 
no abnormalities, whereas the testis, epididymis, and vas deferens 
showed male hypospermatogenesis and aspermia, respectively. 
Interestingly, Lkbl expression in the testis o f L k b ^  hypomorphic 
male mice is dramatically reduced in the testis. The com mon  
50-kDa isoform is 10-fold lower, whereas the 48-kDa form is Q3 
completely absent (33).
R ecom bination o f  the Lkbl occurs w ithin  the GU and is 
associated  with PIN. To confirm that the Lkbl kinase domain had 
been deleted in the neoplastic prostate tissue, LCMD and PCR 
amplification o f extracted DNA samples was carried out. This 
approach was taken as insufficient tissue was available for Western 
blots and immunohistochemistry using anti-Lkbl antibodies did 
not detect a product in control tissue and was therefore 
inappropriate to show loss o f function. For PCR amplification, 
positive controls were derived from A h C re* L k b ^  mice which had 
been exposed to (Vnaphthoflavone. This protocol delivers near
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100% recombination of the target allele in the liver. Laser capture 
microdissected DNA from the anterior prostate epithelia o f both 
normal (N) regions from AhCre* LkbPUJl and AhC reLkblfl/^  mice 
served as a negative control for a PCR specific for the recombined 
Lkbl allele (Fig. 35). Semiquantitative densitometry of PIN in the 
anterior prostate from AhCre* L k b l^  mice showed 64% recombi­
nation (when compared with fully recombined liver controls). This 
correlated with a reduction in the level o f the unrecombined LoxP- 
flanked Lkbl allele. The fact that recombination was below 100% 
presumably reflects the observed stromal content in the PIN lesions. 
These observations establish that recombination of the LoxP- 
flanked Lkbl allele is associated with PIN, but cannot discriminate 
between loss o f function and haploinsufficiency of Lkbl.
To confirm depletion o f Lkbl transcripts in neoplastic tissue, we 
performed an in situ hybridisation specific for Lkbl mRNA 
transcripts. Lkbl mRNA was detected in all wild-type prostate 
lobes (ventral prostate not shown) but was not present in 
AhCre* mice (Fig. 3C).
C haracterization  o f  L kb l-defic ien t PIN. To characterize the 
prostate lesions at a molecular level, immunohistochemistry was 
performed. The proliferation marker Ki-67 was rarely expressed in 
control {AhCre L k b ^ fl) anterior prostate epithelium; however, it 
was significantly elevated in epithelial cells throughout the acini of 
A hC re*Lkbf/Jl mice (Fig. 4A). Basal cells were detected using 
antibodies against p63 and Keratin-5 in the epithelial lining of 
anterior acini, indicating a marked accumulation and clustering of
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Figure 3. Recombination of Lkbl occurs within the GU and is associated with PIN. A, tissues from adult transgenic mice (ages, 6 mo) were harvested for the 
detection of Cre recombinase activity using X-gal staining (blue stain). Cross-sections of the four individual lobes of the murine prostate (ventral, dorsal, lateral, 
and anterior) and the urethral glands for AhCre'Lkb1m  control (i-v) and AhCre*Lkb1m  (vi-x) mice. Recombination events were apparent in AhCre* tissue 
after 1 h incubation with the X-gal solution, whereas controls were negative. Som e punctate staining was observed in the AhCre Lkb1m  anterior prostate, 
which is attributable to endogenous ^-lactamase activity (/V). B, using LCMD, DNA was isolated from anterior prostate lobes of AhCre'Lkb1mi (n = 3) and 
AhCre*Lkb1m  mice (n = 3) and underwent PCR analysis. DNA isolated from induced liver tissue from AhCre* Lkb1m  mice was used as a positive control 
(near 100% recombination). The top gel represents the unrecombined LoxP-flanked Lkbl allele (280 bp), revealing none in the positive control, 100% presence 
in AhCre Lkb1m  and AhCre*Lkb1fI/fl normal (N) samples, and a reduced level of expression in AhCre*Lkb1m  PIN lesions (P). The middle gel refers to Lkbl 
recombined alleles (500 bp), confirming the positive control as -100%  recombined and the AhCre*Lkb1m  PIN sam ples partly recombined. Densitometry 
determined -6 4 %  of AhCre*Lkb1mi PIN is recombined. AhCre'Lkbl'1'11 anterior prostate served as a negative control, and the bottom gel depicts Pten, used 
as a loading control (230 bp). C, in situ hybridization to detect Lkbl mRNA in wild-type dorsolateral and anterior prostate lobes determined no unspecific binding 
using the sen se  probe (I and //'), whereas the antisense probe revealed Lkbl is expressed in wild-type prostate epithelia (Hi and iv). AhCre* Lkbl dorsolateral 
and anterior prostate lesions show reduced Lkbl mRNA transcript levels (v and vi). Images were taken at 4 0 x magnification, and scale bars represent 50 urn.
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Figure 4. Characterisation of L kb l-deficient PIN. A, immunohistochemical analysis of the anterior prostate of control (AhCre Lkbl™') and AhCre*Lkbl"/n mice 
(ages, 2-7 mo) revealed an increase in proliferation using an anti-Ki-67 antibody. B, basal cell clustering was determined by monitoring p63 (/ and ii) and Keratin-5 
(Hi and iv) expression. C, the luminal cell marker Keratin-18 is elevated in PIN foci. D, the androgen receptor (AR) is overexpressed in PIN lesions, suggesting 
deregulation of androgen signaling within neoplastic lesions. Images were taken at 4 0 *  magnification, and the scale bars represent 50 pm.
these cells within the lesions (Fig. 45). This pattern o f expression 
was also recently observed in lung tumors from mice bearing Lkbl 
inactivation (12). Keratin-18 is a luminal cell marker. Here, we show  
an elevation in Keratin-18 expression in PIN foci, mimicking 
human prostate cancer (Fig. 4C). We also show  increased  
expression o f the androgen receptor within the lesions, suggesting 
that PIN developm ent in the context of mutant Lkbl is probably 
androgen sensitive (Fig. AD).
mTOR sig n a lin g  is decreased  in AhCre+L kblfl/fl PIN after p- 
AMPK activation . Lkbl is known to mediate mTOR signaling by 
the phosphorylation o f AMPK under low-energy conditions within 
the small intestine and skeletal muscle (4, 7, 11, 15). Consequently, 
in the absence o f L kbl, the extent o f this phosphorylation event is 
expected to decrease concom itantly with mTOR signaling activa­
tion. To establish on a molecular level whether the loss of Lkbl 
deregulates mTOR signaling in PIN foci, we used immunohisto­
chemistry to stain for active p-AMPKa, p-mTOR, p-S6K (ribosomal 
protein S6 kinase, 70kDa), an mTOR downstream target, and its 
substrate p-Rps6 (Fig. 5A). We observed an increase in cytoplasmic 
p-AMPKa expression in association with loss o f nuclear p-mTOR in 
Lkbl -deficient PIN lesions, contradicting S6K activation and 
phosphorylation o f its substrate p-Rps6. This suggests that an 
alternative AMPK kinase (AMPKK) com pensates for the absence of 
Lkbl, inhibiting mTOR production and stimulating S6K via an
alternative mechanism or that Lkbl does not regulate AMPK in 
prostatic epithelia.
W nt signaling  is deregu lated  in AhCre+L kb lfl/fl PIN. Consid­
ering mTOR signaling is not stimulated in L kbl -deficient prostate 
epithelium, we investigated alternative pathways mediated by 
Lkbl. To this end, we monitored the expression o f a number of Wnt 
signaling com ponents and downstream transcriptional targets 
using immunohistochemistry. The (3-catenin (CTNNB1) oncogene 
plays a dual role in cells by participating in both W nt signaling, 
essential for normal m am m alian developm ent, polarity, and 
migration, as well as forming adheren junctions at the cell surface 
membrane together with E-cadherin (42). We observed elevated 
nuclear [Vcatenin in PIN foci compared with control tissue, 
indicating activation o f the Wnt signal cascade (Fig. 5Bi,ii). 
Aberrant Wnt signaling was further shown through overexpression 
of a number o f (3-catenin transcriptional targets. We detected  
elevated levels o f the migration marker CD44 in PIN foci, a 
known immediate transcriptional target o f  Wnt signaling (ref. 43; 
Fig. 5Biii,iv). Foxal, a Forkhead box factor involved in prostate 
development and an indirect W nt target via Soxl7 (44), was also 
up-regulated in PIN lesions (Fig. 5Bv,vi). Interestingly, we also 
observed high-cytoplasmic expression o f inactivated p-Gsk3(3 
(Ser9), a negative regulator of (3-catenin (Fig. 5Bvikviii), which 
further implies perturbation of the Wnt cascade.
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Considering the role Lkbl plays in organizing cellular polarity via 
Pari A regulation, it is rational for Lkbl -deficient prostate epithelial 
cells to have undergone not only an elevation in Wnt signaling, but 
also to  have lost cell polarity (11, 45). To this end, we analyzed the 
expression pattern of the tight junction protein ZO-1 using 
immunofluorescence. This revealed highly organized tight junc­
tions located on the surface of the luminal cells in control tissues. 
In contrast, AhCre* L /c b ^  m ice showed aberrant expression of 
ZO-1, being either principally lost completely or perturbed in a 
small subset o f cells. In addition, reduced ZO-1 expression 
correlated with nuclear accumulation of ZO-1 (Fig. 5Bix*x), a 
phenomenon previously hypothesized to  reflect altered regulation 
of cell polarity events (46).
D eregu lation  o f  P ten  and  Akt in AhCre+L k b ln/fl PIN. 
Recently, Lkbl has been linked to the Pten/PI3K/Akt pathway 
(3). To determine whether the PI3K/Akt pathway is deregulated 
upon loss o f Lkbl, w e used an antibody directed against total Pten
(Fig bAi,ii) and one that only recognizes inactive/phosphorylated  
(Ser380-385 and Thr382) p-Pten (Fig. 6Aiii,iv) to show that inactive 
Pten is elevated in Lkbl -deficient PIN. This suggests loss o f Pten 
function/stability is a direct consequence of losing Lkbl function, 
ultimately facilitating a predisposition to PIN. Lkbl activation and 
coincident stabilization o f Pten has been shown by in vitro studies, 
supporting our data (3, 23). Consistent with this, the Lkbl mutant 
mice also exhibited increased activation of phosphorylated Akt and 
the AMPKK p-PDKl (47) within PIN foci (Fig. 6Av-viii). This 
indicates that the PI3K/Akt pathway is deregulated after Lkbl 
mutation.
D isc u ss io n
Murine prostate cancer models are becoming increasingly 
powerful in elucidating the m echanism s underlying prostate 
intraepithelial neoplasia, the m ost established precursor to
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Figure 5. Wnt signaling is activated in Lkbl -deficient PIN. A, formalin-fixed, paraffin-embedded anterior prostate tissue sections from AhCre Lkb1mi and 
AhCre* Lkb1M' mice were stained for p-AMPKa (Nil), p-mTOR (iv-vi), p-S6K (vii-ix), and p-Rps6 (x-xii). Within PIN lesions, p-AMPKa expression was elevated 
throughout the cytoplasm, whereas p-mTOR expression is lost, along with a decrease in mTOR downstream signaling components p-S6K and p-Rps6. Lambda 
phosphatase treatment was used to determine the extent of any nonspecific staining after anti-p-AMPKa immunohistochemistry, which was observed weakly 
at the apical surface of the epithelium (as in i and //'). Similar controls for other antibodies used did not identify any nonspecific staining. B, investigations into 
Wnt signaling components determined ^-catenin (i and //'), CD44 (Hi and iv), Foxal (v and vi), and p-Gsk3|i (vii and viii) were all elevated in AhCre*Lkb1m  PIN, 
indicating Wnt signaling is deregulated. Immunofluorescence for ZO-1 revealed ordered cellular polarity in control mice, whereas cell polarity is disrupted in 
AhCre* Lkb1m  PIN foci (ix and x). ZO-1 exhibited aberrant surface expression and punctate nuclear accumulation. Immunohistochemistry images were taken 
at 40 x magnification, and scale bars represent 50 pm; confocal images were taken at 63x magnification, and scale bars represent 10 pm.
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Once Lkbl is lost, mTOR signaling may proceed. Our investigations indicate an alternative AMPK kinase acts on behalf of Lkbl (e.g., p-PDK1, which stimulates 
S6K) to sustain mTOR signaling inhibition. Secondly, Lkbl phosphorylates ParlA to maintain cellular polarity. Upon loss of Lkbl function, ParlA is redirected to 
stimulate Disheveled (D sh) to inhibit the APC/Axin/Gsk3p complex, allowing p-catenin to translocate into the nucleus. Here, it stimulates transcription of downstream 
Wnt target genes and induces growth and proliferation, as well as androgen signaling (51). Finally, although the role of Lkbl interaction and phosphorylation of 
Pten is still undefined, our data suggest that Lkbl maintains R en stability, inhibiting Akt activation. In the absence of Lkbl, we observed inactivation of Pten 
function, a common precursor to prostate cancer. Pten loss results in activated Akt and ultimately results in p-Gsk3p expression, which can act to maintain Wnt 
signaling and drive tumorigenesis.
prostatic carcinoma. Here, we show, for the first time, a role for 
the tumor suppressor Lkbl in prostate cancer using Cre-LoxP 
technology to derive a conditional knockout of Lkbl within the 
prostate epithelial cells. Loss o f Lkbl reduced male longevity and 
predisposed to hyperplasia, which progressed to high-grade PIN 
in the anterior lobe and mild hyperplasia, was also observed 
in the dorsolateral and ventral glands (within 2 -4  months). This 
positively correlated with ^-catenin nuclear translocation and up- 
regulation o f the Wnt and PI3K/Akt signaling cascades within the 
prostate epithelium. Our immunohistochemical analysis suggests 
that mTOR signaling seem s to decrease after an unexpected surge
o f p-AMPK in PIN lesions. It is feasible that either Lkbl does not 
regulate AMPK within prostate tissue or that an alternative 
AMPKK com pensates for the loss o f  Lkbl, resulting in suppression 
o f the mTOR pathway. Our data indicate PDK1 is up-regulated in 
L kbl deficient PIN and may therefore play a role in the observed 
AMPK phosphorylation and activation o f pS6K (47). A speculative 
schem atic of events occurring in the presence and absence of 
Lkbl in prostate epithelium is depicted in Fig. 6B. One caveat o f 
our studies is that we were limited to immunohistochemical 
analysis o f these proteins, owing to the size o f the lesions 
identified.
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Our results from the AhCre*LkbP1^ 1 m ice parallel those of 
previous studies which have monitored the effects o f aberrant Wnt 
signaling in the prostate, dem onstrating an association with 
prostate tum origenesis (20-22). Upon L kbl loss, ParlA can 
propagate the translocation o f (5-catenin into the nucleus to 
initiate transcription o f W nt target genes, instigating tumorigenesis 
accom panied with loss o f cellular polarity (8). This gives a direct 
m echanism whereby m utation o f L kbl may lead to  activated Wnt 
signaling. The phenotype we observe is som ewhat less severe than 
that reported for either constitutive activation o f (Vcatenin or 
conditional deletion o f Ape  (20-22). This difference probably 
reflects differences in gene function (between Lkbl and either Ape 
or fi-catenin) within the prostate, but may also reflect differences in 
the experimental approaches used, such as the pattern o f Cre- 
m ediated recombination.
The L k b l-deficien t p rostate  phenotype also parallels the  
phenotypic characteristics o f  P ten -deficient m ice (25-27), although 
again being som ewhat less severe. Loss o f Pten results in HG-PIN 
which may progress into carcinom a, where tum origenesis is 
positively correlated with the overexpression o f p-PDKl, phosphor- 
ylated Akt, and its dow nstream  targets, such as pG sk3^  
(24, 27). Lkbl m utant m ice paralleled this pattern, and the elevation 
of both total Pten and inactive Pten was previously observed in the 
TRAMP m odel o f prostate neoplasia where elevated Pten protein 
levels, as well as phosphorylation o f stabilization sites, associated  
with inactivation (Ser380, Ser385, and Thr382) correlated with 
progression (48). Our data therefore suggest loss o f L kbl function 
impairs Pten function, possibly as a consequence o f directly 
interacting and regulating Pten stability (3), leading to  enhanced
PDK1 and Akt activity, and ultimately predisposing to PIN. This is 
consistent with an in vitro study that speculates LKB1 phosphor- 
ylates PTEN to stabilize its function (23). Deregulation o f the PI3K/ 
Akt signaling pathway also offers a potential explanation for the 
observed deregulation o f the Wnt pathway via the inactivation o f  
Gsk3^, which m aintains W nt signaling (49, 50).
In summary, we describe here a transgenic m ouse m odel which 
provides the first link between m utation o f the tum or suppressor 
gene L kbl and prostate neoplasia. Conditional biallelic loss o f Lkbl 
leads to the developm ent o f a PIN phenotype and to other lesions 
within the GU. The m echanism  underlying this predisposition to 
PIN involves deregulation o f both the W nt and PI3K/Akt/Pten 
pathways. Indeed, the phenotype o f  L kbl deficiency mirrors 
aspects o f  both Pten loss and W nt deregulation. Surprisingly, we 
observed a decrease in mTOR signaling, which w e hypothesize may 
occur as a consequence o f a negative feedback m echanism  whereby 
AMPK is activated by an alternate AMPKK to Lkbl, possibly PDK1, 
to suppress the mTOR pathway. M echanism s for such deregulation  
and pathway crosstalk have already been described (Fig. 6B), both  
through the phosphorylation o f Parla and by altering Pten activity/ 
stabilization.
Acknowledgments
Received 8/23/2007; revised 1/15/2008; accepted  1/20/2008.
Grant support; Tenovus (H.B. Pearson).
The costs of publication of this article w ere defrayed in pa rt by the paym ent of page 
charges. This article m ust therefore be hereby m arked advertisem ent in accordance 
with 18 U.S.C. Section 1734 solely to  indicate this fact.
We thank M ark Bishop, Lucie Pietzka, and  Derek Scarbrough a t Cardiff University 
for the ir technical assistance.
References
1. Jem al A, Siegel R, W ard E, et al. Cancer statistics, 2006. 
CA Cancer J Clin 2006;56:106-30.
2. Chin JL, Reiter RE. M olecular m arkers and p rostate  
cancer prognosis. Clin P rostate  Cancer 2004;3:157-64.
3. M ehenni H, Lin-M arq N, Buchet-Poyau K, e t al. 
I.KB1 in teracts  w ith and  phosphorylates PTEN: a  func­
tional link betw een two proteins involved in cancer 
predisposing  syndrom es. H um  Mol G enet 2005;14: 
2209-19.
4. Yoo LI, Chung DC, Yuan J. LKBl-a m aster tum our 
suppressor o f the small in testine and  beyond. N at Rev 
Cancer 2002;2:529-35.
5. Giardiello FM. Welsh SB, H am ilton SR, et al. Increased 
risk of cancer in the Peutz-Jeghers syndrom e. N Engl 
J Med 1987;316:1511-4.
6. B oardm an LA, T h ibodeau  SN, Schaid DJ, e t al. 
Increased risk for cancer in pa tien ts  w ith the  Peutz- 
Jeghers syndrome. Ann In tern  M ed 1998;128:896-9.
7. Lizcano JM, G oransson O, Toth R, e t al. LKB 1 is a 
m aster kinase th a t activates 13 kinases of the AMPK 
subfamily, including MARK/PAR-1. EMBO J 2004;23: 
833-43.
8. Spicer J, Rayter S, Young N, Elliott R, Ashworth A, 
Smith D. Regulation o f the W nt signaling com ponent 
PAR1A by the Peutz-Jeghers syndrom e kinase LKBl. 
Oncogene 2003;22:4752-6.
9. M arignani PA. LKB1, the m ultitask ing  tum our sup­
pressor kinase. J Clin Pathol 2005;58:15-9.
10. Alessi DR, Sakam oto K, Bayascas JR. LKBl-depen- 
den t signaling pathways. A nnu Rev Biochem 2006:75: 
137-63.
11. Spicer J, A shw orth A. LKB1 kinase: m aster and 
com m ander o f m etabolism  and  polarity. Curr Biol 2004: 
14:R383-5.
12. Ji H, Ramsey MR, Hayes DN, e t al. LKB1 m odulates 
lung cancer differentiation and m etastasis. N ature 2007; 
448:807-10.
13. Su G, H ruban R, Bansal R, et al. Germline and 
som atic m utations of the STK11/LKB1 Peutz-Jeghers 
gene in pancreatic  and  biliary cancers. Am J Pathol 1999: 
154:1835-40.
14. Guldberg P, th o r S traten P, Ahrenkiel V, Serem et T, 
Kirkin A, Zeuthen J. Som atic m utation  of the Peutz- 
Jeghers syndrom e gene, LKB1/STK11, in m alignant 
m e lanom a Oncogene 1999;18:1777-80.
15. C orradetti MN, Inoki K, Bardeesy N, DePinho RA, 
Guan KL. Regulation o f the TSC pathway by LKBl: 
evidence o f a  m olecular link betw een tuberous sclerosis 
com plex and Peutz-Jeghers syndrom e. Genes Dev 2004; 
18:1533-8.
16. Baas AF, Smit L, Clevers H. LKB1 tum or suppressor 
protein: PARtaker in cell polarity. Trends Cell Biol 2004; 
14:312-9.
17. Shaw RJ, Bardeesy N, M anning BD, et al. The LKB1 
tum or suppressor negatively regulates mTOR signaling. 
Cancer Cell 2004;6:91-9.
18. Kyriakis JM. At the crossroads: AM P-activated kinase 
and the LKB1 tum or suppressor link cell proliferation to 
m etabolic regulation. J Biol 2003:2:26.
19. Lee M, Hwang JT, Yun H, e t al. Critical roles of AMP- 
activated pro tein  kinase in the carcinogenic m etal- 
induced expression o f VEGF and HIF-1 pro te ins in 
DU145 p ro sta te  ca rc in o m a Biochem Pharm acol 2006; 
72:91-103.
20. G ounari F, Signoretti S, Bronson R, et al. Stabilization 
of (i-catenin induces lesions rem iniscent of p rostatic  
intraepithelial neoplasia, bu t term inal squam ous tran s­
differentiation of o ther secretory ep ithe lia  Oncogene 
2002;21:4099-107.
21. Bierie B, Nozawa M, Renou J. e t al. Activation o f b- 
ca ten in  in prostate  epithelium  induces hyperplasias and 
squ am o u s tra n sd iffe ren tia tio n . O ncogene 2003:22: 
3875-87.
22. Bruxvoort KJ, Charbonneau HM, G iam bernardi TA, et 
al. Inactivation o f Ape in the m ouse p rostate  causes 
p rostate  ca rc inom a Cancer Res 2007;67:2490-6.
23. Song P. Wu Y, Xu J, et al. Reactive nitrogen species 
induced by hyperglycemia suppresses Akt signaling and  
triggers apoptosis by upregulating phosphatase PTEN 
(phosphatase and tensin hom ologue deleted on chro ­
m osom e 10) in an LK B l-dependent m anner. Circulation 
2007:116:1585-95.
24. T ro tm an LC, Niki M, D otan ZA, e t al. P ten  dose 
d ic tates cancer progression in the p rostate. PLoS Biol 
2003;1:E59.
25. Di Cristofano A, Pesce B, C ordon-Cardo C, Pandolfi 
PP. P ten is essential for em bryonic developm ent and 
tum our suppression. Nat G enet 1998;19:348-55.
26. Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo 
C, Pandolfi PP. P ten and  p27KJPl coopera te in prostate  
cancer tum or suppression in the mouse. Nat G enet 
2001;27:222-4.
27. W ang S, Gao J, Lei Q, e t al. Prostate-specific deletion 
of the m urine P ten  tum or suppressor gene leads to  
m etasta tic  p rostate  cancer. C ancer Cell 2003;4:209-21.
28. Le Page C, Koumakpayi I, Alam Fahmy M, Mes 
M asson A, Saad F. Expression and  localisation of Akt-1, 
Akt-2 and  Akt-3 correlate  w ith clinical outcom e of 
p ro sta te  cancer patien ts. Br J C ancer 2006;94:1906-12.
29. Conde E, Suarez-G authier A  Garcfa-Garcfa E, e t al. 
Specific pa ttern  o f LKB1 and  phospho-acetyl-CoA carbo­
xylase p ro te in  im m unostain ing  in hum an norm al tissues 
and  lung carcinom as. Hum  Pathol 2007:38:1351-60.
30. Collins SP, Reom aJL, G am m  DM, Uhler MD. LKB1, a 
novel serine /th reon ine  protein kinase and potential 
tu m o u r suppressor, is phosphorylated by cAMP-depen- 
d en t protein kinase (PKA) and prenylated in vivo. 
Biochem J 2000;345:673-80.
31. Ikediobi ON, Davies H, Bignell G, et al. M utation 
analysis o f 24 know n cancer genes in the NCI-60 cell line 
set. Mol C ancer T her 2006;5:2606-12.
32. Neville P, Conti I), Krumroy L, et al. P rostate  cancer 
aggressiveness locus on chrom osom e segm ent 19q 12— 
13.1 identified by linkage and allelic im balance studies. 
Genes C hrom osom es Cancer 2003;36:332-9.
www.aacrjournals.org 9 Cancer Res 2008; 68: (7). April 1, 2008
07-5169
Cancer Research
33. Sakam oto K, M cCarthy A, Smith D, e t al. Deficiency 
of I.kfil in skeletal muscle prevents AMI’K activation 
and glucose uptake during contraction . EMBO J 2005:24: 
I8I0-20.
34. Ireland I I, Kemp R, H oughton C, et al. Inducible Cre- 
m ediated control of gene expression in the m urine 
g astro in tes tin a l trac t: effect o f loss o f (C catenin. 
Cast roenterology 2004; 126:1286-46.
25. Soriano P. Generalized lac/, expression w ith the 
KOSA26 Cre reporter strain. Nat G enet 1999;21:70-1.
26. Shappell SB, Thomas GV, Roberts RI., e t al. P rostate  
pathology of genetically engineered mice: definitions 
and classification. The consensus repo rt from the Bar 
H arbor m eeting o f the M ouse Models o f H um an Cancer 
Consortium  P rostate  Pathology C om m ittee. C ancer Res 
2004;64:2270-205.
27. Kikyo N, W illiamson CM, John RM, e t al. G enetic and 
functional analysis o f neuronatin  in m ice w ith m aternal 
or paternal duplication of distal C hr 2. Dev Biol 1997; 
190:66-77.
28. Brawer MK. P rostatic Intraepithelial Neoplasia: an 
overview. Urology 2005;7:S11-8.
29. Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, et al.
Roles for Nkx2.1 in p rostate  developm ent and cancer. 
Genes Dev 1999;12:966-77.
40. S chneider A, Brand T, Zw eigerdt R, Arnold 11. 
Targeted d isruption o f the Nkx2.1 gene in m ice results 
in m orphogenetic defects o f m inor salivary glands: 
parallels to  glandular duct m orphogenesis in prostate. 
M ech Dev 2000;95:162-74.
41. Sansom O, Griffiths D, Reed KR, W inton D, Clarke A. 
Ape deficiency predisposes to  renal carc inom a in the 
mouse. Oncogene 2005;24:8205-10.
42. Willert K, Nusse R. (Vcatenin: a key m ediato r o f W nt 
signaling. Curr Opin G enet Dev 1998;8:95-102.
43. W ielenga VJM. Smits R, Korinek V, e t al. Expression 
o f CD44 in APC and Tcf m u tan t mice implies regulation 
by the WNT pathway. Am J Pathol 1999;154:515-22.
44. Sinner D, Rankin S, Lee M, 7x)rn AM. Sox 17 and 
(Ucatenin cooperate to regulate the transcrip tion  of 
endoderm al genes. D evelopm ent 2004;121:2069-80.
45. Forcet C, Etienne-M anneville S, G aude H, e t al. 
Functional analysis of Peutz-Jeghers m utations reveals 
th a t the LKB1 C-terminal region exerts a  crucial role in 
regulating both the AMPK pathw ay and  the cell polarity. 
Hum Mol G enet 2005;14:1282-92.
46. G ottardi CJ, Arpin M, Fanning AS, Louvard D. The 
junction-associated protein, zonula occludens-1, local­
izes to  the nucleus before the m atu ration  and during 
the rem odelling of cell-cell contacts. Proc Natl Acad Sci 
U S A  1996;92:10779-84.
47. Bayascas JR, Leslie NR. Parsons R, Flem ing S,
Alessi DR. H ypomorphic m utation  o f PDK1 sup­
presses tum origenesis in PTEN (+/-) mice. Curr Biol
15:1829-46. Q4
48. Shukla S, M aclennan GT, M arengo SR, Resnick MI,
G upta S. Constitutive activation of P12K-Akt and 
NF-kB during p rostate  cancer progression in au to ch ­
thonous transgenic m ouse model. P rostate  2005;64: 
224-29.
49. Green JB. Lkbl and GSK2-(V kinases a t the cen ter and 
poles o f  the action. Cell Cycle 2004;3:12-4.
50. Al-Khouri AM, M a Y, Togo SH, Williams S, M ustelin 
T. C ooperative phosphorylation o f the tum or suppressor 
p hosphatase  and  tensin hom ologue (PTEN) by casein 
k inases and  glycogen synthase kinase 3R. J Biol Chem 
2005:280:35195-202.
51. Yardy GW, Brew ster SF. W nt signaling and p rostate  
cancer. P rostate  C ancer P rostatic Dis 2005;8:119-26.
Cancer Res 2008; 68: (7). April 1, 2008 www.aacrjournals.org
